Clinical trial NCT03980483
Conditions: Arthritis, Rheumatoid
Keywords: Rheumatoid arthritis GSK3196165 Otilimab Tofacitinib Methotrexate Placebo
Sponsor: GlaxoSmithKline
Start date: 2019-05-16; Completion date: 2022-08-16
Enrollment: 1537 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This study \[contRAst 1 (201790: NCT03980483)\] is a phase 3, randomized, multicenter, double blind study to assess the safety and efficacy of GSK3196165, in combination with methotrexate (MTX), for the treatment of adult participants with moderate to severe active rheumatoid arthritis (RA) who have had an inadequate response to MTX. The study will consist of a screening phase of up to 6 weeks followed by a 52-week treatment phase in which participants will be randomized in a ratio of 6:6:3:1:1:1 to receive GSK3196165 150 milligrams (mg) subcutaneous (SC) weekly, GSK3196165 90 mg SC weekly, tofacitinib capsules (cap) 5 mg twice a day or placebo (three arms, each placebo arm will have 12 weeks placebo followed by 40 weeks active treatment) respectively, all in combination with MTX. Participants who, in investigator's judgement will benefit from extended treatment with GSK3196165, may be included in the long-term extension study \[contRAst X (209564: NCT04333147)\]. For those participants who do not continue into the long term-extension study, there will be an 8 week safety follow-up visit following the treatment phase.

Detailed description:

Arms: arm 1: Participants received GSK3196165 90 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with methotrexate (MTX). arm 2: Participants received GSK3196165 150 mg subcutaneous (SC) injection once weekly for 52 weeks in combination with MTX. arm 3: Participants received Tofacitinib 5mg capsule, orally, twice daily (BID) in combination with MTX plus placebo injection weekly to maintain the blind for 52 weeks. arm 4: Participants received Placebo weekly SC injection in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo to GSK3196165 90 mg, SC injection, once weekly in combination with MTX until Week 52. arm 5: Participants received Placebo weekly SC injection in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo to GSK3196165 150 mg, SC injection, once weekly in combination with MTX until Week 52. arm 6: Participants received Placebo capsule weekly in combination with MTX for 12 weeks. At Week 12, participants were switched from placebo capsule to Tofacitinib 5mg, capsule, orally, BID in combination with MTX plus placebo injection to maintain the blind for 52 weeks.
Interventions: intervention 1: GSK3196165 (Otilimab) intervention 2: Tofacitinib 5 mg intervention 3: Placebo intervention 4: Placebo
Intervention descriptions: intervention 1: GSK3196165 solution in vial/pre-filled syringe (PFS) to be administered SC. intervention 2: Tofacitinib cap (over encapsulated 5mg tablet) to be administered orally. intervention 3: Placebo sterile 0.9 percentage (%) weight by volume (w/v) sodium chloride solution in vial/pre-filled syringe (PFS) to be administered SC. intervention 4: Placebo cap (containing lactose) to be administered orally.

Protocol documents:
Prot_002.pdf: 
2018N385734_02
CONFIDENTIAL
GlaxoSmithKline group of companies
201790
1
TITLE PAGE
Protocol Title: A 52-week, phase 3, multicentre, randomised, double blind, efficacy and 
safety study comparing GSK3196165 with placebo and with tofacitinib, in combination 
with methotrexate in participants with moderately to severely active rheumatoid arthritis 
who have an inadequate response to methotrexate.
Protocol Number: 201790 / Amendment 02
Compound Number: GSK3196165
Compound Name:
Otilimab
Study Phase: Phase 3
Short Title: Efficacy and safety of GSK3196165 versus placebo and tofacitinib in 
participants with moderately to severely active rheumatoid arthritis who have an 
inadequate response to methotrexate.
Study Name: contRAst-1
Sponsor Name and Legal Registered Address: 
GlaxoSmithKline Research & Development Limited
980 Great West Road
Brentford
Middlesex, TW8 9GS
UK
Medical Monitor Name and Contact Information can be found in the Study Reference 
Manual
Regulatory Agency Identifying Number(s):
IND: 121958
EudraCT: 2019-000797-39
Approval Date: 21-JAN-2020
Copyright 2020 the GlaxoSmithKline group of companies.  All rights reserved.  
Unauthorised copying or use of this information is prohibited.


PPD
PPD
PPD


2018N385734_02
CONFIDENTIAL
201790
3
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE
DOCUMENT HISTORY
Document
Date
DNG Number
Amendment 2
21-JAN-2020
2018N385734_02
Amendment 1
22-MAY-2019
2018N385734_01
Original Protocol
06-MAR-2019
2018N385734_00
Amendment 2 21-JAN-2020
Overall Rationale for the Amendment: (1) To detail revised risks, entry and stopping 
criteria following the update to comparator drug (tofacitinib) label; (2) To introduce new 
medical device safety reporting wording, required in advance of roll out of pre-filled 
syringes to this study. (3) Other minor corrections and clarifications.
Section # and Name
Description of Change
Brief Rationale
Section 1.1 Synopsis
Addition of time points to safety and 
tolerability endpoint & update to Number 
of Participants section, to clarify key 
Asian country subgroup. 
To reflect the updates in body of 
protocol (detailed below).
Section 1.3 Schedule of 
Activities (SoA)
Updated SoAs: remove fasting 
requirement for lipid test; clarify ECG 
requirement; refer to SAE section for 
reporting times at screening; and add 
urine pregnancy test at safety f/u.
Clarifications and reflect updates 
in body of protocol.
Section 2.3.1 Risk 
Assessment
Injection site reaction mitigation strategy 
- recommend to rotate sites.
Clarification.
Tofacitinib risks and mitigation strategy 
updated.
Recent safety update for 
tofacitinib label.
Handling and usage risks associated 
with the prefilled syringe devices.
Addition to align with introduction 
of prefilled syringes.
Section 3 Objectives and 
Endpoints
Addition of time points to safety and 
tolerability endpoint.
Clarification.
Section 5 Study 
Population
Addition of reference to EULAR 
recommendations for vaccination.
Provide guidance for countries 
where no local guidelines exist. 
Section 5.2 Exclusion 
Criteria
Updates to exclusion criteria 12 and 13.
Due to recent safety update for 
Tofacitinib label.
Exclusion 12: Reduce myocardial 
infarction exclusion to 3 months.
3 months is considered to be 
appropriate to stabilise ischemic 
heart disease.
Change to exclusion criteria 24 to 
remove exclusion of participants with 
prior non-JAKi tsDMARD treatment.
Not necessary to exclude prior 
non-JAKi tsDMARD treatment.
Section 5.4 Screen 
Failures
Update to clarify implications of a 
positive repeat TB test.
Clarification.
Section 6.1.1 Medical 
Devices
Description of pre-filled syringes 
(medical devices) used in the study.
To comply with new regulatory 
requirements.
Section 6.5.1 Permitted 
Therapies, Table 2
Permit PRN use of NSAIDs and weak 
opioids except 24hr before assessment
Clarification to make clear how 
PRN use is managed.


2018N385734_02
CONFIDENTIAL
201790
4
Section # and Name
Description of Change
Brief Rationale
visits, and permit PRN use of strong 
opioids after week 12 except 24hr before 
assessment visits.
Addition of Hyaluronic acid and 
associated restrictions.
To clarify and align with clinical 
practice.
Section 6.5.2 Prohibited 
Therapies, Table 3
Removal of marijuana from prohibited list 
and update to vaccination 
recommendations wording.
To clarify and align with clinical 
practice. 
Update of tsDMARD restrictions and 
clarify duration of exclusion.
Clarification and reflect changes 
to exclusion 24.
Section 7.1.2
Other Stopping Criteria
Updates to permanent stopping criteria
including discontinuation due to VTE, PE 
and DVT.
Recent safety update for 
tofacitinib per local label.
Permit permanent discontinuation due to 
a significant medical event, at discretion 
of investigator.
Clarification.
Section 7.1.3.3
Haematologic 
Abnormalities
Clarification of local confirmatory test 
requirement.
Clarification.
Section 7.1.3.5 Renal 
Abnormalities
Addition of reassessment renal test
Risk mitigation
Section 8.2.7.2 
Tuberculosis Testing
Addition of unscheduled TB testing if 
participant has been in contact with 
someone who has untreated active TB.
To mitigate risk further
Section 8.3.1 Time Period 
and Frequency for 
Collecting AE and SAE 
Information
Clarification that SAE collection is from 
beginning of study intervention (except in 
China, or if related to study 
participation).
Clarification of safety reporting 
requirements.
Section 8.3.8 Medical 
Device Deficiencies
Added sections covering the reporting 
and follow-up of medical device 
deficiencies.
To comply with new regulatory 
requirements.
Section 8.4 Treatment of 
Overdose
Clarify definition, require documentation 
to be handled by unblinded CRA.
Clarification.
Section 9.2 Sample Size 
Determination
Update to more clearly explain that key 
Asian country subgroup may continue to 
be recruited after study target reached.
Clarification.
Section 9.6 Interim 
Analyses
Interim analysis wording updated to 
describe how the key Asian country 
subgroup will be analysed.
Clarification.
Section 10.1.8 Data 
Quality Assurance
Addition of eCOA quality wording.
Clarification
Section 10.2: Clinical 
Laboratory Tests
Removal of fasting requirement for lipid 
tests.
Not considered necessary, so 
remove fasting requirement to 
minimise unnecessary 
inconvenience to participants.
Permit final assessment visit values of 
hsCRP & ESR to be provided to site.
These are baseline for LTE and 
are not individually unblinding.
Section 10.3: Adverse 
Events: definitions and 
procedures for Recording, 
Explain that this section is for AEs and 
SAEs which are not related to medical 
devices, and reference to Appendix 9 for 
To enable addition of medical 
device incidents appendix.


2018N385734_02
CONFIDENTIAL
201790
5
Section # and Name
Description of Change
Brief Rationale
Evaluation, Follow-up and 
Reporting
medical device incidents. 
Section 10.9: Medical 
Device Adverse Events 
(AEs), Adverse Device 
Effects (ADEs), Serious 
Adverse Events (SAEs) 
and Device Deficiencies: 
Definition and procedures 
for Recording, evaluating, 
Follow-up and reporting
Addition of medical device adverse 
effects reporting appendix.
To comply with new regulatory 
requirements.
All sections
Other minor, grammatical and typographical corrections to improve 
readability.


2018N385734_02
CONFIDENTIAL
201790
6
TABLE OF CONTENTS
PAGE
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE.....................................3
1.
PROTOCOL SUMMARY........................................................................................10
1.1.
Synopsis.....................................................................................................10
1.2.
Schema ......................................................................................................13
1.3.
Schedule of Activities (SoA)........................................................................13
2.
INTRODUCTION....................................................................................................17
2.1.
Study Rationale ..........................................................................................17
2.2.
Background ................................................................................................17
2.3.
Benefit/Risk Assessment ............................................................................18
2.3.1.
Risk Assessment .........................................................................19
2.3.2.
Benefit Assessment.....................................................................31
2.3.3.
Overall Benefit: Risk Conclusion..................................................31
3.
OBJECTIVES AND ENDPOINTS...........................................................................32
4.
STUDY DESIGN ....................................................................................................34
4.1.
Overall Design ............................................................................................34
4.2.
Scientific Rationale for Study Design ..........................................................35
4.3.
Justification for Dose ..................................................................................35
4.4.
End of Study Definition ...............................................................................37
5.
STUDY POPULATION...........................................................................................37
5.1.
Inclusion Criteria.........................................................................................38
5.2.
Exclusion Criteria........................................................................................39
5.3.
Lifestyle Considerations..............................................................................42
5.3.1.
Dietary Restrictions......................................................................42
5.4.
Screen Failures...........................................................................................42
6.
STUDY INTERVENTION........................................................................................43
6.1.
Study Intervention(s) Administered .............................................................43
6.1.1.
Medical Devices...........................................................................48
6.2.
Preparation/Handling/Storage/Accountability..............................................48
6.3.
Measures to Minimise Bias: Randomisation and Blinding ...........................49
6.4.
Study Intervention Compliance ...................................................................50
6.5.
Prior and Concomitant Therapies ...............................................................51
6.5.1.
Permitted Therapies ....................................................................51
6.5.2.
Prohibited Therapies....................................................................54
6.5.3.
Rescue Medicine .........................................................................56
6.6.
Dose Modification .......................................................................................56
6.6.1.
Dose Modification of Study Intervention.......................................56
6.6.2.
Dose Modification of Background Medicines (MTX).....................56
6.7.
Intervention after the End of the Study........................................................56
7.
DISCONTINUATION OF STUDY INTERVENTION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL.....................................................................57
7.1.
Discontinuation of Study Intervention..........................................................57
7.1.1.
Liver Chemistry Stopping Criteria ................................................57


2018N385734_02
CONFIDENTIAL
201790
7
7.1.1.1.
Study Intervention Restart or Rechallenge after 
liver stopping criteria met............................................59
7.1.2.
Other Stopping Criteria ................................................................59
7.1.3.
Temporary Discontinuation ..........................................................60
7.1.3.1.
Respiratory Symptoms ...............................................60
7.1.3.2.
Serious and Opportunistic Infections ..........................60
7.1.3.3.
Haematologic Abnormalities.......................................60
7.1.3.4.
TB Reactivation..........................................................61
7.1.3.5.
Renal Abnormalities ...................................................61
7.2.
Participant Discontinuation/Withdrawal from the Study ...............................61
7.3.
Lost to Follow Up........................................................................................62
8.
STUDY ASSESSMENTS AND PROCEDURES .....................................................63
8.1.
Efficacy Assessments.................................................................................63
8.1.1.
Joint Assessments.......................................................................63
8.1.2.
Physician’s Global Assessment of Arthritis ..................................64
8.1.3.
Joint X-Rays ................................................................................64
8.1.4.
Patient Reported Outcomes.........................................................64
8.1.4.1.
Patient’s Assessment of Arthritis Pain ........................64
8.1.4.2.
Patient’s Global Assessment of Arthritis .....................64
8.1.4.3.
Health Assessment Questionnaire – Disability 
Index (HAQ-DI)...........................................................64
8.1.4.7.
Functional Assessment of Chronic Illness 
Therapy (FACIT)-Fatigue............................................65
8.1.4.8.
SF-36 Short Form Health Survey................................65
8.2.
Safety Assessments ...................................................................................66
8.2.1.
Dyspnoea Assessments ..............................................................66
8.2.2.
Physical Examinations.................................................................66
8.2.3.
Electrocardiograms......................................................................66
8.2.4.
Vital Signs....................................................................................67
8.2.5.
Clinical Safety Laboratory Assessments ......................................67
8.2.6.
Pulmonary Assessments .............................................................68
8.2.7.
Tuberculosis Monitoring...............................................................69
8.2.7.1.
Tuberculosis Status Definitions ..................................69
8.2.7.2.
Tuberculosis Testing ..................................................70
8.2.7.3.
Treatment of Latent TB During the Study ...................70
8.2.7.4.
Monitoring for TB Infection and Re-activation 
During the Study.........................................................70
8.2.8.
Hepatitis B Monitoring..................................................................71
8.2.8.1.
Risk of Reactivation in Participants Positive for 
Hepatitis B Core Antibody (HBcAb) ............................72
8.2.8.2.
Treatment of Participants Who Are HBcAb 
Positive and Who Develop Detectable HBV 
DNA Requiring Initiation of Antiviral Therapy..............73
CCI
CCI


2018N385734_02
CONFIDENTIAL
201790
8
8.2.8.3.
Follow Up of Participants Treated With Anti-
viral Therapy...............................................................73
8.3.
Adverse Events and Serious Adverse Events.............................................73
8.3.1.
Time Period and Frequency for Collecting AE and SAE 
Information...................................................................................73
8.3.2.
Method of Detecting AEs and SAEs.............................................74
8.3.3.
Follow-up of AEs and SAEs.........................................................74
8.3.4.
Regulatory Reporting Requirements for SAEs .............................74
8.3.5.
Pregnancy ...................................................................................75
8.3.6.
Cardiovascular and Death Events................................................75
8.3.7.
AEs of Special Interest.................................................................76
8.3.8.
Medical Device Deficiencies ........................................................76
8.3.8.1
Time Period for Detecting Medical Device 
Deficiencies................................................................76
8.3.8.2
Follow-up of Medical Device Deficiencies...................77
8.3.8.3
Prompt Reporting of Medical Device 
Deficiencies to Sponsor..............................................77
8.3.8.4
Regulatory Reporting Requirements for 
Medical Device Incidents............................................77
8.4.
Treatment of Overdose...............................................................................77
8.6.1.
Target engagement .....................................................................78
8.9.
Immunogenicity Assessments.....................................................................80
8.10.
Medical Resource Utilisation and Health Economics ..................................81
9.
STATISTICAL CONSIDERATIONS........................................................................82
9.1.
Statistical Hypotheses.................................................................................82
9.2.
Sample Size Determination ........................................................................82
9.3.
Sample Size Sensitivity...............................................................................83
9.4.
Populations for Analyses ............................................................................83
9.5.
Statistical Analyses.....................................................................................84
9.5.1.
Efficacy Analyses.........................................................................85
9.5.2.
Estimand Strategy .......................................................................85
9.5.3.
Safety Analyses...........................................................................86
9.6.
Interim Analyses .........................................................................................86
9.6.1.
Data Monitoring Committee (DMC)..............................................87
10. SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS...............................................................................................88
10.1.
Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations............................................................................................88
10.1.1.
Regulatory and Ethical Considerations ........................................88
10.1.2.
Financial Disclosure.....................................................................88
10.1.3.
Informed Consent Process ..........................................................89
10.1.4.
Data Protection............................................................................89
CCI
CCI
CCI


2018N385734_02
CONFIDENTIAL
201790
9
10.1.5.
Committees Structure ..................................................................89
10.1.6.
Publication Policy.........................................................................90
10.1.7.
Dissemination of Clinical Study Data ...........................................90
10.1.8.
Data Quality Assurance ...............................................................91
10.1.9.
Source Documents ......................................................................92
10.1.10. Study and Site Closure ................................................................92
10.2.
Appendix 2: Clinical Laboratory Tests.........................................................93
10.3.
Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow-up, and Reporting .......................................95
10.3.1.
Definition of AE............................................................................95
10.3.2.
Definition of SAE..........................................................................96
10.3.3.
Definition of Cardiovascular Events .............................................97
10.3.4.
Recording and Follow-Up of AE and SAE....................................98
10.3.5.
Reporting of SAE to GSK.............................................................99
10.4.
Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information................................................................................................101
10.4.1.
Definitions:.................................................................................101
10.4.1.1.
Woman of Childbearing Potential (WOCBP).............101
10.4.1.2.
Women in the following categories are not 
considered WOCBP .................................................101
10.4.2.
Contraception Guidance: ...........................................................102
10.4.3.
Collection of Pregnancy Information: .........................................103
10.4.4.
Contraception Eligibility Criteria for Female and Male 
Participants................................................................................104
10.5.
Appendix 5: Genetics................................................................................106
10.6.
Appendix 6: Liver Safety: Required Actions and Follow-up 
Assessments ............................................................................................107
10.7.
Appendix 7: Summary of composite endpoints .........................................110
10.7.1.
ACR...........................................................................................110
10.7.2.
Disease Activity Score ...............................................................110
10.7.3.
Clinical Disease Activity Index (CDAI)........................................110
10.8.
Appendix 8: Hierarchy Options to Demonstrate Superiority or Non-
inferiority of Each Dose of GSK3196165 Versus Placebo or 
Tofacitinib, Respectively ...........................................................................112
10.9.
Appendix 9: Medical Device Adverse Events (AEs), Adverse Device 
Effects (ADEs), Serious Adverse Events (SAEs) and Device 
Deficiencies: Definition and Procedures for Recording, Evaluating, 
Follow-up, and Reporting..........................................................................113
10.9.1.
Definition of Medical Device AE and ADE..................................113
10.9.2.
Definition of Medical Device SAE, SADE and USADE ...............113
10.9.3.
Definition of Device Deficiency...................................................114
10.9.4.
Recording and Follow-Up of Medical Device AE and/or 
SAE and Device Deficiencies.....................................................114
10.9.5.
Reporting of Medical Device SAEs ............................................116
10.9.6.
Reporting of SADEs...................................................................117
10.10. Appendix 10: Country-specific requirements.............................................118
10.11. Appendix 11: Abbreviations and Trademarks............................................119
10.12. Appendix 12: Protocol Amendment History...............................................123
11. REFERENCES.....................................................................................................124


2018N385734_02
CONFIDENTIAL
201790
10
1.
PROTOCOL SUMMARY
1.1.
Synopsis
Protocol Title: A 52-week, phase 3, multicentre, randomised, double blind, efficacy and 
safety study comparing GSK3196165 with placebo and with tofacitinib, in combination 
with methotrexate in participants with moderately to severely active rheumatoid arthritis 
who have an inadequate response to methotrexate.
Short Title: Efficacy and safety of GSK3196165 versus placebo and tofacitinib in 
participants with moderately to severely active rheumatoid arthritis who have an 
inadequate response to methotrexate.
Rationale: The aim of this study is to determine the efficacy and safety of GSK3196165, 
in combination with methotrexate (MTX), for the treatment of adults with moderately to 
severely active rheumatoid arthritis (RA) who have had an inadequate response to MTX.  
Two doses of GSK3196165 (90 mg subcutaneous [SC] weekly and 150 mg SC weekly) 
will be compared with placebo (to Week 12) and with tofacitinib (5 mg twice daily 
[BID]), an inhibitor of Janus Kinase (JAK) that is approved for the treatment of adults 
with moderately to severely active RA who have had an inadequate response to MTX.
Objectives and Endpoints:
Objectives
Endpoints
Primary

To compare the efficacy of GSK3196165 at 
doses of 90 mg and 150 mg weekly versus 
placebo for the treatment of participants 
with moderately to severely active RA who 
are on a stable background of MTX and 
who have had an inadequate response to 
MTX.

Proportion of participants achieving ACR20 
at Week 12
Secondary
To compare:

Efficacy of GSK3196165 at doses of 90 
mg and 150 mg weekly versus tofacitinib 
for the treatment of participants with 
moderately to severely active RA who are 
on a stable background of MTX and who 
have had an inadequate response to 
MTX.
Major Secondary Efficacy Endpoints
Week 12 versus placebo:

Proportion of participants achieving CDAI 
total score ≤10 (CDAI LDA).

Change from baseline in HAQ-DI.
Non-inferiority versus tofacitinib at Week 12: 

Proportion of participants achieving 
ACR20.
Other Secondary Efficacy Endpoints
Week 12 (vs. placebo and vs. tofacitinib), 
Week 24 and Week 52 (vs. tofacitinib): 
Proportion of participants achieving:


2018N385734_02
CONFIDENTIAL
201790
11
Objectives
Endpoints

CDAI total score ≤10 (CDAI LDA).

CDAI total score ≤2.8 (CDAI Remission).

ACR20/50/70.

DAS28-CRP ≤3.2 and DAS28(ESR) ≤3.2
(DAS28 LDA).

DAS28-CRP <2.6 and DAS28(ESR) <2.6
(DAS28 Remission).

A good/moderate EULAR response.

ACR/EULAR Remission.

No radiographic progression defined as a 
change from baseline in van der Heijde 
mTSS score of ≤0.5.
Change from baseline in: 

CDAI total score.

DAS28-CRP/DAS28-ESR.

van der Heijde mTSS.

Effect of GSK3196165 on Patient
Reported Outcomes (PROs) versus 
placebo and the active comparator 
tofacitinib
Change from baseline at Week 12 (vs. placebo 
and vs. tofacitinib), Week 24 and Week 52 (vs. 
tofacitinib) in:

HAQ-DI.

Arthritis pain VAS.

SF-36 physical and mental component 
scores, and domain scores.

FACIT-Fatigue.

Safety and tolerability of GSK3196165 
versus placebo and the active comparator 
tofacitinib

Incidence of AEs, SAEs and AESIs.

Change from baseline in key laboratory 
parameters at Weeks 12, 24 and 52.

Proportion of participants with NCI-CTCAE 
≥Grade 3 haematological/clinical chemistry 
abnormalities.

To determine the immunogenic potential of 
GSK3196165
Safety Biomarker Endpoints

GM-CSF autoantibody concentrations.

Anti-GSK3196165 antibodies.
MTX = methotrexate; ACR2050/70 = 20%/50%/70% improvement in American College of Rheumatology criteria; 
CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire disability index; VAS = visual 
analogue scale; LDA = low disease activity; DAS28 = disease activity score including 28 different joints; CRP = C-
reactive protein; EULAR = European league against rheumatism; ESR = erythrocyte sedimentation rate; mTSS = 
modified total sharp score; AEs = adverse events; SAEs = serious adverse events; AESIs = adverse events of 
special interest; NCI-CTCAE = National Cancer Institute-common terminology criteria for adverse events; SF-36 = 
short form-36; FACIT = functional assessment of chronic illness therapy; RA = rheumatoid arthritis; GM-CSF = 
granulocyte-macrophage colony stimulating factor
Overall Design:  This is a double-blind, parallel group, multicentre, placebo and active 
comparator-controlled study of the efficacy and safety of GSK3196165 in participants 
with moderately to severely active RA who have an inadequate response to MTX.  The 
study consists of a screening phase of up to 6 weeks, a 52-week treatment phase and an 
8-week safety follow-up visit.  Upon successful screening, participants will be 


2018N385734_02
CONFIDENTIAL
201790
12
randomised to one of six intervention arms.  Participants who complete this study may be 
eligible to participate in a long-term extension study to further evaluate the efficacy and 
safety of GSK3196165.
Disclosure Statement: This is a parallel group treatment study with 6 arms that is 
participant, investigator and outcomes assessor blinded.
Number of Participants:  Approximately 3000-3400 participants will be screened to 
achieve between 1500 and 1700 randomly assigned to study intervention.  Approximately 
1500 evaluable participants are expected to be included in the primary analysis, of whom 
approximately 1350 are expected to complete the Week 12 visit.  When the approximate 
target of 1500 participants is reached, recruitment may continue up to a maximum of 
1700 participants to ensure sufficient numbers in the key Asian country subgroup.
The number of participants with prior biologic disease-modifying antirheumatic drug 
(bDMARD) exposure will be limited to approximately 20% of the overall sample size 
(approximately 300 participants).  Sites will be informed to stop recruiting participants 
with prior bDMARD exposure once the global limit of approximately 300 participants is 
achieved.
The sample size calculation is provided in Section 9.2.
Intervention Groups and Duration:
Participants will be randomised in a ratio of 6:6:3:1:1:1 to GSK3196165 150 mg SC 
weekly, GSK3196165 90 mg SC weekly, tofacitinib capsules 5 mg BID or placebo (3 
arms) respectively, all in combination with oral or injectable MTX.  At Week 12, the 3 
placebo arms will switch from placebo to active intervention (either GSK3196165 150 
mg SC weekly, GSK3196165 90 mg SC weekly, or tofacitinib capsules 5 mg BID).
A separate randomisation cohort in addition to the main randomisation may be utilised 
for the key Asian subgroup, in order to allow separate analyses for these countries if 
required.
The total treatment period is 52 weeks, with an 8-week safety follow‑up period after the 
last SC dose of study intervention for those participants who do not continue into the long 
term-extension study.
Independent Data Monitoring Committee: Yes.
Major Adverse Cardiac Event/Gastrointestinal Perforation Adjudication 
Committee: Yes.
Pulmonary Adjudication Committee: Yes.


2018N385734_02
CONFIDENTIAL
201790
13
1.2.
Schema
W 0
Tofacitinib BID + MTX
W24
Screening
GSK3196165 90mg weekly + MTX
End of study 
treatment
W52
Option to transition 
to LTE study 209564 
or exit after safety 
follow-up at 8w post 
last SC dose.
MTX-IR
W-6
W24
Endpoint visit
& switch all 
Placebo to active
GSK3196165 150mg weekly + MTX
Placebo + MTX
Tofacitinib BID + MTX
Placebo + MTX
GSK3196165 90mg weekly + MTX
Placebo + MTX
GSK3196165 150mg weekly + MTX
W12
1.3.
Schedule of Activities (SoA)
See Section 8 for further details of study procedures listed in the SoA.
Order of Assessments:

PROs should be completed first, before any other assessments, procedures or 
consultations, to avoid influencing participants’ perception.

Where possible, joint counts should follow PRO completion.  PhGA should then 
take place, followed by other assessments (including safety), ECGs, vital signs 
and blood draws, before dosing.

PK sampling and blood draws must always take place before dosing.
Study SC Dosing and Visit Schedule:

Study SC injection should be administered weekly, on the same day each week. 

A window of 2 days is acceptable for the SC injection (minimum gap of 5 days 
between each dose, for no more than 2 consecutive doses). Participants should 
return to their 7 day dosing schedule as soon as possible thereafter. See 
Section 6.1 for further information.

Where possible, assessment visits should be scheduled to coincide with the 
weekly administration of study SC injection, the injection will then be 
performed at the site, after completion of PK sampling.

The study SC injection must be performed at site on Weeks 0, 1, 12 and 13, after 
completion of study assessments, and participants must be monitored for 1 hour 
post dose.


2018N385734_02
CONFIDENTIAL
201790
14
SoA – Screening Period
Participant Screening
Task List
Screening assessment notes
(after informed consent, all screening assessments 
must be completed within the 42 days prior to 
Randomisation)
Day -42 to Day -1

Informed Consent and optional Genetics consent
1) ECGs should be performed before vital signs 
and blood draws.
2) Joint assessments should be performed by 
an independent assessor. Where possible the 
same assessor should perform all joint 
assessments for an individual participant.
3) Will be read centrally & imaging CRO will 
assess presence or absence of erosion(s).
4) Unless performed within previous 12 weeks
5) For women of child-bearing potential.
6) Fasting is not required, but 6hr fasting status 
at time of blood draw must be noted on 
requisition form.
7) See Section 8.3.1 for the time period of SAE 
collection, which varies between countries.
See Section 5.4 for screen failures and 
rescreening.
Inclusion/exclusion criteria
Participant Demographics
Medical, disease and therapy history
Review of asthma/COPD/pulmonary disease history
Concomitant Medication Review
Assessments
Triplicate 12-lead ECG1
Vital signs
Full Physical Exam
Dyspnoea & Cough assessment, Lung 
Auscultation, Pulse Oximetry
TB evaluation
SAE assessment7
Swollen (66) & Tender (68) joint count2
Hands and feet X-ray3
Chest X-ray (posteroanterior)4
Labs
Haematology, Chemistry, Urinalysis (dip stick)
HIV, TB, Hepatitis B & Hepatitis C screen
hsCRP
Serum pregnancy test5
Lipid profile6


2018N385734_02
CONFIDENTIAL
201790
15
SoA – Treatment Period
Study intervention GSK3196165 
vs tofacitinib vs placebo (W0-11)
Study intervention GSK3196165 vs
tofacitinib (W12-52)
Notes
Week
0
1
2
3
4
5-7
8
9-11
12
13 14-15 16 17-23 24 25-35 36 37-47 48 49-51
52
1. PROs should be completed first, before 
any other assessments, procedures or 
consultations, to avoid influencing 
participants’ perception.
2. ECGs should be performed before vital 
signs and blood draws, where possible.
3. Joint assessments should be performed by 
an independent assessor. Where possible 
the same assessor should perform all joint 
assessments for an individual participant.
4. Where possible, the same individual should 
perform all physician global assessments 
for an individual participant.
5. Will be centrally read & assessed for 
presence or absence of erosion(s).
6. Schedule X-ray between Weeks 48-51.
7. Fasting is not required, but 6hr fasting 
status at time of blood draw must be noted 
on requisition form.
8. For women of child-bearing potential.
9. ESR measured locally (using kit provided) 
by unblind site staff.
10. Day 1 sample includes anti-GM-CSF auto-
antibody and free GM-CSF analysis.
13. Monitor participants for 1 hour after SC 
dosing at site at Weeks 0, 1, 12 and 13. 
SC injection must be administered at site
when dosing on assessment visit days.
14. Dispense weekly for site administration; 
OR if available, dispense PFS in boxes of 
4, every 4 weeks, for home SC dosing.
15. Dispense 2 bottles of oral intervention 
every 4 weeks.
16. Minimum weekly review to Week 12, then 
every two weeks to Week 36, then every 
four weeks to Week 52. A phone call is 
acceptable if a site visit is not scheduled.
17. May be performed before Day 1 if required.
Assessment visit Day   
      Study activities1
Baseline Day 1
Day 8 (2d)
Day 15 (2d)
Day 22 (2d)
Day 29 (2d)
Day 57 (2d)
Primary endpoint 
Day 85 (3d)
Day 92 (3d)
Day 113 (5d)
Day 169 (7d)
Day 253 (7d)
Day 337 (7d)
End of treatment
Day 365 (7d) 
Randomisation
X
PROs1
Arthritis pain VAS, PtGA, HAQ-DI
X
X X
X
X
X
X
X
X
X
X
FACIT-Fatigue, SF-36, PROMIS Sleep
X
X
X
X
X
X
X
Assessments
12-lead ECG2 (S=single, T=triplicate)
S
T
Vital signs
X
X
X
X
X
X
X
X
X
X
Brief Physical Exam
X
X
X
X
X
X
X
X
Dyspnoea & Cough assessment, Lung 
Auscultation, Pulse Oximetry
X
X X
X
X
X
X
X
X
X
X
Pulmonary function tests (FEV1, FVC)
X17
Swollen (66) & Tender (68) joint count3
X
X X
X
X
X
X
X
X
X
X
Physician Global Assessment4
X
X X
X
X
X
X
X
X
X
X
Hands and Feet X-ray5
X
X
X
Chest x-ray (posteroanterior)
X6
Labs and blood draws
Haematology, Chemistry, Urinalysis
X
X
X
X
X
X
X
X
X
X
X
Lipid profile7
X
X
X7
Urine pregnancy test8
X
X
X
X
X
<------ Every 8 weeks ------>
X
hsCRP, ESR9
X
X X
X
X
X
X
X
X
X
X
RF, ACPA (anti-CCP)
X
TB testing
X
Pre-dose PK sample (& GMCSF complex)
X
X
X
X
X
X
X
X
Immunogenicity blood sampling
X10
X
X
X
X
X
X
X
Dose
Dispense: Weekly SC injection13,14
X13 X13 X
<---------- X14 ---------->
X13 X13
<------------------------ X14 ------------------------>
Dispense: BID oral intervention15
X
X
X
X
<------------- Every 4 weeks ----------->
SAE/AE review16
<------------------------------------------------------------- X ------------------------------------------------------------->
Concomitant medication review16
<------------------------------------------------------------- X ------------------------------------------------------------->
AE/conmed phone call if no site visit16
Weekly to Week 12
Every two weeks to W36, every four weeks to W52
CCI
CCI
CCI
CCI


2018N385734_02
CONFIDENTIAL
201790
16
SoA – Safety Follow-up Visit
Safety follow-up visit procedures
(Follow-up visit only for participants who do not 
transition into LTE study 209564)
Week 59 (Day 414 14 days)

Assessments
Vital signs
Full Physical Exam
Dyspnoea & Cough assessment, Lung Auscultation, 
Pulse Oximetry
Concomitant Medication Review
SAE/AE review
Labs
Haematology, Chemistry, Urinalysis (dip stick)
Urine pregnancy test (for women of child bearing 
potential only)
Immunogenicity blood sampling
Assessments for Early Withdrawal from Study
Follow the Week 52 procedures* at the time of withdrawal from the study, or within 1 
week of withdrawal, and schedule a safety follow-up visit 8 weeks post last dose of SC 
administered study intervention.
*Note: A hands/feet x-ray should not be performed at early withdrawal if the 
participant’s last dose of study drug was prior to week 8, OR if a hands/feet x-ray has 
been carried out within 8 weeks of the early withdrawal date, as part of study 
assessments.


2018N385734_02
CONFIDENTIAL
201790
17
2.
INTRODUCTION
GSK3196165 is a novel human monoclonal anti-granulocyte-macrophage colony 
stimulating factor (GM-CSF) antibody that is being developed for once-weekly treatment 
of rheumatoid arthritis (RA).
2.1.
Study Rationale
The aim of this study is to determine the efficacy and safety of GSK3196165, in 
combination with methotrexate (MTX), for the treatment of adults with moderately to 
severely active RA who have had an inadequate response to MTX.  Two doses of 
GSK3196165 (90 mg subcutaneous [SC] weekly and 150 mg SC weekly) will be 
compared with placebo (to Week 12) and with tofacitinib (5 mg twice daily [BID]), an 
inhibitor of Janus Kinase (JAK) that is approved for the treatment of adults with 
moderately to severely active RA who have had an inadequate response to MTX.
2.2.
Background
RA is a chronic, systemic inflammatory autoimmune disease, characterised by a 
symmetrical polyarthritis that is associated with substantial disability and morbidity.  RA 
affects approximately 0.5-1.0% of the worldwide population, primarily women, with a 
peak incidence of onset between 40 and 60 years of age.
A substantial proportion of patients either fail to respond, or have inadequate response, to 
currently available RA therapies [Gaujoux-Viala, 2014; Nam, 2014].  Therefore, there is 
still a medical need for more effective treatments for RA with alternative mechanisms of 
action.
GM-CSF is a pro-inflammatory cytokine that regulates the functions of myeloid lineage 
cells that are considered to play key roles in the pathology of RA including macrophages 
and neutrophils [Avci, 2016; Hamilton, 2016; Wicks, 2016].  Increased levels of GM-
CSF are found in the synovial fluid from RA patients and its receptor is expressed in 
synovial tissue [Avci, 2016; Wicks, 2016].  Preclinical studies using various 
inflammatory arthritis models have shown that GM-CSF removal or neutralisation 
improved pain, function and joint histologic structure [Cook, 2001; Plater-Zyberk, 2007; 
Cook, 2013; Cook 2018a] and inhibited matrix metalloproteinase (MMP)-mediated 
cartilage degradation in experimental arthritis induced by joint instability [Cook, 2012].
GSK3196165 is a high-affinity recombinant human monoclonal antibody (mAb) that 
binds specifically to human GM-CSF and prevents its interaction with its cell surface 
receptor [Steidl, 2008].  Clinical studies in patients with RA have then shown that 
GSK3196165 [Behrens, 2015] and mavrilimumab (an anti-GM-CSF receptor -subunit 
antibody) [Burmester, 2017; Burmester, 2018; Cook, 2018b] are able to reduce RA 
disease activity and pain.  A Phase IIb dose-ranging study of GSK3196165 with 
methotrexate (MTX) treatment, in patients with RA and an inadequate response to MTX, 
has now been completed.
In the BAROQUE Phase IIb study (201755), treatment with GSK3196165 in 
combination with MTX demonstrated efficacy in the treatment of active RA.  At Week 


2018N385734_02
CONFIDENTIAL
201790
18
12 of the study all doses above 22.5 mg resulted in a significant reduction in 
DAS28(CRP) (Disease Activity Score including 28 different joints) and significantly 
higher ACR20 (20% improvement in American College of Rheumatology criteria)
response rates in comparison with placebo.  Substantial improvements in tender and 
swollen joint counts, a large effect in CDAI (Clinical Disease Activity Index) and rapid 
improvements in pain were also identified.  The overall adverse event (AE) and serious 
adverse event (SAE) profile was unremarkable.  The majority of AEs were of mild or 
moderate intensity and there were no deaths, malignancies or venous thromboembolisms 
during the trial.  Additional information is provided in the GSK3196165 Investigator’s 
Brochure (IB) [GSK Document Number 2014N190256_02].  It is therefore hypothesised 
that GSK3196165, in combination with MTX, may provide clinical benefit to patients 
with RA.
2.3.
Benefit/Risk Assessment
More detailed information about the known and expected benefits and risks and 
reasonably expected adverse events of GSK3196165 may be found in the IB.  The risks 
associated with the active comparator tofacitinib can be found in the approved product 
label or local prescribing information.
The potential risk assessment and mitigation strategy for the administration of 
GSK3196165 in this protocol is outlined below.


2018N385734_02
CONFIDENTIAL
201790
19
2.3.1.
Risk Assessment
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
Investigational Product (IP) [GSK3196165]
Infections
Immune-modulating biologic drugs used in RA (such 
as anti-TNF agents) are associated with an increased 
risk of serious and opportunistic infections.  Similarly, 
because of the role of GM-CSF in anti-infective 
immunity, GSK3196165 also has the potential to 
increase the risk of infection.
Non-clinical Data:
No changes in peripheral blood populations 
(lymphocytes, neutrophils, monocytes, eosinophils or 
basophils), phagocytic activity of peripheral blood 
polymorphonuclear cells (investigational endpoint in 
the 26 week study), T-cell dependent B-cell primary or 
secondary response, or circulating cytokine levels (26 
week study) were observed.
Studies in knock-out mice showed that GM-CSF 
deficiency (GM-CSF-/-) affects the ability of mice to 
control infection when infected with M. tuberculosis or 
pulmonary group B streptococcus [LeVine, 1999].
Clinical Data:
Based on the mechanism of action of GSK3196165 
an increased risk of infection including TB, fungal and 
opportunistic infections could be expected for anti-
GM-CSF treatment, because of the role of GM-CSF in 
anti-infective immunity.
One healthy volunteer (HV) in study MSC-1000 
experienced septic shock secondary to pneumonia 29 
days after receiving a single dose of 1.5 mg/kg but 
Eligibility Criteria (Section 5.2):
Exclusion of participants with:

Active infections (including localised 
infections), or a history of recurrent infections 
or has required interventions to manage 
acute/chronic infections.

Symptomatic herpes zoster.

Hereditary or acquired immunodeficiency 
disorder, including immunoglobulin 
deficiency.

History of infected joint prosthesis, chronic leg 
ulcers, permanent in-dwelling catheters, 
chronic sinusitis, recurrent chest infections or 
recurrent urinary tract infections.

White blood cell (WBC) count ≤3.0 x 109/L

Evidence of untreated latent TB (unless 
willing to undergo TB therapy or have 
successfully undergone TB therapy).

Current or previous active TB regardless of 
treatment.

Previous close contact with a person with 
active TB and did not receive satisfactory 
anti-tuberculosis treatment.

Current acute or chronic Hepatitis B and/or 
Hepatitis C.

Known infection with human 
immunodeficiency virus (HIV) or positive test 


2018N385734_02
CONFIDENTIAL
201790
20
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
recovered after treatment with antibiotics.
In Phase II completed studies, no significant infections 
or opportunistic infections were reported.
at screening.

Assessment of vaccination status (including 
against influenza and pneumococcus, 
according to local guidelines) prior to 
enrolment.
Monitoring:

Serious and opportunistic infections, TB and 
TB reactivation are categorised as AESIs.

Monitoring for signs of infection with 
appropriate diagnostic tests as necessary.

Instructions to participants as to the signs and 
symptoms of infection, and to contact site 
personnel should they develop (also 
contained within the ICF).

TB evaluation at screening and monitoring for 
TB and TB re-activation throughout the study 
(Section 8.2.7.4).

Participants diagnosed with latent TB during 
screening will need to complete a course of at 
least 6 months of isoniazid (INH) therapy 
during the study including at least 4 weeks of 
therapy prior to randomisation (Section 
8.2.7.3).
Withdrawal Criteria:
Temporarily discontinue the study intervention for: 

Serious infections until the infection has 
resolved.

Suspected TB reactivation.

WBC count (<2 x 109/L)
Permanently discontinue the study intervention for:

New latent or active TB infection


2018N385734_02
CONFIDENTIAL
201790
21
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy

HBV DNA level ≥200 IU/mL or HBV DNA 
detected at any level with recent increase in 
hepatic transaminases (see Figure 2 in 
Section 8.2.8).

HBV DNA positive (any level ≤200 IU/mL) 
and on repeat testing within 1 week either: 
HBV DNA positive (any level) OR HBV 
surface antigen positive OR increase in 
hepatic transaminases (see Figure 2 in 
Section 8.2.8).
Pulmonary alveolar proteinosis (PAP)
GM-CSF signalling is required to maintain the normal 
function of alveolar macrophages.  Long-term 
absence of GM-CSF signalling (e.g., via hereditary 
GM-CSF deficiency or development of anti-GM-CSF 
auto-antibodies) is known to cause the extremely rare 
condition of PAP.  PAP is characterised by the 
accumulation of surfactant lipids and protein in the 
alveolar spaces, which might lead to persistent dry 
cough and is also associated with impairment in gas 
exchange which may lead to an increased risk of 
dyspnoea and pulmonary infection.
The exposure duration to GSK3196165 in this study is 
12 months.  Although the time course of PAP 
development in humans is unknown, the published 
literature suggests that the clinical onset of PAP 
requires prolonged and complete inhibition of GM-
CSF [Martinez-Moczygemba, 2008; Suzuki, 2008]. 
Risk of PAP is anticipated to be low.
Non-clinical Data:
Non-adverse minimal to mild foamy alveolar 
macrophage accumulation were noted in lungs of 
Eligibility Criteria (Section 5.2):
Exclusion of participants with:

Any baseline symptomatology that in the 
investigator’s opinion would confound the 
early detection of PAP based upon clinical 
features, such as persistent cough (CTC 
Grade ≥2) or dyspnoea (dyspnoea scale 
Grade ≥2).
Monitoring:

Diagnosis of PAP, persistent cough (CTCAE 
Grade 2) or persistent dyspnoea (dyspnoea 
scale Grade 2) are categorised as AESIs.

Regular chest auscultation and pulse 
oximetry measurements.

Specific pulmonary assessments throughout 
the study with referral to a pulmonologist for 
clinically-significant pulmonary events.

Pulmonary Safety Guidance Document 
containing pulmonary assessment and 
management algorithms will be provided to 
the investigator.


2018N385734_02
CONFIDENTIAL
201790
22
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
monkeys in the 13-week SC and 26-week IV 
toxicology studies but were reversible following an off 
drug period.  Dose levels at which foamy alveolar 
macrophages were not observed were identified in 
these studies.
Clinical Data:
No cases of PAP have been reported to date in the 
clinical development program.  Pulmonary function 
tests have not identified any safety signals.

A Pulmonary Adjudication Panel consisting of 
external experts is available for adjudication 
of cases.
Withdrawal Criteria:
Temporarily discontinue study intervention for:

persistent cough (CTCAE Grade 2) or 
persistent dyspnoea (dyspnoea scale Grade 
2) for 3 consecutive weeks (21 days).
Permanently discontinue study intervention for:

Confirmed PAP
Hypersensitivity reactions
There is a potential risk of hypersensitivity reactions, 
including anaphylaxis, during and following the 
administration of protein-based products, such as 
GSK3196165.
Clinical Data:
No serious allergic or acute systemic reactions have 
been observed to date in the clinical development 
program.
Eligibility Criteria (Section 5.2):
Exclusion of participants with:

Significant allergies to humanised monoclonal 
antibodies.

Clinically significant multiple or severe drug 
allergies, or severe post-treatment 
hypersensitivity reactions

A history of sensitivity to any of the study 
interventions, or components thereof.
Monitoring:

Serious hypersensitivity reactions are 
categorised as AESIs.

Instructions to participants as to the signs and 
symptoms of an acute hypersensitivity 
reaction and to seek immediate medical care 
should they develop (also contained within 
the ICF)

Hypersensitivity to be managed appropriately 
per local guidelines/medical judgement


2018N385734_02
CONFIDENTIAL
201790
23
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy

All participants will be monitored for 1 hour 
after the first two exposures of GSK3196165 
(i.e. Weeks 0, 1, 12, and 13).
Withdrawal Criteria:

Permanently discontinue study intervention 
for serious hypersensitivity reactions
Injection site reactions
SC injections may be associated with local reactions 
(e.g., swelling, induration, pain).
Non-clinical Data:
No macroscopic or microscopic changes indicative of 
local injection site reactions were observed following 
SC administration in cynomolgus monkeys.
Clinical Data:
Injection site reactions have been reported in 
completed Phase II studies and were non-serious and 
of mild to moderate intensity.
Monitoring:

Injection site reactions are categorised as 
AESIs and reported as an AE.

Monitor for injection site reactions throughout 
study.

Recommended that injection sites are 
rotated.
Neutropenia
Although there is a perceived theoretical risk that GM-
CSF blockade may affect maturation of leukocytes 
and their precursors, mice lacking GM-CSF do not 
develop neutropenia or show any major perturbation 
of haematopoiesis [Stanley, 1994].
Clinical Data:
Neutropenia has been observed in completed studies 
of GSK3196165; however, no clinically significant 
cases have been observed.
Eligibility Criteria (Section 5.2):
Exclusion of participants with 

Significant neutropenia (absolute neutrophil 
count <1.0 x 109/L) at screening.
Monitoring:

Neutropenia Grade 3 (<1.0 x 109/L) is 
categorised as an AESI.

Full blood count (with differential) performed 
at regular intervals throughout the study
Withdrawal Criteria:
Temporarily discontinue study intervention for the 
following haematological abnormality until resolved 
(Section 7.1.3.3):

Absolute neutrophil count (ANC) ≤1.0 x 109/L
Permanently discontinue study intervention for the 


2018N385734_02
CONFIDENTIAL
201790
24
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
following haematological abnormality (Section 7.1.2):

ANC <0.5 x 109/L
Reproductive toxicity
Published studies performed with GM-CSF -/- mice 
have indicated that GM-CSF depletion potentially 
affects fertility, establishment of pregnancy and 
postpartum development of offspring in the mouse.
Non-clinical data
No GSK3196165-related effects on female or male 
fertility were noted in the SC 13-week repeat dose 
monkey study at doses up to 100 mg/kg/week (highest 
dose tested).  In addition, no maternal, embryofoetal 
or effects on fertility were noted in the reproductive 
toxicology studies using the surrogate rat anti-mouse 
GM-CSF monoclonal antibody, 22E9.
Clinical Data:
Two pregnancies have been reported during clinical 
studies with GSK3196165, 1 in a female partner of a 
HV participant and 1 in an MS participant. Both 
pregnancies were electively terminated. The effect of 
GSK3196165 on human pregnancy is unknown.
Eligibility Criteria (Section 5.1 and Section 5.2):

WOCBP and males to meet contraceptive 
requirements.

Negative serum pregnancy test at screening.
Exclusion of female participants who are:

Pregnant, lactating, planning to become 
pregnant or initiating breastfeeding.
Monitoring:

Females of reproductive potential using 
hormonal contraceptives, including oral, 
injections, implants, and patches, are required 
to use a secondary method of contraception.

Routine urine pregnancy testing of WOCBP 
throughout the study.

Collection of pregnancy information in 
females and in female partners of male 
participants.

Pregnancy to be followed to determine 
outcome.

Report as AE/SAE any pregnancy 
complication or elective termination.
Withdrawal criteria:

Permanently discontinue study intervention in 
event of pregnancy (Section 7.1.2).
Malignancy
Risk of malignancy is increased in RA and the 
immunomodulatory therapies may also increase the 
risk.
Non-clinical & Clinical Data:
There are no reports of malignancy in the non-clinical 
Eligibility Criteria (Section 5.2):
Exclusion of participants with:

Breast cancer within the past 10 years or 
lymphoma, leukaemia, or any other 


2018N385734_02
CONFIDENTIAL
201790
25
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
or clinical GSK3196165 program.
malignancy within the past 5 years except for 
cervical carcinoma in situ that has been 
resected with no evidence of recurrence or 
metastatic disease, or basal cell or squamous 
epithelial cancers of the skin that have been 
resected with no evidence of recurrence or 
metastatic disease for at least 3 years.

History of any lymphoproliferative disorder, 
such as Epstein Barr Virus (EBV) related 
lymphoproliferative disorder, or signs and 
symptoms suggestive of current lymphatic 
disease.
Immunogenicity
GSK3196165 is a humanised monoclonal antibody 
that will be delivered by the subcutaneous route and is 
targeted to bind and neutralise a soluble target, and 
for these reasons, is considered to be a relatively low 
risk of inducing adverse immune responses [FDA, 
2014].
Non-clinical Data:
Anti-drug antibodies (ADAs) to GSK3196165 were 
detected in some monkeys and this was associated 
with reduced serum levels of GSK3196165; ADA 
associated toxicity was not observed.
Clinical Data:
In clinical trials to date, there is no evidence that anti-
GSK3196165 antibodies affect GSK3196165 serum 
concentrations.
Blood samples will be tested for anti-drug antibodies 
(ADAs) to GSK3196165 on Day 1 and at select time 
points throughout the study (including Follow-up). If 
present, ADA titres and presence of neutralising 
antibodies will be assessed. 
In addition to scheduled immunogenicity assessments, 
“event-driven” testing will be performed in the context 
of serious hypersensitivity reactions or AEs deemed to 
be clinically significant in the opinion of the investigator 
resulting in discontinuation from study intervention.
Potential drug interaction with CYP450 substrates
Cytokines can produce concentration-dependent 
inhibition on various CYP isoforms at the transcription 
level or by alteration of CYP enzyme stability in 
patients with infection or inflammation and increase 

Information will be collected on concomitant 
warfarin use (e.g. INR results and any 
information related to warfarin dose).

Participants of reproductive potential using 


2018N385734_02
CONFIDENTIAL
201790
26
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
the plasma concentrations of specific CYP substrate 
drugs.
Cytokine modulators may reverse the apparent 
“inhibition” effect of the cytokines on CYP substrates, 
resulting in a “normalisation” of CYP activities. 
GSK3196165 is a cytokine modulator, so it has the 
potential to ‘normalise’ CYP expression from a 
suppressed state in patients with a pro-inflammatory 
disease (RA).
Clinical Data:
In a phase II study for GSK3196165, the ratio of 4β-
hydroxycholesterol to cholesterol was monitored as a 
biomarker predictive of change in CYP3A4 activity.
Based on the data, GSK3196165 showed no risk of 
alteration of CYP450 3A4 enzyme.
hormonal contraceptives, including oral, 
injections, implants, and patches are required 
to use a secondary method of contraception.

Participants receiving a concomitant CYP450 
substrate with narrow therapeutic index (e.g. 
theophylline) should be monitored for signs in 
changes in drug exposure.
Study Procedures
Placebo
Due to ethical considerations, placebo control will only 
be allowed until week 12, with all placebo participants 
being switched to one of the 3 active intervention 
arms (GSK3196165 90 mg, 150 mg or tofacitinib 5 mg 
BID) at their Week 12 visit. This will enable the study 
to generate controlled data in participants initially 
randomised to placebo.

Participants randomised to the placebo arm 
will switch at Week 12 to 1 of 3 active 
intervention arms (Section 4.1, Section 6.3).

Randomisation ratio of 6:6:3:1:1:1 will 
minimise the number of participants in the 
placebo arm (Section 1.1, Section 4.1, 
Section 6.1, Section 6.3).

Although background therapy with MTX is 
permitted, the participants have already failed 
MTX therapy.

Changes in background medication are not 
permitted unless required for safety and any 
dose adjustments must be documented.


2018N385734_02
CONFIDENTIAL
201790
27
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy

Participants are permitted to receive a stable 
dose of ≤10 mg/day oral prednisolone or 
equivalent and/or a stable dose of NSAID(s).
Blood draws
Venous access in some participants may be 
problematic and the needles used may cause bruising 
(ecchymosis) around the access site.

A maximum of approximately 450 mL of 
whole blood will be collected over the course 
of the study. 

At visits to collect whole blood samples, one 
or more samples of sufficient volume will be 
collected and divided into suitable portions for 
the various analyses such as PD biomarkers.

Whole blood samples for genetic research will 
only be collected from those consenting to 
participate in this research 

Whole blood samples will be collected by site 
personnel experienced in phlebotomy.
Chest X-ray
Generally, the amount of radiation during an X-ray is 
equivalent to between a few days and a few years of 
exposure to natural radiation from the environment. 
The risk of cancer from exposure to X-rays is very 
small.

Minimal procedures performed at Screening 
and end of treatment phase (Week 52).

No requirement for screening X-ray if one 
was performed within the previous 12 weeks.

Exposure to radiation from X-rays is far less 
than the exposure to natural radiation.
X-rays of the hands/feet
Structural joint damage evaluation by X–rays (van der 
Heijde modified total Sharp scores mTSS) is an 
established endpoint that is accepted in the US and 
EMA regulatory guidelines to demonstrate prevention 
of joint damage.  Tofacitinib prevents structural joint 
damage and this study aims to establish if structural 
bone damage does or does not deteriorate after 
treatment with GSK3196165.

Minimal procedures performed at Screening 
and 3 times post-randomisation (Weeks 12, 
24 and 52) to assess structural joint damage

Exposure to radiation from X-rays is far less 
than the exposure to natural radiation.

A repeat X-ray is not required for participants 
who are re-screened, only if re-screening is 
within 4 weeks of original screening X-ray.

Positioning devices will be used to minimise 


2018N385734_02
CONFIDENTIAL
201790
28
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
the risk of repeat X-ray
Study Medical Devices
Handling and usage risks associated with the prefilled 
syringe devices.
A life-threatening serious risk has been identified that 
is caused by the participant removing the rigid needle 
shield with their teeth and choking on the small part. 
This risk is considered improbable and non-intuitive, it 
has not been observed in human factors studies for 
this patient group and is not precedented with other 
GSK products using the same devices.
All other anticipated device effects are non-serious 
and primarily unlikely, improbable, occasional or 
remote and are due to user error.
Instructions For Use (IFU) on how to correctly handle 
and use the device is provided.
Other
Tofacitinib
Serious infections, malignancies and serious cases of 
thrombosis including pulmonary embolism, deep vein 
thrombosis, and arterial thrombosis have been 
reported with tofacitinib.
An interim analysis from a post marketing safety study
evaluating tofacitinib 5 and 10 mg twice daily 
compared to TNF inhibitors in RA patients who were 
50 years of age and older and had at least one 
cardiovascular risk factor showed that tofacitinib in a 
dose dependent fashion was associated with:  1) 
higher all-cause mortality and 2) increased risk of VTE 
and serious infections. of. Tofacitinib should be used 
with caution in patients who have known risk factors 
See GSK3196165 above for serious infections, 
malignancies and laboratory changes.
Eligibility criteria (Section 5.2):
Exclusion of participants with:

Any condition or contraindication as 
addressed in the local product information or 
local clinical practice for tofacitinib that would 
preclude the participant from participating in 
this protocol.  For all participants, 
investigators should carefully review potential 
risk factors related to VTE, including deep 
vein thrombosis (DVT) and pulmonary 
embolism (PE) and review the risk of infection 
in participants older than 65 years of age.

Evidence of untreated latent TB (unless 


2018N385734_02
CONFIDENTIAL
201790
29
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
for VTE, regardless of indication and dosage. 
There is a higher incidence of serious and fatal 
infections in patients over 65 years of age.  Patients 
should be monitored for signs of serious infection 
including active TB even if the initial latent 
tuberculosis test is negative.
Increases in lipid parameters including total 
cholesterol, low-density lipoprotein (LDL) cholesterol, 
and high-density lipoprotein (HDL) cholesterol have 
been noted in clinical studies with tofacitinib with 
maximal effects within 6 weeks. The effect of these 
lipid parameter elevations on cardiovascular morbidity 
and mortality has not been determined.
GI perforations have been reported in clinical studies 
with tofacitinib in RA, although the role of JAK 
inhibition in these events is not known. Tofacitinib 
should be used with caution in patients at increased 
risk of GI perforations.
willing to undergo TB therapy or have 
successfully undergone TB therapy).

Current or previous active TB regardless of 
treatment.

Previous close contact with a person with 
active TB and did not receive satisfactory 
anti-tuberculosis treatment.

Rare hereditary problems of galactose 
intolerance, the Lapp lactase deficiency or 
glucose-galactose malabsorption.
Monitoring:
As above for GSK3196165

Laboratory tests to assess potential changes 
in lymphocytes, neutrophils, haemoglobin, 
liver enzymes and lipids. Participants should 
be managed according to clinical 
guidelines/standard of care for the 
management of hyperlipidaemia.

TB evaluation at screening and monitoring for 
TB and TB re-activation throughout the study 
(Section 8.2.7.4).

Participants diagnosed with latent TB during 
screening will need to complete a course of at 
least 6 months of INH therapy during the 
study including at least 4 weeks of therapy 
prior to randomisation (Section 8.2.7.3).

Participants with signs and symptoms of VTE 
should be promptly evaluated.

All potential events of GI perforation will be 
adjudicated.


2018N385734_02
CONFIDENTIAL
201790
30
Potential Risk of Clinical Significance
Summary of Data/Rationale for Risk
Mitigation Strategy
Withdrawal:
In addition to the above for GSK3196165:

Temporarily discontinue study intervention in 
the event of serious or opportunistic infection 
or sepsis develops. Do not restart until 
infection has resolved.

Permanently discontinue study intervention in 
event of venous thromboembolism, including 
PE and DVT, requiring anticoagulation 
(Section 7.1.2).


2018N385734_02
CONFIDENTIAL
201790
31
2.3.2.
Benefit Assessment
GM-CSF plays a key role in initiation and progression of inflammation in RA and 
indirectly increases the destruction of the bone and cartilage.  GSK3196165 binds human 
GM-CSF and inhibits GM-CSF mediated responses in vitro.  Clinical studies in RA have 
shown that GSK3196165 [Behrens, 2015] and mavrilimumab (an anti-GM-CSF alpha-
subunit receptor antibody) [Burmester, 2017, Burmester, 2018; Cook 2018b] were able to 
reduce RA disease activity and pain.  In addition, results from BAROQUE showed that 
all doses of GSK3196165 above 22.5 mg in combination with MTX resulted in a 
significant reduction in DAS28(CRP), significantly higher ACR20 response rates, 
substantial improvements in tender and swollen joint counts, a large effect in CDAI and 
rapid improvements in pain with an acceptable safety profile when compared with 
placebo. These data support further evaluation of GSK3196165 as a treatment option in 
RA.
Participants randomised to the active comparator arm, will receive the marketed drug 
tofacitinib, which is approved globally for the treatment of adults with moderately to 
severely active RA.  Participants randomised to one of the placebo arms, will receive 
placebo intervention only for 12 weeks, and will switch at Week 12 to receiving either 
GSK3196165 or active comparator for the remainder of the study.
Furthermore, each participant will benefit from extensive monitoring of their disease 
activity with numerous assessments throughout the study such as physical examinations, 
X-rays, ECGs, vital signs, pulse oximetry, respiratory function tests, laboratory tests, and 
swollen/tender joint assessments among others.
2.3.3.
Overall Benefit: Risk Conclusion
Current preclinical and clinical data with GSK3196165 indicates that it binds and inhibits 
the function of GM-CSF and that this inhibition may have clinical utility in the treatment 
of inflammatory and autoimmune diseases, such as RA. 
The main potential risks are those that may be associated with inhibition of GM-CSF, 
including infection, pulmonary alveolar proteinosis, neutropenia, malignancy and 
reproductive toxicity, plus those associated with the administration of a therapeutic 
monoclonal antibody, including hypersensitivity reactions, injection site reactions and 
immunogenicity.
In addition to routine pharmacovigilance, the safety review team (SRT) will review 
blinded safety data approximately every 4 weeks during the period of study conduct and 
unblinded safety data will be reviewed by the Independent Data Monitoring Committee 
(IDMC) at scheduled intervals (see Section 10.1.5).  Key safety data that meets 
predefined thresholds will be reviewed by the IDMC allowing ongoing assessment of the 
overall benefit:risk throughout the study.  Full details of safety thresholds will be 
provided in the IDMC charter.
Taking into account the measures taken to minimise risk to participants randomised in 
this study, the potential risks identified in association with GSK3196165 are justified by 
the anticipated benefits that may be afforded to participants with RA.


2018N385734_02
CONFIDENTIAL
201790
32
3.
OBJECTIVES AND ENDPOINTS
Objectives
Endpoints
Primary

To compare the efficacy of GSK3196165 at 
doses of 90 mg and 150 mg weekly versus 
placebo for the treatment of participants 
with moderately to severely active RA who 
are on a stable background of MTX and 
who have had an inadequate response to 
MTX.

Proportion of participants achieving ACR20 
at Week 12.
Secondary
To compare:

Efficacy of GSK3196165 at doses of 90 
mg and 150 mg weekly versus tofacitinib 
for the treatment of participants with 
moderately to severely active RA who are 
on a stable background of MTX and who 
have had an inadequate response to 
MTX.
Major Secondary Efficacy Endpoints
Week 12 versus placebo:

Proportion of participants achieving CDAI 
total score ≤10 (CDAI LDA).

Change from baseline in HAQ-DI.
Non-inferiority versus tofacitinib at Week 12: 

Proportion of participants achieving 
ACR20.
Other Secondary Efficacy Endpoints
Week 12 (vs. placebo and vs. tofacitinib), 
Week 24 and Week 52 (vs. tofacitinib): 
Proportion of participants achieving:

CDAI total score ≤10 (CDAI LDA).

CDAI total score ≤2.8 (CDAI Remission).

ACR20/50/70.

DAS28-CRP ≤3.2 and DAS28(ESR) ≤3.2
(DAS28 LDA).

DAS28-CRP <2.6 and DAS28(ESR) <2.6
(DAS28 Remission).

A good/moderate EULAR response.

ACR/EULAR Remission.

No radiographic progression defined as a 
change from baseline in van der Heijde 
mTSS score of ≤0.5.
Change from baseline in: 

CDAI total score.

DAS28-CRP/DAS28-ESR.

van der Heijde mTSS.

Effect of GSK3196165 on Patient 
Reported Outcomes (PROs) versus 
placebo and the active comparator 
Change from baseline at Week 12 (vs. placebo 
and vs. tofacitinib), Week 24 and Week 52 (vs. 
tofacitinib) in:

HAQ-DI.


2018N385734_02
CONFIDENTIAL
201790
33
Objectives
Endpoints
tofacitinib

Arthritis pain VAS.

SF-36 physical and mental component 
scores, and domain scores.

FACIT-Fatigue.

Safety and tolerability of GSK3196165 
versus placebo and the active comparator 
tofacitinib

Incidence of AEs, SAEs and AESIs.

Change from baseline in key laboratory 
parameters at Weeks 12, 24 and 52.

Proportion of participants with NCI-CTCAE 
≥Grade 3 [NCI, 2017] 
haematological/clinical chemistry 
abnormalities.

To determine the immunogenic potential of 
GSK3196165
Safety Biomarker Endpoints

GM-CSF autoantibody concentrations.

Anti-GSK3196165 antibodies.
MTX = methotrexate; ACR2050/70 = 20%/50%/70% improvement in American College of Rheumatology criteria; 
CDAI = clinical disease activity index; HAQ-DI = health assessment questionnaire disability index; VAS = visual 
analogue scale; LDA = low disease activity; DAS28 = disease activity score including 28 different joints; CRP = C-
CCI


2018N385734_02
CONFIDENTIAL
201790
34
reactive protein; EULAR = European league against rheumatism; ESR = erythrocyte sedimentation rate; mTSS = 
modified total sharp score; AEs = adverse events; SAEs = serious adverse events; AESIs = adverse events of 
special interest; NCI-CTCAE = National Cancer Institute-common terminology criteria for adverse events; RNA = 
ribonucleic acid; SF-36 = short form-36; FACIT = functional assessment of chronic illness therapy; RA = rheumatoid 
arthritis; GM-CSF = granulocyte-macrophage colony stimulating factor; 
 
; 
4.
STUDY DESIGN
4.1.
Overall Design

This is a Phase 3, randomised, multicentre, double-blind, parallel group, placebo 
and active comparator (tofacitinib) controlled study, with primary objective to 
assess the efficacy and safety of GSK3196165 in combination with MTX in 
participants with moderately to severely active RA, who have an inadequate 
response to MTX.

This is a 52-week study with the primary endpoint at Week 12 to coincide with 
the duration of placebo intervention.

This study includes X-rays of the hands and feet to assess radiographic 
progression of structural joint damage. 

Upon successful screening, participants will be randomised to one of six 
intervention arms in a ratio of 6:6:3:1:1:1 to GSK3196165 150 mg SC weekly, 
GSK3196165 90 mg SC weekly, tofacitinib capsules 5 mg BID or placebo (three 
arms) respectively, all in combination with MTX.  At Week 12, participants in the 
three placebo arms will switch from placebo to active intervention (either 
GSK3196165 150 mg SC weekly, GSK3196165 90 mg SC weekly, or tofacitinib 
capsules 5 mg BID).

To maintain the blind, all participants will receive capsules BID and weekly SC 
injections.  A double dummy approach will be followed with matching placebo 
capsules to tofacitinib, and either weekly SC dosing of GSK3196165 and placebo 
to GSK3196165 by an unblinded administrator or by the use of matching pre-
filled syringes of GSK3196165 and GSK3196165 placebo.

Due to ethical considerations, placebo control will only be allowed until Week 12.  
At their Week 12 visit, participants in the three placebo arms will switch to 
receiving the active intervention specified for that arm.  This will enable placebo 
participants to receive active intervention from Week 12 onwards and for the 
study to accrue additional randomised safety data.

Participants who successfully complete the 52 week treatment period may be 
eligible to transition into the long-term extension study 209564.  Any participant 
who does not transition into Study 209564 will undergo a safety follow-up visit at 
8 weeks post last dose of SC study intervention.
CCI
CCI
CCI


2018N385734_02
CONFIDENTIAL
201790
35

Participants who transition into the long-term extension study 209564, will be 
instructed to take their last capsule of oral study intervention no later than 6pm
on the evening before their Week 52 visit.
4.2.
Scientific Rationale for Study Design
This study is a placebo-controlled, tofacitinib-controlled, parallel-dose study of SC doses 
of GSK3196165 added on to a stable dose of MTX.  Participants will be allowed to 
receive a stable dose of ≤10 mg/day oral prednisolone or equivalent and/or a stable dose 
of NSAID(s).
The double-blind, placebo-controlled, randomised clinical study is considered the gold 
standard for the safety and efficacy assessment of a new therapy both by clinicians and 
regulatory authorities.  Control with a comparator, tofacitinib, will also comply with 
recent guidelines from regulatory authorities and help further establish the safety and 
efficacy in comparison with an established targeted synthetic disease-modifying 
antirheumatic drug (tsDMARD).  In the proposed study, participants will continue to 
receive a stable dose of MTX.  Participants are not allowed to receive any additional 
biologic DMARDs (bDMARDs) other than GSK3196165 or any other additional JAK 
inhibitor other than tofacitinib during the study, to mitigate the potential increased safety 
risks of administering a combination of bDMARDs, or a combination of a bDMARD and 
a JAK inhibitor, or a combination of JAK inhibitors.
Efficacy and safety of GSK3196165 will be compared with placebo (until Week 12) and 
an established active comparator (until Week 52), tofacitinib which is approved globally 
for the treatment of RA in participants inadequately controlled with MTX.
ACR20 is considered an established endpoint which continues to be an acceptable 
measure to demonstrate reduction in disease activity as recommended in the US 
regulatory guidelines.
Health Assessment Questionnaire Disability Index (HAQ-DI) is considered an 
established endpoint to demonstrate improvement in physical function as recommended 
in the US and EU regulatory guidelines.
The prevention of structural joint damage will be assessed via X-rays using change from 
baseline in van der Heijde modified total Sharp scores (mTSS), which is the only 
currently accepted approach by regulatory agencies.  Data from the placebo control and 
comparative data from tofacitinib, which has established efficacy in the prevention of 
structural damage, will also be analysed to ascertain how the effects with GSK3196165 
compare with tofacitinib.
4.3.
Justification for Dose
GSK3196165
The GSK3196165 doses for this study have been selected based on pharmacokinetics 
(PK), efficacy, safety data, exposure-response and dose-response relationships for 
efficacy endpoints from the phase 2b dose finding BAROQUE (201755) study.


2018N385734_02
CONFIDENTIAL
201790
36
The BAROQUE study showed an acceptable safety profile and clinically meaningful 
efficacy at the highest dose of 180 mg SC weekly for 5 injections, then every other week 
until Week 50.  The efficacy however started to plateau after Week 6 with no further 
improvement post Week 12.  This effect is likely due to lower trough concentrations 
achieved in BAROQUE than predicted from PK data from historic studies (MSC-1000, 
MSC1001 and MOR103C104).  The reason for the lower than expected exposure to 
GSK3196165 in RA participants in BAROQUE is being investigated.  The PK of 
GSK3196165 was linear over the tested dose range (IV; 0.025 – 3 mg/kg and SC; 22.5 –
180 mg), which is consistent with the PK profile of a mAb against soluble cytokine [GSK 
Document Number 2017N353526_00].  However, GSK3196165 clearance in healthy 
volunteers (HV) was 3 times higher (0.93, confidence interval [CI]: 0.83 – 1.04 L/day) 
than generally reported for a mAb (0.3 L/day) and the half-life (t1/2) of 12 days was 
shorter than a typical mAb.  In addition, the SC bioavailability (0.34, CI: 0.26 – 0.44) was 
lower than expected for a mAb.  In RA participants, the apparent clearance (CL/F) after 
SC administration of GSK3196165 was 2.4 times higher than HV and the estimated t1/2 
was 10 days. 
In this study, the dosing frequency will be increased to every week to overcome the 
higher CL/F and lower t1/2 of 10 days.  The GM-CSF-GSK3196165 complex data from 
BAROQUE also supports weekly administration as an optimal dosing regimen for 
GSK3196165.  This dosing frequency with a 90 and 150 mg dose is predicted to result in 
steady-state pre-dose concentrations of 1500 and 2500 ng/mL, respectively.  Based on a 
longitudinal exposure-response model of DAS28(CRP), a dose of 90 mg SC every week 
is predicted to provide clinically meaningful efficacy similar to the 180 mg regimen in 
the BAROQUE study and in line with other RA targeted DMARDs, whilst 150 mg SC 
every week dose is predicted to provide greater efficacy to that achieved in BAROQUE.
Figure 1
Comparison of PK/PD Model Predicted Median Change from 
Baseline in DAS28(CRP) given 3 Dose Regimens of GSK3196165: 
180 mg Weekly for 5 Weeks Followed by Every Other Week 
(BAROQUE Regimen), 90 mg Weekly and 150 mg Weekly


2018N385734_02
CONFIDENTIAL
201790
37
Based on dose-response relationship at Week 4 (matching the weekly dose regimen to be 
used in this study) the 90 mg and 150 mg doses translate into a ED70 and ED80 
respectively.  Logistic regression analysis of ACR20 and ACR50 response at Week 12, 
also indicated higher trough concentrations are associated with a higher response rate.  
The predicted ACR20 response rate for the 90 mg and 150 mg weekly doses are 63% and 
69%, respectively.
Furthermore, the safety profile of GSK3196165 in BAROQUE was acceptable at all 
doses with no apparent dose response in the incidence of AEs or SAEs.  More details are 
provided in the GSK3196165 IB.
Given the GSK3196165 half-life of 10 days, steady-state is expected to be reached after 5 
weekly doses (as in BAROQUE), therefore GSK3196165 concentrations with the 150 mg 
every week dosing regimen should not exceed concentrations studied in BAROQUE.  
The highest dose of 150 mg weekly provides a 3 to 5-fold safety margin to the 5 mg/kg 
dose in the 26-week monkey toxicology study where no foamy alveolar macrophages 
were observed (NOEL).
In summary, PK, exposure-response, dose-response and safety data from the BAROQUE 
study, supported by modelling strongly support the selection of the 90 mg and 150 mg 
weekly doses, where 90 mg is expected to provide clinically-meaningful efficacy at 
levels similar to BAROQUE and existing targeted DMARDs, and 150 mg is predicted to 
provide greater clinical benefit.  Both doses are also covered by an appropriate safety 
margin.
Tofacitinib
The tofacitinib dose has been selected based on the recommended approved dose (5 mg 
BID) in the countries where the study is intended to be executed.
4.4.
End of Study Definition
A participant is considered to have completed the study if he/she has completed all 
phases of the study including the last visit.  This will be the Week 52 visit for those 
participants who transition into the long-term follow-up study or the safety follow-up 
visit for all other participants.
The end of the study is defined as the date of the last visit of the last participant in the 
study.
5.
STUDY POPULATION
Prospective approval of protocol deviations to recruitment and enrolment criteria, also 
known as protocol waivers or exemptions, is not permitted.
Investigators should review and update the vaccination status of potential participants as 
per local guidelines for adult vaccination prior to entering them into the study (refer to 
EULAR recommendations where no local guidelines are available [Furer, 2019]), with 
particular attention to the vaccination status of participants over 65 years of age.  All


2018N385734_02
CONFIDENTIAL
201790
38
participants who have not received the herpes zoster vaccine at study entry will be 
recommended to complete vaccination >30 days prior to randomisation.  All participants 
may receive inactivated flu vaccines during the study at the discretion of the investigator.
Note that “Inadequate response” to prior treatment in this population, is defined as: In the 
opinion of the investigator, after at least 3 months of treatment the participant 
experienced insufficient efficacy or loss of response (e.g. no EULAR response; failure to 
achieve ACR20; any other clinical criteria recommended per local guidelines that would 
trigger a change of treatment), or the participant discontinued treatment due to 
intolerability or toxicity irrespective of treatment duration.
5.1.
Inclusion Criteria
Participants are eligible to be included in the study only if all of the following criteria 
apply:
AGE
1. Age ≥18 years at the time of signing informed consent.
TYPE OF PARTICIPANT AND DISEASE CHARACTERISTICS
2. Meets ACR/EULAR 2010 RA Classification Criteria (see study reference manual 
[SRM]) with a duration of RA disease of ≥6 months at time of screening and 
participant not diagnosed before 16 years of age.
3. Must have active disease at both screening and baseline, as defined by having both:
a.
≥6/68 tender/painful joints (TJC), and
b. ≥6/66 swollen joints (SJC).
If surgical treatment of a joint has been performed, that joint cannot be 
counted in the TJC or SJC for enrolment purposes
4. Must have a high sensitivity C-reactive protein (hsCRP) measurement ≥3 mg/L at 
screening.
5. Must meet Class I, II or III of the ACR 1991 Revised Criteria for Global Functional 
Status in RA (see SRM). 
6. Must have at least 1 bone erosion present on hand/wrist or foot radiographs confirmed 
by central reading at screening.
7. Must have inadequate response, despite currently taking Methotrexate (MTX): 
weekly 15-25 mg oral or injected, for at least 12 weeks at the maximum tolerated 
dose prior to Day 1, with no change in route of administration in this time.  MTX 
dose must be stable and tolerated for at least 8 weeks prior to Day 1.  A lower dose of 
≥7.5 mg/week is acceptable if reduced for reasons of intolerance to MTX, e.g. 
nausea/vomiting, hepatic or hematologic toxicity, or per local requirement (there must 
be clear documentation in the medical record).  Exception: A lower dose of 6 
mg/week is allowed if the minimum locally approved or recommended dose is lower 
than 7.5 mg/week.


2018N385734_02
CONFIDENTIAL
201790
39
WEIGHT
8. Body weight 40 kg
SEX
9. Male or female participants are eligible to participate so long as they meet and agree 
to abide by the contraceptive criteria detailed in Appendix 4.
INFORMED CONSENT
10. Capable of giving signed informed consent which includes compliance with the 
requirements and restrictions listed in the informed consent form (ICF) and in this 
protocol.
OTHER SAFETY-RELATED
11. Willing to continue or initiate treatment with oral folic acid (at least 5 mg/week) or 
equivalent and be treated during the entire study (mandatory co-medication for MTX 
treatment).
5.2.
Exclusion Criteria
A participant will not be eligible for inclusion in this study if any of the following criteria 
apply:
MEDICAL CONDITIONS
1. Active infections (including localised infections), or history of recurrent infections 
(excluding recurrent fungal infections of the nail bed), or has required management of 
acute or chronic infections, as follows:

Currently taking any suppressive anti-infective therapy for a chronic infection 
(such as pneumocystis, cytomegalovirus, herpes simplex virus, herpes zoster 
and atypical mycobacteria) OR

Hospitalisation for treatment of infection within 26 weeks of Day 1 OR

Use of parenteral (IV) or intramuscular (IM) antimicrobials (antibacterials, 
antivirals, antifungals, or antiparasitic agents) within 26 weeks of Day 1 or 
oral antimicrobials (apart from INH use for latent TB treatment) within 
14 days of Day 1.
2. Symptomatic herpes zoster within 3 months prior to screening.
3. Hereditary or acquired immunodeficiency disorder, including immunoglobulin 
deficiency.
4. Known infection with human immunodeficiency virus (HIV) or positive test at 
screening.
5. History of infected joint prosthesis at any time, with the prosthesis still in situ.  


2018N385734_02
CONFIDENTIAL
201790
40
History of chronic leg ulcers, permanent in-dwelling catheters, chronic sinusitis, 
recurrent chest infections or recurrent urinary tract infections.
6. Any baseline symptomatology that in the investigator’s opinion would confound the 
early detection of pulmonary alveolar proteinosis based upon clinical features, such as 
persistent cough (CTC Grade ≥2) or persistent dyspnoea (dyspnoea scale Grade ≥2).
7. Current unstable liver or biliary disease per investigator assessment defined by the 
presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal 
or gastric varices, persistent jaundice, or cirrhosis.
8. Current acute or chronic Hepatitis B and/or Hepatitis C.
9. Current or history of renal disease or estimated glomerular filtration rate (eGFR) by 
Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI) 
calculation <60 mL/min/1.73m2 at screening.
10. Breast cancer within the past 10 years or lymphoma, leukaemia, or any other 
malignancy within the past 5 years except for cervical carcinoma in situ that has been 
resected with no evidence of recurrence or metastatic disease, or basal cell or 
squamous epithelial cancers of the skin that have been resected with no evidence of 
recurrence or metastatic disease for at least 3 years.
11. History of any lymphoproliferative disorder, such as Epstein Barr Virus (EBV)
related lymphoproliferative disorder, or signs and symptoms suggestive of current 
lymphatic disease.
12. History or presence of significant other concomitant illness according to the 
Investigator judgment such as, but not limited to cardiovascular (including Stage III 
or IV cardiac failure according to New York Heart Association classification, 
myocardial infarction within 3 months, unstable angina pectoris, uncontrolled 
hypertension, uncontrolled hypercholesterolemia, uncontrolled diabetes mellitus, 
VTE requiring anticoagulation), neurological, endocrinological, gastrointestinal 
(including diverticulitis), hepatic disease, metabolic, lymphatic disease, or previous 
renal transplant that would adversely affect the participant’s participation in this 
study.
13. Any condition or contraindication as addressed in the local product information or 
local clinical practice for tofacitinib that would preclude the participant from 
participating in this protocol.  For all participants, investigators should carefully 
review potential risk factors related to VTE, including deep vein thrombosis (DVT) 
and pulmonary embolism (PE) and review the risk of infection in participants older 
than 65 years of age.  Refer to the risk table for tofacitinib in Section 2.3.1.
14. History of other inflammatory rheumatologic or systemic autoimmune disorder, other 
than Sjögren’s syndrome secondary to RA, that may confound the evaluation of the 
effect of the study intervention such as mixed connective tissue disease, psoriatic 
arthritis, juvenile chronic arthritis, spondyloarthritis, Felty’s Syndrome, systemic 
lupus erythematosus, scleroderma, Crohn’s disease, ulcerative colitis, or vasculitis. 
15. Presence of fibromyalgia that, in the investigator’s opinion, would make it difficult to 
appropriately assess RA activity for the purposes of this study.
16. Undergone any major surgery within 8 weeks prior to study entry or will require 


2018N385734_02
CONFIDENTIAL
201790
41
major surgery during the study that, in the opinion of the investigator in consultation 
with the medical monitor, would pose an unacceptable risk to the participant.
17. Current or previous active Mycobacterium tuberculosis (TB) regardless of treatment.
18. Evidence of latent TB (as documented by a positive QuantiFERON-TB Gold plus test 
or T-SPOT.TB test at screening, no findings on medical history or clinical 
examination consistent with active TB, and a normal chest radiograph) except for 
participants that either:

Are willing to complete at least 4 weeks of anti-TB therapy as per WHO or 
national guidelines prior to randomisation and agree to complete the 
remainder of treatment while in the study OR

Are documented as having evidence of satisfactory anti-TB treatment as per 
WHO or national guidelines within the last 5 years following review by a 
physician specialising in TB.
19. Previous close contact with a person with active TB and did not receive satisfactory 
anti-tuberculosis treatment as per WHO or national guidelines.
20. Significant allergies to humanised monoclonal antibodies. 
21. Clinically significant multiple or severe drug allergies or severe post-treatment 
hypersensitivity reactions (including, but not limited to, erythema multiforme major, 
linear immunoglobulin A [IgA] dermatosis, toxic epidermal necrolysis, and 
exfoliative dermatitis).
22. Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or 
glucose-galactose malabsorption.
PRIOR/CONCOMITANT THERAPY 
23. Any prior treatment antagonising GM-CSF or its receptor.
24. Any prior treatment with Janus Kinase (JAK) inhibitor(s) (either experimental or 
approved) including, but not limited to tofacitinib, baricitinib, upadacitinib, filgotinib 
and peficitinib.
25. Any prior treatment with a biologic DMARD (either experimental or approved) 
which has been discontinued due to an inadequate response.
26. Participants who are expected to be non-compliant with restrictions on medications 
and vaccinations prior to the study, during the study or during the 8-week safety 
follow-up of the study.  See Table 3 in Section 6.5.2 for details of prohibited 
medications/treatments and Table 2 in Section 6.5.1 for details of permitted 
medications/treatments.
PRIOR/CONCURRENT CLINICAL STUDY EXPERIENCE
27. Current enrolment or past participation within the last 42 days before randomisation 
in any other clinical study involving an investigational study treatment or any other 
type of medical research.


2018N385734_02
CONFIDENTIAL
201790
42
DIAGNOSTIC ASSESSMENTS
28. Alanine transferase (ALT) or aspartate transaminase (AST) >1.5 x upper limit of 
normal (ULN).
29. Bilirubin >1.5 x ULN (isolated bilirubin >1.5 x ULN is acceptable if bilirubin is 
fractionated and direct bilirubin <35%).
30. Has a positive test for hepatitis B (HBV) defined as either:

positive for hepatitis B surface antigen (HBsAg) or

positive for hepatitis B core antibody (HBcAb) and positive for HBV 
deoxyribonucleic acid (DNA).
31. Positive test for hepatitis C antibody at screening. Participants with positive Hepatitis 
C antibody due to prior resolved disease can be enrolled, only if a confirmatory 
negative hepatitis C RNA test is obtained.
32. Haemoglobin ≤9 g/dL; white blood cell (WBC) count ≤3.0 x 109/L; platelet count 
≤100 x 109/L; absolute neutrophil count (ANC) <1.0 x 109/L; lymphocyte count 
≤0.75 x 109/L at screening.
33. Abnormal chest radiograph within 12 weeks of screening judged by the investigator 
as clinically-significant.
OTHER EXCLUSIONS
34. Pregnant or lactating, or women planning to become pregnant or initiating 
breastfeeding.
35. Current drug or alcohol abuse or dependence, or a history of drug or alcohol abuse or 
dependence within a year prior to Day 1. 
36. History of sensitivity to any of the study treatments, or components thereof or a 
history of drug or other allergy that, in the opinion of the investigator or Medical 
Monitor, contraindicates their participation.
5.3.
Lifestyle Considerations
5.3.1.
Dietary Restrictions
Participants must refrain from consumption of grapefruit and grapefruit juice from 5 days 
before the start of study intervention until after the final assessment visit.
5.4.
Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study 
but are not subsequently randomised.  A minimal set of screen failure information is 
required to ensure transparent reporting of screen failure participants to meet the 
Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities.  Minimal information includes 
demography, screen failure details, eligibility criteria, and any serious adverse events 
(SAEs).


2018N385734_02
CONFIDENTIAL
201790
43
Individuals who do not meet the criteria for participation in this study (screen failure) 
may be rescreened once with the agreement of the Medical Monitor.  The entire 
screening process must be repeated (except for the chest X-ray if performed within 12 
weeks of the re-screening period, and hands and feet x-ray, if the original screening 
hands/feet x-ray was performed within 4 weeks of the re-screening period and passed 
central reading). 
A QuantiFERON-TB Gold plus test may be repeated once during screening if the initial 
result is indeterminate, alternatively a T-Spot test may be used following an 
indeterminate result.  This is not considered a rescreening.  If the repeat test is positive or 
indeterminate, the participant will be considered to have active or latent TB.
For those participants requiring Isoniazid (INH) therapy for latent TB, LFTs must be 
assessed following 3 weeks of INH treatment in screening.  Participants will fail 
screening if ALT >1.5 x ULN is identified; these participants may be re-screened if ALT 
elevation resolves to ALT <1.5 x ULN during ongoing INH therapy following discussion 
with the medical monitor.
If a participant fails any of the laboratory exclusion criteria, the test may be repeated once 
within the screening period.  If the participant fails the laboratory criteria for a second 
time, they will be considered a screen failure.
Retesting within screening window of any blood sample withdrawn due to sample 
handling problems, breakage or sample integrity is not considered a rescreening. 
Further details regarding the procedure for re-screening can be found in the SRM.
6.
STUDY INTERVENTION
Study intervention is defined as any investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study participant according 
to the study protocol.
6.1.
Study Intervention(s) Administered
An overview of the study interventions is provided in Table 1.  Investigators should note 
the following:

Study SC injection should be administered weekly, on the same day each week.  
The weekly SC injections of study intervention should rotate between the thighs 
and abdomen.

Study oral capsules should be taken twice daily (one in morning, one in evening).

A window of 2 days is acceptable for the SC injection (minimum gap of 5 days 
between each dose, for no more than 2 consecutive doses).  Participants should 
return to their 7 day dosing schedule as soon as possible thereafter.

Participants must receive their SC injection at the site and be monitored for 
general safety for 1 hour after the injection at Weeks 0, 1, 12, and 13; the safety 


2018N385734_02
CONFIDENTIAL
201790
44
monitoring at Weeks 12 and 13 is due to the switch of the placebo participants to 
active intervention at the Week 12 visit.  Safety monitoring will include 
monitoring for systemic hypersensitivity and local injection site reactions.

Until such time as GSK3196165 becomes available in a pre-filled syringe, every 
SC injection must be delivered by an unblinded administrator and the syringe 
must be shielded from the participant at all times, to avoid unblinding.

If/when GSK3196165 becomes available in a pre-filled syringe, participants may 
be permitted to receive some of their SC injections at home; in this case, the 
investigator should first ensure the participant (or caregiver) is able to correctly 
administer the injection from PFS.  PFS for home dosing will be dispensed every 
4 weeks as a 4-week supply.  Any participant who doses at home must be 
instructed to contact the site immediately if they experience any symptoms 
following dosing.

Where possible, assessment visits should be scheduled to coincide with the 
weekly administration of study SC injection, the injection will then be 
performed at the site, after completion of PK sampling (see Section 1.3).

Participants who are initially dosed with SC injections of study intervention 
supplied from vials, should continue to be dosed from the vials until at least Week 
12 to coincide with the timing of the primary endpoint unless this is impractical 
due to supply issues; these participants may be switched to SC injections from the 
pre-filled syringes after Week 12, if sufficient supply is available.

Participants who are initially dosed with SC injections of study intervention from 
the pre-filled syringes should continue to be dosed in this manner for the duration 
of the study providing sufficient supplies are available.

Participants who transition into the long-term extension study 209564, will 
receive their last weekly SC injection at Week 51 and will be instructed to take 
their last capsule of oral study intervention no later than 6pm on the evening 
before their Week 52 visit.
In parallel to receiving study intervention, all participants will receive a stable dose of 
background MTX and ≥5 mg/week folic (or folinic) acid orally (dosing regimen at the 
discretion of the investigator).  Dose modifications to background MTX therapy are
discussed in Section 6.6.2.
All local standard-of-care practices for the administration of MTX, including laboratory 
testing, follow-up care, contraindications, and folic acid administration should be 
performed throughout the study.


2018N385734_02
CONFIDENTIAL
201790
45
Table 1
Overview of Study Intervention
ARM Name
GSK3196165 
90 mg
GSK3196165
150 mg
Placebo*
Tofacitinib
Intervention Name
GSK3196165 (Approved 
Name not yet assigned)
GSK3196165 
(Approved Name not 
yet assigned)
Placebo to 
GSK3196165
Placebo to tofacitinib
Xeljanz
Type 
Biologic
Biologic
Placebo to Biologic
Placebo Drug
Drug
Dose Formulation
Solution in vial (1.2 mL) 
or PFS (1.0 mL)
Solution in vial (1.2 
mL) or PFS (1.0 mL)
Sterile 0.9% (w/v) 
sodium chloride 
solution or PFS (1.0 
mL)
Capsule (containing 
lactose)
Capsule (over-
encapsulated tablet)
Unit Dose Strength(s)
180 mg/vial 
(180 mg/1.2 mL)
PFS 90 mg/mL
180 mg/vial 
(180 mg/1.2 mL)
PFS 150 mg/mL
Not applicable
Not applicable
5 mg
Dosage Level(s)
90 mg once-weekly
150 mg once weekly
Weekly injection
One capsule BID
5 mg BID (10 mg/day)
Route of 
Administration
SC injection
SC injection
SC injection
Oral
Oral
IMP and NIMP
IMP
IMP
IMP
IMP
IMP
Sourcing
Provided centrally by the 
Sponsor
Provided centrally by 
the Sponsor
Locally approved 
sodium chloride
solution may be 
sourced at site or 
Provided centrally by 
the Sponsor
Provided centrally by 
the Sponsor


2018N385734_02
CONFIDENTIAL
201790
46
ARM Name
GSK3196165 
90 mg
GSK3196165
150 mg
Placebo*
Tofacitinib
provided centrally. PFS 
provided centrally by 
the Sponsor
Dosing instructions
Vials: withdraw 0.6 mL 
into a small syringe and 
dose immediately; 
discard remaining 
material.
PFS: Inject all
Vials: withdraw 1.0 mL 
into a small syringe 
and dose immediately; 
discard remaining 
material.
PFS: Inject all
Withdraw 1.0 mL into a 
small syringe and dose 
immediately; discard 
remaining material.
PFS: Inject all
Instruct participant to 
take 1 capsule in the 
morning and 1 
capsule in the 
evening
Instruct participant to 
take 1 capsule in the 
morning and 1 capsule 
in the evening
Special instructions
Avoid excessive shaking 
of GSK3196165 vials as 
this could lead to product 
precipitation. Do not 
administer with other 
drugs concomitantly in 
the same syringe
Avoid excessive 
shaking of 
GSK3196165 vials as 
this could lead to 
product precipitation. 
Do not administer with 
other drugs 
concomitantly in the 
same syringe
None
None
None
Packaging and 
Labelling
Study Intervention will be 
provided in a single use 
vial or PFS in an 
individual carton and 
labelled as required per 
country requirement
Study Intervention will 
be provided in a single 
use vial or PFS in an 
individual carton and 
labelled as required 
per country 
Commercial saline may 
be sourced at site or 
provided centrally / 
PFS will be provided 
for single-use in an 
individual carton and 
labelled as required 
Study Intervention will 
be provided in a bottle 
containing 31 
capsules and labelled 
as required per 
country requirement
Study Intervention will 
be provided in a bottle 
containing 31 
capsules and labelled 
as required per 
country requirement


2018N385734_02
CONFIDENTIAL
201790
47
ARM Name
GSK3196165 
90 mg
GSK3196165
150 mg
Placebo*
Tofacitinib
requirement
per country 
requirement
Current/Former 
Name(s) or Alias(es)
GSK3196165, otilimab, 
anti-human GM-CSF 
monoclonal Ab, 
MOR103, MOR04357
GSK3196165, otilimab, 
anti-human GM-CSF 
monoclonal Ab, 
MOR103, MOR04357
Not applicable
Not applicable
Xeljanz, tofacitinib, 
Jakvinus, Jaquinus,
CP-690,550
* Placebo consists of 3 arms to Week 12, after which participants will be switched to 1 of the 3 active intervention arms.
PFS = prefilled syringe; GM-CSF = granulocyte macrophage colony stimulating factor; Ab = antibody.
GSK3196165 in vials and placebo will be administered SC, using syringes and needles commonly used for SC administration; compatibility with commonly used syringes and needles 
has been demonstrated.


2018N385734_02
CONFIDENTIAL
201790
48
6.1.1.
Medical Devices

The medical devices provided for use in this study are injection devices: 
o
a prefilled syringe (PFS) containing 150 mg or 90 mg otilimab solution, or 
placebo, assembled into a safety syringe device (SSD)
The otilimab PFS/SSD devices used in the study are representative of the 
devices and regionally appropriate device instructions planned to be marketed 
for the product.

The components that comprise the otilimab and placebo PFS/SSD, including glass 
barrel with prestaked needle, flange, plunger and needle guard are sourced for GSK 
by a third party provider.  The otilimab and placebo PFS is filled and assembled 
with the safety syringe components by GSK (or its affiliates). 

The instructions for use (IFU) for these injection devices are provided in the study 
reference manual (SRM).  

The otilimab and placebo PFS instructions were developed and optimised as a result 
of formative human factors (HF) studies and are representative of those that are 
planned for the product.  The summary HF information will be provided in the 
regulatory submission.

All device deficiencies (including malfunction, use error and inadequate labelling) 
shall be documented and reported by the investigator throughout the clinical 
investigation (see Section 8.3.8) and appropriately managed by the sponsor.
6.2.
Preparation/Handling/Storage/Accountability

The site pharmacist or unblinded administrator must confirm appropriate 
temperature conditions have been maintained during transit for all study 
intervention received and any discrepancies are reported and resolved before use 
of the study intervention.

Only participants enrolled in the study may receive study intervention and only 
authorised site staff may supply or administer study intervention. All study 
interventions must be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the labeled storage 
conditions with access limited to the investigator and authorised site staff.

The investigator, institution, or the head of the medical institution (where 
applicable) is responsible for study intervention accountability, reconciliation, and 
record maintenance (i.e., receipt, reconciliation, and final disposition records).

Further guidance and information for the final disposition of unused study 
intervention are provided in the SRM.

Under normal conditions of handling and administration, study intervention is not 
expected to pose significant safety risks to site staff.  Take adequate precautions 
to avoid direct eye contact and the generation of aerosols or mists. In the case of 
unintentional occupational exposure notify the monitor, Medical Monitor and/or 
GSK study contact.


2018N385734_02
CONFIDENTIAL
201790
49

A Material Safety Data Sheet (MSDS)/equivalent document describing 
occupational hazards and recommended handling precautions either will be 
provided to the investigator, where this is required by local laws, or is available 
upon request from GSK.
6.3.
Measures to Minimise Bias: Randomisation and Blinding
All participants will be centrally randomised using Interactive Response Technology 
(IRT).  Before the study is initiated, the log in information and directions for the IRT will 
be provided to each site.  Study intervention will be dispensed at the study visits 
summarised in the SoA for the treatment period (Section 1.3).  Returned study 
intervention should not be re-dispensed to the participants.
The IRT will be programmed with blind-breaking instructions.  In case of an emergency, 
the investigator has the sole responsibility for determining if unblinding of a participant’s 
intervention assignment is warranted.  Participant safety must always be the first 
consideration in making such a determination.  If the investigator decides that unblinding 
is warranted, the investigator should make every effort to contact GSK or designee prior 
to unblinding a participant’s intervention assignment unless this could delay emergency 
intervention of the participant.  If a participant’s intervention assignment is unblinded 
GSK must be notified within 24 hours after breaking the blind.  The date and reason that 
the blind was broken must be recorded in the source documentation and case report form, 
as applicable.
Participants will be randomised in a ratio of 6:6:3:1:1:1 to receive study intervention 
(Section 1.2 and Section 6.1).  Investigators will remain blinded to each participant’s 
assigned study intervention throughout the course of the study.  To maintain this blind, all 
participants will receive oral capsules twice daily and once-weekly SC injections.  Until 
such time as a matched placebo becomes available for GSK3196165, every SC injection 
must be delivered by an unblinded administrator and the syringe must be shielded from 
the participant to avoid unblinding.
An unblinded pharmacist (or unblinded designee) will be responsible for the dispensation 
of the study intervention and will endeavour to ensure that there are no differences in 
time taken to dispense between the different intervention arms.  While the study drug is 
supplied in vials, care will be taken to ensure that participants are not able to see the 
injection volume, syringe size or colour of liquid. The syringe should be prepared away 
from view of the participant, and appropriate shielding or masking of the syringe applied 
prior to administration.
In addition, investigators and site staff will not have access to ongoing post-
randomisation hsCRP/ESR analyses and should refrain from performing either routine 
ESR or CRP assessments unless clinically indicated for AE assessment.  Furthermore, the 
results of the PK analyses of GSK3196165 will not be provided to the sites.
Dose modifications to the oral study intervention will not be permitted in this study as it 
will have the potential to unblind the treatment assignments.  For this reason, the 
eligibility criteria have been designed to exclude potential participants that may require a 


2018N385734_02
CONFIDENTIAL
201790
50
dose reduction for safety reasons and any concomitant medications that may require a 
dose reduction will also be prohibited.
In order to reduce bias, an independent joint assessor will perform all joint assessments 
(Section 8.1.1).
Unblinded monitors and in the event of a Quality Assurance audit, the auditor(s) will be 
allowed access to unblinded study intervention records at the site(s) to verify that 
randomisation/dispensing has been done accurately.
A participant may continue in the study if that participant’s intervention assignment is 
unblinded.
GSK’s Pharma Safety staff may unblind the intervention assignment for any participant 
with an SAE.  If the SAE requires that an expedited regulatory report be sent to one or 
more regulatory agencies, a copy of the report, identifying the participant’s intervention 
assignment, may be sent to investigators in accordance with local regulations and/or GSK 
policy.
6.4.
Study Intervention Compliance
GSK3196165 or matching placebo will be administered by SC injection at the times 
indicated in the SoA (Section 1.3).  Participants should receive all doses per schedule, 
however exceptional circumstances may lead to a dose being missed.  If a dose is missed, 
the dose may be rescheduled to a new date/time providing the new date is within the SoA 
window for the missed dose.  If the dose cannot be rescheduled within the visit window, 
the dose must not be given outside the window and must be marked as missed in the IRT.  
After a missed dosed, further dosing may continue per SoA with the following 
requirements:

Except for doses temporarily interrupted for safety reasons, the investigator must 
meet to discuss compliance with the study intervention with any participant who 
appears to be non-compliant.

If the participant continues to be non-compliant and missed further doses, the 
investigator may decide to permanently discontinue the participant from study 
intervention and initiate standard of care.  The participant will be encouraged to 
continue to attend study visits until Week 52.
A record of the number of study intervention injections dispensed to and taken by each 
participant must be maintained by the site staff and reconciled with study intervention 
and compliance records.  Intervention start and stop dates, including dates for 
intervention delays will also be recorded in the CRF.
Compliance with tofacitinib and matching placebo capsules will be assessed through 
querying the participant during the site visits and documented in the source documents.  
A record of the number of capsules dispensed to and taken by each participant must be 
maintained and reconciled with study intervention and compliance records.  Intervention 


2018N385734_02
CONFIDENTIAL
201790
51
start and stop dates, including dates for intervention delays will also be recorded in the 
CRF.
6.5.
Prior and Concomitant Therapies
Due to effect of cytokines on the CYP450 enzymes (Section 2.3.1) initiation or 
discontinuation of study intervention may have clinically relevant effect for CYP 
substrates with a narrow therapeutic index e.g. warfarin and theophylline.  Where a 
CYP3A4 substrate drug is co-administered during the study, in addition to recording the 
initial dose and any dosage changes over time in the CRF, the results of any therapeutic 
monitoring (e.g. INR results), if available, should also be recorded.
Investigators should exercise caution when study intervention is co-administered with 
CYP3A4 substrate drugs where decrease in effectiveness is undesirable, e.g., oral 
contraceptives, lovastatin, atorvastatin, etc.
6.5.1.
Permitted Therapies
Medications or treatments deemed necessary by the investigator to provide supportive 
care will be permitted during the study except when administration would occur during a 
time of restricted use, as in Table 2, or if the medication is specifically excluded, as in 
Section 6.5.2.  The permitted dose is the usual marketed dose approved in the country in 
which the study is being conducted. Any use of these medications must be recorded in 
the eCRF, along with:

reason for use

dates of administration including start and end dates

dosage information including dose and frequency
The Medical Monitor should be contacted if there are any questions regarding 
concomitant or prior therapy. The requirements for use of specific permitted 
medications/treatments are listed in Table 2.


2018N385734_02
CONFIDENTIAL
201790
52
Table 2
Requirements for Use of Specific Permitted Medications/Treatments
Medications/Treatments
Restriction
Prior to study treatment 
period
During study treatment 
period
Day 1 to Week 52
During 8-week 
follow-up
Conventional synthetic DMARDs
Methotrexate 15-25mg/week oral or 
injected. 
A lower dose of ≥7.5 mg/week is 
acceptable if reduced for reasons of 
intolerance to MTX. e.g. hepatic or 
hematologic toxicity, or per local 
requirement (this must be clearly 
documented in medical records). 
Exception: A lower dose of 6 mg/week 
is only allowed if the minimum locally 
approved or recommended dose is 
lower than 7.5 mg/week.
Required
(must have received at least 
12 weeks treatment prior to 
Day 1, with stable and 
tolerated dose for at least 8 
weeks prior to Day 1)
Required
(dose must remain stable 
except adjustment for safety 
reasons)
Permitted
Corticosteroids
Stable dosing regimen of oral 
corticosteroids ≤10 mg/day 
prednisolone or equivalent.
Permitted
(dose must be stable 4 
weeks prior to Day 1 and 
during screening if longer, 
with no changes except for 
safety reasons)
Permitted
(dose must remain stable 
except for safety reasons)
Permitted
Intra-articular corticosteroids
Prohibited within 4 weeks 
prior to Day 1 and during 
screening, if longer.
Permitted after Week 12
(Post week 12, the number 
of IA steroid injections 
should be limited to 2 
injections through Week 52, 
administration should not 
occur during the 4 weeks 
prior to Week 24 or Week 
52. The site(s) of injection 
must be recorded)
Permitted
Inhaled steroids, topical steroids or 
topical immunosuppressive agents 
(e.g., eye drops, creams)
Permitted
Permitted
Permitted
Analgesics
Acetaminophen (paracetamol) taken as 
rescue for RA pain: up to a maximum 
of 4g/day or locally approved maximum 
(if lower).
Permitted as needed
(but not within 24 hours of 
Day 1 baseline visit)
Permitted as needed
(but not within 24 hours of 
assessment visits)
Permitted


2018N385734_02
CONFIDENTIAL
201790
53
Medications/Treatments
Restriction
Prior to study treatment 
period
During study treatment 
period
Day 1 to Week 52
During 8-week 
follow-up
NSAIDs including aspirin and selective 
cyclooxygenase inhibitors.

In this study, aspirin is considered 
a NSAID, except for low-doses 
(e.g. 75-150 mg/day) prescribed 
for cardiovascular or 
cerebrovascular disease.
Permitted
Participants on regular 
doses: Dosing regimen 
must be stable 7 days prior 
to Day 1, no changes 
except for safety reasons. 
Do not discontinue in 
advance of visits.
Participants on PRN 
prescription: Record each 
dose during screening, or 
frequency with start/end 
dates, in CRF. Should not 
be taken within 24h of Day 1 
baseline visit.
Permitted
Participants on stable, 
regular doses: From Day 1 
to Week 12, dose regimen 
must not change except for 
safety reasons. Do not 
discontinue in advance of 
visits.
After Week 12, any new 
analgesic or change in 
regimen should not occur 
within 24h of assessment 
visits.
Participants on PRN 
prescription: Record each 
dose, or frequency with 
start/end dates, in CRF.
Should not be taken within 
24h of assessment visits.
Permitted
Weak opioid analgesics (e.g. tramadol 
up to 400 mg/day, codeine)
Strong opioid analgesics (e.g. 
morphine, hydromorphone, oxycodone, 
hydrocodone, fentanyl, meperidine, 
methadone)
Prohibited within 4 weeks 
prior to Day 1 and during 
screening, if longer.
Permitted after Week 12
After week 12, PRN or 
regular doses may be 
considered, but any new 
analgesic or change in 
regimen should not occur 
within 24h of assessment 
visits. 
Participants on PRN 
prescription: Record each 
dose, or frequency with 
start/end dates, in CRF.
Should not be taken within 
24h of assessment visits.
Permitted
Other Medications
Intra-articular Hyaluronic acid and any 
other intra-articular compounds used as 
lubricant in the joints.
Prohibited within 2 weeks 
prior to Day 1 and during 
screening, if longer.
Prohibited within 2 weeks 
prior to Week 12, Week 24 
and Week 52 assessments.
Permitted
Prior to any dose changes in MTX or oral corticosteroids, it is recommended that the 
Investigator contacts the medical monitor to discuss and agree with the dose change.
Use of analgesics is restricted during the first 12 weeks of study intervention and 
thereafter, investigators should follow routine clinical practice to manage RA pain (see 
Table 2).  Any new analgesic or change in analgesic use must be recorded in the 
concomitant medication eCRF.


2018N385734_02
CONFIDENTIAL
201790
54
Other medications (including vitamins, herbal and dietary supplements) will be 
considered on a case-by-case basis and will be permitted if in the opinion of the 
Investigator, after consultation with the medical monitor as necessary, the medication 
will not interfere with the study procedures or compromise participant safety.
6.5.2.
Prohibited Therapies
Medications prohibited or restricted prior to the study, during the study and/or during the 
safety follow-up of the study are listed in Table 3, along with any period of exclusion 
which must be applied.
Table 3
Prohibited Medications/Treatments
Medications/Treatments
Restriction
Prior to study treatment 
period
During study treatment 
period
Day 1 to Week 52
During 8-week 
follow-up
Treatments affecting GM-CSF pathway
Any treatment antagonising GM-CSF or 
its receptor
Prohibited
(Exclusion criterion)
Prohibited
(except study intervention)
Prohibited
Conventional synthetic DMARDs
Hydroxychloroquine, chloroquine, 
sulfasalazine, minocycline, 
cyclosporin, tacrolimus, bucillamine, 
iguratimod
Discontinue at least 4 
weeks prior to Day 1
Prohibited
No restriction
Azathioprine
Discontinue at least 4 
weeks prior to Day 1
Prohibited
No restriction
Leflunomide
Without washout 
treatment
Discontinue at least 12 
weeks prior to Day 1
Prohibited
No restriction
Leflunomide
With washout treatment 
for 11 days with oral 
cholestyramine (8 g 
three times daily) or 
charcoal (50 g four 
times daily)
Washout treatment must 
complete at least 2 weeks 
prior to Day 1
Prohibited
No restriction
Other csDMARDs
Discontinue at least 4 
weeks prior to Day 1
Prohibited
No restriction
Biologic DMARDs
The number of participants with prior bDMARD exposure will be limited to approximately 20% of overall sample size (~300 
participants).
Etanercept (including its biosimilars). 
Only if discontinued for reasons other 
than inadequate response*
Discontinue at least 4 
weeks prior to Day 1
Prohibited
Prohibited
Any cell-depleting therapies, e.g., anti-
CD20. Only if discontinued for reasons 
other than inadequate response*
Discontinue at least 52 
weeks prior to Day 1.
Prohibited
Prohibited


2018N385734_02
CONFIDENTIAL
201790
55
Medications/Treatments
Restriction
Prior to study treatment 
period
During study treatment 
period
Day 1 to Week 52
During 8-week 
follow-up
Any other biologic DMARDs 
(experimental or approved) discontinued 
for reasons other than inadequate 
response*
Discontinue at least 8 
weeks prior to Day 1.
Prohibited
Prohibited
Any biologic DMARD (experimental or 
approved) that was discontinued due to
inadequate response*
Prohibited
(Exclusion criterion)
Prohibited
Prohibited
Targeted synthetic DMARDs
Janus kinase (JAK) inhibitors, 
experimental or approved (e.g. tofacitinib, 
baricitinib, upadacitinib, filgotinib and 
peficitinib).
Prohibited
(Exclusion criterion)
Prohibited
(except study intervention)
Prohibited
Other (non-JAKi) tsDMARDs, either 
experimental or approved.
Discontinue at least 4 
weeks or 5 half-lives, 
(whichever is longer) prior 
to Day 1.
Prohibited
Prohibited
Other RA therapies
Plasmapheresis or intravenous 
immunoglobulin (IVIG) or use of plasma 
filtering devices (e.g. Staph protein A 
column (Prosorba))
Discontinue at least 26 
weeks prior to Day 1.
Prohibited
Prohibited
Corticosteroids
Dose changes in oral corticosteroids ≤10 
mg/day prednisolone or equivalent
Prohibited 4 weeks prior to 
Day 1, and during 
screening if longer, except 
for safety reasons
Prohibited (except for 
safety reasons)
No restriction
Oral corticosteroids >10 mg/day 
prednisolone or equivalent
Discontinue or reduce to 
≤10 mg/day, at least 4 
weeks prior to Day 1.
Prohibited (except for 
safety reasons)
No restriction
Intra-muscular or intravenous 
corticosteroids
Discontinue at least 4 
weeks prior to Day 1, and 
during screening if longer.
Prohibited (except for 
safety reasons)
No restriction
Other Medications
Potent inhibitors of Cytochrome P450 
3A4 (CYP3A4) (e.g., ketoconazole). 
One or more concomitant medications 
that result in both moderate inhibition of 
CYP3A4 and potent inhibition of 
CYP2C19 (e.g., fluconazole).
Potent CYP3A4 inducers (e.g., rifampin).
Refer to SRM for 
additional guidance
Prohibited 
No restriction


2018N385734_02
CONFIDENTIAL
201790
56
Medications/Treatments
Restriction
Prior to study treatment 
period
During study treatment 
period
Day 1 to Week 52
During 8-week 
follow-up
Vaccine Immunisations
Note: Investigators should review and update the vaccination status of potential participants as per local guidelines for 
adult vaccination prior to entering them into the study (refer to EULAR recommendations where no local guidelines are 
available [Furer, 2019]), with particular attention to the vaccination status of participants over 65 years of age. All 
participants who have not received the herpes zoster vaccine at study entry will be recommended to complete vaccination 
>30 days prior to randomisation. All participants may receive inactivated flu vaccines during the study at the discretion of 
the investigator.
Live-attenuated vaccinations
Discontinue at least 30 
days prior to Day 1
Prohibited
Prohibited
BCG vaccination
Discontinue at least 365 
days prior to Day 1.
Prohibited
Prohibited
*Inadequate response to treatment is defined as: In the opinion of the investigator, after at least 3 months of treatment 
the participant experienced insufficient efficacy or loss of response (e.g. no EULAR response; failure to achieve ACR20; 
any other clinical criteria recommended per local guidelines that would trigger a change of treatment), or the participant 
discontinued treatment due to intolerability or toxicity irrespective of treatment duration.
6.5.3.
Rescue Medicine
Acetaminophen (paracetamol) is permitted as needed, both prior to and during the study 
as rescue medicine for RA pain management, up to 4g/day or to the maximum permitted 
under local label (if lower than 4g/day).  However, acetaminophen (paracetamol) must 
not be taken within 24 hours prior to the baseline (Day 1) or any assessment visit.
Any use of rescue medication must be recorded in the appropriate concomitant 
medication form, in the CRF.
6.6.
Dose Modification
6.6.1.
Dose Modification of Study Intervention
Dose reduction of the SC and/or oral study interventions is not permitted in this study. 
6.6.2.
Dose Modification of Background Medicines (MTX)
Dose reduction or temporary interruption of the background MTX may be performed at 
any time for safety reasons (e.g. intolerance or toxicity) but must be clearly documented.  
If clinically indicated, MTX may be re-started following an interruption and increased
back to the dose taken prior to the change.
Dose modifications for reasons other than safety are not permitted during the study 
treatment period.
6.7.
Intervention after the End of the Study
Participants who complete the 52-week treatment period may have the option to 
transition into long term extension study 209564.  Exceptionally, participants who missed 


2018N385734_02
CONFIDENTIAL
201790
57
their final SC dose at Week 51 in this study may still be eligible, after consultation with 
the medical monitor.  Participants receiving GSK3196165 in this study will continue to 
receive the same dose in the extension study.  Participants receiving tofacitinib in this 
study will be re-randomised in a 1:1 ratio to either GSK3196165 90 mg or GSK3196165 
150 mg once-weekly in the extension study.
Participants who do not transition into long term extension study 209564, will not receive 
any further treatment with GSK3196165 but will be treated according to local standard of 
care for RA disease.
7.
DISCONTINUATION OF STUDY INTERVENTION AND 
PARTICIPANT DISCONTINUATION/WITHDRAWAL
7.1.
Discontinuation of Study Intervention
In rare instances, it may be necessary for a participant to permanently discontinue study 
intervention (oral capsules and SC injection).  A participant will permanently discontinue
study intervention if there is no longer a positive risk:benefit ratio at any time point in the 
study as determined by the investigator.  If study intervention is permanently 
discontinued, the participant will, where possible, remain in the study and continue with 
study visits in order to be evaluated for efficacy and safety.  These participants will not 
be eligible to participate in long term extension study 209564.
7.1.1.
Liver Chemistry Stopping Criteria
Liver chemistry stopping and increased monitoring criteria have been designed to 
assure participant safety and evaluate liver event etiology.
Discontinuation of study intervention for abnormal liver tests is required when a 
participant meets one of the conditions outlined in the algorithms.  Additionally, study
intervention must be discontinued if there are any clinical signs/symptoms suggestive of 
hepatic decompensation such as ascites and hepatic encephalopathy.


2018N385734_02
CONFIDENTIAL
201790
58
Algorithm A: Phase III-IV Liver Chemistry Stopping and Increased Monitoring 
Algorithm
Continue Study Treatment 
Discontinue Study Treatment 
Plus 
Bilirubin≥2x
ULN (>35% 
direct) or plus
INR>1.5*
Possible  
Hy’s Law
ALT≥3xULN
ALT
≥8xULN
Plus
Symptoms of 
liver injury
or 
hypersensitivity
No
Yes
Yes
Yes
No
No
No
See algorithm 
for continued 
therapy with 
increased liver 
chemistry 
monitoring
Yes
*INR value not applicable to subjects on anticoagulants 
ALT 
≥3xULN 
but 
<8xULN
Yes
Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix
Report as an SAE if possible Hy’s Law case: ALT≥3xULN and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5*
Abbreviations: ALT = alanine transaminase; bili = bilirubin; INR = international normalised ratio; SAE = 
serious adverse event; ULN = upper limit of normal.
Liver Safety Required Actions and Follow up Assessments Section can be found in 
Appendix 6.


2018N385734_02
CONFIDENTIAL
201790
59
Algorithm B: Phase III-IV Liver Chemistry Increased Monitoring Algorithm with 
Continued Therapy for ALT 3xULN but <8xULN
Continue Study Treatment   and   Monitor Liver Chemistry
Discontinue Study Treatment 
ALT≥5xULN 
but <8xULN
+ bili <2xULN +
no symptoms
No
Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix
Yes
ALT ≥3xULN 
but <5xULN
+ bili <2xULN  +
no symptoms
Able to 
monitor  
weekly 
for  ≥2 
weeks
Persists for 
≥2 weeks  
or other 
stopping 
criteria  
met
No
Yes
Yes
Yes
No
No
Able to 
monitor  
weekly 
for  ≥4 
weeks
Persists for 
≥4 weeks  
or other 
stopping 
criteria  
met
No
Yes
Yes
Yes
Yes
ALT ≥5xULN 
ALT <5xULN 
Yes
Yes
*INR value not applicable to subjects on anticoagulants 
Must refer to Liver Safety Required Actions and Follow up Assessments section in the Appendix
Report as an SAE if possible Hy’s Law case: ALT≥3xULN and  Bilirubin≥2xULN (>35% direct)  or 
INR>1.5*
Abbreviations: ALT = alanine transaminase; bili = bilirubin; INR = international normalised ratio; SAE = 
serious adverse event; ULN = upper limit of normal.
Liver Safety Required Actions and Follow up Assessments Section can be found in 
Appendix 6.
7.1.1.1.
Study Intervention Restart or Rechallenge after liver stopping criteria 
met
Study intervention restart or rechallenge after liver chemistry stopping criteria are met by 
any participant in this study is not allowed.
7.1.2.
Other Stopping Criteria
A participant will be permanently discontinued from study intervention (but may 
continue to be followed in the study) if any of the following criteria are met:

VTE, including PE and DVT, requiring anticoagulation

Pregnancy (see Section 8.3.5 and Appendix 4).

Confirmed pulmonary alveolar proteinosis (see Section 8.2.6).

Serious hypersensitivity reactions (see Section 8.3.7).

Other serious or severe adverse events or other significant medical event, at the 
discretion of the investigator, after consultation with the Medical Monitor.


2018N385734_02
CONFIDENTIAL
201790
60

HBV DNA level ≥200 IU/mL or HBV DNA detected at any level with recent 
increase in hepatic transaminases (see Figure 2 in Section 8.2.8).

HBV DNA positive (any level ≤200 IU/mL) and on repeat testing within 1 week 
(see Figure 2 in Section 8.2.8) either:
o
HBV DNA positive (any level) OR
o
HBV surface antigen positive OR
o
increase in hepatic transaminases.

New latent or active TB infection (see Section 8.2.7.4).

Gastrointestinal perforation.

Absolute neutrophil count (ANC) <0.5 x 109/L.

Lymphocyte count <0.5 x 109/L.

Severe renal impairment (eGFR <30 mL/min/1.73m2) and confirmed upon repeat 
testing.

Introduction of prohibited therapies or dosages where continuation of the study 
intervention would place the participant at risk in the opinion of the investigator 
and medical monitor.
7.1.3.
Temporary Discontinuation
7.1.3.1.
Respiratory Symptoms
Study intervention will be temporarily discontinued if a participant develops a persistent 
cough (CTCAE Grade 2) [NCI, 2017] or persistent dyspnoea (dyspnoea scale Grade 
2) for 3 consecutive weeks (21 days).  The participant should be referred to a 
pulmonologist for further assessment.  Study intervention should remain suspended until 
the symptoms or signs that caused referral have resolved and/or the diagnosis has been 
determined and clinically significant events have been excluded by the pulmonologist.  
Participants with a confirmed diagnosis of pulmonary alveolar proteinosis must 
permanently discontinue study intervention (Section 7.1).  Suggested pulmonary 
assessment and management algorithms are provided in a separate Pulmonary Safety 
Guidance Document in the SRM.
7.1.3.2.
Serious and Opportunistic Infections
If a serious or opportunistic infection or sepsis develops, temporarily discontinue study 
intervention until the infection is controlled and discuss further management with the 
medical monitor.
7.1.3.3.
Haematologic Abnormalities
Study intervention will be temporarily discontinued upon confirmatory (local) repeat test, 
for the following haematological abnormalities:

White blood cell (WBC) count <2.0 x 109/L.


2018N385734_02
CONFIDENTIAL
201790
61

ANC ≤1.0 x 109/L.

Lymphocyte count ≤0.75 x 109/L.

Decrease in haemoglobin >2g/dL or haemoglobin <8.0g/dL. Dosing should be 
interrupted until haemoglobin values have normalised.
The local repeat test must be performed and assessed within 7 days (ideally 3-5 days), 
with additional sample(s) sent for central testing.
If study intervention is temporarily discontinued, the abnormality must be reported as an 
AE and a further repeat test should be performed within 7 days of discontinuation.  The 
medical monitor should be consulted if the repeat test is still abnormal.  Study 
intervention can be restarted if the haematological parameters rise above these values.
7.1.3.4.
TB Reactivation
Study intervention may be temporarily discontinued for the following after consultation 
with the medical monitor:

Suspected TB reactivation (see Section 8.2.7.4).
7.1.3.5.
Renal Abnormalities
Study intervention will be temporarily discontinued for the following renal abnormality:

Moderate to severe renal impairment (eGFR ≥30 to <45 mL/min/1.73m2).
A repeat test must be performed locally and assessed within 7 days with additional 
sample(s) sent for central testing.  The medical monitor should be consulted if the repeat 
test is still abnormal and a further repeat test performed again within 7 days.  Study 
intervention can be restarted if renal function improves to eGFR ≥45 mL/min/1.73m2.
7.2.
Participant Discontinuation/Withdrawal from the Study

A participant may withdraw from the study at any time at his/her own request or 
may be withdrawn at any time at the discretion of the investigator for safety, 
behavioural, compliance or administrative reasons.  This is expected to be 
uncommon.

At the time of discontinuing from the study, if possible, an early withdrawal visit 
should be conducted following the procedures at the Week 52 visit, as shown in 
the SoA (Section 1.3).  A safety follow-up visit should be scheduled at 8 weeks 
post last dose of study SC intervention.

The participant will be permanently discontinued both from the study intervention 
and withdrawn from the study at that time.

If the participant withdraws consent for disclosure of future information, the 
sponsor may retain and continue to use any data collected before such a 
withdrawal of consent.


2018N385734_02
CONFIDENTIAL
201790
62

If a participant withdraws from the study, he/she may request destruction of any 
samples taken and not tested, and the investigator must document this in the site 
study records.
7.3.
Lost to Follow Up
A participant will be considered lost to follow-up if he or she repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.
The following actions must be taken if a participant fails to return to the clinic for a 
required study visit:

The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant wishes to 
and/or should continue in the study.

Before a participant is deemed lost to follow up, the investigator or designee must 
make every effort to regain contact with the participant (where possible, 3 
telephone calls and, if necessary, a certified letter to the participant’s last known 
mailing address or local equivalent methods).  These contact attempts should be 
documented in the participant’s medical record.

Should the participant continue to be unreachable, he/she will be considered to 
have withdrawn from the study.
Discontinuation of specific sites or of the study as a whole are handled as part of 
Appendix 1.


2018N385734_02
CONFIDENTIAL
201790
63
8.
STUDY ASSESSMENTS AND PROCEDURES

Study procedures and their timing are summarised in the SoA (Section 1.3).

Protocol waivers or exemptions are not allowed 

Immediate safety concerns should be discussed with the medical monitor 
immediately upon occurrence or awareness to determine if the participant should 
continue or discontinue study intervention.

Adherence to the study design requirements, including those specified in the SoA 
(Section 1.3), is essential and required for study conduct.

All screening evaluations must be completed and reviewed to confirm that 
potential participants meet all eligibility criteria.  The investigator will maintain a 
screening log to record details of all participants screened and to confirm 
eligibility or record reasons for screening failure, as applicable.

Procedures conducted as part of the participant’s routine clinical management 
(e.g., blood count) and obtained before signing of ICF may be utilised for 
screening or baseline purposes provided the procedure met the protocol-specified 
criteria and was performed within the time frame defined in the SoA (Section 
1.3).

The maximum amount of blood collected from each participant over the duration 
of the study, including any extra assessments that may be required, will not 
exceed 450 mL.

Repeat or unscheduled samples may be taken for safety reasons or for technical 
issues with the samples.
8.1.
Efficacy Assessments
8.1.1.
Joint Assessments
An evaluation of all 68 joints for tenderness and 66 joints for swelling will be performed 
by an independent joint evaluator. Replaced or fused joints are considered non-evaluable 
and will not be included in joint evaluations.  The reason for absence of the evaluations 
of those joints must be recorded.  If a joint has undergone intra-articular injection of 
corticosteroid during the course of the study, the injected joint must be recorded.
One or more independent assessors, who have documented experience in performing 
joint assessments, will be designated at each trial site to perform joint assessments.  
Preferably the same independent assessor will perform all joint assessment for the same 
participant throughout the trial.  The principal investigator must ensure that the 
independent joint assessor has documented experience and he/she is adhering to locally 
accepted and implemented standards.  This also applies if the independent joint assessor 
is replaced during the trial.
The independent joint assessor should have no other contact with the participant during 
the trial, must not be the treating physician (investigator), should not discuss the clinical 
status of the participant with them during the joint assessment nor with other site 


2018N385734_02
CONFIDENTIAL
201790
64
personnel, and will not be permitted to review the participant’s medical records, the 
eCRF, nor any of the previous joint assessments.
The procedure for joint assessments is provided in the SRM.
8.1.2.
Physician’s Global Assessment of Arthritis
Investigators will complete a global assessment of rheumatoid arthritis disease activity 
using the physician global assessment item (PhGA), a visual analogue scale (VAS) with 
anchors “0” (
) to “100” (
), respectively.
8.1.3.
Joint X-Rays
Radiographic progression of structural joint damage will be assessed using X-rays of the 
hands and feet.  All X-rays will be read centrally by the imaging CRO and will be 
assessed for the presence or absence of erosion(s).  X-rays will be taken at screening to 
confirm eligibility.
8.1.4.
Patient Reported Outcomes
All patient reported outcomes (PROs) should be administered before any laboratory 
assessments and other procedures or consultations to avoid influencing the participants’ 
perception of their RA disease.
8.1.4.1.
Patient’s Assessment of Arthritis Pain
Participants will assess the severity of their arthritis pain over the past week, using a 100 
unit VAS, with anchors “0” (
) and “100” (
).
The results of this question will be used for the HAQ-DI, where the local version of 
HAQ-DI asks the same question.
8.1.4.2.
Patient’s Global Assessment of Arthritis
Participants will complete a global assessment of disease activity using the patient global 
assessment (PtGA) item, a VAS with anchors “0” (
) to “100” (
).
8.1.4.3.
Health Assessment Questionnaire – Disability Index (HAQ-DI)
The functional status of the participant will be assessed by means of the Disability Index 
of the Stanford Health Assessment Questionnaire (HAQ-DI).  This 20-question 
instrument assesses the degree of difficulty a person has in accomplishing tasks in eight 
functional areas [Fries, 1980]: dressing and grooming, arising, eating, walking, hygiene, 
reach, grip, and common daily activities.
CCI
CCI
CCI
CCI
CCI
CCI
CCI


2018N385734_02
CONFIDENTIAL
201790
65
8.1.4.7.
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue
The Functional Assessment of Chronic Illness Therapy (FACIT)-fatigue questionnaire is 
a validated patient-reported measure developed originally to assess fatigue in individuals 
with cancer.  The FACIT-fatigue has subsequently been used and validated in numerous 
chronic conditions, including RA.
8.1.4.8.
SF-36 Short Form Health Survey
Health-related quality of life (HRQL) will be assessed using the participant-completed 
Medical Outcomes Study (MOS) Short-Form 36 (SF-36) which is a generic health survey 
that contains 36 questions covering eight domains of health.  The SF-36 yields an eight-
scale profile of functional health and well-being scores as well as physical and mental 
component health summary scores.  The version 2, 1-week recall questionnaire will be 
used.
CCI
CCI


2018N385734_02
CONFIDENTIAL
201790
66
8.2.
Safety Assessments
Planned time points for all safety assessments are provided in the SoA (Section 1.3).
In the event that pulmonary follow-up criteria are triggered, all sites must have access to 
a pulmonologist (see Section 7.1.3.1 and Section 8.2.6).
8.2.1.
Dyspnoea Assessments
The dyspnoea scale grades the effect of breathlessness on daily activities and measures 
perceived respiratory disability.  The scale will be completed by the investigator in 
consultation with the participant.  Dyspnoea will be reported on a rating scale from 0 (
 
) through 4 (
).
8.2.2.
Physical Examinations

A complete physical examination (e.g. at the Screening visit) will include, at a 
minimum, assessments of the Skin, Cardiovascular, Respiratory, Gastrointestinal 
and Neurological systems.  Height and weight will also be measured and 
recorded.

A brief physical examination will include, at a minimum, assessments of the skin, 
lungs, cardiovascular system, and abdomen (liver and spleen).

Investigators should pay special attention to clinical signs related to previous 
serious illnesses.

All physical examinations will include monitoring for signs and symptoms of TB 
(see Section 8.2.7).
8.2.3.
Electrocardiograms

12-lead ECG measurements should be recorded pre-dose, and where possible 
before vital sign measurements and blood draws.

Participants should be in a quiet setting without distractions and rest in a supine 
position for at least 5 or 10 minutes before ECG collection.

Triplicate 12-lead ECG measurements will be obtained at screening with single 
ECG measurements obtained post-baseline as outlined in the SoA (see 
CCI
CCI
CCI
CCI


2018N385734_02
CONFIDENTIAL
201790
67
Section 1.3) using an ECG machine that automatically calculates the heart rate 
and measures PR, QRS, QT, and QTc intervals.

At the screening visit where triplicate ECG are required, three individual ECG 
tracings should be obtained as closely as possible in succession, but no more than 
2 minutes apart.  The full set of triplicates should be completed in less than 
4 minutes.

ECG traces will be read locally.
8.2.4.
Vital Signs

Vital signs should be measured pre-dose, and where possible before blood draws.

Temperature, pulse rate, respiratory rate and blood pressure will be assessed.

Blood pressure and pulse measurements will be assessed with a completely 
automated device.  Manual techniques will be used only if an automated device is 
not available.  The participant should use the same position throughout all visits.

All blood pressure readings will be recorded using an appropriate cuff size with 
the same arm being used throughout the study.

Blood pressure and pulse measurements should be preceded by at least 5 minutes 
of rest for the participant in a quiet setting without distractions (e.g., television, 
cell phones).

When the timing of these measurements coincides with blood collection, the 
blood pressure and heart rate should be obtained first.
8.2.5.
Clinical Safety Laboratory Assessments

Refer to Appendix 2 for the list of clinical laboratory tests to be performed and to 
the SoA in Section 1.3 for the timing and frequency.

All study-required laboratory assessments will be performed by a central 
laboratory except erythrocyte sedimentation rate (ESR), dipstick urinalysis, and 
urine pregnancy tests which will be analysed locally.

The investigator must review the laboratory report, document this review, and 
record any clinically relevant changes occurring during the study in the AE 
section of the CRF. The laboratory reports must be filed with the source 
documents. Clinically significant abnormal laboratory findings are those which 
are not associated with the underlying disease, unless judged by the investigator 
to be more severe than expected for the participant’s condition.

All laboratory tests with values considered clinically significantly abnormal 
during participation in the study or within 8 weeks after the last dose of study 
intervention should be repeated until the values return to normal or baseline or are 
no longer considered significantly abnormal by the investigator or medical 
monitor. 


2018N385734_02
CONFIDENTIAL
201790
68

If such values do not return to normal/baseline within a period of time judged 
reasonable by the investigator, the etiology should be identified and the sponsor 
notified.

In this study, the key laboratory parameters are WBCs, lipids, haemoglobin, 
platelets, lymphocytes, neutrophils and liver function tests.

Participants who develop hyperlipidemia should be managed according to clinical 
guidelines [e.g., National Cholesterol Educational Program (NCEP)].

All protocol-required laboratory assessments, as defined in Appendix 2, must be 
conducted in accordance with the laboratory manual and the SoA (Section 1.3).
8.2.6.
Pulmonary Assessments
Pulmonary assessments are a key aspect of the safety monitoring in this study.  The 
following pulmonary assessments will be performed as specified in the SoA 
(Section 1.3).

Chest X-ray (posteroanterior).

Cough assessment.

Dyspnoea assessment (see Section 8.2.1).

Lung auscultation.

Pulse oximetry.

Pulmonary function tests (PFTs) – spirometry (FEV1 and FVC) at baseline (or 
prior to Day 1) only or as required by the pulmonologist in the event of 
participant referrals for further assessment.
In the event of any new or clinically significant pulmonary abnormalities that may 
develop during the study (e.g., increased shortness of breath/dyspnoea, or unexplained 
and persistent coughing), it is recommended that the participant be referred to a 
pulmonologist for further assessment.  
If, at any time during the study, a participant reports new onset or an increase (if present 
at baseline) in cough (CTC Grade ≥2) or dyspnoea (Grade ≥2), they must be questioned 
again (either by phone or during the site visit) on a weekly basis for 3 further consecutive 
weeks or until the symptoms resolve, if earlier.  Any new onset or worsening cough 
and/or dyspnoea must be reported as an AE.
If a participant experiences persistent cough Grade ≥2 for three consecutive weeks (≥21 
days) or persistent dyspnoea Grade ≥2 for three consecutive weeks (≥21 days), study 
intervention must be temporarily discontinued immediately, and the participant undergo a 
local pulmonologist review within 1-2 days.  Chest X-ray and repeat spirometry must be 
performed within 1 week in addition to any other assessments deemed appropriate by the 
consulting pulmonologist.  The study intervention must be temporarily discontinued as 
per the pulmonary guidance document until the symptoms or signs that caused referral 
have resolved and/or the underlying diagnosis has been determined and clinically 


2018N385734_02
CONFIDENTIAL
201790
69
significant events have been excluded by the pulmonologist.  Pulmonary 
assessment/management algorithms are provided in a separate Pulmonary Safety 
Guidance Document in the SRM.
The participant may undergo additional pulmonary imaging (high-resolution computed 
tomography [HRCT]) or other tests during the study to investigate pulmonary 
abnormalities; the Pulmonary Adjudication Committee (PAC), IDMC or SRT may 
request copies of any reports or images for central review.
Any participant with a diagnosis of pulmonary alveolar proteinosis must permanently 
discontinue study intervention (Section 7.1.2).
8.2.7.
Tuberculosis Monitoring
8.2.7.1.
Tuberculosis Status Definitions
In this study the following definitions for active TB, latent TB and adequate treatment of 
latent TB will be utilised.
Active TB is defined as:

Microbiological evidence of TB (including, but not limited to, microscopy for 
acid-fast bacilli, mycobacterial culture, GeneXpert, or other validated PCR) in 
any clinical sample (including, but not limited to, sputum, pus, or biopsied tissue),
OR

Findings on medical history or clinical examination and/or chest radiograph 
consistent with active TB as assessed by a physician specialising in TB, sufficient 
to warrant empirical treatment for active TB even in the absence of 
microbiological evidence of TB.
Latent TB is defined as:

A positive QuantiFERON-TB Gold plus test or T-SPOT.TB test, no findings on 
medical history or clinical examination consistent with active TB and a normal 
chest radiograph.
Adequate latent TB treatment status
For participants that have received treatment for latent TB within the previous 5 years, a 
participant is considered to have received adequate treatment if a physician specialising 
in TB agrees that:

sufficient evidence exists demonstrating that completion of treatment has 
occurred AND

the participant has no findings on medical history or clinical examination 
consistent with active TB, and a normal chest radiograph.


2018N385734_02
CONFIDENTIAL
201790
70
Appropriate treatment for latent TB is considered to be:

Completion of at least 6 months of INH or an alternative regimen consistent with 
WHO or national guidelines.

Participants who received treatment more than 5 years ago for latent TB infection 
and who remain QuantiFERON-TB Gold plus or T-SPOT.TB test positive will 
need to complete treatment for latent TB prior to study entry as per Section 
8.2.7.3.
8.2.7.2.
Tuberculosis Testing
In this study the following testing for TB must be followed:

The QuantiFERON-TB Gold plus test will be used in countries where it is 
available.  Where QuantiFERON-TB Gold plus test is not available T-SPOT.TB 
will be used.

A QuantiFERON-TB Gold plus test may be repeated once during screening if the 
initial result is indeterminate, alternatively a T-SPOT.TB test may be used 
following an indeterminate result.  This is not considered a rescreening.

Unscheduled TB testing should be performed if a participant is known or 
suspected to have come in close contact with someone who has untreated active
TB.
8.2.7.3.
Treatment of Latent TB During the Study
Participants diagnosed with latent TB during screening will need to complete a course of 
at least 6 months of INH therapy during the study including at least 4 weeks of therapy 
prior to randomisation.
Following 3 weeks of INH treatment in screening, LFTs must be assessed.  Participants 
will fail screening if ALT >1.5 x ULN is identified, these participants may be re-screened 
if ALT elevation resolves to ALT <x 1.5 ULN during ongoing INH therapy following 
discussion with the medical monitor.  Participants who are randomised will require LFT 
assessment every 4 weeks during the study.
8.2.7.4.
Monitoring for TB Infection and Re-activation During the Study
Routine monitoring for the signs and symptoms of TB will be performed during this 
study as part of every full or brief physical exam (see SoA in Section 1.3).
If at any point during the study, the investigator suspects that a participant may have TB 
reactivation or new TB infection, an immediate and thorough investigation should be 
undertaken including consultation with a physician specialising in TB.  The investigator 
should discuss with the medical monitor and interruption of study intervention should be 
considered.


2018N385734_02
CONFIDENTIAL
201790
71
A QuantiFERON-TB Gold Plus test or a T.SPOT.TB test must be performed as part of 
the Week 48 assessment (see SoA in Section 1.3).  If a participant has a positive result at 
Week 48 who previously had a negative result at study start, then the participant must be 
referred to a physician specialising in TB to determine if the participant has active or 
latent TB.
If latent or active TB infection is diagnosed, study intervention must be discontinued.
8.2.8.
Hepatitis B Monitoring
All participants with positive HBcAb results will have HBV DNA levels monitored 
throughout the study as summarised in Figure 2.


2018N385734_02
CONFIDENTIAL
201790
72
Figure 2
Monitoring of HBV DNA Levels in HBcAb Positive Participants
HBV DNA level ≥ 200 IU/mL
or
HBV DNA detected at any level with 
recent increase in hepatic 
transaminases
HBV DNA level <200 IU/mL 
(with no increase in hepatic 
transaminases)
Discontinue study intervention and 
refer to expert for initiation of 
appropriate antiviral therapy
Repeat HBV DNA with HBV surface 
antigen and hepatic transaminases 
within 1 week
Result:  HBV DNA 
positive (any level) 
or HBV surface 
antigen positive or 
increase in hepatic 
transaminases
Discontinue study 
intervention and refer 
to expert for initiation of
appropriate antiviral 
therapy
Result: HBV DNA 
negative, HBV surface 
antigen negative and no 
increase in hepatic 
transaminases
Repeat HBV DNA at 
4 weeks then return 
to routine 
monitoring
HBV DNA detected
From the start of study intervention, HBV DNA levels will be assessed every 4 weeks to 
Week 24, then every 8 weeks to Week 40 and then every 12 weeks to Week 52.
8.2.8.1.
Risk of Reactivation in Participants Positive for Hepatitis B Core 
Antibody (HBcAb)
Participants who are HBcAb positive, will be informed of the risk of reactivation and that 
if this occurs treatment with antiviral therapy, such as with nucleo(s)tide analogues such 
as entecavir or tenofovir, will be needed.


2018N385734_02
CONFIDENTIAL
201790
73
8.2.8.2.
Treatment of Participants Who Are HBcAb Positive and Who Develop 
Detectable HBV DNA Requiring Initiation of Antiviral Therapy
HBcAb positive participants who become positive for HBV DNA and require antiviral 
therapy must have study intervention discontinued.  The participant must also be referred 
to a hepatologist or infectious diseases expert so that treatment advice regarding whether 
to commence anti-viral therapy is received within 7 days of HBV DNA elevation being 
identified.  The participant should then be reviewed by the expert within 14 days of HBV 
DNA elevation being identified and managed as per local guidelines or under EASL or 
AASLD guidelines if none are available.
8.2.8.3.
Follow Up of Participants Treated With Anti-viral Therapy
All participants will be followed up within the study by the investigator in addition to 
local expert follow up.  After completion of the study, participants should be followed up 
as per local expert opinion based on guideline recommendations.
8.3.
Adverse Events and Serious Adverse Events

The definitions of an AE or SAE can be found in Appendix 3.

The investigator and any qualified designees are responsible for detecting, 
documenting, and reporting events that meet the definition of an AE or SAE and 
remain responsible for following up AEs that are serious, considered related to the 
study intervention or the study, or that caused the participant to discontinue the 
study intervention. (see Section 7).

Participants will be assessed for cough or dyspnoea at selected visits as specified 
in the SoA (Section 1.3).  The investigator will complete the CTC cough scale if a 
cough is present and will record dyspnoea as per the dyspnoea scale.  Lung 
auscultation and pulse oximetry will also be performed at the visits specified in 
the SoA (Section 1.3).

If a participant, at times other than scheduled visits, reports new onset or an 
increase (if present at baseline) in cough (CTCAE Grade ≥2) or dyspnoea 
(dyspnoea scale Grade ≥2), the participant will be questioned (in clinic or by 
phone) on a weekly basis for 3 further consecutive weeks or until symptoms 
resolve, if earlier.  Any new onset or worsening cough and/or dyspnoea must be 
reported as an AE.
8.3.1.
Time Period and Frequency for Collecting AE and SAE 
Information

All SAEs will be collected from the start of study intervention until the follow-up visit 
(for participants who do not enter the long-term safety study) or the Week 52 visit (for 
participants who enter the long-term safety study) at the time points specified in the SoA 
(Section 1.3). 

In addition, any SAEs assessed as related to study participation (e.g., study 
intervention, protocol-mandated procedures, invasive tests, or change in existing 
therapy) or related to a GSK product will be recorded from the time a participant 


2018N385734_02
CONFIDENTIAL
201790
74
consents to participate in the study. In China (and where this is a local 
requirement) all SAEs will be collected from the time of signing informed consent 
form.

Medical occurrences that begin before the start of study intervention but after 
obtaining informed consent will be recorded on the Medical History/Current 
Medical Conditions section of the case report form (CRF) not the AE section.

All SAEs will be recorded and reported to the sponsor or designee immediately 
and under no circumstance should this exceed 24 hours, as indicated in Appendix 
3.  The investigator will submit any updated SAE data to the sponsor within 
24 hours of it being available.

Investigators are not obligated to actively seek AEs or SAEs after the conclusion 
of the study participation.  However, if the investigator learns of any SAE, 
including a death, at any time after a participant has been discharged from the 
study, and he/she considers the event to be reasonably related to the study 
intervention or study participation, the investigator must promptly notify the 
sponsor.
8.3.2.
Method of Detecting AEs and SAEs

The method of recording, evaluating, and assessing causality of AEs and SAEs 
and the procedures for completing and transmitting SAE reports are provided in 
Appendix 3.

Care will be taken not to introduce bias when detecting AE and/or SAE.  Open-
ended and non-leading verbal questioning of the participant is the preferred 
method to inquire about AE occurrence.
8.3.3.
Follow-up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactively follow each 
participant at subsequent visits/contacts.  All SAEs, and non-serious AEs of special 
interest (as defined in Section 8.3.7), will be followed until the event is resolved, 
stabilised, otherwise explained, or the participant is lost to follow-up (as defined in 
Section 7.3).  Further information on follow-up procedures is given in Appendix 3.
8.3.4.
Regulatory Reporting Requirements for SAEs

Prompt notification by the investigator to the sponsor of a SAE is essential so that 
legal obligations and ethical responsibilities towards the safety of participants and 
the safety of a study intervention under clinical investigation are met.

The sponsor has a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a study intervention under 
clinical investigation.  The sponsor will comply with country-specific regulatory 
requirements relating to safety reporting to the regulatory authority, Institutional 
Review Boards (IRB)/Independent Ethics Committees (IEC), and investigators.


2018N385734_02
CONFIDENTIAL
201790
75

Investigator safety reports must be prepared for suspected unexpected serious 
adverse reactions (SUSAR) according to local regulatory requirements and 
sponsor policy and forwarded to investigators as necessary.

An investigator who receives an investigator safety report describing a SAE or 
other specific safety information (e.g., summary or listing of SAEs) from the 
sponsor will review and then file it along with the Investigator’s Brochure and 
will notify the IRB/IEC, if appropriate according to local requirements.
8.3.5.
Pregnancy

Details of all pregnancies in female participants and, if indicated, female partners 
of male participants will be collected after the start of study intervention and until 
8 weeks after the last SC dose.

If a pregnancy is reported, the investigator should inform GSK within 24 hours of 
learning of the pregnancy and should follow the procedures outlined in Appendix 
4.

Female participants who become pregnant after the start of study intervention 
must permanently discontinue study intervention but can continue to be followed 
in the study if they wish (Section 7.1.2).  If the participant does not wish to 
continue in the study, follow guidance in Section 7.2.

Abnormal pregnancy outcomes (e.g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies, ectopic pregnancy) are considered SAEs.
8.3.6.
Cardiovascular and Death Events
For any cardiovascular (CV) events detailed in Appendix 3 and all deaths, whether or not 
they are considered SAEs, specific CV and Death sections of the CRF will be required to 
be completed. These sections include questions regarding CV (including sudden cardiac 
death) and non-CV death.
The CV CRFs are presented as queries in response to reporting of certain CV MedDRA 
(Medical dictionary for regulatory activities) terms. The CV information should be 
recorded in the specific CV section of the CRF within one week of receipt of a CV Event 
data query prompting its completion.
The Death CRF is provided immediately after the occurrence or outcome of death is 
reported. Initial and follow-up reports regarding death must be completed within one 
week of when the death is reported.
Investigators will be required to fill out event specific data collection tools for the 
following AEs and SAEs:

Myocardial infarction/unstable angina.

Congestive heart failure.

Arrhythmias.


2018N385734_02
CONFIDENTIAL
201790
76

Valvulopathy.

Pulmonary hypertension.

Cerebrovascular events/stroke and transient ischemic attack.

Peripheral arterial thromboembolism.

Deep venous thrombosis/pulmonary embolism.

Revascularisation.
This information should be recorded in the specific CV CRF/eCRF within one week of 
when the AE/SAE(s) are first reported.
8.3.7.
AEs of Special Interest
The potential risks with GSK3196165 are discussed in Section 2.3.1. 
Adverse events of special interest (AESIs) for GSK3196165 include:

Serious infections

Opportunistic infections

TB and TB reactivation

Neutropenia Grade 3 (<1.0 x 109/L)

Pulmonary alveolar proteinosis

Hypersensitivity reactions

Injection site reactions

Persistent cough (CTCAE Grade 2)

Persistent dyspnoea (dyspnoea scale Grade 2).
8.3.8.
Medical Device Deficiencies
In order to fulfil regulatory reporting obligations worldwide, the investigator is 
responsible for the detection and documentation of events meeting the definitions of 
device deficiency that occur during the study with such devices.
The definition of a Medical Device Deficiency can be found in Appendix 9.
NOTE: Incidents fulfilling the definition of an AE/SAE will also follow the processes 
outlined in Section 8.3.3 and Appendix 3 of the protocol.
8.3.8.1
Time Period for Detecting Medical Device Deficiencies

Medical device deficiencies will be detected, documented, and reported during 
all periods of the study in which the medical device is used. 

If the investigator learns of any device deficiency at any time after a participant 
has been discharged from the study, and such device deficiency is considered 


2018N385734_02
CONFIDENTIAL
201790
77
reasonably related to a medical device provided for the study, the investigator 
will promptly notify the sponsor.

The method of documenting Medical Device Incidents is provided in Appendix 
9.
8.3.8.2
Follow-up of Medical Device Deficiencies

Follow-up applies to all participants, including those who discontinue study 
intervention or the study.

The investigator is responsible for ensuring that follow-up includes any 
supplemental investigations as indicated to elucidate the nature and/or causality 
of the deficiency.

New or updated information will be recorded on the originally completed form 
with all changes signed and dated by the investigator.
8.3.8.3
Prompt Reporting of Medical Device Deficiencies to Sponsor

Device deficiencies will be reported to the sponsor using the Medical Device 
Deficiency Report Form (provided in the Pharmacy Manual), within 24 hours 
after the investigator determines that the event meets the protocol definition of a 
device deficiency.

The Medical Device Deficiency Report Form will be sent to the sponsor device 
complaints email address, as provided in the Pharmacy Manual.

The sponsor will be the contact for the receipt of device deficiency reports.

Refer to the Pharmacy Manual for further guidance.
8.3.8.4
Regulatory Reporting Requirements for Medical Device Incidents

The investigator will promptly report all deficiencies occurring with any medical 
device provided for use in the study in order for the sponsor to fulfil the legal 
responsibility to notify appropriate regulatory authorities and other entities about 
certain safety information relating to medical devices being used in clinical 
studies.

The investigator, or responsible person according to local requirements (e.g., the 
head of the medical institution), will comply with the applicable local regulatory 
requirements relating to the reporting of device deficiencies to the IRB/IEC.
8.4.
Treatment of Overdose
For this study, any dose of GSK3196165 or tofacitinib greater than the dose used in this 
study, or used more frequently than permitted (GSK3196165 once-weekly, tofacitinib
twice daily) will be considered an overdose.  It should be noted that the minimum 
permitted time between dosing with GSK3196165 is 5 days, but it is strongly 
recommended that dosing should revert back to 7 days as soon as possible.
No specific treatment is recommended for an overdose of GSK3196165, and the 
investigator should treat as clinically indicated. Investigators should refer to the 


2018N385734_02
CONFIDENTIAL
201790
78
approved product label or local prescribing information for treatment of an overdose of 
tofacitinib.
In the event of a potential overdose, the investigator should:

Contact the Medical Monitor immediately.

Closely monitor the participant for AE/SAE and laboratory abnormalities.

Obtain a plasma sample for PK analysis within 3-5 days from the date of the last 
dose of study SC intervention if requested by the Medical Monitor (determined on 
a case-by-case basis).

Contact the unblinded CRA/Monitor with the quantity and duration of the 
overdose to be documented.
Decisions regarding dose interruptions or modifications will be made by the investigator 
in consultation with the Medical Monitor based on the clinical evaluation of the 
participant.
CCI


2018N385734_02
CONFIDENTIAL
201790
79
8.8.1.
Pharmacodynamic (PD) Biomarkers
A blood sample of approximately 12 mL will be collected and divided into suitable 
portions for measurement of the following biomarkers associated with GM-CSF 
signalling and/or disease pathology:

Measurement of serum PD biomarkers of downstream signalling of GM-CSF to 
assess the response to GSK3196165. The biomarkers may include but are not 
limited to CCL17.

Measurement of serum PD biomarkers to assess or predict the response to 
GSK3196165. The biomarkers may include but are not limited to CCL22, soluble 
interleukin (IL)2R, and IL6.

Assessment of serum biomarkers of ECM degradation. The biomarkers may 
include but are not limited to C1M, C3M, and P4NP7S.
CCI


2018N385734_02
CONFIDENTIAL
201790
80
8.9.
Immunogenicity Assessments
Whole blood samples of approximately 6 mL will be collected from all participants and 
divided into suitable portions for immunogenicity assessments of anti-drug antibody 
(ADA) development.  Antibodies to GSK3196165 will be evaluated in serum samples 
collected from all participants according to the SoA (Section 1.3).  Serum samples should 
also be collected at the final visit from participants who discontinued study intervention 
or are withdrawn from the study.  In addition to scheduled immunogenicity assessments, 
“event-driven” testing will be performed in the context of serious hypersensitivity 
reactions or AEs deemed to be clinically significant in the opinion of the investigator 
resulting in discontinuation from study intervention.
Serum samples will be screened for antibodies binding to GSK3196165 and the titre of 
confirmed positive samples will be reported.  Other analyses may be performed to verify 
the stability of antibodies to GSK3196165 and/or further characterise the immunogenicity 
of GSK3196165.  The serum sample collected at Day 1 will also be analysed for anti-
GM-CSF auto-antibodies and free GM-CSF levels.
CCI


2018N385734_02
CONFIDENTIAL
201790
81
The detection and characterisation of antibodies to GSK3196165 will be performed using 
validated assay methods by or under the supervision of the sponsor.  Antibodies may be 
further characterised and/or evaluated for their ability to neutralise the activity of the 
study intervention(s).  Samples may be stored for a maximum of 15 years (or according 
to local regulations) following the last participant’s last visit for the study at a facility 
selected by the sponsor to enable further analysis.
8.10.
Medical Resource Utilisation and Health Economics
Medical Resource Utilisation and Health Economics parameters are not evaluated in this 
study.


2018N385734_02
CONFIDENTIAL
201790
82
9.
STATISTICAL CONSIDERATIONS
9.1.
Statistical Hypotheses
The primary objective of the study is to determine whether GSK3196165 is superior to 
placebo in the treatment of participants with moderately to severely active RA despite 
MTX treatment (i.e. MTX-IR), as assessed by the proportion of participants achieving 
ACR20 response at Week 12.
The study will test the null hypothesis that there is no difference between 150 mg dose of 
GSK3196165 and placebo in the proportion of participants achieving ACR20 response at 
Week 12 versus the alternative hypothesis that the 150 mg dose of GSK3196165 differs 
from placebo in the proportion of participants achieving ACR20 response at Week 12.
9.2.
Sample Size Determination
Approximately 3000-3400 participants will be screened to achieve between 1500 and 
1700 randomly assigned to study intervention.  Approximately 1500 evaluable 
participants are expected to be included in the primary analysis, of whom approximately 
1350 are expected to complete the Week 12 visit.  When the approximate target of 1500 
participants is reached, recruitment may continue up to a maximum of 1700 participants 
to ensure sufficient numbers in the key Asian country subgroup.
For the purpose of analyses up to Week 12, the placebo-sequence groups will be pooled 
into a single placebo arm.
The minimum sample size of 1500 will provide:

>99% power to detect a 25% difference between GSK3196165 and placebo in the 
ACR20 response at Week 12 (55% vs 30%) based on a 2-sided significance level 
of 0.05 using a pooled z-test.  The least significant difference this sample size will 
detect is 7.2%.

>99% power to detect a 20% difference between GSK3196165 and placebo in the 
CDAI-LDA response at Week 12 (37% vs 17%) based on a 2-sided significance 
level of 0.025 using a pooled z-test.  The least significant difference this sample 
size will detect is 7.2%.

Approximately 82% power for the non-inferiority analysis of ACR20 response 
rate at Week 12 between GSK3196165 and tofacitinib groups, where a response 
rate of 60% in each group, a non-inferiority margin of 12% and a 1 sided 
significance level of 0.0125 using a pooled z-test are assumed.  The non-
inferiority margin was calculated using the FDA fixed margin approach [FDA, 
2016].  With this sample size, the difference in proportions between tofacitinib 
and GSK3196165 can be up to 3% in favour of tofacitinib and still conclude non-
inferiority.  In order to conclude superiority, the difference in proportions must be 
at least 8% in favour of GSK3196165.
The above sample size and power estimates were obtained from PASS version 12.0.2.


2018N385734_02
CONFIDENTIAL
201790
83
9.3.
Sample Size Sensitivity
The power of the primary analysis of the study will be affected by changes in the 
assumed response rate.  The effect on power under varying response rates on both 
placebo and GSK3196165 assuming a fixed sample size of 500 in the GSK3196165 arm 
and 250 on the placebo arm based on a 2-sided significance level of 0.05 using a pooled 
z-test are shown in Table 4.
Table 4
Power for ACR20 Response at Week 12 Under Varying Response 
Rates on GSK3196165 and Placebo
Placebo Response Rate
GSK3196165 Response Rate
50%
55%
60%
30%
>99%
>99%
>99%
35%
98%
>99%
>99%
40%
74%
97%
>99%
The power of the non-inferiority analysis will be affected by changes in the assumed 
response rate.  The effect on power under varying response rates on both tofacitinib and 
GSK3196165 assuming a fixed sample size of 500 in the GSK3196165 arm and 250 on 
the tofacitinib arm, and a fixed non-inferiority margin of 12% based on a 1 sided 
significance level of 0.0125 using a pooled z-test are shown in Table 5.
Table 5
Power for Non-Inferiority Analysis on ACR20 Response at Week 12 
Under Varying Response Rates on GSK3196165 and Tofacitinib
Tofacitinib Response Rate
GSK3196165 Response Rate
58%
60%
62%
58%
82%
92%
98%
60%
65%
82%
93%
62%
44%
66%
83%
9.4.
Populations for Analyses
For purposes of analyses, the following populations are defined:
Population
Description
Enrolled
All participants who sign the ICF
Intent-to-Treat (ITT)
All randomised participants who receive at least one dose of study 
intervention.
Per-protocol (PP)
All randomised participants who are compliant with intervention, who 
do not have significant protocol violations, and whose investigator site 
does not have any GCP issues that require reporting to the regulatory 
agencies.


2018N385734_02
CONFIDENTIAL
201790
84
Population
Description
Safety
All randomised participants who take at least 1 dose of study 
intervention. Participants will be analysed according to the 
intervention they actually received.
The primary analysis population will be the ITT population.  In addition, the primary and 
major secondary analyses will be repeated using the PP population.  Full details of all 
protocol violations that lead to exclusion from the PP population will be listed in the 
Reporting and Analysis plan (RAP).
9.5.
Statistical Analyses
Full details of all analyses will be described in the RAP.
All inferences will be drawn from the primary analysis.
The proposed sequence of primary and key secondary endpoints is: 
1.
ACR20 at Week 12
2.
CDAI LDA at Week 12
3.
HAQ-DI at Week 12.
In order to preserve the type I error, each endpoint will be assessed sequentially using a 
step-down approach where statistical significance can be claimed for the second endpoint 
only if the first endpoint in the sequence meets the requirements for significance.
Additionally, as there are two doses of GSK3196165 within each endpoint, each to be 
compared with placebo, a step-down procedure, where the high dose will be tested first, 
will be used within each endpoint, i.e. the high dose (150 mg) at a given endpoint can 
achieve significance only if the high dose at the prior endpoint is significant; the low dose 
(90 mg) at a given endpoint can achieve significance only if both the high dose at the 
same endpoint and the low dose at the prior endpoint are significant.  For each endpoint, 
and for each GSK3196165 dose group, the comparison with placebo will be conducted 
using a 2-sided significance level of either 0.05 or 0.025.
Following all comparisons with placebo, assuming that the full sequence of endpoints 
meets the requirements for significance, the step down approach will be used for the non-
inferiority comparison with tofacitinib on the ACR20 endpoint using a 1-sided 
significance level of 0.0125.
A graphical presentation of the step-down procedure is provided in Appendix 8.


2018N385734_02
CONFIDENTIAL
201790
85
9.5.1.
Efficacy Analyses
Endpoint
Statistical Analysis Methods
Primary
The proportion of participants with ACR20 response will be summarised 
using counts and proportions of responders, and analysed using a 
Generalised Estimating Equations (GEE) model, comparing intervention 
group with placebo at each time point, with fixed effects of intervention, visit, 
baseline swollen joint count (66), baseline tender joint count (68), 
intervention-by-visit interaction and a random effect of participant.
Key 
Secondary
The proportion of participants achieving CDAI LDA response will be analysed 
using the same method as described for the primary endpoint, however this 
model will include fixed effects of intervention, visit, baseline CDAI Total 
Score, intervention-by-visit interaction and a random effect of participant.
The HAQ-DI will be expressed as a change from baseline and will be 
analysed using a mixed effect repeated measures model (MMRM) with fixed 
effects of intervention, visit, baseline value, intervention-by-visit interaction 
and a random effect of participant.  An unstructured covariance structure will 
be used to model the between and within-participant errors, however if this 
analysis fails to converge, other structures will be tested.  The Kenward-
Roger method will be used to estimate the degrees of freedom.  Least 
Squares means will be used for the statistical comparisons; CIs will also be 
reported.  Intervention group comparisons versus placebo at Week 12 and 
other visits will be tested.
Additional 
Secondary 
and 
Exploratory
Full details on all additional analyses will be described in the RAP.
9.5.2.
Estimand Strategy
The main intercurrent (post-randomisation) event anticipated to impact on the 
interpretation of the treatment effect for the primary objective is discontinuation of study 
intervention.
The estimand for the primary comparison will be defined using:
1. Population: defined through the inclusion/exclusion criteria.
2. Variable: Proportion of participants at Week 12 with ACR20 response.
3. Intercurrent Event: the participant withdrew from study intervention.
4. Population Level Summary: Comparisons of proportions between the active 
groups and placebo.
The primary estimand used will be the treatment policy estimand.  This follows the 
principle that participants should be followed up, assessed and analysed irrespective of 


2018N385734_02
CONFIDENTIAL
201790
86
compliance to planned intervention.  This strategy answers the question of what the effect 
is of assigning participants to an intervention.  Therefore, if a participant discontinues 
study intervention but efficacy data continues to be collected, their data will be analysed 
as if they were still on the original randomised intervention.  If a participant discontinues 
study intervention and data does not continue to be collected or if missing data occurs 
while on study intervention, their missing data will be imputed using multiple imputation.  
Full details on the missing data techniques will be provided in the RAP.
Further details on any sensitivity estimators and supplementary estimands used to assess 
the primary objective and any estimands used to assess the secondary objectives will be 
provided in the RAP.
9.5.3.
Safety Analyses
All safety analyses will be performed on the Safety Population. 
Endpoint
Statistical Analysis Methods
Secondary
For safety data, no formal hypotheses will be tested. Incidence of AEs, SAEs, and 
AESIs, including laboratory tests, vital signs, pulmonary function tests and 12-Lead 
ECGs will be displayed in the form of listings, frequencies, summary statistics, 
graphs, and statistical analyses where appropriate. Interpretation will be aided by 
clinical expertise. Full details, including example outputs, will be documented in the 
RAP.
9.6.
Interim Analyses
The primary analysis will be conducted when the planned target of 1500 randomised 
participants has been reached. No interim analysis with respect to this population is 
planned. However, if at the time of reaching approximately 1500 randomised participants 
a sufficient number of participants that are required for the key Asian country subgroups 
is not reached, then recruitment in these countries may continue. Participants who have 
already been enrolled from Asian country subgroups at the time of reaching the 1500 
target will be included in the primary analysis. Double-blinding will be maintained for 
any subjects continuing in the study at the time of the primary analysis. The primary 
analysis will be the basis of all inferences. If enrolment continues beyond the planned 
target of 1500 randomised participants, secondary analyses will be conducted upon 
completion of enrolment/follow-up for the entire study population, based on all 
randomised subjects.
CCI


2018N385734_02
CONFIDENTIAL
201790
87
9.6.1.
Data Monitoring Committee (DMC)
An IDMC will be utilised in this study to ensure ongoing objective medical and/or 
statistical review of safety data in order to protect the ethical and safety interests of 
participants and to protect the scientific validity of the study.  See Section 10.1.5 for 
further details.
Full details of the data to be reviewed and membership of the committee will be available 
in the charter which will be available prior to the first participant’s visit.


2018N385734_02
CONFIDENTIAL
201790
88
10.
SUPPORTING DOCUMENTATION AND OPERATIONAL
CONSIDERATIONS
10.1.
Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations
10.1.1.
Regulatory and Ethical Considerations

This study will be conducted in accordance with the protocol and with:

Consensus ethical principles derived from international guidelines 
including the Declaration of Helsinki and Council for International 
Organisations of Medical Sciences (CIOMS) International Ethical 
Guidelines

Applicable ICH Good Clinical Practice (GCP) Guidelines

Applicable laws and regulations

The protocol, protocol amendments, ICF, Investigator Brochure, and other 
relevant documents (e.g., advertisements) must be submitted to an IRB/IEC by 
the investigator and reviewed and approved by the IRB/IEC before the study is 
initiated.

Any amendments to the protocol will require IEC/IRB approval before 
implementation of changes made to the study design, except for changes 
necessary to eliminate an immediate hazard to study participants.

The investigator will be responsible for the following:

Providing written summaries of the status of the study to the IRB/IEC 
annually or more frequently in accordance with the requirements, policies, 
and procedures established by the IRB/EC

Notifying the IRB/IEC of SAE or other significant safety findings as 
required by IRB/IEC procedures

Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations
10.1.2.
Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate 
financial information as requested to allow the sponsor to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. 
Investigators are responsible for providing information on financial interests during the 
course of the study and for 1 year after completion of the study.


2018N385734_02
CONFIDENTIAL
201790
89
10.1.3.
Informed Consent Process

The investigator or his/her representative will explain the nature of the study to 
the participant or his/her legally authorised representative and answer all 
questions regarding the study. 

Participants must be informed that their participation is voluntary. Participants 
or their legally authorised representative will be required to sign a statement of 
informed consent that meets the requirements of 21 CFR 50, local regulations, 
ICH guidelines, Health Insurance Portability and Accountability Act (HIPAA) 
requirements, where applicable, and the IRB/IEC or study centre. 

The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study and the date the written 
consent was obtained. The authorised person obtaining the informed consent 
must also sign the ICF.

Participants must be re-consented to the most current version of the ICF(s) 
during their participation in the study. 

A copy of the ICF(s) must be provided to the participant or the participant’s 
legally authorised representative. 

Participants who are rescreened are required to sign a new ICF.
10.1.4.
Data Protection

Participants will be assigned a unique identifier by the sponsor. Any participant 
records or datasets that are transferred to the sponsor will contain the identifier 
only; participant names or any information which would make the participant 
identifiable will not be transferred. 

The participant must be informed that his/her personal study-related data will be 
used by the sponsor in accordance with local data protection law. The level of 
disclosure must also be explained to the participant. 

The participant must be informed that his/her medical records may be examined 
by Clinical Quality Assurance auditors or other authorised personnel appointed 
by the sponsor, by appropriate IRB/IEC members, and by inspectors from 
regulatory authorities.
10.1.5.
Committees Structure
An Independent Data Monitoring Committee (IDMC), a Major Adverse Cardiac 
Event/Gastrointestinal Perforation (MACE/GI Perforation) Adjudication Committee and 
a Pulmonary Adjudication Committee (PAC) will be utilised in this study, in addition to 
the routine sponsor review of blinded safety data that will occur approximately every 4 
weeks during the period of study conduct.


2018N385734_02
CONFIDENTIAL
201790
90
The overall responsibility of the IDMC is to protect the ethical and safety interests of 
participants recruited into this study while protecting as far as possible the scientific 
validity of the data. The IDMC and Adjudication Committees will include physicians 
with relevant clinical expertise and a statistician, none of whom is affiliated with the 
sponsor. The IDMC will adopt a staggered approach to reviewing unblinded data.  The 
initial early review, frequency of further reviews and the safety data included, will be 
detailed in the IDMC charter.
The MACE/GI Perforation Adjudication Committee and PAC will function as detailed in 
the IDMC charter.
10.1.6.
Publication Policy

The results of this study may be published or presented at scientific meetings. If 
this is foreseen, the investigator agrees to submit all manuscripts or abstracts to 
the sponsor before submission. This allows the sponsor to protect proprietary 
information and to provide comments. 

The sponsor will comply with the requirements for publication of study results. 
In accordance with standard editorial and ethical practice, the sponsor will 
generally support publication of multicentre studies only in their entirety and not 
as individual site data. In this case, a coordinating investigator will be 
designated by mutual agreement.

Authorship will be determined by mutual agreement and in line with 
International Committee of Medical Journal Editors authorship requirements.
10.1.7.
Dissemination of Clinical Study Data

Where required by applicable regulatory requirements, an investigator signatory 
will be identified for the approval of the clinical study report.  The investigator 
will be provided reasonable access to statistical tables, figures, and relevant 
reports and will have the opportunity to review the complete study results at a 
GSK site or other mutually-agreeable location.

GSK will also provide the investigator with the full summary of the study 
results.  The investigator is encouraged to share the summary results with the 
study participants, as appropriate.

GSK will provide the investigator with the randomisation codes for their site 
only after completion of the full statistical analysis.

The procedures and timing for public disclosure of the protocol and results 
summary and for development of a manuscript for publication for this study will 
be in accordance with GSK Policy.

GSK intends to make anonymised participant-level data from this trial available 
to external researchers for scientific analyses or to conduct further research that 
can help advance medical science or improve patient care. This helps ensure the 
data provided by trial participants are used to maximum effect in the creation of 
knowledge and understanding.


2018N385734_02
CONFIDENTIAL
201790
91
10.1.8.
Data Quality Assurance

All participant data relating to the study will be recorded on printed or electronic 
CRF unless transmitted to the sponsor or designee electronically (e.g., 
laboratory data). The investigator is responsible for verifying that data entries 
are accurate and correct by physically or electronically signing the CRF. 

This study uses a number of assessments and questionnaires to evaluate the 
participant’s symptoms and impacts at a particular moment in time (see efficacy 
assessments listed in Section 8.1).  These patient-reported outcomes and impact 
instruments completed directly by participants, investigators and joint assessors 
as source records (e.g. site tablet or electronic clinical outcome assessment 
(eCOA) portal) contribute to the secondary and exploratory endpoints and must 
not be changed or overwritten (with the exception of administrative/operational 
data items), in order to minimise bias.

The investigator must maintain accurate documentation (source data) that 
supports the information entered in the CRF. 

The investigator must permit study-related monitoring, audits, IRB/IEC review, 
and regulatory agency inspections and provide direct access to source data 
documents. 

Monitoring details describing strategy (e.g., risk-based initiatives in operations 
and quality such as Risk Management and Mitigation Strategies and Analytical 
Risk-Based Monitoring), methods, responsibilities and requirements, including 
handling of noncompliance issues and monitoring techniques (central, remote, 
or on-site monitoring) are provided in the Monitoring Plan.

The sponsor or designee is responsible for the data management of this study 
including quality checking of the data. 

The sponsor assumes accountability for actions delegated to other individuals 
(e.g., Contract Research Organisations).

Study monitors will perform ongoing source data verification to confirm that 
data entered into the CRF by authorised site personnel are accurate, complete, 
and verifiable from source documents; that the safety and rights of participants 
are being protected; and that the study is being conducted in accordance with the 
currently approved protocol and any other study agreements, ICH GCP, and all 
applicable regulatory requirements. 

Records and documents, including signed ICF, pertaining to the conduct of this 
study must be retained by the investigator for 25 years from the issue of the final 
Clinical Study Report (CSR)/ equivalent summary unless local regulations or 
institutional policies require a longer retention period. No records may be 
destroyed during the retention period without the written approval of the 
sponsor. No records may be transferred to another location or party without 
written notification to the sponsor.


2018N385734_02
CONFIDENTIAL
201790
92
10.1.9.
Source Documents

Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the 
investigator’s site.

Data reported on the CRF or entered in the eCRF that are transcribed from 
source documents must be consistent with the source documents or the 
discrepancies must be explained. The investigator may need to request previous 
medical records or transfer records, depending on the study. Also, current 
medical records must be available.

Definition of what constitutes source data can be found in the Source Document 
Acknowledgement.
10.1.10.
Study and Site Closure
GSK or its designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of GSK. Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study 
supplies have been collected and a study-site closure visit has been performed.
The investigator may initiate study-site closure at any time, provided there is reasonable 
cause and sufficient notice is given in advance of the intended termination.
Reasons for the early closure of a study site by the sponsor or investigator may include 
but are not limited to:

Failure of the investigator to comply with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor’s procedures, or GCP guidelines

Inadequate recruitment of participants by the investigator

Discontinuation of further study intervention development


2018N385734_02
CONFIDENTIAL
201790
93
10.2.
Appendix 2: Clinical Laboratory Tests

The tests detailed in Table 6 will be performed by the central laboratory except 
for ESR, dipstick urinalysis, and urine pregnancy tests, which will be analysed 
locally.

Except for ESR, dipstick urinalysis, and urine pregnancy tests, local laboratory 
results are only required in the event that the central laboratory results are not 
available in time for either study intervention administration and/or safety 
evaluation.  If a local sample is required, it is important that the sample for 
central analysis is obtained at the same time.

Protocol-specific requirements for inclusion or exclusion of participants are 
detailed in Section 5 of the protocol.

Additional tests may be performed at any time during the study as determined 
necessary by the investigator or required by local regulations.

Pregnancy Testing 

Refer to Section 5.1 Inclusion Criteria for screening pregnancy criteria.

Pregnancy testing (urine or serum as required by local regulations) for 
WOCBP should be conducted once every 4 weeks to Week 16 and then every 
8 weeks to Week 52 during intervention.

Pregnancy testing (urine or serum as required by local regulations) will also
be conducted at the safety follow up visit.

Additional serum or urine pregnancy tests may be performed, as determined 
necessary by the investigator or required by local regulation, to establish the 
absence of pregnancy at any time during the participation of a WOCBP in the 
study.
Table 6
Protocol-Required Safety Laboratory Assessments
Laboratory 
Assessments
Parameters
Haematology
Platelet Count
RBC Indices:
MCV
MCH
%Reticulocytes
WBC count with 
Differential:
Neutrophils
Lymphocytes
Monocytes
Eosinophils
Basophils
RBC Count
Haemoglobin
Haematocrit
Clinical 
Chemistry1
Blood Urea 
Nitrogen (BUN)
Potassium
Aspartate 
Aminotransferase (AST)
Total and direct 
bilirubin
Creatinine
Sodium
Alanine 
aminotransferase (ALT)
Total Protein
Glucose
(non-fasting)
Calcium
Alkaline phosphatase 
(AP)
Albumin


2018N385734_02
CONFIDENTIAL
201790
94
Laboratory 
Assessments
Parameters
Albumin/globulin 
ratio
Phosphate
Creatine Phosphokinase 
(CPK)
High sensitivity 
C-reactive 
protein (hsCRP)
γ-Glutamyl 
transpeptidase 
(GGT)
Lactate 
dehydrogenase
(LDH)
Lipid profile
Total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density 
lipoprotein-cholesterol, triglycerides and other lipoprotein tests as needed
Urinalysis

Performed locally by dipstick
Urine 
pregnancy test

Highly sensitive urine human chorionic gonadotropin (hCG) pregnancy test 
(as needed for women of childbearing potential)2
Other Tests

Follicle-stimulating hormone (FSH) and estradiol (as needed in women of 
non-childbearing potential only)

Highly sensitive serum hCG pregnancy test (as needed for women of 
childbearing potential)2

Serology [HIV antibody, hepatitis B surface antigen (HBsAg), hepatitis B core 
antibody (HBcAb), HBV DNA, HCV RNA, and hepatitis C virus antibody], 
rheumatoid factor (RF), ACPA (anti-CCP), hsCRP, ESR, QuantiFERON-TB 
Gold plus test (or, if unavailable, T-Spot TB)

eGFR calculated by the CKD-EPI calculation.

All study-required laboratory assessments will be performed by a central 
laboratory, except ESR, dipstick urinalysis and urine pregnancy tests which 
will be performed locally. Only the results of tests performed locally will be 
recorded in the eCRF. Details for recording the post-randomisation ESR 
values will be provided in the SRM
NOTES :
1.
Details of liver chemistry stopping criteria and required actions and follow-up assessments after liver stopping or 
monitoring event are given in Section 7.1 and Appendix 6. All events of ALT 3 × upper limit of normal (ULN) and 
bilirubin 2 × ULN (>35% direct bilirubin) or ALT 3 × ULN and international normalised ratio (INR) >1.5, if INR 
measured, which may indicate severe liver injury (possible Hy’s Law), must be reported as an SAE (excluding
studies of hepatic impairment or cirrhosis).
2.
Local urine testing will be standard for the protocol unless serum testing is required by local regulation or IRB/IEC.
Laboratory/analyte results that could unblind the study will not be reported to 
investigative sites or other blinded personnel until the study has been unblinded.  This 
includes results of PK analyses, ESR (performed locally by an unblinded independent 
study team member) and hsCRP.  The only exception is the result of ESR and hsCRP at
the participant’s final assessment visit, if the participant is moving to the extension study.
Note: Monitoring of CRP/hsCRP during the course of this study by local measurements, 
is not permitted, in order to protect the blind.  However individual local measured 
CRP/hsCRP may be performed if required for safety reasons.


2018N385734_02
CONFIDENTIAL
201790
95
10.3.
Appendix 3: Adverse Events: Definitions and Procedures for 
Recording, Evaluating, Follow-up, and Reporting

This Appendix contains definitions and procedures required for AEs and SAEs 
which do not involve Medical Devices used in this study (see Section 6.1.1 for the 
list of medical devices).

Refer to Appendix 9 for definitions and reporting requirements of Medical Device 
AEs, SAEs, incidents and deficiencies.
10.3.1.
Definition of AE
AE Definition

An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of a study intervention, whether or not considered related to 
the study intervention.

NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of a study intervention.
Events Meeting the AE Definition

Any abnormal laboratory test results (haematology, clinical chemistry, or urinalysis) 
or other safety assessments (e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the 
medical and scientific judgment of the investigator (i.e., not related to progression of 
underlying disease).

Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency and/or intensity of the condition.

New conditions detected or diagnosed after study intervention administration even 
though it may have been present before the start of the study.

Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.

Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self-
harming intent. Such overdoses should be reported regardless of sequelae.

“Lack of efficacy” or “failure of expected pharmacological action” per se will not be 
reported as an AE or SAE. Such instances will be captured in the efficacy 
assessments. However, the signs, symptoms, and/or clinical sequelae resulting from 
lack of efficacy will be reported as AE or SAE if they fulfil the definition of an AE 
or SAE. 


2018N385734_02
CONFIDENTIAL
201790
96
Events NOT Meeting the AE Definition 

Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by the 
investigator to be more severe than expected for the participant’s condition.

The disease/disorder being studied or expected progression, signs, or symptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.

Medical or surgical procedure (e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is the AE.

Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).

Anticipated day-to-day fluctuations of pre-existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2.
Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalisation for signs/symptoms of the disease under study, 
death due to progression of disease).
A SAE is defined as any untoward medical occurrence that, at any dose:
Results in death
Is life-threatening
The term ‘life-threatening’ in the definition of ‘serious’ refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more severe.
Requires inpatient hospitalisation or prolongation of existing hospitalisation
In general, hospitalisation signifies that the participant has been detained (usually 
involving at least an overnight stay) at the hospital or emergency ward for observation 
and/or treatment that would not have been appropriate in the physician’s office or 
outpatient setting. Complications that occur during hospitalisation are AE. If a 
complication prolongs hospitalisation or fulfils any other serious criteria, the event is 
serious. When in doubt as to whether “hospitalisation” occurred or was necessary, the AE 
should be considered serious.
Hospitalisation for elective treatment of a pre-existing condition that did not worsen from 
baseline is not considered an AE.
Results in persistent disability/incapacity


2018N385734_02
CONFIDENTIAL
201790
97

The term disability means a substantial disruption of a person’s ability to conduct 
normal life functions.

This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (e.g., sprained ankle) which may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.
Is a congenital anomaly/birth defect
Other situations:

Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that may 
not be immediately life-threatening or result in death or hospitalisation but may 
jeopardise the participant or may require medical or surgical intervention to prevent 
one of the other outcomes listed in the above definition. These events should usually 
be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convulsions that do not result in hospitalisation, or development of drug dependency 
or drug abuse.
10.3.3.
Definition of Cardiovascular Events
Cardiovascular Events (CV) Definition:
Investigators will be required to fill out the specific CV event page of the CRF for the 
following AEs and SAEs:

Myocardial infarction/unstable angina

Congestive heart failure

Arrhythmias

Valvulopathy

Pulmonary hypertension

Cerebrovascular events/stroke and transient ischemic attack

Peripheral arterial thromboembolism

Deep venous thrombosis/pulmonary embolism

Revascularisation


2018N385734_02
CONFIDENTIAL
201790
98
10.3.4.
Recording and Follow-Up of AE and SAE
AE and SAE Recording

When an AE/SAE occurs, it is the responsibility of the investigator to review all 
documentation (e.g., hospital progress notes, laboratory, and diagnostics reports) 
related to the event.

The investigator will then record all relevant AE/SAE information in the CRF.

It is not acceptable for the investigator to send photocopies of the participant’s 
medical records in lieu of completion of the AE/SAE CRF page.

There may be instances when copies of medical records for certain cases are 
requested by GSK. In this case, all participant identifiers, with the exception of the 
participant number, will be redacted on the copies of the medical records before 
submission to GSK.

The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not
the individual signs/symptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the study and assign it to one of the following categories: 

Mild: An event that is easily tolerated by the participant, causing minimal discomfort 
and not interfering with everyday activities.

Moderate: An event that causes sufficient discomfort and interferes with normal 
everyday activities.

Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with an SAE. Severe is a category utilised for rating 
the intensity of an event; and both AE and SAE can be assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality

The investigator is obligated to assess the relationship between study intervention 
and each occurrence of each AE/SAE.

A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.

The investigator will use clinical judgment to determine the relationship.

Alternative causes, such as underlying disease(s), concomitant therapy, and other 
risk factors, as well as the temporal relationship of the event to study intervention 


2018N385734_02
CONFIDENTIAL
201790
99
administration will be considered and investigated.

The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.

For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality.

There may be situations in which a SAE has occurred and the investigator has 
minimal information to include in the initial report to GSK. However, it is very 
important that the investigator always make an assessment of causality for 
every event before the initial transmission of the SAE data to GSK.

The investigator may change his/her opinion of causality in light of follow-up 
information and send an SAE follow-up report with the updated causality 
assessment.

The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.
Follow-up of AE and SAE

The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by GSK to 
elucidate the nature and/or causality of the AE or SAE as fully as possible. This may 
include additional laboratory tests or investigations, histopathological examinations, 
or consultation with other health care professionals.

If a participant dies during participation in the study or during a recognised follow-
up period, the investigator will provide GSK with a copy of any post-mortem 
findings including histopathology.

New or updated information will be recorded in the originally completed CRF.

The investigator will submit any updated SAE data to GSK within 24 hours of 
receipt of the information.
10.3.5.
Reporting of SAE to GSK
SAE Reporting to GSK via Electronic Data Collection Tool

The primary mechanism for reporting SAE to GSK will be the electronic data 
collection tool.

If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.

The site will enter the SAE data into the electronic system as soon as it becomes
available.

The investigator or medically-qualified sub-investigator must show evidence within 
the eCRF (e.g., check review box, signature, etc.) of review and verification of the 


2018N385734_02
CONFIDENTIAL
201790
100
relationship of each SAE to IP/study participation (causality) within 72 hours of SAE 
entry into the eCRF.

After the study is completed at a given site, the electronic data collection tool will be 
taken off-line to prevent the entry of new data or changes to existing data.

If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off-line, then the site can report this information on a paper SAE form (see 
next section) or to the medical monitor by telephone.

Contacts for SAE reporting can be found in the SRM.
SAE Reporting to GSK via Paper CRF

Secure email transmission of the scanned SAE paper CRF is the preferred method to 
transmit this information to the medical monitor or the SAE coordinator.

In rare circumstances and in the absence of secure email facilities, notification by 
telephone is acceptable with a copy of the SAE data collection tool sent by overnight 
mail or courier service.

Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.

Contacts for SAE reporting can be found in the SRM.


2018N385734_02
CONFIDENTIAL
201790
101
10.4.
Appendix 4: Contraceptive Guidance and Collection of 
Pregnancy Information
10.4.1.
Definitions:
10.4.1.1.
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal 
unless permanently sterile (see below).
If fertility is unclear (e.g., amenorrhea in adolescents or athletes) and a menstrual cycle 
cannot be confirmed before first dose of study intervention, additional evaluation should 
be considered.
10.4.1.2.
Women in the following categories are not considered WOCBP
1.
Premenarchal
2.
Premenopausal female with 1 of the following:

Documented hysterectomy

Documented bilateral salpingectomy

Documented bilateral oophorectomy
For individuals with permanent infertility due to an alternate medical cause other 
than the above, (e.g., mullerian agenesis, androgen insensitivity), investigator 
discretion should be applied to determining study entry.
Note: Documentation can come from the site personnel’s: review of the 
participant’s medical records, medical examination, or medical history interview.
3.
Postmenopausal female

A postmenopausal state is defined as no menses for 12 months without an 
alternative medical cause. 

A high follicle stimulating hormone (FSH) level in the postmenopausal 
range may be used to confirm a postmenopausal state in women not using 
hormonal contraception or hormonal replacement therapy (HRT). 
However, in the absence of 12 months of amenorrhea, confirmation with 
more than one FSH measurement is required.

Females on HRT and whose menopausal status is in doubt will be required to 
use one of the non-estrogen hormonal highly effective contraception methods 
if they wish to continue their HRT during the study. Otherwise, they must 
discontinue HRT to allow confirmation of postmenopausal status before study 
enrolment.


2018N385734_02
CONFIDENTIAL
201790
102
10.4.2.
Contraception Guidance:

CONTRACEPTIVESa ALLOWED DURING THE STUDY INCLUDE:

Highly Effective Methodsb That Have Low User Dependency Failure rate of <1% per year 
when used consistently and correctly.

Implantable progestogen-only hormone contraception associated with inhibition of ovulationc

Intrauterine device (IUD)

Intrauterine hormone-releasing system (IUS)c

Bilateral tubal occlusion

Vasectomised partner

Note: Vasectomised partner is a highly effective contraceptive method provided that the 
partner is the sole sexual partner of the woman of childbearing potential and the absence of 
sperm has been confirmed. If not, an additional highly effective method of contraception 
should be used. Spermatogenesis cycle is approximately 90 days.

Highly Effective Methodsb That Are User Dependent Failure rate of <1% per year when used 
consistently and correctly.

Combined (estrogen- and progestogen-containing) hormonal contraception associated with 
inhibition of ovulationc
oral
intravaginal
transdermal

injectable

Progestogen-only hormone contraception associated with inhibition of ovulationc
oral

injectable

Sexual abstinence

Note: Sexual abstinence is considered a highly effective method only if defined as refraining 
from heterosexual intercourse during the entire period of risk associated with the study 
intervention. The reliability of sexual abstinence needs to be evaluated in relation to the 
duration of the study and the preferred and usual lifestyle of the participant.
a.
Contraceptive use by men or women should be consistent with local regulations regarding the use of contraceptive 
methods for those participating in clinical studies.
b.
Failure rate of <1% per year when used consistently and correctly. Typical use failure rates differ from those when 
used consistently and correctly.
c.
Male condoms must be used in addition to hormonal contraception. If locally required, in accordance with Clinical 
Trial Facilitation Group (CTFG) guidelines, acceptable contraceptive methods are limited to those which inhibit 
ovulation as the primary mode of action.
Note: Periodic abstinence (calendar, sympto-thermal, post-ovulation methods), withdrawal (coitus interruptus), 
spermicides only, and lactational amenorrhoea method (LAM) are not acceptable methods of contraception. Male condom 
and female condom should not be used together (due to risk of failure with friction)


2018N385734_02
CONFIDENTIAL
201790
103
10.4.3.
Collection of Pregnancy Information:
Male participants with partners who become pregnant

Investigator will attempt to collect pregnancy information on any male participant’s 
female partner of a male study participant who becomes pregnant while participating 
in this study.  This applies only to male participants who receive study intervention.

After obtaining the necessary signed informed consent from the pregnant female 
partner directly, the investigator will record pregnancy information on the 
appropriate form and submit it to GSK within 24 hours of learning of the partner’s 
pregnancy.

The female partner will also be followed to determine the outcome of the pregnancy. 
Information on the status of the mother and child will be forwarded to GSK.

Generally, follow-up will be no longer than 6 to 8 weeks following the estimated 
delivery date.  Any termination of the pregnancy will be reported regardless of fetal 
status (presence or absence of anomalies) or indication for procedure.
Female Participants who become pregnant

Investigator will collect pregnancy information on any female participant, who 
becomes pregnant while participating in this study.

Information will be recorded on the appropriate form and submitted to GSK within 
24 hours of learning of a participant’s pregnancy.

Participant will be followed to determine the outcome of the pregnancy.  The 
investigator will collect follow up information on participant and neonate, which will 
be forwarded to GSK.  Generally, follow-up will not be required for longer than 6 to 
8 weeks beyond the estimated delivery date.

Any termination of pregnancy will be reported, regardless of fetal status (presence or 
absence of anomalies) or indication for procedure.

While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy will be reported as an AE or 
SAE.

A spontaneous abortion is always considered to be an SAE and will be reported as 
such.

Any SAE occurring as a result of a post-study pregnancy which is considered 
reasonably related to the study intervention by the investigator, will be reported to 
GSK as described in Appendix 3.  While the investigator is not obligated to actively 
seek this information in former study participants, he or she may learn of an SAE 
through spontaneous reporting.
Any female participant who becomes pregnant while participating will discontinue study 
intervention but can continue in the study and attend all clinic visits if she wishes.


2018N385734_02
CONFIDENTIAL
201790
104
10.4.4.
Contraception Eligibility Criteria for Female and Male Participants
Contraceptive use by men or women should be consistent with local regulations 
regarding the methods of contraception for those participating in clinical studies.
a.
Male Participants:
Male participants are eligible to participate if they agree to the following during the 
intervention period and for at least 8 weeks after last dose of study SC intervention:

Refrain from donating sperm
PLUS, either:

Be abstinent from heterosexual or homosexual intercourse as their preferred 
and usual lifestyle (abstinent on a long term and persistent basis) and agree to 
remain abstinent
OR

Must agree to use contraception/barrier as detailed below
o
Agree to use a male condom AND female partner to use an additional 
highly effective contraceptive method with a failure rate of <1% per year 
(as described in Section 10.4.2) when having sexual intercourse with a 
woman of childbearing potential who is not currently pregnant.
b. Female Participants: 

A female participant is eligible to participate if she is not pregnant or 
breastfeeding, and at least one of the following conditions applies:
o
Is NOT a woman of childbearing potential (WOCBP) as defined in Section 
10.4.1.
OR
o
Is a WOCBP and using a contraceptive method that is highly effective with 
a failure rate of <1% per year (see Section 10.4.2), for 30 days before the 
first dose of study intervention, during the intervention period and at least 8 
weeks after the last dose of study SC intervention and agrees not to donate 
eggs (ova, oocytes) for the purpose of reproduction during this period.  
Additionally, WOCBP using hormonal contraceptives, including oral, 
injections, implants, and patches, are required to use a secondary method of 
contraception. The investigator should evaluate the effectiveness of the 
contraceptive method in relationship to the first dose of study intervention.

In addition to contraception requirements for blinded study medication as 
outlined above, participants should follow MTX local labelling.

A WOCBP must have both: 

A confirmed menstrual period prior to the first dose of study intervention
AND


2018N385734_02
CONFIDENTIAL
201790
105

A negative highly sensitive pregnancy test (urine or serum as required by 
local regulations) within 24 hours before the first dose of study 
intervention.
If a urine test cannot be confirmed as negative (e.g., an ambiguous result), a 
serum pregnancy test is required.  In such cases, the participant must be 
excluded from participation if the serum pregnancy result is positive.

The investigator is responsible for review of medical history, menstrual history, 
and recent sexual activity to decrease the risk for inclusion of a woman with an 
early undetected pregnancy.
Pregnancy tests for WOCBP are specified in the SoA (Section 1.3).


2018N385734_02
CONFIDENTIAL
201790
106
10.5.
Appendix 5: Genetics
USE/ANALYSIS OF DNA

Genetic variation may impact a participant’s response to study intervention, 
susceptibility, severity and progression of disease.  Variable response to study 
intervention may be due to genetic determinants that impact drug absorption, 
distribution, metabolism, and excretion; mechanism of action of the drug; disease 
etiology; and/or molecular subtype of the disease being treated.  Therefore, where 
local regulations and IRB/IEC allow, a blood sample will be collected for DNA 
analysis.

DNA samples will be used for research related to GSK3196165 or RA and related 
diseases.  They may also be used to develop tests/assays including diagnostic tests) 
related to GSK3196165, and RA.  Genetic research may consist of the analysis of 
one or more candidate genes or the analysis of genetic markers throughout the 
genome or analysis of the entire genome (as appropriate).

DNA samples will be analysed if it is hypothesised that this may help further 
understand the clinical data.

The samples may be analysed as part of a multi-study assessment of genetic factors 
involved in the response to GSK3196165 or study interventions of this class.  The 
results of genetic analyses may be reported in the clinical study report or in a 
separate study summary.

The sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality.

The samples will be retained while research on GSK3196165 (or study interventions 
of this class) or RA continues but no longer than 15 years after the last participant 
last visit or other period as per local requirements.


2018N385734_02
CONFIDENTIAL
201790
107
10.6.
Appendix 6: Liver Safety: Required Actions and Follow-up 
Assessments
Phase 3-4 liver chemistry stopping and increased monitoring criteria have been 
designed to assure participant safety and evaluate liver event etiology 
Phase 3-4 liver chemistry stopping criteria and required follow up assessments 
Liver Chemistry Stopping Criteria 
ALT-absolute
ALT 8xULN
ALT Increase
ALT 5xULN but <8xULN persists for 2 weeks
ALT 3xULN but <5xULN persists for 4 weeks
Bilirubin1, 2
ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) 
INR2
ALT 3xULN and INR>1.5
Cannot 
Monitor
ALT 5xULN but <8xULN and cannot be monitored weekly for 2 weeks
ALT 3xULN but <5xULN and cannot be monitored weekly for 4 weeks
Symptomatic3
ALT 3xULN associated with symptoms (new or worsening) believed to be related 
to liver injury or hypersensitivity
Symptomatic
Any clinical signs/symptoms suggestive of hepatic decompensation such as ascites 
and hepatic encephalopathy
Required Actions and Follow up Assessments 
Actions
Follow Up Assessments

Immediately discontinue study intervention

Report the event to GSK within 24 hours

Complete the liver event CRF and complete 
an SAE data collection tool if the event also 
meets the criteria for an SAE2

Perform liver event follow up assessments 

Monitor the participant until liver chemistries 
resolve, stabilise, or return to within baseline 
(see MONITORING below)

If restart/rechallenge not allowed or not 
granted, permanently discontinue study 
intervention and continue participant in the 
study for any protocol specified follow up 

Viral hepatitis serology4

Obtain INR and recheck with each liver 
chemistry assessment until the 
transaminases values show downward 
trend

Obtain blood sample for pharmacokinetic 
(PK) analysis, obtained less than 8 weeks
after last dose5

Serum creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH).

Fractionate bilirubin, if total 
bilirubin 2xULN


2018N385734_02
CONFIDENTIAL
201790
108
assessments
MONITORING:
For bilirubin or INR criteria:

Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin and INR) and 
perform liver event follow up assessments 
within 24 hrs

Monitor participants twice weekly until liver 
chemistries resolve, stabilise or return to within 
baseline

A specialist or hepatology consultation is 
recommended
For All other criteria:

Repeat liver chemistries (include ALT, AST, 
alkaline phosphatase, bilirubin and INR) and 
perform liver event follow up assessments 
within 24-72 hrs 

Monitor participants weekly until liver 
chemistries resolve, stabilise or return to 
within baseline

Obtain complete blood count with 
differential to assess eosinophilia

Record the appearance or worsening of 
clinical symptoms of liver injury, or 
hypersensitivity, on the AE report form

Record use of concomitant medications on 
the concomitant medications report form
including acetaminophen, herbal remedies, 
other over the counter medications.

Record alcohol use on the liver event 
alcohol intake case report form (CRF) page
For bilirubin or INR criteria:

Anti-nuclear antibody, anti-smooth muscle 
antibody, Type 1 anti-liver kidney 
microsomal antibodies, and quantitative 
total immunoglobulin G (IgG) or gamma 
globulins.

Serum acetaminophen adduct high 
performance liquid chromatography (HPLC) 
assay (quantifies potential acetaminophen 
contribution to liver injury in participants with 
definite or likely acetaminophen use in the 
preceding week [James, 2009]). NOTE: not 
required in China

Liver imaging (ultrasound, magnetic 
resonance, or computerised tomography) 
and /or liver biopsy to evaluate liver disease; 
complete Liver Imaging and/or Liver Biopsy 
CRF forms.
1.
Serum bilirubin fractionation should be performed if testing is available. If serum bilirubin fractionation is not 
immediately available, discontinue study intervention for that participant if ALT 3xULN and bilirubin 2xULN. 
Additionally, if serum bilirubin fractionation testing is unavailable, record presence of detectable urinary 
bilirubin on dipstick, indicating direct bilirubin elevations and suggesting liver injury. 
2.
All events of ALT 3xULN and bilirubin 2xULN (>35% direct bilirubin) or ALT 3xULN and INR >1.5 which 
may indicate severe liver injury (possible ‘Hy’s Law’), must be reported as an SAE (excluding studies of 
hepatic impairment or cirrhosis); the threshold value stated will not apply to participants receiving 
anticoagulants
3.
New or worsening symptoms believed to be related to liver injury (such as fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, or jaundice) or believed to be related to hypersensitivity (such as fever, rash or 
eosinophilia)   


2018N385734_02
CONFIDENTIAL
201790
109
4.
Includes: Hepatitis A immunoglobulin M (IgM) antibody; HBsAg and HBcAb; hepatitis C RNA; cytomegalovirus 
IgM antibody; Epstein-Barr viral capsid antigen IgM antibody (or if unavailable, heterophile antibody or monospot 
testing); and hepatitis E IgM antibody.
5.
PK sample may not be required for participants known to be receiving placebo or non-comparator interventions. 
Record the date/time of the PK blood sample draw and the date/time of the last dose of study intervention prior to 
the PK blood sample draw on the CRF. If the date or time of the last dose is unclear, provide the participant’s best 
approximation. If the date/time of the last dose cannot be approximated OR a PK sample cannot be collected in 
the time period indicated above, do not obtain a PK sample. Instructions for sample handling and shipping are in 
the SRM.
Phase 3-4 liver chemistry increased monitoring criteria with continued therapy
Liver Chemistry Increased Monitoring Criteria – Liver Monitoring Event
Criteria
Actions
ALT 5xULN and <8xULN and
bilirubin <2xULN without symptoms 
believed to be related to liver injury or 
hypersensitivity, and who can be 
monitored weekly for 2 weeks.
OR
ALT 3xULN and <5xULN and
bilirubin <2xULN without symptoms 
believed to be related to liver injury or 
hypersensitivity, and who can be 
monitored weekly for 4 weeks.

Notify the GSK medical monitor within 24 hours
of learning of the abnormality to discuss 
participant safety. 

Participant can continue study intervention

Participant must return weekly for repeat liver 
chemistries (ALT, AST, alkaline phosphatase, 
bilirubin) until they resolve, stabilise or return to 
within baseline 

If at any time participant meets the liver chemistry 
stopping criteria, proceed as described above

If ALT decreases from ALT 5xULN and <8xULN 
to ≥3xULN but <5xULN, continue to monitor liver 
chemistries weekly. 

If, after 4 weeks of monitoring, ALT <3xULN and 
bilirubin <2xULN, monitor participants twice 
monthly until liver chemistries normalise or return 
to within baseline.
References
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern TJ, Lee 
WM. Pharmacokinetics of Acetaminophen-Adduct in Adults with Acetaminophen 
Overdose and Acute Liver Failure. Drug Metab Dispos 2009; 37:1779-1784.


2018N385734_02
CONFIDENTIAL
201790
110
10.7.
Appendix 7: Summary of composite endpoints
These composite endpoints are derived using the data collected from assessments 
described in Section 8.1.
10.7.1.
ACR
The American College of Rheumatology’s definition for calculating improvement in RA 
(ACR20) is calculated as a 20% improvement from baseline in tender and swollen joint 
counts and 20% improvement in 3 of the 5 remaining ACR-core set measures: patient and 
physician global assessments, pain, disability, and an acute-phase reactant.  Similarly, 
ACR50 and ACR70 are calculated with the respective percent improvement.
The specific components of the ACR Assessments that will be used in this study are:

Tender/Painful Joint count (68).

Swollen Joint Count (66).

Pain VAS.

Patient’s Global Assessment of Arthritis.

Physician’s Global Assessment of Arthritis.

Acute-phase reactant (hsCRP or ESR).

Health Assessment Questionnaire – Disability Index (HAQ-DI).
10.7.2.
Disease Activity Score
The Disease Activity Score (DAS) assessment is a derived measurement with differential 
weighting given to each component.  The DAS 28(CRP) or DAS 28(ESR) will be 
calculated at each assessment timepoint.
The components of the DAS 28 arthritis assessment include:

Tender/Painful Joint Count (28).

Swollen Joint Count (28).

hsCRP or ESR.

Patient’s Global Assessment of Arthritis.
10.7.3.
Clinical Disease Activity Index (CDAI)
The CDAI for rheumatoid arthritis is a clinical composite score to determine disease 
severity using only clinical data.  The CDAI score will be calculated at each assessment 
timepoint.
The components of the CDAI include:

Tender/Painful Joint Count (28).


2018N385734_02
CONFIDENTIAL
201790
111

Swollen Joint Count (28).

Patient’s Global Assessment of Arthritis.

Physician’s Global Assessment of Arthritis.


2018N385734_02
CONFIDENTIAL
201790
112
10.8.
Appendix 8: Hierarchy Options to Demonstrate Superiority 
or Non-inferiority of Each Dose of GSK3196165 Versus 
Placebo or Tofacitinib, Respectively


2018N385734_02
CONFIDENTIAL
201790
113
10.9.
Appendix 9: Medical Device Adverse Events (AEs), Adverse 
Device Effects (ADEs), Serious Adverse Events (SAEs) and 
Device Deficiencies: Definition and Procedures for 
Recording, Evaluating, Follow-up, and Reporting

The detection and documentation procedures described in this Appendix apply to 
the medical devices provided for use in the study as detailed in Section 6.1.1.  
Refer to Appendix 3 for all other AE/SAE reporting not involving a medical 
device.

The definitions and procedures detailed in this appendix are in accordance with 
ISO 14155.

Both the investigator and the sponsor will comply with all local medical device 
reporting requirements.
10.9.1.
Definition of Medical Device AE and ADE
Medical Device AE and ADE Definition 

An AE is defined as any untoward medical occurrence, unintended disease or injury, or 
untoward clinical signs (including abnormal laboratory finding) in study participants, 
users, or other persons, whether or not related to the investigational medical device. 
This definition includes events related to the investigational medical device or 
comparator and events related to the procedures involved except for events in users or 
other persons, which only include events related to investigational devices.

An adverse device effect (ADE) is defined as an adverse event related to the use of an 
investigational medical device. This definition includes any adverse events resulting 
from insufficient or inadequate instructions for use, deployment, implantation, 
installation, or operation, or any malfunction of the investigational medical device as 
well as any event resulting from use error or from intentional misuse of the 
investigational medical device.
10.9.2.
Definition of Medical Device SAE, SADE and USADE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (e.g., hospitalization for signs/symptoms of the disease under study, 
death due to progression of disease).
A Medical Device SAE is a Medical Device AE that:
a.
Led to death 
b.
Led to serious deterioration in the health of the participant, that either resulted in:
1. A life-threatening illness or injury. The term ‘life-threatening' in the definition of 
serious' refers to an event in which the participant was at risk of death at the time of 
the event. It does not refer to an event, which hypothetically might have caused 
death, if it were more severe


2018N385734_02
CONFIDENTIAL
201790
114
2. A permanent impairment of a body structure or a body function,
3. Inpatient or prolonged hospitalization, Planned hospitalization for a pre-existing 
condition, or a procedure required by the protocol, without serious deterioration in 
health, is not considered an SAE
4. Medical or surgical intervention to prevent life-threatening illness or injury or 
permanent impairment to a body structure or a body function
c.
Led to fetal distress, fetal death or a congenital abnormality or birth defect
Serious Adverse Device Effect (SADE) definition

A SADE is defined as an adverse device effect that has resulted in any of the 
consequences characteristic of a serious adverse event.
Unanticipated Serious Adverse Device Effect (USADE) definition

A USADE is a serious adverse device effect which by its nature, incidence, severity or 
outcome has not been identified in the current version of the risk analysis report (see 
Section 2.3.1).
10.9.3.
Definition of Device Deficiency
Device Deficiency definition

A device deficiency is an inadequacy of a medical device with respect to its identity, 
quality, durability, reliability, safety, or performance. Device deficiencies include 
malfunctions, use errors, and inadequate labelling.
10.9.4.
Recording and Follow-Up of Medical Device AE and/or SAE and 
Device Deficiencies
Medical Device AE, SAE and Device Deficiency Recording

When an AE/SAE/device deficiency occurs, it is the responsibility of the investigator to 
review all documentation (e.g., hospital progress notes, laboratory reports, and 
diagnostics reports) related to the event.

The investigator will then record all relevant AE/SAE/device deficiency information in 
the participant’s medical records, in accordance with the investigator’s normal clinical 
practice, and on the appropriate form of the CRF.

It is not acceptable for the investigator to send photocopies of the participant’s medical 
records to GSK in lieu of completion of the AE/SAE/device deficiency CRF page.

There may be instances when copies of medical records for certain cases are requested 
by GSK. In this case, all participant identifiers, with the exception of the participant 
number, will be redacted on the copies of the medical records before submission to 
GSK.


2018N385734_02
CONFIDENTIAL
201790
115

The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE/SAE.

For device deficiencies, it is very important that the investigator describes any 
corrective or remedial actions taken to prevent recurrence of the incident.

A remedial action is any action other than routine maintenance or servicing of a 
medical device where such action is necessary to prevent recurrence of a device 
deficiency. This includes any amendment to the device design to prevent recurrence.
Assessment of Intensity

The investigator will make an assessment of intensity for each AE/SAE/device 
deficiency reported during the study and assign it to one of the following categories: 

Mild: An event that is easily tolerated by the participant, causing minimal discomfort 
and not interfering with everyday activities.

Moderate: An event that causes sufficient discomfort and interferes with normal 
everyday activities.

Severe: An event that prevents normal everyday activities. An AE that is assessed as 
severe should not be confused with a SAE. Severe is a category utilized for rating the 
intensity of an event; and both AEs and SAEs can be assessed as severe.

An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as 
described in the definition of an SAE, NOT when it is rated as severe.

Other measures to evaluate AEs and SAEs may be utilized (e.g., National Cancer 
Institute Common Terminology Criteria for Adverse Events [NCI-CTCAE]).
Assessment of Causality

The investigator is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE/device deficiency

A “reasonable possibility” of a relationship conveys that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.

The investigator will use clinical judgment to determine the relationship.

Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention 
administration will be considered and investigated.

The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.

For each AE/SAE/device deficiency, the investigator must document in the medical 
notes that he/she has reviewed the AE/SAE/device deficiency and has provided an 


2018N385734_02
CONFIDENTIAL
201790
116
assessment of causality.

There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to GSK. However, it is very 
important that the investigator always make an assessment of causality for every event 
before the initial transmission of the SAE data to GSK.

The investigator may change his/her opinion of causality in light of follow-up 
information and send a SAE follow-up report with the updated causality assessment.

The causality assessment is one of the criteria used when determining regulatory 
reporting requirements.
Follow-up of Medical Device AE/SAE/device deficiency

The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by GSK to 
elucidate the nature and/or causality of the AE/SAE/device deficiency as fully as 
possible. This may include additional laboratory tests or investigations, 
histopathological examinations, or consultation with other health care professionals.

If a participant dies during participation in the study or during a recognized follow-up 
period, the investigator will provide GSK with a copy of any post-mortem findings 
including histopathology.

New or updated information will be recorded in the originally completed CRF.

The investigator will submit any updated SAE data to GSK within 24 hours of receipt 
of the information.
10.9.5.
Reporting of Medical Device SAEs
Medical Device SAE Reporting to GSK via an Electronic Data Collection Tool

The primary mechanism for reporting an SAE to GSK will be the electronic data 
collection tool.

If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.

The site will enter the SAE data into the electronic system as soon as it becomes 
available.

After the study is completed at a given site, the electronic data collection tool will be 
taken off-line to prevent the entry of new data or changes to existing data.

If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken off-line, then the site can report this information on a paper SAE form (see 
next section) or to the medical monitor or the SAE coordinator by telephone.


2018N385734_02
CONFIDENTIAL
201790
117

Contacts for SAE reporting can be found in SRM.
Medical Device SAE Reporting to GSK via Paper CRF

Secure email transmission of the scanned SAE paper CRF is the preferred method to 
transmit this information to the medical monitor or the SAE coordinator.

In rare circumstances and in the absence of secure email facilities, notification by 
telephone is acceptable with a copy of the SAE data collection tool sent by 
overnight mail or courier service.

Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.

Contacts for SAE reporting can be found in the SRM.
10.9.6.
Reporting of SADEs
SADE Reporting to GSK 
NOTE: There are additional reporting obligations for medical device incidents that are 
potentially related to SAEs that must fulfil the legal responsibility to notify appropriate 
regulatory authorities and other entities about certain safety information relating to medical 
devices being used in clinical studies. For medical device deficiencies with no associated 
AE or SAE please refer to Section 8.3.8.4.

Any device deficiency that is associated with an SAE must be reported to GSK 
within 24 hours after the investigator determines that the event meets the definition 
of a device deficiency.

GSK shall review all device deficiencies and determine and document in writing 
whether they could have led to an SAE. These shall be reported to the regulatory 
authorities and IRBs/IECs as required by national regulations.

Contacts for SAE reporting can be found in the SRM.


2018N385734_02
CONFIDENTIAL
201790
118
10.10.
Appendix 10: Country-specific requirements
Not Applicable


2018N385734_02
CONFIDENTIAL
201790
119
10.11.
Appendix 11: Abbreviations and Trademarks
Abbreviations
AASLD
American Association for the Study of Liver Diseases
ACPA
Anti-citrullinated protein antibody
ACR
American College of Rheumatology
ACR20/50/70
20%/50%/70% improvement in American College of Rheumatology 
Criteria
AE
Adverse event
AESI
Adverse event of special interest
ALT
Alanine transaminase
AP
Alkaline phosphatase
AST
Aspartate transaminase
BCG
Bacillus Calmette-Guérin
bDMARD
Biologic disease-modifying antirheumatic drug
BID
Twice daily
CDAI
Clinical disease activity index
CD20
Cluster of differentiation antigen 20
CDC
Complement-dependent cytotoxicity
CI
Confidence interval
CIOMS
Council for International Organizations of Medical Sciences
CKD-EPI
Chronic Kidney Disease Epidemiology Collaboration
COX
Cyclo-oxygenase
CPK
Creatine phosphokinase
CRP
C-reactive protein
csDMARD
Conventional synthetic disease modifying antirheumatic drug
CTC
Common terminology criteria
CTFG
Clinical Trial Facilitation Group
DAS28
Disease activity score including 28 different joints
DAS28(CRP)
Disease activity score including 28 different joints with CRP value
DAS28(ESR)
Disease activity score including 28 different joints with ESR value
DNA
Deoxyribonucleic acid
DMARD
Disease-modifying antirheumatic drug
DRE
Disease-related event
DVT
Deep vein thrombosis
EASL
European Association for the Study of the Liver
EBV
Epstein Barr Virus
ECG
Electrocardiogram
eCRF
Electronic case report form
ED
Effective dose
ESR
Erythrocyte sedimentation rate
EULAR
European League against Rheumatism
FACIT
Functional assessment of chronic illness therapy
FEV1
Forced expiratory volume in one second
CCI


2018N385734_02
CONFIDENTIAL
201790
120
FSH
Follicle-stimulating hormone
FVC
Forced vital capacity
GCP
Good Clinical Practice
GEE
Generalised Estimating Equation
GFR
Glomerular filtration rate
GM-CSF
Granulocyte-macrophage colony stimulating factor
GSK
GlaxoSmithKline
HAQ-DI
Health Assessment Questionnaire Disability Index
hCG
Human chorionic gonadotropin
HF
Human Factors
HOA
Hand osteoarthritis
HRCT
High-resolution computed tomography
HRT
Hormone replacement therapy
hsCRP
High sensitivity C-reactive protein
HV
Healthy volunteer
IA
Intra-articular
IB
Investigator’s brochure
ICF
Informed consent form
ICH
International Conference on Harmonisation
IDMC
Independent Data Monitoring Committee
IEC
Institutional ethics committee
IFU
Instructions For Use
IgM
Immunoglobulin M
IL
Interleukin
IM
Intramuscular
IMP
Investigational medicinal product
INH
Isoniazid
INR
International normalised ratio
IP
Investigational product
IR
Inadequate response
IRB
Institutional review board
IRT
Interactive Response Technology
ITT
Intent to Treat
IU
International units
IUD
Intrauterine device
IUS
Intrauterine hormone-releasing system
IV
Intravenous
IVIG
Intravenous immunoglobulin
JAK
Janus Kinase
kg
Kilogram
L
Litre
LAM
Lactational amenorrhoea method
LDA
Low disease activity
LDH
Lactate dehydrogenase
LFT
Liver function test
LTE
Long-term extension


2018N385734_02
CONFIDENTIAL
201790
121
mAb
Monoclonal antibody
MCV
Mean cell volume
MCH
Mean corpuscular haemoglobin
MCHC
Mean corpuscular haemoglobin concentration
MedDRA
Medical dictionary for regulatory activities
mg
Milligram
mL
Millilitre
MMP
Matrix metalloproteinase
MMRM
Mixed Model for Repeated Measures
MOS
Medical Outcomes Study
MS
Multiple sclerosis
MSDS
Material safety data sheet
mTSS
Modified Total Sharp Score
MTX
Methotrexate
NCEP
National Cholesterol Educational Program
NCI-CTCAE
National Cancer Institute Common Terminology Criteria for Adverse 
Events
NOEL
No observed effect level
NRS
Numerical Rating Scale
NSAID
Non-steroidal anti-inflammatory drug
PAC
Pulmonary Adjudication Committee
PAP
Pulmonary alveolar proteinosis
PCP
Pneumocystis Pneumonia
PCR
Polymerase chain reaction
PD
Pharmacodynamic
PE
Pulmonary embolism
PFS
Prefilled syringe
PFT
Pulmonary function test
PP
Per Protocol
PRN
Pro re nata (as needed)
PtGA
Patient’s Global Assessment of Arthritis
PhGA
Physician’s Global Assessment of Arthritis
PK
Pharmacokinetics
RA
Rheumatoid arthritis
RAP
Reporting and analysis plan
RF
Rheumatoid factor
RNA
Ribonucleic acid
SC
Subcutaneous
SAE
Serious adverse event
SJC
Swollen joint count
SF-36
Short form (36)
SRM
Study Reference Manual
SRT
Safety Review Team
SSD
Safety Syringe Device
TB
Mycobacterium tuberculosis
CCI


2018N385734_02
CONFIDENTIAL
201790
122
TE
Target engagement
TJC
Tender joint count
TNFα
Tumor necrosis factor alpha
tsDMARD
Targeted synthetic disease-modifying antirheumatic drug
TST
Tuberculin skin test
ULN
Upper limit of normal
VAS
Visual Analogue Scale
VTE
Venous thromboembolism
WOCBP
Woman of Childbearing Potential
Trademark Information
Trademarks of the GlaxoSmithKline 
group of companies
Trademarks not owned by the 
GlaxoSmithKline group of companies
None
Jakvinus
Jaquinus
MedDRA
Prosorba
QuantiFERON
T.SPOT TB
Xeljanz
CCI


2018N385734_02
CONFIDENTIAL
201790
123
10.12.
Appendix 12: Protocol Amendment History
The Protocol Amendment Summary of Changes Table for the current amendment is 
located directly before the Table of Contents (TOC).
Protocol Amendment 01 22 MAY 2019
Overall Rationale for the Amendment:  Correction of contraceptive requirements for 
Women of Child Bearing Potential (WOCBP) and additional clarifications.
Section # and Name
Description of Change
Brief Rationale
Section 10.4.4 
Contraception Eligibility 
Criteria for Female and 
Male Participants
Correction of bullet ‘b’ for WOCBP, to 
remove “with low user dependency” 
wording and remove requirement for 
“two” methods except if hormonal 
contraceptives are used.
Corrected to align with the 
Investigator Brochure (IB) 
Development Core Safety 
Information and the Study Risk 
Assessment (see Section 2.3).
Section 8.1.4 Patient 
reported outcomes
Clarification that some (exploratory) 
PROs will only be implemented if, and 
when translations are available.
Some PROs may be delayed or 
may not be available in all 
languages for the global study.
Section 1.3 SoA, Section 
2.3.1 Study risk table and
Section 5.4 Screen 
Failures
Correction, a baseline chest X-ray and 
hands/feet X-ray are required during 
rescreening (if not carried out recently), 
but a hands/feet x-ray is not required at 
early withdrawal, if carried out recently.
Correction of requirements.
Section 8.2.6 Pulmonary 
Assessments
Clarification that baseline Pulmonary 
function tests (PFTs) may be carried out 
prior to Day 1 if necessary.
Clarification.
Section 6.5.2 Prohibited 
therapies
Washout period for Marijuana corrected 
to “at least 4 weeks prior to Day 1.”
Correction.
Section 8.6.1 Target 
engagement and Section 
8.9 Immunogenicity
Clarification that free GM-CSF levels will 
be measured at baseline using excess 
material from immunogenicity sample.
Clarification of procedure.
Section 1.3 SoA
Footnotes updated for above changes.
Guidance.
Section 9 Statistical 
Considerations
Correction of hypothesis to state 150 mg 
dose.
Align hypothesis with multiple 
testing hierarchy.
All sections
Minor grammatical and typographical corrections to improve readability.


2018N385734_02
CONFIDENTIAL
201790
124
11.
REFERENCES
Avci AB, Feist E, Burmester GR. Targeting GM-CSF in rheumatoid arthritis. Clin Exp 
Rheumatol. 2016, 34(4 Suppl 98):39-44.
Behrens F, Tak PP, Østergaard M, Stoilov R, Wiland P, Huizinga TW, et al. MOR103, a 
human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the 
treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa 
randomised, double-blind, placebo-controlled, dose-escalation trial. Ann Rheum Dis 
2015;74:1058-64.
Burmester G, McInnes IB, Kremer JM, Miranda P, Korkosz M, Vencovsky J, et al. A 
randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha 
monoclonal antibody, in the treatment of rheumatoid arthritis. Ann Rheum Dis 
2017;76:1020-30.
Burmester GR, McInnes IB, Kremer JM, Miranda P, Vencovský J, Godwood A, et al. M. 
Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor 
Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With 
Rheumatoid Arthritis. Arthritis Rheumatol. 2018;70(5):679-689.
Cook AD, Braine EL, Campbell IK, Rich MJ, Hamilton JA. Blockade of collagen-
induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating 
factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res 
2001;3:293-8.
Cook AD, Pobjoy J, Steidl S, Dürr M, Braine EL, Turner AL, et al. Granulocyte-
macrophage colony-stimulating factor is a key mediator in experimental osteoarthritis 
pain and disease development. Arthritis Res Ther 2012;14:R199.
Cook AD, Pobjoy J, Sarros S, Steidl S, Dürr M, Lacey DC, et al. Granulocyte-
macrophage colony-stimulating factor is a key mediator in inflammatory and arthritic 
pain. Ann Rheum Dis. 2013, 72(2):265-70.
Cook AD, Lee MC, Saleh R, Khiew HW, Christensen AD, Achuthan A, et al. TNF and 
granulocyte macrophage-colony stimulating factor interdependence mediates 
inflammation via CCL17. JCI Insight. 2018a, 3(6).
CCI
CCI


2018N385734_02
CONFIDENTIAL
201790
125
Cook AD, Hamilton JA Investigational therapies targeting the granulocyte macrophage 
colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab. 
Ther Adv Musculoskelet Dis. 2018b;10(2):29-38.
FDA (Food and Drug Administration, 2014). Guidance for Industry: Immunogenicity 
Assessment for Therapeutic Protein Products. 
http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidanc
es/ucm338856.pdf
FDA (Food and Drug Administration, 2016). Guidance for Industry: Non-Inferiority 
Clinical Trials to Establish Effectiveness.
Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcomes in arthritis. 
Arthritis Rheum 1980;23:137-45.
Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, van Assen S, Bijl M,et al. 2019 
update of EULAR recommendations for vaccination in adult patients with autoimmune 
inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Jan;79(1):39-52.
Gaujoux-Viala C, Nam J, Ramiro S, Landewé R, Buch MH, Smolen JS, et al. Efficacy of 
conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and 
tofacitinib: a systematic literature review informing the 2013 update of the EULAR 
recommendations for management of rheumatoid arthritis. Ann Rheum Dis 2014;73:510-
5.
GSK Document Number 2017N353526_00. Pharmacokinetic Study Analysis Report. 
Population Pharmacokinetic Analysis of GSK3196165 Following Intravenous and 
Subcutaneous Administration to Healthy Volunteers, and Subjects with Rheumatoid 
Arthritis and Multiple Sclerosis, Date: 07-Dec-2017.
GSK Document Number 2014N190256_02. GSK3196165 Investigator's Brochure 
Version 9 (2019).
Hamilton JA, Cook AD, Tak PP. Anti-colony-stimulating factor therapies for 
inflammatory and autoimmune diseases. Nat Rev Drug Discov. 2016 29;16(1):53-70.
LeVine AM, Reed JA, Kurak KE, Cianciolo E, Whitsett JA. GM-CSF-deficient mice are 
susceptible to pulmonary group B streptococcal infection. J Clin Invest 1999;103:563-9.
Martinez-Moczygemba M, Doan ML, Elidemir O, Fan LL, Cheung SW, Lei JT, et al. 
Pulmonary alveolar proteinosis caused by deletion of GM-CSFRalpha gene in the X 
chromosome pseudoautosomal region 1. J Exp Med 2008;205:2711-6.
Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al. Efficacy 
of biological disease-modifying antirheumatic drugs: a systematic literature review 
informing the 2013 update of the EULAR recommendations for the management of 
rheumatoid arthritis. Ann Rheum Dis 2014;73:516-28.


2018N385734_02
CONFIDENTIAL
201790
126
NCI. National Cancer Institute Common Terminology Criteria for Adverse Events v5.0 
NCI, NIH, DHHS. November 27th. 2017. 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Q
uick_Reference_5x7.pdf
Plater-Zyberk C, Joosten LAB, Helsen MM, Hepp J, Baeuerle PA, van den Berg WB. 
GM-CSF neutralisation suppresses inflammation and protects cartilage in acute 
streptococcal cell wall arthritis of mice. Ann Rheum Dis 2007;66:452-7.
Stanley E, Lieschke GJ, Grail D, Metcalf D, Hodgson G, Gall JA, et al. 
Granulocyte/macrophage colony-stimulating factor-deficient mice show no major 
perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc 
Natl Acad Sci USA 1994;91:5592-6.
Steidl S, Ratsch O, Brocks B, Dürr M, Thomassen-Wolf E. In vitro affinity maturation of 
human GM-CSF antibodies by targeted CDR-diversification. Mol Immunol 2008;46:135-
44.
Suzuki T, Sakagami T, Rubin BK, Nogee LM, Wood RE, Zimmerman SL, et al. Familial 
pulmonary alveolar proteinosis caused by mutations in CSF2RA. J Exp Med 
2008;205:2703-10.
Wicks IP, Roberts AW. Targeting GM-CSF in inflammatory diseases. Nat Rev 
Rheumatol. 2016; 12(1):37-48.

SAP_003.pdf: 
 
CONFIDENTIAL 
The GlaxoSmithKline group of companies 
 
201790 
 
 
1 
 
Division 
: Worldwide Development 
Information Type 
: Reporting and Analysis Plan (RAP) 
 
Title 
: Reporting and Analysis Plan for a 52-week, phase 3, 
multicentre, randomised, double blind, efficacy and safety 
study comparing GSK3196165 with placebo and with 
tofacitinib, in combination with methotrexate in participants 
with moderately to severely active rheumatoid arthritis who 
have an inadequate response to methotrexate. 
Compound Number  : GSK3196165 
Compound Name 
: Otilimab 
Effective Date  
: 08 Aug 2022 
 
Description: 
• 
The purpose of this RAP is to describe the planned analyses and output to be 
included in the Clinical Study Report for Protocol 2018N385734_02. 
• 
This RAP is intended to describe the final analyses required for the study.  
• 
This RAP will be provided to the study team members to convey the content of 
the Statistical Analysis Complete (SAC) deliverable. 
 
RAP Author(s): 
Approver 
Date 
 
Refer to Document 
Date 
Statistics Leader (Biostatistics) 
 
 
 
 
 
 
 
 
 
 
 
Copyright 2022 the GlaxoSmithKline group of companies. All rights reserved.  
Unauthorised copying or use of this information is prohibited.
PPD


 
CONFIDENTIAL 
 
 
 
201790 
 
2 
 
Biostatistics Line Approvals: 
 
Approver 
Date 
Approval 
Method 
 
 (Biostatistics) 
Refer to 
Document Date 
eSignature 
 
Programming Leader (Biostatistics) 
Refer to 
Document Date 
eSignature 
 
 
 
PPD
PPD
PPD


 
CONFIDENTIAL 
 
 
 
201790 
 
3 
 
TABLE OF CONTENTS 
PAGE 
1. 
INTRODUCTION ...................................................................................................... 6 
1.1. 
RAP Amendments ........................................................................................ 6 
2. 
SUMMARY OF KEY PROTOCOL INFORMATION .................................................. 6 
2.1. 
Changes to the Protocol Defined Statistical Analysis Plan ............................ 6 
2.2. 
Study Objective(s) and Endpoint(s)............................................................... 8 
2.3. 
Study Design .............................................................................................. 10 
2.4. 
Statistical Hypotheses................................................................................. 11 
3. 
PLANNED ANALYSES .......................................................................................... 12 
3.1. 
Interim Analyses ......................................................................................... 12 
3.2. 
Final Analyses ............................................................................................ 12 
4. 
ANALYSIS POPULATIONS ................................................................................... 13 
4.1. 
Protocol Deviations ..................................................................................... 14 
5. 
CONSIDERATIONS FOR DATA ANALYSES AND DATA HANDLING 
CONVENTIONS ..................................................................................................... 15 
5.1. 
Study Treatment & Sub-group Display Descriptors ..................................... 15 
5.1.1. 
Study Treatment & Sub-group Display Descriptors for 
Study Population Displays ........................................................... 15 
5.1.2. 
Study Treatment & Sub-group Display Descriptors for 
Efficacy Displays .......................................................................... 15 
5.1.3. 
Study Treatment & Sub-group Display Descriptors for 
Safety Displays - Adverse Events (AEs) and Laboratory 
Assessments ............................................................................... 16 
5.1.4. 
Study Treatment descriptors used for Figures ............................. 18 
5.2. 
Baseline Definitions .................................................................................... 19 
5.2.1. 
Baseline definition in Period 1 and Period 1+2 ............................. 19 
5.2.2. 
Baseline definition in Period 2 ...................................................... 20 
5.3. 
Multicentre Studies ..................................................................................... 20 
5.4. 
Examination of Covariates, Other Strata and Subgroups ............................ 20 
5.4.1. 
Covariates and Other Strata ........................................................ 20 
5.4.2. 
Examination of Subgroups ........................................................... 21 
5.5. 
Multiple Comparisons and Multiplicity ......................................................... 21 
5.6. 
Other Considerations for Data Analyses and Data Handling 
Conventions ................................................................................................ 25 
6. 
STUDY POPULATION ANALYSES ....................................................................... 26 
6.1. 
Overview of Planned Study Population Analyses ........................................ 26 
7. 
EFFICACY ANALYSES .......................................................................................... 27 
7.1. 
Primary Efficacy Analyses .......................................................................... 27 
7.1.1. 
Primary Estimand Strategy .......................................................... 27 
7.1.2. 
Supplementary Analyses ............................................................. 29 
7.1.3. 
Statistical Analyses / Methods ..................................................... 30 
7.2. 
Secondary Efficacy Analyses ...................................................................... 31 
7.2.1. 
Estimand strategy ........................................................................ 31 
7.2.2. 
Supplementary Analysis .............................................................. 33 


 
CONFIDENTIAL 
 
 
 
201790 
 
4 
 
7.2.3. 
Statistical Analyses / Methods ..................................................... 33 
8. 
SAFETY ANALYSES ............................................................................................. 41 
8.1. 
Adverse Event Analyses ............................................................................. 41 
8.1.1. 
Adverse Events of Special Interest and Other Important 
AEs Analyses .............................................................................. 41 
8.2. 
Clinical Laboratory Analyses ....................................................................... 42 
8.3. 
Other Safety Analyses ................................................................................ 42 
8.3.1. 
Immunogenicity Analyses ............................................................ 43 
13. REFERENCES ....................................................................................................... 49 
14. APPENDICES ........................................................................................................ 50 
14.1. 
Appendix 1: Protocol Deviation Management and Definitions for Per 
Protocol Population ..................................................................................... 50 
14.1.1. 
Exclusions from Per Protocol Population ..................................... 50 
14.2. 
Appendix 2: Schedule of Activities .............................................................. 51 
14.2.1. 
Protocol Defined Schedule of Events ........................................... 51 
14.3. 
Appendix 3: Assessment Windows ............................................................. 54 
14.3.1. 
Definitions of Assessment Windows for Analyses ........................ 54 
14.4. 
Appendix 4: Study Phases and Treatment Emergent Adverse 
Events ........................................................................................................ 55 
14.4.1. 
Study Phases .............................................................................. 55 
14.4.2. 
Treatment Emergent Flag for Adverse Events ............................. 56 
14.5. 
Appendix 5: Data Display Standards & Handling Conventions .................... 57 
14.5.1. 
Reporting Process ....................................................................... 57 
14.5.2. 
Reporting Standards .................................................................... 57 
CCI
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
5 
 
14.5.4. 
Reporting Standards for Log-transformed Parameters ................. 58 
14.6. 
Appendix 6: Derived and Transformed Data ............................................... 59 
14.6.1. 
General ........................................................................................ 59 
14.6.2. 
Study Population .......................................................................... 60 
14.6.3. 
Efficacy ........................................................................................ 64 
14.6.4. 
Safety .......................................................................................... 75 
14.7. 
Appendix 7: Reporting Standards for Missing Data ..................................... 81 
14.7.1. 
Premature Withdrawals ................................................................ 81 
14.7.2. 
Handling of Missing Data ............................................................. 81 
14.8. 
Appendix 8: Laboratory Parameters of  Interest .......................................... 83 
14.8.1. 
Laboratory Values Gradings ........................................................ 83 
14.8.2. 
Laboratory Values of Potential Clinical Importance ...................... 83 
14.8.3. 
ECG Values of Potential Clinical Importance ............................... 86 
14.8.4. 
Vital Signs Values of Potential Clinical Importance ...................... 86 
14.9. 
Appendix 9: List of Preferred Terms ............................................................ 87 
14.9.1. 
Herpes Zoster .............................................................................. 87 
14.9.2. 
Mycobacterium Tuberculosis ....................................................... 87 
14.10. Appendix 10: Missing Data Imputation Strategies ....................................... 88 
14.10.1. Primary Estimand Strategy .......................................................... 88 
14.10.2. Supplemental Estimand 1 Strategy .............................................. 88 
14.10.3. Supplemental Estimand 2 Strategy .............................................. 89 
14.10.4. Intermittent Missing Data Multiple Imputation ............................... 89 
14.11. Appendix 11: Abbreviations & Trade Marks ................................................ 90 
14.11.1. Abbreviations ............................................................................... 90 
14.11.2. Trademarks ................................................................................. 92 
14.12. Appendix 12: List of Data Displays.............................................................. 93 
14.12.1. Data Display Numbering .............................................................. 93 
14.12.2. Mock Example Shell Referencing ................................................ 93 
14.12.3. Deliverables ................................................................................. 93 
14.13. Appendix 13: Example Mock Shells for Data Displays .............................. 157 
 
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
6 
 
1. 
INTRODUCTION 
The purpose of this reporting and analysis plan (RAP) is to describe the analyses to be 
included in the Clinical Study Report for Protocol: 
Revision Chronology: 
2018N385734_00 
06-Mar-2019 
Original 
2018N385734_01 
22-May-2019 
Correction of contraceptive requirements for 
Women of Child Bearing Potential (WOCBP) and additional 
clarifications. 
2018N385734_02 
21-Jan-2020 
(1) To detail revised risks, entry and stopping criteria 
following the update to comparator drug (tofacitinib) label; 
(2) To introduce new medical device safety reporting 
wording, required in advance of roll out of pre-filled syringes 
to this study. (3) Other minor corrections and clarifications. 
1.1. 
RAP Amendments 
Revision chronology:  
RAP Section 
Amendment Details 
Statistical Analysis Plan Final Reporting and Analysis Plan_201790_V1 [14-Feb-2022] 
Statistical Analysis Plan Final Reporting and Analysis Plan Amendment_201790_V1 
Section 5.5 
• 
Ordering of multiple testing procedure was amended. 
Section 7.2 
• 
Separate Section for radiographic endpoints was removed and these 
endpoints were added into Section 7.2. 
Section 14.6.2 
• 
Correction to the Corticosteroid Scaling Factors.  
Section 14.6.4 
• 
Update to the derivation of Broad MACE and clarifications on CV 
events 
Section 14.12 
• 
Addition of 3 tables and 3 figures for statistical analysis on radiographic 
endpoints 
General 
• 
Minor typos corrected 
 
2. 
SUMMARY OF KEY PROTOCOL INFORMATION 
2.1. 
Changes to the Protocol Defined Statistical Analysis Plan 
Changes from the originally planned statistical analysis specified in the protocol 
amendment 2 (Dated: 21/Jan/2020) are outlined in Table 1. 


 
CONFIDENTIAL 
 
 
 
201790 
 
7 
 
Table 1 
Changes to Protocol Defined Analysis Plan 
Protocol 
Reporting & Analysis Plan 
Statistical Analysis Plan 
Statistical Analysis Plan 
Rationale for Changes 
• 
In order to preserve type 1 error, 
each of the primary and key 
secondary endpoints (ACR20, 
CDAI-LDA and HAQ-DI) will be 
assessed sequentially using a 
step-down approach.  
• 
The step-down approach 
detailed in the protocol is 
extended to make use of a 
graphical multiple testing 
procedure and the principle 
of alpha-propagation. 
• 
The following are added 
into the multiplicity control: 
o Superiority versus 
placebo: 
▪ 
FACIT-Fatigue   
o Superiority comparisons 
versus tofacitinib: 
▪ 
 CDAI total score  
▪ 
Pain VAS 
▪ 
ACR20 
▪ 
FACIT-Fatigue 
• 
Non-inferiority and 
superiority comparisons 
versus tofacitinib are at 
week 24 in the multiplicity 
control. 
• 
To ensure that comparisons 
of interest are controlled for 
multiplicity per the 
regulatory agency’s 
feedback. 
• 
Major Secondary Efficacy 
Endpoints are CDAI-LDA and 
HAQ-DI. 
• 
CDAI total score, FACIT 
Fatigue and Pain VAS are 
added as Major Secondary 
Efficacy Endpoints. 
• 
Major Secondary Efficacy 
Endpoints aligned with the 
updated hierarchy 
(described on row above) 
• 
ACR20 and CDAI-LDA will be 
analysed using GEE 
• 
ACR20 and CDAI-LDA will 
be analysed using Logistic 
Regression 
• 
Missing data handling 
strategies will implement 
multiple imputation to 
generate full analysis 
datasets. GEE analysis 
provides no additional 
benefit over logistic 
regression when working 
with full datasets. 
• 
HAQ-DI will be analysed using 
MMRM 
• 
HAQ-DI will be analysed 
using ANCOVA 
• 
Missing data handling 
strategies will implement 
multiple imputation to 
generate full analysis 
datasets. MMRM analysis 
provides no additional 
benefit over ANCOVA when 
working with full datasets. 
• 
Intercurrent Event specified as 
discontinuation of study 
intervention  
• 
Additional intercurrent 
events specified: 
o Discontinuation of 
study intervention for 
any reason 
• 
Following regulatory 
feedback. 


 
CONFIDENTIAL 
 
 
 
201790 
 
8 
 
Protocol 
Reporting & Analysis Plan 
Statistical Analysis Plan 
Statistical Analysis Plan 
Rationale for Changes 
o  Use of prohibited 
medication 
o  Change in stable 
dose of background 
medication 
2.2. 
Study Objective(s) and Endpoint(s) 
Objectives 
Endpoints 
Primary Objectives 
Primary Endpoints 
• 
To compare the efficacy of 
GSK3196165 at doses of 90 mg and 
150 mg weekly versus placebo for the 
treatment of participants with 
moderately to severely active RA who 
are on a stable background of MTX 
and who have had an inadequate 
response to MTX. 
• 
Proportion of participants achieving ACR20 at Week 12 
Secondary Objectives 
Secondary Endpoints 
To compare: 
• 
Efficacy of GSK3196165 at doses of 
90 mg and 150 mg weekly versus 
tofacitinib for the treatment of 
participants with moderately to 
severely active RA who are on a 
stable background of MTX and who 
have had an inadequate response to 
MTX. 
Major Secondary Efficacy Endpoints 
Week 12 versus placebo: 
• 
Proportion of participants achieving CDAI total score ≤10 
(CDAI LDA). 
• 
Change from baseline in HAQ-DI. 
• 
Change from baseline in FACIT-Fatigue 
 
Non-inferiority versus tofacitinib at Week 24: 
• 
Proportion of participants achieving ACR20. 
 
Superiority versus tofacitinib at Week 24: 
• 
Change from baseline in CDAI total Score 
• 
Change from baseline in Pain VAS 
• 
Proportion of participants achieving ACR20  
• 
Change from baseline in FACIT Fatigue 
 
Other Secondary Efficacy Endpoints 
Week 12 (vs. placebo and vs. tofacitinib), Week 24 and Week 
52 (vs. tofacitinib): 
Proportion of participant achieving: 
• 
CDAI total score ≤10 (CDAI LDA). 
• 
CDAI total score ≤2.8 (CDAI Remission). 
• 
ACR20/50/70. 
• 
DAS28-CRP ≤3.2 or DAS28-ESR ≤3.2 (DAS28 LDA). 
• 
DAS28-CRP <2.6 or DAS28-ESR <2.6 (DAS28 
Remission). 
• 
A good/moderate EULAR response. 
• 
ACR/EULAR Remission. 
• 
A change from baseline in van der Heijde mTSS score of 
≤0.5. 


 
CONFIDENTIAL 
 
 
 
201790 
 
9 
 
Objectives 
Endpoints 
Change from baseline in: 
• 
CDAI total score. 
• 
DAS28-CRP or DAS28-ESR. 
• 
van der Heijde mTSS. 
 
• 
Effect of GSK3196165 on Patient 
Reported Outcomes (PROs) versus 
placebo and the active comparator 
tofacitinib 
Change from baseline at Week 12 (vs. placebo and vs. 
tofacitinib), Week 24 and Week 52 (vs. tofacitinib) in: 
• 
HAQ-DI. 
• 
Arthritis pain VAS. 
• 
SF-36 physical and mental component scores, and 
domain scores. 
• 
FACIT-Fatigue. 
 
• 
Safety and tolerability of GSK3196165 
versus placebo and the active 
comparator tofacitinib 
• 
Incidence of AEs, SAEs and AESIs. 
• 
Change from baseline in key laboratory parameters. 
• 
Proportion of participants with NCI CTCAE ≥ Grade 3 
haematological/clinical chemistry abnormalities. 
 
To determine the immunogenic potential of 
GSK3196165 
Safety Biomarker Endpoints 
• 
GM-CSF autoantibody concentrations. 
• 
Anti-GSK3196165 antibodies. 
 
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
10 
 
2.3. 
Study Design 
Overview of Study Design and Key Features 
Design 
Features 
• 
Phase 3, randomised, double-blind, parallel group, multicentre, placebo and active 
comparator (tofacitinib)-controlled study in participants with moderately to severely 
active RA who have an inadequate response to methotrexate (MTX). 
Dosing 
• 
To maintain the blind, all participants will receive capsules BID and weekly 
subcutaneous (SC) injections.  
• 
A double dummy approach will be followed with matching placebo capsules to 
tofacitinib All treatments will be given in combination with oral or injectable MTX. 
Time & 
Events 
• 
Refer to Appendix 2: Schedule of Activities 
Treatment 
Assignment 
• 
Approximately 3000 to 3400 participants will be screened to achieve between 1500 
and 1700 randomly assigned to study intervention. 
• 
Upon successful screening, participants will be randomised to one of six 
intervention arms in a ratio of 6:6:3:1:1:1 to GSK3196165 150 mg SC weekly, 
GSK3196165 90 mg SC weekly, tofacitinib capsules 5 mg BID or placebo (three 
arms) respectively, all in combination with MTX.  
• 
At Week 12, participants in the three placebo arms will switch from placebo to 
active intervention (either GSK3196165 150 mg SC weekly, GSK3196165 90 mg 
SC weekly, or tofacitinib capsules 5 mg BID). 
• 
For the purpose of all analyses up to week 12, the placebo-sequence arms will be 
pooled into a single placebo arm. 
• 
Participants will be randomised using the cenduit interactive response technology 
(CIRT) system. A separate randomisation cohort in addition to the main 
randomisation will be utilised for participants in the China subgroup, in order to 
allow separate analyses for this country if required for regulatory purposes. 
• 
The number of participants with prior biologic disease-modifying antirheumatic drug 
(bDMARD) exposure will be limited to approximately 20% of the overall sample size 
(approximately 300 to 340 participants). 
Interim 
Analysis 
• 
The primary analysis will be conducted when the planned target of 1500 
randomised participants has been reached. No interim analysis with respect to this 
population is planned. However, if at the time of reaching approximately 1500 


 
CONFIDENTIAL 
 
 
 
201790 
 
11 
 
Overview of Study Design and Key Features 
randomised participants a sufficient number of participants that are required for the 
China subgroup is not reached, then recruitment in China may continue.  
• 
Participants who have already been enrolled from the China subgroup at the time of 
reaching the 1500 target will be included in the primary analysis. Double-blinding 
will be maintained for any subjects continuing in the study at the time of the primary 
analysis. The primary analysis will be the basis of all inferences.  
• 
If enrolment continues beyond the planned target of 1500 randomised participants, 
secondary analyses will be conducted upon completion of enrolment/follow-up for 
the entire study population, based on all randomised subjects. 
 
2.4. 
Statistical Hypotheses  
The primary objective of the study is to determine whether GSK3196165 is superior to 
placebo in the treatment of participants with moderately to severely active RA despite 
MTX treatment (i.e. MTX-IR), as assessed by the proportion of participants achieving 
ACR20 response at Week 12. 
The study will first test the null hypothesis that there is no difference between the 150mg 
dose of GSK3196165 and placebo in the proportion of participants achieving ACR20 
response at Week 12, versus the alternative hypothesis that the 150mg dose of 
GSK3196165 differs from placebo in the proportion of participants achieving ACR20 
response at Week 12. 


 
CONFIDENTIAL 
 
 
 
201790 
 
12 
 
3. 
PLANNED ANALYSES 
3.1. 
Interim Analyses 
The primary analysis will be conducted when the planned target of 1500 randomised 
participants has been reached. No interim analysis with respect to this population is 
planned. However, if at the time of reaching approximately 1500 randomised participants 
a sufficient number of participants that are required for the China subgroup is not 
reached, then recruitment in this country may continue. Participants who have already 
been enrolled from the China subgroup at the time of reaching the 1500 target will be 
included in the primary analysis. Double-blinding will be maintained for any subjects 
continuing in the study at the time of the primary analysis. The primary analysis will be 
the basis of all inferences. If enrolment continues beyond the planned target of 1500 
randomised participants, secondary analyses will be conducted upon completion of 
enrolment/follow-up for the entire study population, based on all randomised subjects. 
An Independent Data Monitoring Committee (IDMC) will be utilised in this study to 
ensure ongoing objective medical and/or statistical review of safety data in order to 
protect the welfare of participants in the study and the scientific validity of the study. Full 
details of the data to be reviewed, the frequency of review and members of the committee 
are included in the IDMC Charter [Version 1.0 09 May 2019]. Full details of the analyses 
are included in a separate IDMC RAP [Version 1.0 30 Apr 2020]. Monthly Safety 
Review Team (SRT) reviews will be performed using blinded SDTM datasets and will be 
reviewed using Spotfire software.  
3.2. 
Final Analyses 
The final planned analyses on the primary analysis cohort (i.e. the first approximately 
1500 randomised participants) will be performed after the completion of the following 
sequential steps: 
1. All participants to be included in the primary analyses have completed the study as 
defined in the protocol.  
2. All required database cleaning activities have been completed and final database 
release (DBR) and database freeze (DBF) has been declared by Data Management. 
3. All criteria for unblinding the randomization codes have been met.  
4. Prior to unblinding, all protocol deviations that will result in an exclusion from the 
per-protocol population have been assigned in the analysis dataset. 
5. Randomization codes have been distributed according to Cenduit Interactive 
Response Technology (C.I.R.T) system procedures. 
If required, the final planned analyses on the full analysis set will be performed after the 
completion of the following sequential steps: 
1. All additional participants from the China country cohort who are not included in the 
primary analysis have completed the study as defined in the protocol.  


 
CONFIDENTIAL 
 
 
 
201790 
 
13 
 
2. All required database cleaning activities have been completed and final database 
release (DBR) and database freeze (DBF) has been declared by Data Management. 
3. All criteria for unblinding the randomization codes have been met.  
4. Prior to unblinding, all protocol deviations that will result in an exclusion from the 
per-protocol population have been assigned in the analysis dataset. 
5. Randomization codes have been distributed according to Cenduit Interactive 
Response Technology (C.I.R.T) system procedures. 
 
4. 
ANALYSIS POPULATIONS 
Population 
Definition / Criteria 
Analyses Evaluated 
Screened  
• 
All participants who were screened for eligibility 
• 
Study Population 
Randomized  
 
• 
All participants who were randomly assigned to 
treatment in the study. 
• 
This population will be based on the treatment the 
participant was randomized to. 
• 
Any participants who receives a treatment 
randomization number will be considered to have been 
randomized. 
• 
Study Population 
Enrolled 
• 
All participants who passed screening and entered the 
study.  
• 
Note screening failures (who never passed screening 
even if rescreened) and participants screened but never 
enrolled into the study (Reserve, Not Used) are 
excluded from the Enrolled population as they did not 
enter the study. 
• 
Study Population 
Safety 
• 
All randomized participants who received at least one 
dose of study treatment. 
• 
This population will be based on the treatment the 
subject actually received. 
• 
Note: Participants who were not randomized but 
received at least one dose of study treatment should be 
listed. 
• 
Safety 
• 
Biomarker 
Safety – Subjects 
who Entered 
Period 2 
• 
All participants randomized to a placebo switch 
treatment arm (i.e. Placebo to GSK3196165 90mg, 
Placebo to GSK3196165 150mg or Placebo to 
Tofacitinib 5mg) who received at least one dose of study 
treatment in period 2. 
• 
This population will be based on the treatment the 
subject actually received. 
• 
Safety 
Intent-To-Treat 
(ITT) 
• 
All randomized participants who received at least one 
dose of study treatment. 
• 
This population will be based on the treatment the 
subject was randomized to. 
• 
Any participants who receives a treatment 
randomization number will be considered to have been 
randomized. 
• 
Study Population 
• 
Efficacy 
 


 
CONFIDENTIAL 
 
 
 
201790 
 
14 
 
Population 
Definition / Criteria 
Analyses Evaluated 
Per-Protocol  
(PP) 
• 
All participants in the ITT population who comply with 
the protocol. 
• 
Protocol deviations that would exclude participants from 
the PP population are defined in Section 4.1 (Protocol 
Deviations) and Appendix 1: Protocol Deviation 
Management and Definitions for Per Protocol 
Population). 
• 
The PP set will not be analysed if this population 
comprises more than 85% of the ITT population. 
• 
Efficacy 
Refer to Appendix 12: List of Data Displays which details the population used for each display. 
 
4.1. 
Protocol Deviations 
Important protocol deviations (including deviations related to study inclusion/exclusion 
criteria, conduct of the trial, patient management or patient assessment) will be 
summarised by IQVIA CTMS category. GSK subcategories will be included in 
individual subject listings. 
Important deviations and other criteria which result in exclusion from the analysis 
population will also be summarised and listed. (Please refer to Appendix 1: Protocol 
Deviation Management and Definitions for Per Protocol Population). 
Protocol deviations will be tracked by IQVIA and overseen by the GSK study team 
throughout the conduct of the study in accordance with the latest version of the Protocol 
Deviation Management Plan maintained by IQVIA in their TMF system. 
o Data will be reviewed prior to unblinding and freezing the database to ensure all 
important deviations are captured and categorised in the protocol deviations 
dataset.  
o Deviations leading to exclusion from the Per Protocol Population will be 
identified in the ADDV dataset. 
A separate listing of all inclusion/exclusion criteria deviations will also be provided. This 
summary will be based on data as recorded on the inclusion/exclusion page of the eCRF. 
Additional protocol deviations may be identified during the study and will be 
documented in protocol deviation adjudication meeting minutes prior to database freeze.   
All violations will be discussed and adjudicated as important or not important. Only 
protocol deviations that have the potential to impact the efficacy evaluation (and are 
important) will lead to exclusion from the per-protocol population. 
 
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
15 
 
5. 
CONSIDERATIONS FOR DATA ANALYSES AND DATA 
HANDLING CONVENTIONS 
5.1. 
Study Treatment & Sub-group Display Descriptors 
5.1.1. 
Study Treatment & Sub-group Display Descriptors for Study 
Population Displays 
Unless otherwise specified, all study population outputs will display the pooled placebo 
arm as follows: 
Treatment Group Descriptions  
Cenduit Interactive Response 
Technology (CIRT) 
Data Displays for Reporting 
Code 
Description 
Description 
Order in TLF  
1 
GSK3196165 150mg 
OTI 150mg QW 
3 
2 
GSK3196165 90mg 
OTI 90mg QW 
2 
3 
Tofacitinib BID 
TOFA 5mg BID  
4 
4+5+6 Placebo to GSK3196165 150mg 
+ Placebo to GSK3196165 90mg 
+ Placebo to Tofacitinib BID 
Pooled PBO 
1 
All study population outputs required to be displayed by randomised treatment arm will 
display all randomised treatment arms as follows: 
Treatment Group Descriptions  
Cenduit Interactive Response 
Technology (CIRT) 
Data Displays for Reporting 
Code Description 
Description 
Order in TLF  
1 
GSK3196165 150mg 
OTI 150mg QW 
5 
2 
GSK3196165 90mg 
OTI 90mg QW 
4 
3 
Tofacitinib BID 
TOFA 5mg BID 
6 
4 
Placebo to GSK3196165 150mg 
PBO to OTI 150mg QW 
2 
5 
Placebo to GSK3196165 90mg 
PBO to OTI 90mg QW 
1 
6 
Placebo to Tofacitinib BID 
PBO to TOFA 5mg BID 
3 
 
5.1.2. 
Study Treatment & Sub-group Display Descriptors for Efficacy 
Displays 
Treatment Group Descriptions  
Cenduit Interactive Response 
Technology (CIRT) 
Data Displays for Reporting 
Code 
Description 
Description 
Order in TLF  
1 
GSK3196165 150mg 
OTI 150mg QW 
3 
2 
GSK3196165 90mg 
OTI 90mg QW 
2 
3 
Tofacitinib BID 
TOFA 5mg BID 
4 
4 
Placebo to GSK3196165 150mg 
PBO to OTI 150mg QW 
6 
5 
Placebo to GSK3196165 90mg 
PBO to OTI 90mg QW 
5 


 
CONFIDENTIAL 
 
 
 
201790 
 
16 
 
Treatment Group Descriptions  
6 
Placebo to Tofacitinib BID 
PBO to TOFA 5mg BID 
7 
4+5+6 Placebo to GSK3196165 150mg 
+ Placebo to GSK3196165 90mg 
+ Placebo to Tofacitinib BID 
Pooled PBO 
1 
For the purpose of analyses up to week 12. the placebo-sequence groups will be pooled 
into a single placebo arm. 
Treatment comparisons will be displayed as follows using the descriptors as specified: 
1. Otilimab 90mg vs Pooled Placebo 
2. Otilimab 150mg vs Pooled Placebo 
3. Tofacitinib 5mg vs Pooled Placebo 
4. Otilimab 90mg vs Tofacitinib 5mg 
5. Otilimab 150mg vs Tofacitinib 5mg  
5.1.3. 
Study Treatment & Sub-group Display Descriptors for Safety 
Displays - Adverse Events (AEs) and Laboratory Assessments 
Each AE display will be produced for the time periods below (see Figure 1 for graphical 
representation): 
1. Period 1 – up to week 12, to be displayed for all participants. 
• Period 1 is defined as time from randomisation up to dosing of Period 2 treatment 
(Week 12) or date of study withdrawal or date of treatment withdrawal plus 
safety follow up, whichever is earlier. AEs that occur at week 12 visit i.e. AE 
start date is at week 12 visit will be assigned to Period 2. 
• The placebo-sequence groups up to week 12 will be pooled into a single placebo 
arm. 
2. Period 2 – post week 12, to be displayed for participants who were originally 
randomised to receive placebo and switched at week 12, only. 
• Period 2 is defined as time from first dose of treatment of period 2 (week 12) 
until date of study completion or date of study withdrawal or date of treatment 
withdrawal plus safety follow up, whichever is earlier. 
3. Period 1+2 – from week 0 to week 52, to be displayed for participants who were 
originally randomised to Otilimab 150mg, Otilimab 90mg or Tofacitinib 5mg, only. 
• Period 1+2 is defined as time from randomisation until date of study completion 
or date of study withdrawal or date of treatment withdrawal plus safety follow 
up, whichever is earlier. 


 
CONFIDENTIAL 
 
 
 
201790 
 
17 
 
Figure 1 
Graphical Representation of Study Design with Periods and 
Treatment Arms within Each Period  
 
 
For displays for Period 1 (up to week 12), the following treatment group descriptions will 
be used: 
Treatment Group Descriptions  
Cenduit Interactive Response 
Technology (CIRT) 
Data Displays for Reporting 
Code 
Description 
Description 
Order in TLF  
1 
GSK3196165 150mg 
OTI 150mg QW 
3 
2 
GSK3196165 90mg 
OTI 90mg QW 
2 
3 
Tofacitinib BID 
TOFA 5mg BID  
4 
4+5+6 Placebo to GSK3196165 150mg 
+ Placebo to GSK3196165 90mg 
+ Placebo to Tofacitinib BID 
Pooled PBO 
1 
 
Treatment comparisons will be displayed as follows using the descriptors as specified: 
1. Otilimab 150mg vs Pooled Placebo 
2. Otilimab 90mg vs Pooled Placebo 
3. Tofacitinib 5mg vs Pooled Placebo 
4. Otilimab 150mg vs Tofacitinib 5mg 
5. Otilimab 90mg vs Tofacitinib 5mg 
6. Otilimab 150mg vs Otilimab 90mg  
 


 
CONFIDENTIAL 
 
 
 
201790 
 
18 
 
For displays for Period 2 (post week 12), the following treatment group descriptions will 
be used: 
Treatment Group Descriptions  
Cenduit Interactive Response 
Technology (CIRT) 
Data Displays for Reporting 
Code Description 
Description 
Order in TLF  
4 
Placebo to GSK3196165 150mg 
PBO to OTI 150mg QW 
2 
5 
Placebo to GSK3196165 90mg 
PBO to OTI 90mg QW 
1 
6 
Placebo to Tofacitinib BID 
PBO to TOFA 5mg BID 
3 
 
Treatment comparisons will be displayed as follows using the descriptors as specified: 
1. Placebo to Otilimab 150mg vs Placebo to Tofacitinib 5mg 
2. Placebo to Otilimab 90mg vs Placebo to Tofacitinib 5mg 
3. Placebo to Otilimab 150mg vs Placebo to Otilimab 90mg 
 
For displays for Period 1+2 (Week 0 to Week 52), the following treatment group 
descriptions will be used: 
Treatment Group Descriptions  
Cenduit Interactive Response 
Technology (CIRT) 
Data Displays for Reporting 
Code Description 
Description 
Order in TLF  
1 
GSK3196165 150mg 
OTI 150mg QW 
2 
2 
GSK3196165 90mg 
OTI 90mg QW 
1 
3 
Tofacitinib BID 
TOFA 5mg BID  
3 
 
Treatment comparisons will be displayed as follows using the descriptors as specified: 
1. Otilimab 150mg vs Tofacitinib 5mg  
2. Otilimab 90mg vs Tofacitinib 5mg 
3. Otilimab 150mg vs Otilimab 90mg 
 
5.1.4. 
Study Treatment descriptors used for Figures 
Table 2 describes the format required for the reporting of figures.  
 


 
CONFIDENTIAL 
 
 
 
201790 
 
19 
 
Table 2 
Treatment Descriptors, Colours, Line Style and Symbols to be used 
for Figures 
Treatment Description 
Colour 
SAS Colour 
Marker 
Symbol 
Line pattern 
Pooled PBO 
Black 
#333333 
X 
2 
PBO to OTI 90mg QW 
Orange 
#F36633 
SquareFilled 
2 
PBO to OTI 150mg QW 
Green 
#167716 
DiamondFilled 
2 
PBO to TOFA 5mg BID 
Blue 
#3131DD 
CircleFilled 
2 
OTI 90mg QW 
Orange 
#F36633 
Square 
1 
OTI 150mg QW 
Green 
#167716 
Diamond 
1 
TOFA 5mg BID 
Blue 
#3131DD 
Circle 
1 
 
5.2. 
Baseline Definitions 
5.2.1. 
Baseline definition in Period 1 and Period 1+2 
For all endpoints (except as noted in baseline definitions) the baseline value will be the 
latest pre-dose assessment with a non-missing value, including those from unscheduled 
visits. If time is not collected, Day 1 assessments are assumed to be taken prior to first 
dose and used as baseline. 
Parameter 
Study Assessments Considered as 
Baseline 
Baseline Used in 
Data Display 
Screening 
Day 1 (Pre-Dose) 
Efficacy 
Tender Joint Count 28 
 
X 
Day 1 (Pre-Dose) 
Tender Joint Count 68 
 
X 
Day 1 (Pre-Dose) 
Swollen Joint Count 28 
 
X 
Day 1 (Pre-Dose) 
Swollen Joint Count 66 
 
X 
Day 1 (Pre-Dose) 
Pain VAS 
 
X 
Day 1 (Pre-Dose) 
Patient’s Global Assessment of 
Arthritis (PtGA) 
 
X 
Day 1 (Pre-Dose) 
Physician’s Global Assessment of 
Arthritis (PhGA) 
 
X 
Day 1 (Pre-Dose) 
CRP 
 
X 
Day 1 (Pre-Dose) 
ESR 
 
X 
Day 1 (Pre-Dose) 
HAQ-DI 
 
X 
Day 1 (Pre-Dose) 
DAS28-CRP Total Score 
 
X 
Day 1 (Pre-Dose) 
DAS28-ESR Total Score 
 
X 
Day 1 (Pre-Dose) 
Van der Heijde mTSS 
X 
 
Screening 
SF-36 
 
X 
Day 1 (Pre-Dose) 
FACIT-Fatigue 
 
X 
Day 1 (Pre-Dose) 


 
CONFIDENTIAL 
 
 
 
201790 
 
20 
 
Parameter 
Study Assessments Considered as 
Baseline 
Baseline Used in 
Data Display 
Screening 
Day 1 (Pre-Dose) 
Safety 
Vital Signs 
X 
X 
Day 1 (Pre-Dose) [1] 
ECG (12-lead) 
X 
X 
Day 1 (Pre-Dose) [1] 
Laboratory 
X 
X 
Day 1 (Pre-Dose) [1] 
Pulmonary assessments 
X 
X 
Day 1 (Pre-Dose) [1] 
Immunogenicity 
 
X 
Day 1 (Pre-Dose)  
[1] the baseline value will be the latest pre-dose assessment with a non-missing value 
Unless otherwise stated, if baseline data is missing no derivation will be performed and 
baseline will be set to missing. 
5.2.2. 
Baseline definition in Period 2 
For all safety assessments the baseline value will be the latest pre-dose assessment before 
the first dose in period 2 with a non-missing value, including those from unscheduled 
visits. 
5.3. 
Multicentre Studies 
In this multicentre global study, enrolment will be presented by investigative site, 
country, and the regions. 
Region 
Countries 
US and Canada 
United States and Canada 
European Continent 
Czech Republic, Hungary, Italy, Latvia, Lithuania, Poland, Russian 
Federation, Serbia, Spain, Ukraine, United Kingdom 
Latin America and South Africa 
Argentina, Brazil, Mexico, South Africa 
Asia 
India, Malaysia, Philippines, China 
 
5.4. 
Examination of Covariates, Other Strata and Subgroups 
5.4.1. 
Covariates and Other Strata 
The list of covariates and other strata may be used in descriptive summaries and 
statistical analyses, some of which may also be used for subgroup analyses. Additional 
covariates and other strata of clinical interest may also be considered. 
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
21 
 
Category 
Details 
Strata 
Not applicable 
Covariates 
Relevant baseline score 
 
5.4.2. 
Examination of Subgroups 
The list of subgroups may be used in descriptive summaries and statistical analyses for 
the primary and/or key secondary endpoints. Additional subgroups of clinical interest 
may also be considered. 
• 
If the percentage of subjects is small within a particular subgroup, then the subgroup 
categories may be refined prior to unblinding the study. 
• 
If the category cannot be refined further, then descriptive rather than statistical 
comparisons may be performed for the particular subgroup. 
Subgroup 
Categories  
Overall Group 
Region 
US and Canada, European Continent, 
Latin America and South Africa, Asia 
Demographic 
Specific Region 
Europe, other 
Demographic  
Specific Region 
USA, other 
Demographic 
Specific Region 
China, other 
Demographic 
Age 
<50 years, 50 to 64 years, ≥65 years 
Demographic 
Ethnicity 
Hispanic or Latino, Not Hispanic or Latino 
Demographic 
Race 
Black or African American/African Heritage, 
Asian, White, Other (American Indian or 
Alaskan Native, Native Hawaiian or Other 
Pacific Islander, Multiple) 
Demographic 
Gender 
Male, Female 
Demographic 
Baseline Body Weight 
<60kg, 60-100kg, >100kg 
Demographic 
Baseline both RF Negative 
and Anti-CCP Negative 
Both Negative, At Least One Positive 
Disease Characteristic 
Baseline DAS28-CRP 
<5.1, ≥5.1 
Disease Characteristic 
Baseline CDAI 
<22, ≥22 
Disease Characteristic 
Duration of RA 
≤5 years, >5 to ≤10 years, >10 years 
Disease Characteristic 
BMI 
<25, ≥25 and <30, ≥30 
Demographic 
 
 
5.5. 
Multiple Comparisons and Multiplicity 
The graphical multiple testing procedure described in (Bretz, 2009) will be used to 
control the type I error for the primary and key secondary endpoints. 
Each hypothesis will be assessed sequentially using a step-down approach where testing 
of the second hypothesis will commence only if all null hypotheses of the prior steps are 
rejected. Additionally, as there are two doses of GSK3196165 within each test, this will 
also be incorporated into the step-down procedure.  


 
CONFIDENTIAL 
 
 
 
201790 
 
22 
 
A graphical presentation of the multiplicity control is provided in Figure 2.  
If any of the hypotheses in the list are not rejected (i.e. the testing sequence fails at this 
step), the subsequent test(s) will still be performed but the results will be uncontrolled for 
multiplicity. 
The proposed testing sequence of primary and key secondary hypotheses is: 
1. ACR20 GSK3196195 vs. Placebo for Superiority at Week 12 
2. CDAI-LDA GSK3196195 vs. Placebo for Superiority at Week 12 
3. HAQ-DI GSK3196195 vs. Placebo for Superiority at Week 12 
4. ACR20 GSK3196195 vs. Tofacitinib for Non-Inferiority at Week 24 
5. FACIT-Fatigue GSK3196165 vs. Placebo for Superiority at Week 12 
6. CDAI Total Score GSK3196195 vs. Tofacitinib for Superiority at Week 24 
7. Pain VAS GSK3196195 vs. Tofacitinib for Superiority at Week 24 
8. ACR20 GSK3196195 vs. Tofacitinib for Superiority at Week 24 
9. FACIT-Fatigue GSK3196165 vs. Tofacitinib for Superiority at Week 24  
The following steps will be followed to test the aforementioned hypotheses: 
Step 
Test 
Pre-requisite(s) 
P-value (2-
sided) 
1 
ACR20 at week 12 for 
GSK3196165 150mg vs. 
placebo 
None 
0.05 
2a 
CDAI-LDA at week 12 for 
GSK3196165 150mg vs. 
placebo 
Step 1 passed 
0.025 
2b 
HAQ-DI at week 12 for 
GSK3196165 150mg vs. 
placebo 
Step 2a passed 
0.025 
3a 
ACR20 at week 12 for 
GSK3196165 90mg vs. placebo 
Step 1 passed 
0.025 
3b 
CDAI-LDA at week 12 for 
GSK3196165 90mg vs. placebo 
Step 3a passed 
0.025 
3c 
HAD-DI at week 12 for 
GSK3196165 90mg vs. placebo 
Step 3b passed 
0.025 
4 
ACR20 at week 24 for non-
inferiority of GSK3196165 
150mg vs. tofacitinib 
Both step 2b and 3c passed 
0.05 
Step 2b passed and step 3c failed or not 
reached 
0.025 
Step 3c passed and step 2b failed or not 
reached 
0.025 
5 
FACIT-Fatigue at week 12 for 
superiority of GSK3196165 
150mg vs. placebo 
Step 4 tested at p=0.05 and passed 
0.05 
Step 4 tested at p=0.025 and passed 
0.025 


 
CONFIDENTIAL 
 
 
 
201790 
 
23 
 
Step 
Test 
Pre-requisite(s) 
P-value (2-
sided) 
6 
ACR20 at week 24 for non-
inferiority of GSK3196165 
90mg vs. tofacitinib  
Step 5 tested at p=0.05 and passed 
0.05 
Step 5 tested at p=0.025 and passed 
0.025 
7 
FACIT-Fatigue at week 12 for 
superiority of GSK3196165 
90mg vs. placebo 
Step 6 tested at p=0.05 and passed 
0.05 
Step 6 tested at p=0.025 and passed 
0.025 
8 
CDAI total score at week 24 for 
superiority of GSK3196165 
150mg vs. tofacitinib 
Step 7 tested at p=0.05 and passed 
0.05 
Step 7 tested at p=0.025 and passed 
0.025 
9 
Pain VAS at week 24 for 
superiority of GSK3196165 
150mg vs. tofacitinib 
Step 8 tested at p=0.05 and passed 
0.05 
Step 8 tested at p=0.025 and passed 
0.025 
10 
ACR20 at week 24 for 
superiority of GSK3196165 
150mg vs. tofacitinib 
Step 9 tested at p=0.05 and passed 
0.05 
Step 9 tested at p=0.025 and passed 
0.025 
11 
CDAI total score at week 24 for 
superiority of GSK3196165 
90mg vs. tofacitinib  
Step 10 tested at p=0.05 and passed 
0.05 
Step 10 tested at p=0.025 and passed 
0.025 
12 
Pain VAS at week 24 for 
superiority of GSK3196165 
90mg vs. tofacitinib 
Step 11 tested at p=0.05 and passed 
0.05 
Step 11 tested at p=0.025 and passed 
0.025 
13 
ACR20 at week 24 for 
superiority of GSK3196165 
90mg vs. tofacitinib 
Step 12 tested at p=0.05 and passed 
0.05 
Step 12 tested at p=0.025 and passed 
0.025 
14 
FACIT-Fatigue at week 24 for 
superiority of GSK3196165 
150mg vs. tofacitinib 
Step 13 tested at p=0.05 and passed 
0.05 
Step 13 tested at p=0.025 and passed 
0.025 
15 
FACIT-Fatigue at week 24 for 
superiority of GSK3196165 
90mg vs. tofacitinib 
Step 14 tested at p=0.05 and passed 
0.05 
Step 14 tested at p=0.025 and passed 
0.025 
 
Analyses of other efficacy endpoints will not be subject to any multiplicity adjustment. 


 
CONFIDENTIAL 
 
 
 
201790 
 
24 
 
Figure 2 
Graphical presentation of the Multiple Testing Procedure  
 
Note: The number in the circles refer to the initial weighting of alpha. The number along 
the arrows refer to the weighting of alpha which is passed along to the next test. 


 
CONFIDENTIAL 
 
 
 
201790 
 
25 
 
5.6. 
Other Considerations for Data Analyses and Data Handling 
Conventions 
Other considerations for data analyses and data handling conventions are outlined in the 
appendices: 
Section Component 
14.3 
Appendix 3: Assessment Windows 
14.4 
Appendix 4: Study Phases and Treatment Emergent Adverse Events 
14.5 
Appendix 5: Data Display Standards & Handling Conventions 
14.6 
Appendix 6: Derived and Transformed Data 
14.7 
Appendix 7: Reporting Standards for Missing Data 
14.8 
Appendix 8: Laboratory Parameters of Interest 
14.9 
Appendix 9: List of Preferred Terms 
14.10 
Appendix 10: Missing Data Imputation Strategies 
 


 
CONFIDENTIAL 
 
 
 
201790 
 
26 
 
6. 
STUDY POPULATION ANALYSES 
6.1. 
Overview of Planned Study Population Analyses 
The study population analyses will be based on the “Screened”, “Randomised”, 
“Enrolled” or “ITT” population, unless otherwise specified. 
Study population analyses including analyses of subject’s disposition, protocol 
deviations, demographic and baseline characteristics, prior and concomitant medications, 
and exposure and treatment compliance will be based on GSK Core Data Standards.   
All concomitant medications summaries will use the “while on treatment” approach, i.e. 
any concomitant medications which are taken post discontinuation of study intervention 
plus safety follow-up (+56 days), will be excluded. 
Additional study population outputs relating to the COVID-19 pandemic will be based on 
GSK Core Data Standards, including: 
• Baseline characteristics by pre and post COVID-19 pandemic measures 
• Participant status and disposition by relationship to COVID-19 pandemic 
• Treatment status and reasons for discontinuation of study treatment by relationship to 
COVID-19 pandemic 
• Participants by country and site by implementation of pandemic measures 
• Protocol deviations by relationship to COVID-19 pandemic 
• COVID-19 Visits and Assessments Impacts 
• Recruitment relative to COVID-19 pandemic measures 
Details of the planned displays are presented in Appendix 12: List of Data Displays. 


 
CONFIDENTIAL 
 
 
 
201790 
 
27 
 
7. 
EFFICACY ANALYSES 
As discussed in the addendum ICH E9 (R1) [ICH, 2019] the specification of treatment 
effects to be estimated (the estimand) should include: 
• The population of interest. 
• The treatment condition of interest. 
• The outcome variable of interest. 
• The summary measure (which may be a model-based estimate or comparison). 
• The identification and strategy for handling potential intercurrent events. 
The following sections provide clarity on each of these components for the efficacy 
treatment effects to be estimated in this study and details on how missing outcomes will 
be handled. 
7.1. 
Primary Efficacy Analyses 
7.1.1. 
Primary Estimand Strategy 
The primary estimand for this study is derived directly from the primary objective of the 
study to determine whether GSK3196165 is superior to placebo in the treatment of 
participants with moderately to severely active RA despite MTX treatment (i.e. MTX-
IR). This will be assessed by the odds ratio of ACR20 response at Week 12 for 
GSK3196165 versus placebo , regardless of: IP discontinuation for any reason, prohibited 
medication use or change in stable dose of background therapy. Each component of this 
estimand is described below. 
7.1.1.1. 
Population 
Participants with moderately to severely active RA despite MTX treatment, which is 
targeted using the inclusion and exclusion criteria.  
7.1.1.2. 
Treatment 
Those who receive at least one dose of GSK3196165 150mg, compared to those who 
receive at least one dose of placebo, in addition to any other medication taken during the 
study. 
7.1.1.3. 
Outcome Variable 
ACR20 response at week 12. 
 
7.1.1.4. 
Summary Measure 
The odds ratio comparing the GSK3196165 150mg arm with placebo. This measure will 
be derived from model-based adjusted estimates. 


 
CONFIDENTIAL 
 
 
 
201790 
 
28 
 
7.1.1.5. 
Strategy for Intercurrent (Post-Randomization) Events 
The intercurrent (post-randomisation) events (IEs) anticipated to impact on the 
interpretation of the treatment effect for the primary objective are:  
1. Discontinuation of study intervention for any reason 
2.  Use of prohibited medication 
3.  Change in stable dose of background medication 
The handling strategy for all of these IEs will be based on a treatment policy approach; 
specifically, the effects estimated will be based on initial randomized treatment arm 
regardless of whether the participant had experienced an IE. Data will continue to be 
collected after the occurrence of the IEs, until the participant either completes the study 
or withdraws from the study before completion.  
7.1.1.6. 
Handling of Missing Data 
Intermittent missing data (i.e. data between two non-missing assessments) for the ACR20 
response will be imputed under a missing at random (MAR) assumption. 
If a participant experiences any of the IEs but efficacy data continues to be collected, 
their data will be analysed per their original randomised intervention.  
Study withdrawal before the completion of the study will create missing outcome data. 
This may occur concurrently or after the IE.  
Missing data for the ACR20 response resulting from study withdrawal will be imputed 
using three possible MI models depending on the availability of off-treatment data (i.e. 
data that has been collected post discontinuation of study intervention), using principles 
introduced by (Roger, 2019) (Computational details are included in Section 14.10):  
1. MI using off-treatment data within randomised treatment arm:  
If there is sufficient off-treatment data within a randomised treatment arm (i.e. at 
least 3 participants per arm per visit), then missing data will be imputed 
conditional on the participant’s observed outcomes, using off-treatment data 
within randomised treatment arm. The use of this MI model assumes that missing 
outcomes resulting from participants withdrawing from the study would behave in 
a similar way to other participants who discontinued study intervention, were 
randomised to the same treatment arm, and continued providing data post-
discontinuation of study intervention. 
 
2. MI using off-treatment data across all treatment arms: 
If there is insufficient off-treatment data within a randomised treatment arm (i.e. 
failure of the imputation model in option 1) but there is sufficient off-treatment 
data across all treatment arms combined (i.e. at least 3 participants per visit), then 
missing data will be imputed conditional on the participant’s observed outcomes, 
using off-treatment data across all treatment arms. The use of this MI model 
assumes that missing outcomes resulting from participants withdrawing from the 
study would behave in a similar way to other participants who discontinued study 


 
CONFIDENTIAL 
 
 
 
201790 
 
29 
 
intervention and continued providing data post-discontinuation of study 
intervention regardless of randomised treatment arm. 
 
3. MI under MAR assumption: 
If there is insufficient off-treatment data (i.e. neither option 1 nor 2 is feasible) 
then all missing data will be imputed under a MAR assumption. This MI model 
uses all available data collected on- and off-treatment within randomised 
treatment arm, and assumes missing outcomes resulting from participants 
withdrawing from the study would behave in a similar way to participants who 
were randomised to the same treatment arm and had data collected in the study, 
with no adjustment for values before or after intercurrent events. 
 
Note: Week 1 data will not be included in any imputation models due to the 
unavailability of off-treatment data at this visit by design of the study. 
7.1.1.7. 
Sensitivity Analysis for the Handling of Missing Data 
An additional tipping point analysis will be performed as sensitivity if the endpoint is 
statistically significant and it is plausible that the imputation strategy for missing data 
could alter the conclusions of the analysis. This will be performed at an ACR20 
responder level assuming all possible ACR20 response rates from 0 to 100% amongst 
those with missing ACR20 response in GSK3196165 arm and pooled placebo arm, 
separately. Full details of this analysis will be included in a separate analysis plan and 
results included in a separate report. 
7.1.2. 
Supplementary Analyses  
Two additional estimands for the primary objective will be considered and are described 
in this section. Computational details on both of these strategies are included in Section 
14.10. 
7.1.2.1. 
Supplemental Estimand 1 
As an additional estimand for the primary objective, a composite strategy will be 
considered for the handling of the IE of discontinuation of study intervention for any 
reason; specifically, a composite response definition will be used. A participant will be 
considered to be a non-responder if they do not meet the ACR20 response criterion or 
they discontinue study intervention for any reason. All other IEs will be handled using 
the same strategy as for the Primary Estimand Strategy (i.e. treatment policy). 
7.1.2.2. 
Supplemental Estimand 2 
As a second additional estimand for the primary objective, a hypothetical strategy will be 
considered for the handling of the IE of discontinuation of study intervention for any 
reason; specifically, the effects estimated will be under the hypothetical scenario where 
the IE did not occur.  
Any efficacy data collected after the occurrence of this IE will be excluded from the 
analysis. All data for the treatment response after the occurrence of the IE will be 


 
CONFIDENTIAL 
 
 
 
201790 
 
30 
 
imputed conditional on the participant’s observed outcomes, using on- and off-treatment 
data within randomised treatment arm. The use of this MI model assumes that missing 
outcomes would behave in a similar way to other participants who were randomised to 
the same treatment arm and had data collected in the study, with no adjustment for values 
before or after intercurrent events. 
All other IEs will be handled using the same strategy as for the Primary Estimand 
Strategy (i.e. treatment policy). 
7.1.2.3. 
Per-protocol Analysis 
As a supportive analysis, the primary analyses may be repeated using the “Per-protocol” 
population (see Section 14.1 for the definition).  
7.1.3. 
Statistical Analyses / Methods 
The efficacy analyses will be based in the “Intent-to-Treat” population, unless otherwise 
specified.  
Details of the planned displays are provided in Appendix 12: List of Data Displays and 
will be based on GSK data standards and statistical principles. 
Unless otherwise specified, endpoints / variables defined in Section 7.1.1.3 will be 
summarised using descriptive statistics and graphically presented (where appropriate). 
7.1.3.1. 
Statistical Methodology Specification 
Endpoint / Variables 
• Proportion of participants with ACR20 response at week 12. 
Model Specification 
• Each estimate will be generated for each imputed dataset produced by the multiple 
imputation (MI) procedure described in Section 7.1.1.6, and the corresponding results will be 
combined using Rubin’s rules. 
• The proportion of participants with ACR20 response will be statistically analysed using a 
Logistic Regression model, comparing each randomised treatment arm with control group. 
• The Logistic Regression model will be fitted including fixed effects for treatment arm 
(GSK3196165 150mg, GSK3196165 90mg, tofacitinib 5mg, pooled placebo), baseline 
swollen joint count 66 and baseline tender joint count 68. 
Model Checking & Diagnostics 
• If the logistic model fails to converge (e.g. due to a small number of responders), the primary 
endpoint will be analysed using an exact logistic regression. In case of response rates of 0% 
or 100% in any of the treatment groups, confidence intervals for risk difference and p-values 
from the t-test for the risk difference comparing to 0 will be provided. 
Model Results Presentation 
• Results will be summarised using proportions of subjects (after MI) achieving a response. 
• Differences in the proportions of subjects (after MI) achieving response between each 
randomised treatment arm and pooled placebo will be summarised. 95% CI for the 


 
CONFIDENTIAL 
 
 
 
201790 
 
31 
 
Endpoint / Variables 
differences will be constructed using their asymptotic standard errors (asymptotic Wald 
confidence limits) without continuity correction. 
• Estimates of the Odds Ratio (OR), corresponding 95% confidence intervals and p-values will 
be constructed using the least squared (LS) means estimates from the logistic regression 
model.  
• Plots of the proportion of subjects (after MI) achieving a response and their corresponding 
asymptotic standard errors will be generated for each treatment group by time. 
Subgroup Analyses 
• See Section 5.4 for details on subgroup analyses. 
Sensitivity and Supportive Analyses 
• Sensitivity Analysis on the missing data imputation methods may be performed as described 
in Section 7.1.1.7. 
• Supportive Analysis will be performed as described in Section 7.1.2. 
7.2. 
Secondary Efficacy Analyses 
7.2.1. 
Estimand strategy 
The secondary efficacy analysis will use the same estimand as the primary efficacy 
analysis (see Section 7.1.1 for details). 
7.2.1.1. 
Population 
The population of interest for the secondary efficacy analysis is the same as is stated for 
the primary efficacy analysis (see Section 7.1.1.1). 
7.2.1.2. 
Treatment 
The treatment of interest for the secondary efficacy analysis is the same as is stated for 
the primary efficacy analysis (see Section 7.1.1.2). 
7.2.1.3. 
Outcome Variables 
The key secondary outcomes of interest are: 
• ACR20 response at week 12 (superiority of GSK3196165 90mg over placebo 
comparison) and at week 24 (non-inferiority and superiority over tofacitinib 
comparisons). 
• CDAI-LDA (CDAI Total Score≤10) at week 12 (superiority over placebo 
comparisons).  
• HAQ-DI at week 12 (superiority over placebo comparisons). 
• CDAI Total Score at week 24 (superiority over tofacitinib comparisons). 
• FACIT-Fatigue at week 12 (superiority over placebo comparison) and at week 24 
(superiority over tofacitinib comparison). 
• Pain VAS at week 24 (superiority over tofacitinib comparison). 


 
CONFIDENTIAL 
 
 
 
201790 
 
32 
 
The other secondary outcomes of interest are: 
• ACR20/50/70 response at each assessment visit. 
• CDAI-LDA (CDAI Total Score≤10) at each assessment visit. 
• CDAI Remission (CDAI Total Score≤2.8) at each assessment visit. 
• DAS28-CRP LDA (DAS28-CRP≤3.2) at each assessment visit. 
• DAS28-ESR LDA (DAS28-ESR≤3.2) at each assessment visit. 
• DAS28-CRP Remission (DAS28-CRP<2.6) at each assessment visit. 
• DAS28-ESR Remission (DAS28-ESR<2.6) at each assessment visit. 
• Good/moderate EULAR response at each assessment visit. 
• ACR/EULAR Remission at each assessment visit. 
• Change from baseline in Van der Heijde mTSS≤0/0.5 at each assessment visit. 
• HAQ-DI at each assessment visit. 
• TJC28/68 and SJC28/66 at each assessment visit. 
• CRP (mg/L) at each assessment visit. 
• PtGA/PhGA at each assessment visit. 
• DAS28-(CRP/ESR) at each assessment visit. 
• Arthritis pain VAS at each assessment visit. 
• SF-36 physical and mental component scores, and individual domain scores at each 
assessment visit. 
• FACIT-Fatigue score at each assessment visit. 
• Van der Heijde mTSS at each assessment visit. 
7.2.1.4. 
Summary Measure 
The key secondary summary measures are: 
• The odds ratio comparing GSK3196165 90mg arm with placebo in the proportion of 
participants achieving ACR20 at week 12. 
• The odds ratio comparing GSK3196165 arms with placebo in the proportion of 
participants achieving CDAI-LDA at week 12. 
• The difference between GSK3196165 arms and placebo in the change from baseline 
in HAQ-DI at week 12. 
• The difference between GSK3196165 arms and tofacitinib in the change from 
baseline in CDAI Total Score at week 24. 
• The difference between GSK3196165 arms and placebo in the change from baseline 
in FACIT-Fatigue Score at week 12. 
• The difference between GSK3196165 arms and tofacitinib in the proportion of 
participants achieving ACR20 at week 24. 
• The difference between GSK3196165 arms and tofacitinib in the change from 
baseline in Arthritis Pain VAS at week 24. 
• The odds ratio comparing GSK3196165 arms with tofacitinib in the proportion of 
participants achieving ACR20 at week 24. 
• The difference between GSK3196165 arms and tofacitinib in the change from 
baseline in FACIT-Fatigue Score at week 24. 


 
CONFIDENTIAL 
 
 
 
201790 
 
33 
 
For all secondary endpoints (including the key secondary endpoints), the following 
summary measures are: 
• Odds ratio and/or difference from placebo at all assessment visits up to week 12.   
• Odds ratio and/or difference from tofacitinib at all assessment visits.  
All summary measures will be derived from model-based adjusted estimates for each 
treatment arm. 
7.2.1.5. 
Strategy for Intercurrent (Post-Randomization) Events 
The same  strategy as the primary efficacy analysis will be implemented for all secondary 
efficacy analyses (See Section 7.1.1.5 for full details). 
7.2.1.6. 
Handling of Missing Data 
The same missing data handling strategy as the primary efficacy analysis will be 
implemented for all secondary efficacy analyses (See Section 7.1.1.6 for full details). 
7.2.1.7. 
Sensitivity Analysis for the Handling of Missing Data 
A tipping point analysis will be performed as sensitivity of the key secondary efficacy 
analyses if the endpoints are statistically significant and it is plausible that the imputation 
strategy for missing data could alter the conclusions of the analysis. For binary endpoints, 
the same tipping point strategy as for the primary endpoint will be implemented (see 
Section 7.1.1.7 for full details). For continuous endpoints, this will be performed by 
applying a shift parameter to the mean for the participants with missing outcomes in the 
GSK3196165 arms and the control arm, separately. Full details of this analysis will be 
included in a separate analysis plan and results included in a separate report. 
7.2.2. 
Supplementary Analysis 
The same supplemental strategies as the primary efficacy analysis will be implemented 
for the key secondary efficacy endpoint analyses as follows: 
• Supplemental estimand 1 will be applied to ACR20 and CDAI-LDA (see Section 
7.1.2.1 for details). 
• Supplemental estimand 2 will be applied to ACR20, CDAI Total score and Pain VAS 
(see Section 7.1.2.2 for details). 
7.2.3. 
Statistical Analyses / Methods 
The secondary efficacy analyses will be based in the “Intent-to-Treat” population, unless 
otherwise specified. 
Details of the planned displays are provided in Appendix 12: List of Data Displays, and 
will be based on GSK data standards and statistical principles. 
Unless otherwise specified, endpoints / variables defined in Section 7.2.1.3 will be 
summarised using descriptive statistics and graphically presented (where appropriate). 


 
CONFIDENTIAL 
 
 
 
201790 
 
34 
 
 
7.2.3.1. 
Statistical Methodology Specification 
Binary Endpoints 
Endpoint / Variables 
• Proportion of participants achieving ACR20 response. 
• Proportion of participants achieving CDAI-LDA (CDAI Total Score≤10).  
• Proportion of participants achieving ACR50/70 response. 
• Proportion of participants achieving CDAI Remission (CDAI Total Score≤2.8). 
• Proportion of participants achieving DAS28-(CRP/ESR) LDA (DAS28-CRP≤3.2 or DAS28-
ESR≤3.2). 
• Proportion of participants achieving DAS28-(CRP/ESR) remission (DAS28-CRP<2.6 or 
DAS28-ESR<2.6). 
• Proportion of participants achieving good/moderate EULAR response. 
• Proportion of participants achieving change from baseline in Van der Heijde mTSS≤0.5/0 
Model Specification 
• Each estimate will be generated for each imputed dataset produced by the multiple 
imputation (MI) procedure described in Section 7.1.1.6, and the corresponding results will be 
combined using Rubin’s rules. 
• Binary Endpoints will be statistically analysed using the same methods as for the primary 
endpoint (see Section 7.1.3.1 for full details), however the model will be adjusted for the 
following baseline values: 
Binary Endpoint  
Baseline adjustment 
ACR20  
TJC68, SJC66 
ACR50  
TJC68, SJC66 
ACR70  
TJC68, SJC66 
CDAI-LDA  
CDAI Total Score 
CDAI Remission  
CDAI Total Score 
DAS28-CRP LDA  
DAS28-CRP 
DAS28-CRP Remission  
DAS28-CRP 
DAS28-ESR LDA  
DAS28-ESR 
DAS28-ESR Remission  
DAS28-ESR 
Good/Moderate EULAR (CRP)  
DAS28-CRP 
Change from baseline in Van der 
Heijde mTSS≤0.5 
mTSS 
change from baseline in Van der Heijde 
mTSS≤0 
mTSS 
 
• A separate logistic regression model will be fitted for each assessment time point. For time 
points up to week 12, all treatment arms will be included in the model (i.e. pooled placebo, 
GSK3196165 150mg, GSK3196165 90mg, tofacitinib 5mg). For time points beyond week 


 
CONFIDENTIAL 
 
 
 
201790 
 
35 
 
Endpoint / Variables 
12, only GSK3196165 150mg, GSK3196165 90mg and tofacitinib 5mg randomised 
treatment arms will be included in the model. 
• If at any time point the convergence criterion is not satisfied or maximum likelihood 
estimates do not exist, then the results of this model will not be reported. 
Model Checking & Diagnostics 
• The same model checking and diagnostics will be used as for the primary endpoint. See 
Section 7.1.3.1 for full details. 
Model Results Presentation 
• Binary Endpoints will be presented using the same methods as the primary endpoint. See 
Section 7.1.3.1 for full details. 
• The results from each assessment time point model will be presented within the same 
output. 
• Non-inferiority over tofacitinib on ACR20 will be concluded if the lower limit of the multiplicity 
corrected 95% CI in the difference in proportions (GSK3196165 minus tofacitinib) is greater 
than -12% (Note: non-inferiority was calculated using the FDA fixed margin approach [FDA, 
2016]). 
Subgroup Analyses 
• See Section 5.4 for details on subgroup analyses. 
Sensitivity and Supportive Analyses 
• Sensitivity Analysis on the missing data imputation methods may be performed as described 
in Section 7.2.1.7. 
• Supportive Analysis may be performed as described in Section 7.2.2. 
Continuous Endpoints 
Endpoint / Variables 
• Change from baseline in HAQ-DI. 
• Change from baseline in CDAI Total Score.  
• Change from baseline in FACIT-Fatigue score. 
• Change from baseline in arthritis pain VAS. 
• Change from baseline in TJC28/68 and SJC28/66. 
• Change from baseline in CRP (mg/L) 
• Change from baseline in PtGA/PhGA. 
• Change from baseline in DAS28-(CRP/ESR). 
• Change from baseline in SF-36 physical and mental component scores. 
• Change from baseline in Van der Heijde mTSS 
Model Specification 
• Each estimate will be generated for each imputed dataset produced by the multiple 
imputation (MI) procedure described in Section 7.1.1.6, and the corresponding results will be 
combined using Rubin’s rules. 


 
CONFIDENTIAL 
 
 
 
201790 
 
36 
 
Endpoint / Variables 
• Continuous endpoints will be statistically analysed using an analysis of covariance 
(ANCOVA) comparing each randomised treatment arm with control groups when controlling 
for treatment arm and respective baseline value. 
• A separate ANCOVA will be conducted for each assessment time point.  
o For time points up to week 12, all treatment arms will be included in the model (i.e. 
pooled placebo, GSK3196165 150mg, GSK3196165 90mg, tofacitinib 5mg).  
o For time points beyond week 12, only GSK3196165 150mg, GSK3196165 90mg 
and tofacitinib 5mg randomised treatment arms will be included in the model. 
o For time points beyond week 12, estimates of the least squares means for the 
placebo switch treatment arms (i.e. placebo to GSK3196165 150mg, placebo to 
GSK3196165 90mg and placebo to tofacitinib 5mg) will be derived from the model 
including all six randomised treatment arms. 
Model Checking & Diagnostics 
• If there are any departures from the distributional assumptions, alternative models will be 
explored using appropriate transformed data. 
Model Results Presentation 
• The results from each assessment time point will be presented within the same output. 
• Point estimates and corresponding 95% confidence intervals will be constructed for the 
treatment differences over placebo and over tofacitinib at each visit using the least squared 
(LS) means estimates.  
• Plots of LS means and corresponding standard errors from the model will be generated for 
each treatment group by visit. 
• Non-inferiority over tofacitinib on change from baseline in CDAI Total score will be 
concluded if the upper limit of the multiplicity corrected 95% CI in the treatment difference 
(GSK3196165 minus tofacitinib) is less than 3.5 (Note: non-inferiority was calculated using 
the FDA fixed margin approach [FDA, 2016]). 
• Non-inferiority over tofacitinib on change from baseline in Pain VAS will be concluded if the 
upper limit of the multiplicity corrected 95% CI in the treatment difference (GSK3196165 
minus tofacitinib) is less than 5.3 (Note: non-inferiority was calculated using the FDA fixed 
margin approach [FDA, 2016]). 
Subgroup Analyses 
• See Section 5.4 for details on subgroup analyses. 
Sensitivity and Supportive Analyses 
• 
Sensitivity Analysis on the missing data imputation methods may be performed as 
described in Section 7.2.1.7. 
• 
Supportive Analysis may be performed as described in Section 7.2.2. 
• 
Non-parametric analyses may be conducted if the normality assumption does not hold. 
 
 
 


 
CONFIDENTIAL 
 
 
 
201790 
 
37 
 
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
38 
 
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
39 
 
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
40 
 
 
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
41 
 
8. 
SAFETY ANALYSES 
The safety analyses will be based on the “Safety” population, unless otherwise specified.  
Safety analysis will be displayed in three different ways (see Section 5.1.3 for details). 
 
All primary safety analysis will use the “while on treatment” approach, i.e. any safety 
events which occur post discontinuation of study intervention which are not classified as 
treatment emergent under the definition specified in Section 14.4.1.2, will be excluded. A 
sensitivity analysis will be performed on key safety outputs using the “treatment policy” 
approach, i.e. all safety events reported in the study will be included. 
Missing safety data will not be imputed.  
The details of the planned displays are provided in Appendix 12: List of Data Displays. 
8.1. 
Adverse Event Analyses 
• Adverse events analyses including the analysis of adverse events (AEs), Serious 
adverse events (SAEs) and other important adverse events will be based on GSK 
Core Data Standards.  
• All AEs will be classified using the current standard GSK Medical Dictionary for 
Regulatory Activities (i.e. MedDRA version in use at the time of reporting), and 
grouped by SOC and PT, unless otherwise stated.  The MedDRA version will be 
detailed on every table that uses MedDRA. 
• Exposure adjusted event rates per 100 patient years by treatment group will be 
presented separately for AEs and SAEs. 
• Common AEs will be defined as ≥ 5% incidence in any treatment group, unless 
otherwise specified. Relative risks, based on observed frequencies, for the proportions 
of subjects with common AEs will be calculated for the comparisons specified in 
Section 5.1.3. 
• AEs with missing intensity will be considered severe. 
• Additional safety outputs relating to COVID-19 adverse events including COVID-19 
assessments and symptom assessments will be based on GSK Core Data Standards. 
8.1.1. 
Adverse Events of Special Interest and Other Important AEs 
Analyses 
A comprehensive list of MedDRA terms based on clinical review will be used to identify 
each type of event. Changes to the MedDRA dictionary may occur between the start of 
the study and the time of reporting and/or emerging data from on-going studies may 
highlight additional adverse events of special interest, therefore the list of terms to be 
used for each event of interest and the specific events of interest will be based on the 
safety review team (SRT) agreements in place at the time of reporting.  


 
CONFIDENTIAL 
 
 
 
201790 
 
42 
 
The details regarding the derivations of adverse events of special interest (AESI) and 
other important AEs are provided in Section 14.6.4.   
Exposure adjusted event rates per 100 patient-years by treatment group will be calculated 
for each category of AESI and other important AE. 
Relative risks, based on observed frequencies, for the proportions of subjects with AESIs 
will be calculated for the comparisons specified in Section 5.1.3. 
8.2. 
Clinical Laboratory Analyses 
Laboratory evaluations including the analyses of Chemistry laboratory tests, Hematology 
laboratory tests, Urinalysis, fasting lipids, and liver function tests will be based on GSK 
Core Data Standards.  
All laboratory parameters will be summarised, but only laboratory parameters of interest 
with available CTCAE grades will be used in summary table by grades. 
Laboratory parameters of interest are: 
• WBCs 
• Neutrophils  
• Lymphocytes 
• Hemoglobin 
• Platelets 
• ALT 
• AST 
• ALP 
• Bilirubin  
• Creatinine  
• eGFR  
• Total cholesterol  
• Low-density lipoprotein (LDL)  
• High-density lipoprotein (HDL) 
• Triglycerides  
 
Local laboratory parameters will not be included in any summaries and will appear in the 
listing only. 
8.3. 
Other Safety Analyses 
The analyses of non-laboratory safety test results including ECGs and vital signs will be 
based on GSK Core Data Standards, unless otherwise specified. 


 
CONFIDENTIAL 
 
 
 
201790 
 
43 
 
8.3.1. 
Immunogenicity Analyses  
An immune response to GSK3196165 can lead to generation of anti-drug antibodies 
(ADA). For the immunogenicity assessment, two types of antibody assays will be 
performed, a binding antibody assay and a neutralizing antibody assay. 
For the binding antibody assay, there will be three testing steps: screening, confirmation 
and titration. The screening assay produces a result of positive or negative relative to a 
screening cut point. Positive samples continue with the confirmation assay, which also 
produces a result of positive or negative relative to a confirmation cut point. For samples 
with a positive confirmation result, a titre value will also be obtained to quantify the 
degree of binding in a titration assay. Subjects with confirmed positive results, will also 
be tested in the neutralizing antibody assay, which also reports results as positive or 
negative. 
Subjects will be categorized as positive or negative based on confirmation step and a 
positive ADA event will further be categorized as transient positive or persistent positive 
at each visit and for anytime post baseline visit. Transient positive is defined as a single 
positive immunogenic response where the previous visit is negative, that does not occur 
at the final study assessment and persistent positive is defined as a positive immunogenic 
response where the previous visit is positive, or the final study assessment is positive. 
Titers will be summarized by median, minimum and maximum. 
 A summary of treatment emergent positive confirmation binding ADA assay results in 
the subset of subjects who did not have a positive confirmation binding ADA assay result 
prior to the dosing of study treatment will also be presented. 
Neutralizing antibody assay results will be summarised by visit. For anytime post 
baseline visit, highest result will be used, i.e. according to the following hierarchy: ADA 
result will be Persistent Positive > Transient Positive > Negative, NAB result will be 
Positive > Negative and highest titer value.  


 
CONFIDENTIAL 
 
 
 
201790 
 
44 
 
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
45 
 
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
46 
 
 
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
47 
 
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
48 
 
CCI


 
CONFIDENTIAL 
 
 
 
201790 
 
49 
 
13. 
REFERENCES 
Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to sequentially rejective 
multiple test procedures. Stat Med. 2009;28(4):586-604. 
FDA (Food and Drug Administration). Guidance for Industry: Non-Inferiority Clinical 
Trials to Establish Effectiveness. 2016. https://www.fda.gov/media/78504/download  
Freynhagen R, Baron R, Gockel U, Tölle T.R, CurrMed ResOpin Vol 22, 2006, 1911-
1920 © 2006 Pfizer Pharma GmbH, Pfizerstr.1, 76139 Karlsruhe, Germany. 
ICH HARMONISED GUIDELINE. Addendum on estimands and sensitivity analysis in 
clinical trials to the guideline on statistical principles for clinical trials E9(R1). 2019. 
https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf 
NCI. National Cancer Institute Common Terminology Criteria for Adverse Events 
v5.0NCI, NIH, DHHS. 2017. 
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Q
uick_Reference_5x7.pdf 
Roger JH, Bratton DJ, Mayer B, Abellan JJ, Keene ON. Treatment policy estimands for 
recurrent event data using data collected after cessation of randomised treatment. 
Pharmaceutical Statistics. 2019; 18:85–95. 


 
CONFIDENTIAL 
 
 
 
201790 
 
50 
 
14. 
APPENDICES 
14.1. 
Appendix 1: Protocol Deviation Management and Definitions 
for Per Protocol Population 
14.1.1. 
Exclusions from Per Protocol Population 
A subject meeting any of the following criteria will be excluded from the Per Protocol 
population: 
Number 
Exclusion Description 
01 
Participant was randomised despite not meeting an eligibility criteria which, in the 
judgement of the clinical team, constitutes an exclusion from the Per protocol population 
(Subset of Important Protocol Deviations with GSK category 2) 
02 
Medication/Vaccine excluded by the protocol was administered, including those restricted 
prior to the study, during the study and/or during the safety follow-up of the study (Important 
Protocol Deviations with GSK categories 4A or 4B) 
03 
Participant substantially did not receive medication as planned per protocol (Important 
Protocol Deviations with GSK category 7A). 
04 
Participant received medication while in contraindication (Important Protocol Deviations with 
GSK category 7B) 
05 
Participant received wrong study treatment or assignment (Important Protocol Deviations 
with GSK category 7C) 
06 
Participant had significant non-compliance or dose modification of background treatment 
(Important Protocol Deviations with GSK category 7OT) 
07 
Participant developed withdrawal criteria specified in the protocol but were not withdrawn 
and continued dosing (Important Protocol Deviations with GSK category 3A, 3B or 3OT) 
08 
Study blind/unblind procedures: Investigator/site staff/participant/GSK Clinical team did not 
remain blinded to treatment assignment through Week 52 Exit visit efficacy evaluation, 
includes emergency unblinding for medical reasons (Important Protocol Deviations with 
GSK category 8B) 
09 
Other: a deviation that does not satisfy the above criteria, however, in the judgment of the 
clinical team, including the medical monitor, constitutes an exclusion from the Per Protocol 
population. 
 


 
CONFIDENTIAL 
 
 
 
201790 
 
51 
 
14.2. 
Appendix 2: Schedule of Activities 
14.2.1. 
Protocol Defined Schedule of Events 
SoA – Screening Period 
 
Participant Screening 
Task List 
 
 
Screening assessment notes 
 
 
 
 
(after informed consent, all screening assessments must 
be completed within the 42 days prior to Randomisation) 
 
Day -42 to Day -1 
 
 
 
 
Informed Consent and optional Genetics consent 
 
 
1) ECGs should be performed before vital signs and 
blood draws. 
2) Joint assessments should be performed by an 
independent assessor. Where possible the same 
assessor should perform all joint assessments for an 
individual participant. 
3) Will be read centrally & imaging CRO will assess 
presence or absence of erosion(s). 
4) Unless performed within previous 12 weeks. 
5) For women of child-bearing potential. 
6) Fasting is not required, but 6hr fasting status at time 
of blood draw must be noted on requisition form.  
 
 
Inclusion/exclusion criteria 
 
 
 
Participant Demographics 
 
 
 
Medical, disease and therapy history 
 
 
 
Review of asthma/COPD/pulmonary disease history 
 
 
 
Concomitant Medication Review 
 
 
Assessments 
12-lead ECG1 
 
 
Vital signs 
 
 
Full Physical Exam 
 
 
Dyspnoea & Cough assessment, Lung Auscultation, Pulse 
Oximetry 
 
 
TB evaluation 
 
 
SAE assessment 
 
 
Swollen (66) & Tender (68) joint count2 
 
 
Hands and feet X-ray3 
 
 
Chest X-ray (posteroanterior)4 
 
 
 
Labs 
Haematology, Chemistry, Urinalysis (dip stick) 
 
 
 
HIV, TB, Hepatitis B & Hepatitis C screen 
 
 
 
hsCRP 
 
 
 
Serum pregnancy test5 
 
 
 
Lipid profile6 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
52 
 


 
CONFIDENTIAL 
 
 
201790 
 
53 
 
SoA – Safety Follow-up Visit 
 
Safety follow-up visit procedures 
 
 
 
(Follow-up visit only for participants who do not 
transition into LTE study 209564) 
 
Week 59 (Day 414 +/- 14 days) 
 
 
 
Assessments 
Vital signs 
 
 
Full Physical Exam 
 
 
Dyspnoea & Cough assessment, Lung Auscultation, 
Pulse Oximetry 
 
 
Concomitant Medication Review 
 
 
SAE/AE review 
 
 
Labs 
Haematology, Chemistry, Urinalysis (dip stick) 
 
 
Urine pregnancy test (for women of child bearing 
potential only) 
 
 
Immunogenicity blood sampling 
 
 
 
Assessments for Early Withdrawal from Study 
Follow the Week 52 procedures* at the time of withdrawal from the study, or within 1 
week of withdrawal, and schedule a safety follow-up visit 8 weeks post last dose of SC 
administered study intervention. 
 
*Note: A hands/feet x-ray should not be performed at early withdrawal if the 
participant’s last dose of study drug was prior to week 8, OR if a hands/feet x-ray has 
been carried out within 8 weeks of the early withdrawal date, as part of study 
assessments. 
 


 
CONFIDENTIAL 
 
 
201790 
 
54 
 
14.3. 
Appendix 3: Assessment Windows 
14.3.1. 
Definitions of Assessment Windows for Analyses 
Data will be analysed as per the planned visit assignment.  
Early withdrawal and unscheduled visits will be slotted to the appropriate planned visit.  
The assigned visit will be based on the interval in which the Study Day for the early 
withdrawal or unscheduled visit falls according to intervals provided below. 
Analysis Set / Domain 
Target  
Analysis Window 
Analysis Timepoint 
Beginning 
Timepoint 
Ending 
Timepoint 
All 
Day-1 
Day -42 
Day -1 
Screening 
All [1] 
Day 1 
Day 1 
Day 1 
Baseline 
All (Efficacy, lung 
auscultation and pulse 
oximetry) [1] 
Day 8 
Day 2 
Day 11 
Week 1 
All (Safety) [2] 
Day 15 
Day 2 
Day 22 
Week 2 
All (Efficacy, lung 
auscultation and pulse 
oximetry) [1] 
Day 15 
Day 12 
Day 22 
Week 2 
All [1] 
Day 29 
Day 23 
Day 43 
Week 4 
All [1] 
Day 57 
Day 44 
Day 71 
Week 8 
Imaging 
Day 85 
Day 2 
Day 127 
Week 12 
All [1] 
Day 85 
Day 72 
Day 88 
Week 12 
All [1] 
Day 92 
Day 89 
Day 95 
Week 13 
All [1] 
Day 113 
Day 96 
Day 141 
Week 16 
All [1] 
Day 169 
Day 142 
Day 211 
Week 24 
Imaging 
Day 169 
Day 128 
Day 267 
Week 24 
All (Safety) 
Day 253 
Day 212 
Day 295 
Week 36 
All (Efficacy) [1] 
Day 253 
Day 212 
Day 309 
Week 36 
All (Safety) 
Day 337 
Day 296 
Day 351 
Week 48 
All (Safety) 
Day 365 
Day 352 
Day 399 
Week 52 
All (Efficacy) [1] 
Day 365 
Day 310 
Day 399 
Week 52 
Imaging 
Day 365 
Day 268 
Day 399 
Week 52 
All (Safety) 
Day 414 
Day 400 
Day 400+ 
8 Week Follow-up (for 
participants who don’t 
transition into LTE study) 
Safety (participants 
withdrawn early from 
treatment) 
56 days after 
last treatment 
42 days after 
last treatment 
70 days after 
last treatment 
8 Week Follow Up 
NOTES: 
• 
If there are two slotted values within a time window, the value closest to the target day for that window will 
be used except for ECGs and X-Rays where multiple measures are expected. If values are the same 
distance from the target, then the mean will be taken. 
• 
[1] Excluding Imaging. 
• 
[2] Excluding lung auscultation and pulse oximetry 


 
CONFIDENTIAL 
 
 
201790 
 
55 
 
 
14.4. 
Appendix 4: Study Phases and Treatment Emergent 
Adverse Events 
14.4.1. 
Study Phases 
Assessments and events will be classified according to the time of occurrence relative to 
study treatment start date. 
On-Treatment AEs well be reported as treatment emergent AEs (TEAE). Definition for 
TEAE can be found in Section 14.4.1.2. 
If an AE happened at week 12 visit, it will be assigned to Period 2. 
For Placebo: 
Study Phase 
Period 
Definition 
Pre-Treatment 
 
Date ≤ Study Treatment Start Date 
On-Treatment 
Period 1 
Study Treatment Start Date < Date ≤ Week 12 Visit Date or Early 
Withdrawal (if before Week 12) Visit Date  
Off-Treatment 
Safety Follow-Up[1] 
 
Study Treatment Stop Date < Date ≤ Study Treatment Stop Date + 56 
days 
Off-Treatment 
 
Date ≥ Study Treatment Stop Date + 56 days 
[1] The safety follow up definition for Placebo is only valid for participants who withdraw early. The participants that are 
on placebo who complete Period 1, will continue into Period 2. 
For GSK3196165: 
Study Phase 
Period 
Definition 
Pre-Treatment  
 
Date ≤ Study Treatment Start Date 
On-Treatment 
Period 1 
Study Treatment Start Date < Date ≤ Week 12 Visit Date or Early 
Withdrawal (if before week 12) Visit Date+ 7 days 
Period 2 
Week 12 Visit Date < Date ≤ Study Treatment Stop Date + 7 days or 
Early Withdrawal (if after week 12) Visit Date + 7 days 
Off-Treatment 
Safety Follow-Up 
 
Study Treatment Stop Date + 7 days < Date ≤ Study Treatment Stop 
Date + 56 days 
Off-Treatment 
 
Date ≥ Study Treatment Stop Date + 56 days 
 
For Tofacitinib: 
 
Study Phase 
Period 
Definition 
Pre-Treatment  
 
Date ≤ Study Treatment Start Date 
On-Treatment 
Period 1 
Study Treatment Start Date < Date ≤ Week 12 Visit Date or Early 
Withdrawal (if before week 12) Visit Date+ 1 day 
Period 2 
Week 12 visit Date < Date ≤ Study Treatment Stop Date + 1 day or 
Early Withdrawal (if after week 12) Visit Date + 1 day 
Off-Treatment 
Safety Follow-Up 
 
Study Treatment Stop Date + 7 days < Date ≤ Study Treatment Stop 
Date + 56 days 


 
CONFIDENTIAL 
 
 
201790 
 
56 
 
Study Phase 
Period 
Definition 
Off-Treatment 
 
Date ≥ Study Treatment Stop Date + 56 days 
14.4.1.1. 
Study Phases for Concomitant Medication 
Study Phase 
Definition 
Prior 
Any medication that started before first dose of study treatment 
Concomitant 
Any medication that is taken post first dose of study treatment, regardless of whether it 
was started prior to the first dose of study treatment or not 
NOTES:  
• 
Please refer to Appendix 7: Reporting Standards for Missing Data for handling of missing and partial dates for 
concomitant medication. Use the rules in this table if concomitant medication date is completely missing. 
 
14.4.1.2. 
Study Phases for Efficacy Assessments 
Study Phase 
Definition 
Pre Early 
Treatment 
Withdrawal 
Date ≤ Study Treatment Stop Date + 7 days 
Post Early 
Treatment 
Withdrawal (Off-
Treatment)  
Date ≥ Study Treatment Stop Date +7 days 
 
14.4.2. 
Treatment Emergent Flag for Adverse Events 
Flag 
Definition 
Treatment 
Emergent 
• 
Study Treatment Start Date ≤ AE Start Date ≤ Study Treatment Stop Date + 56 
days. 
NOTES:  
• 
If the study treatment stop date is missing, then the AE will be considered to be On-Treatment. 
• 
Time of study treatment dosing and start/stop time of AEs should be considered, if collected. 
• 
If AE happens on the week 12 visit date, it will be assigned to period 2. 
 


 
CONFIDENTIAL 
 
 
201790 
 
57 
 
14.5. 
Appendix 5: Data Display Standards & Handling 
Conventions 
14.5.1. 
Reporting Process 
Software 
• 
The currently supported versions of SAS software SAS software 9.4 will be used. 
Reporting Area 
HARP Server 
: UK1SALX00175 
HARP Compound 
: GSK3196165/MID201790 
Analysis Datasets  
• 
Analysis datasets will be created according to CDISC standards (SDTM IG Version 3.2 & ADaM IG 
Version 1.1). 
Generation of RTF Files 
• 
RTF files will be generated for the final reporting effort for tables and listings. 
14.5.2. 
Reporting Standards 
General 
• 
The current GSK Integrated Data Standards Library (IDSL) will be applied for reporting, unless 
otherwise stated (IDSL Standards Location: 
https://spope.gsk.com/sites/IDSLLibrary/SitePages/Home.aspx): 
• 
4.03 to 4.23: General Principles 
• 
5.01 to 5.08: Principles Related to Data Listings 
• 
6.01 to 6.11: Principles Related to Summary Tables 
• 
7.01 to 7.13: Principles Related to Graphics  
Do not include subject level listings in the main body of the GSK Clinical Study Report. All subject level 
listings should be located in the modular appendices as ICH or non-ICH listings 
Formats 
• 
GSK IDSL Statistical Principles (5.03 & 6.06.3) for decimal places (DP’s) will be adopted for 
reporting of data based on the raw data collected, unless otherwise stated. 
• 
Numeric data will be reported at the precision collected on the eCRF. 
• 
The reported precision from non eCRF sources will follow the IDSL statistical principles but may be 
adjusted to a clinically interpretable number of DP’s.  
Planned and Actual Time 
• 
Reporting for tables, figures and formal statistical analyses: 
• 
Planned time relative to dosing will be used in figures, summaries, statistical analyses and 
calculation of any derived parameters, unless otherwise stated. 
• 
The impact of any major deviation from the planned assessment times and/or scheduled visit 
days on the analyses and interpretation of the results will be assessed as appropriate. 
• 
Reporting for Data Listings:  
• 
Planned and actual time relative to study drug dosing will be shown in listings (Refer to IDSL 
Statistical Principle 5.05.1). 
• 
Unscheduled or unplanned readings will be presented within the subject’s listings.  
Unscheduled Visits 
• 
Unscheduled visits will be slotted as stated in Section 14.3.1 unless otherwise stated. 
• 
All unscheduled visits will be included in listings. 


 
CONFIDENTIAL 
 
 
201790 
 
58 
 
Descriptive Summary Statistics 
Continuous Data 
Refer to IDSL Statistical Principle 6.06.1 
Categorical Data 
N, n, frequency, % 
Graphical Displays 
• 
Refer to IDSL Statistical Principals 7.01 to 7.13. 
14.5.4. 
Reporting Standards for Log-transformed Parameters 
Reporting of Log-Transformed Parameters 
Descriptive 
Summary Statistics  
N, n, geometric mean, 95% CI of geometric mean, geometric coefficient of 
variation (CVb (%)) will be reported. 
[1] CVb (%) = √ (exp(SD2) - 1) * 100  
Figures 
Axes will be presented with actual values with an appropriate log-scale (either 
base 2 or base 10) depending on range of values 
 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
59 
 
14.6. 
Appendix 6: Derived and Transformed Data 
14.6.1. 
General 
Multiple Measurements at One Analysis Time Point 
• 
Mean of the measurements will be calculated and used in any derivation of summary statistics but if 
listed, all data will be presented. 
• 
Data will be analysed as per the planned visit assignment. 
• 
Early withdrawal and unscheduled visits will be slotted to the appropriate planned visit (as per 
Section 14.3.1). If there are two slotted values within a time window the value closest to the target 
day for that window will be used except for ECGs and X-Rays where multiple measures are 
expected. If values are the same distance from the target, then the mean will be taken. 
• 
In the instance of both local and central labs being collected at the same timepoint, only the central 
labs will be used in any analysis. 
• 
Triplicate ECG measures will be averaged for each subject and visit prior to generating summary 
tables. 
• 
Multiple X-Ray measures from multiple readers will be handled as described in Section 14.6.3.10.  
• 
Participants having both High and Low values for Normal Ranges at any post-baseline visit for safety 
parameters will be counted in both the High and Low categories of “Any visit post-baseline” row of 
related summary tables. This will also be applicable to relevant Potential Clinical Importance 
summary tables. 
Study Day 
• 
Calculated as the number of days from First Dose Date: 
• 
Ref Date = Missing              → Study Day = Missing  
• 
Ref Date < First Dose Date → Study Day = Ref Date – First Dose Date 
• 
Ref Data ≥ First Dose Date → Study Day = Ref Date – (First Dose Date) + 1     
Period 1 (Up to Week 12) 
• 
Period 1 (up to week 12) is defined as time from randomisation up to dosing of period 2 study 
medication (week 12) or date of study withdrawal or date of treatment withdrawal plus follow up, 
whichever is earlier. 
• 
A participant completed 12 weeks of treatment if study medication (injection) was administered at 
week 11 visit or later up to next study medication administration or study medication (capsule) was 
administered at week 11 plus 6 days or later up to next study medication administration 
• 
A participant completed week 12 if week 12 assessments were performed and study medication of 
the next period was administered. 
• 
A participant withdrew from the study if the withdrawal date is < date of study medication 
administration of period 2 (week 12) 
Period 2 (Post Week 12)  
• 
Period 2 (post week 12) is defined as time from first dose of study medication of period 2 (Week 12) 
until date of study completion or date of study withdrawal or date of treatment withdrawal plus safety 
follow up whichever is earlier. 
• 
A participant withdrew from the study if the withdrawal date > date of study medication administration 
of period 2 
Study Completion  
• 
For subjects not entering LTE study: completion of study is defined as completion of treatment plus 
follow up period. 
• 
For subjects entering LTE: completion of study is defined as completion of the week 52 visit. 


 
CONFIDENTIAL 
 
 
201790 
 
60 
 
14.6.2. 
Study Population 
Treatment Compliance 
• 
Treatment compliance will be calculated based on the formula: 
For GSK3196165:   
Treatment Compliance =  
(Number of Actual Doses / Planned Treatment Duration in Weeks) *100 
For tofacitinib: 
Treatment Compliance =  
(Number of Actual Doses / (Planned Treatment Duration in Weeks*14)) *100 
• 
Treatment compliance could be greater than 100% if there are events of overdose. Cumulative 
compliance (since Day 1) at each visit will be calculated. 
• 
Planned Treatment Duration is 52 weeks. 
• 
Compliance for early treatment discontinuation participants will only be calculated up until the date of 
early treatment discontinuation. 
Date of Birth and Age 
• 
Only the year of birth will be captured, and therefore the date of birth is then derived as follows: 
Year of birth = YYYY → Date of birth = 30th June YYYY 
• 
Age in years will be calculated as integer part of (latest of (randomisation date, screening date)– date 
of birth). 
• 
Birth date will be presented in listings as ‘YYYY’. 
Extent of Exposure 
• 
Number of days of exposure to study drug will be calculated based on the formula:   
For GSK3196165: 
Duration of Exposure in Days = [(Treatment stop date – treatment start date) + 7]-
[(Number of missed injections) * 7] 
For Tofacitinib: 
Duration of Exposure in Days =(Total capsules consumed/2) + 1  
 
• 
Participants who were randomized but did not report a treatment start date will be categorised as 
having zero days of exposure.  
• 
The cumulative dose will be based on the formula: 
Cumulative Dose = Sum of Total Dose at Each Visit 
 
Disease History/Duration 
• RA duration since diagnosis in years will be calculated based on the formula: 
RA Duration Since Diagnosis in Years =   
(Date of First Dose of Study Treatment - Start date of RA diagnosis + 1)/365.25 
• RA duration since first symptoms in years will be calculated based on the formula: 
RA Duration Since First Symptoms in Years =   
• (Date of First Dose of Study Treatment - Start date of first symptoms + 1)/365.25 


 
CONFIDENTIAL 
 
 
201790 
 
61 
 
Corticosteroid Scaling Factor 
• To assess corticosteroid use and determine average daily corticosteroid dose, all 
corticosteroid dosages will be converted to a prednisone equivalent in milligrams by 
multiplying the dose of the steroid (using the coded term from GSKDrug) by the conversion 
factor to get prednisone equivalent units.  
• The following conversion factors will be used: 
 
 
 
 
 
 
 
 
 
 
Corticosteroid 
Scaling Factor 
Betamethasone 
8.333 
Dexamethasone 
6.667 
Meprednisone 
1.25 
Methylprednisolone 
1.25 
Methylprednisolone Sodium 
Succinate 
1.25 
Prednisolone 
1 
Prednisone, Prednisone Acetate 
1 
Triamcinolone 
1.25 
Predmet (NOS) 
1.25 
Deflazacort 
0.833 
 
 
Prior and Concomitant Medication 
RA Concomitant medication will be split into following categories: 
             - DMARDs 
                        - Methotrexate (all methotrexate medications combined into one category) 
                        - Other csDMARDs (not Methotrexate) 
                        - csDMARDs > 1 
                        - bsDMARDs/boDMARDs/tsDMARDs 
- Corticosteroids (the following groups will be derived by route) 
           -Oral  
           -Intra-Articular 
- Other RA medications 
 
Prior RA medications will be split into following categories: 
-DMARDs 
           - Methotrexate (all methotrexate medications combined into one category) 
           - Other csDMARDs (not Methotrexate) 
           - csDMARDs >1 
            -bsDMARDs/boDMARDs/tsDMARDs 
                       ->=1 of the above 
                       -=1 of the above 
                       ->1 of the above 
                       -Inadequate response to >=1 bs/boDMARD 
                       -Inadequate response to >=1 tsDMARD 
                       -Inadequate response to >1 bsDMARD/boDMARD/tsDMARD 
-Oral corticosteroids   


 
CONFIDENTIAL 
 
 
201790 
 
62 
 
-Other RA medications 
 
RA Concomitant medication will be derived as following: 
Follow Section 14.4.1.1 for definition of “concomitant” medication. 
o DMARDs: 
Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=”DISEASE-
MODIFYING ANTIRHEUMATIC DRUG” using all “medication type” which includes 
C1SCAT=“CONVENTIONAL SYNTHETIC DMARDS”, C1SCAT=“BIOLOGICAL ORIGINATOR 
DMARDS”, C1SCAT=“BIOSIMILAR DMARDS”, and C1SCAT=“TARGETED SYNTHETIC 
DMARDS”. 
 
o Methotrexate: 
Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=”DISEASE-
MODIFYING ANTIRHEUMATIC DRUG”, using C1SCAT=“CONVENTIONAL SYNTHETIC DMARDS” 
where ingredient/CMDECOD contains “METHOTREXATE”. All methotrexate medications will be 
combined together into one category called “Methotrexate” 
 
o Other csDMARDs (not methotrexate): 
Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=”DISEASE-
MODIFYING ANTIRHEUMATIC DRUG”, using C1SCAT=“CONVENTIONAL SYNTHETIC 
DMARDS”, but excluding methotrexate (where ingredient/CMDECOD contains “METHOTREXATE”) 
 
o csDMARDs > 1: 
 Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=”DISEASE-
MODIFYING ANTIRHEUMATIC DRUG” using C1SCAT=“CONVENTIONAL SYNTHETIC DMARDS” 
where a participant has taken more than 1 csDMARD (2 or more). 
 
o bsDMARDs/boDMARDs/tsDMARDs: 
Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=”DISEASE-
MODIFYING ANTIRHEUMATIC DRUG” using “medication type” which includes 
C1SCAT=“BIOLOGICAL ORIGINATOR DMARDS”, C1SCAT=“BIOSIMILAR DMARDS” and 
C1SCAT=“TARGETED SYNTHETIC DMARDS”. 
 
o Corticosteroids Oral: 
Derived from “RA other medication” page in eCRF, C1CAT=”OTHER RHEUMATOID ARTHRITIS 
MEDICATION” using C1SCAT= “CORTICOSTEROID” and C1ROUTE=”ORAL”  
 
o Corticosteroids IA: 
 Derived from “Intra-Articular Corticosteroids” page in eCRF,C1CAT=”OTHER RHEUMATOID 
ARTHRITIS MEDICATION” using C1SCAT=”CORTICOSTEROID” and C1ROUTE = “INTRA-
ARTICULAR”  
 
o Other RA medication:  
Derived from “RA other medication” page in eCRF, C1CAT=”OTHER RHEUMATOID ARTHRITIS 
MEDICATION” using all “medication type” which includes C1SCAT=“Corticosteroid” all routes except 
C1ROUTE=“ORAL” and C1ROUTE=“INTRA-ARTICULAR”, C1SCAT=“OPIOID” and 
C1SCAT=“OTHER”. 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
63 
 
Non-RA Concomitant medication will be derived as following: 
Follow Section 14.4.1.1 for definition of “concomitant” medication. 
 
Non RA medication is derived from “Non-RA concomitant medications” page in eCRF, C1CAT=”NON 
RHEUMATOID ARTHRITIS MEDICATION”. 
 
Uncoded concomitant medication will be combined together in one category called “Uncoded” 
 
Prior RA medication will be derived as following: 
Follow Section 14.4.1.1 for definition of “prior” medication. 
 
o DMARDs:  
Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=”DISEASE-
MODIFYING ANTIRHEUMATIC DRUG”  using all “medication type” which includes 
C1SCAT=“CONVENTIONAL SYNTHETIC DMARDS”, C1SCAT=“BIOLOGICAL ORIGINATOR 
DMARDS”, C1SCAT=“BIOSIMILAR DMARDS” and C1SCAT=“TARGETED SYNTHETIC DMARDS”. 
 
o Methotrexate: 
Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=”DISEASE-
MODIFYING ANTIRHEUMATIC DRUG” using C1SCAT=“CONVENTIONAL SYNTHETIC DMARDS” 
where ingredient/CMDECOD contains “METHOTREXATE”. All methotrexate medications will be 
combined together into one category called “Methotrexate” 
 
o Other csDMARDs (not methotrexate): 
Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=”DISEASE-
MODIFYING ANTIRHEUMATIC DRUG” using C1SCAT=“CONVENTIONAL SYNTHETIC DMARDS” 
where ingredient/ CMDECOD contains “METHOTREXATE”. 
 
o csDMARDs > 1: 
Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=”DISEASE-
MODIFYING ANTIRHEUMATIC DRUG” using C1SCAT=“CONVENTIONAL SYNTHETIC DMARDS” 
where a participant has taken more than 1 csDMARD. 
 
o bsDMARDS/boDMARDs/tsDMARDs: 
Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=”DISEASE-
MODIFYING ANTIRHEUMATIC DRUG” using C1SCAT=“BIOSIMILAR DMARDS”, 
C1SCAT=“BIOLOGICAL ORIGINATOR DMARDS” and C1SCAT=“TARGETED SYNTHETIC 
DMARDS”. 
o >=1 of the above is derived as above for participants that have taken at least 
one of the bsDMARDS, boDMARDs or tsDMARDs  
o =1 of the above is derived as above for participants that have taken one of the 
bsDMARDS, boDMARDs or tsDMARDs  
o >1 of the above is derived as above for participants that have taken more than 
one of the bsDMARDS, boDMARDs or tsDMARDs  
 
o Inadequate response to >=1 bs/boDMARD: 
Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=”DISEASE-
MODIFYING ANTIRHEUMATIC DRUG”  where a subject had at least one of the following: 
C1SCAT=“BIOSIMILAR DMARDS” or C1SCAT=“BIOLOGICAL ORIGINATOR DMARDS”, with one 
or more of the following selected “lack of initial efficacy” or “loss of efficacy” or “adverse event”, 


 
CONFIDENTIAL 
 
 
201790 
 
64 
 
QNAM=”PRSMEDEN” and QVAL contains "ADVERSE EVENT", "LACK OF INITIAL EFFICACY", or 
"LOSS OF EFFICACY".  
 
o Inadequate response to >=1 tsDMARD: 
Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=”DISEASE-
MODIFYING ANTIRHEUMATIC DRUG”  where a subject had at least one C1SCAT=“TARGETED 
SYNTHETIC DMARDS” , with one or more of the following selected “lack of initial efficacy” or “loss of 
efficacy” or “adverse event”, QNAM=”PRSMEDEN” and QVAL contains "ADVERSE EVENT", "LACK 
OF INITIAL EFFICACY", or "LOSS OF EFFICACY".  
 
o Inadequate response to >1 bsDMARD/boDMARD/tsDMARD: 
Derived from “RA Medications MTX, csDMARD and bDMARD” page in eCRF, C1CAT=”DISEASE-
MODIFYING ANTIRHEUMATIC DRUG”  where a subject had at least two of the following: C1SCAT= 
“BIOSIMILAR DMARDS” or C1SCAT=“BIOLOGICAL ORIGINATOR DMARDS” or 
“C1SCAT=TARGETED SYNTHETIC DMARDS”, with one or more of the following selected “lack of 
initial efficacy” or “loss of efficacy” or “adverse event”, QNAM=”PRSMEDEN” and QVAL contains 
"ADVERSE EVENT", "LACK OF INITIAL EFFICACY", or "LOSS OF EFFICACY".   
 
o Corticosteroids Oral: 
Derived from “RA other medication” page in eCRF, C1CAT=”OTHER RHEUMATOID ARTHRITIS 
MEDICATION” using C1SCAT= “CORTICOSTEROID” and C1ROUTE= ”ORAL”. 
 
o Other RA medication: 
Derived from “RA other medication” page in eCRF, C1CAT=”OTHER RHEUMATOID ARTHRITIS 
MEDICATION”  using all “medication type” which includes C1SCAT=“corticosteroid” which includes 
all routes except C1ROUTE=“ORAL”, C1SCAT=“OPIOID” and C1SCAT=“OTHER”. 
 
The following medications will be combined into one category: 
o All Methotrexate medications will be combined into one category called “Methotrexate”  
o Hydroxychloroquine and Hydroxychloroquine Sulfate will be combined into “Hydroxychloroquine” 
o Chloroquine, Chloroquine Phosphate and Chloroquine Sulfate will be combined into 
“Chloroquine” 
o 
Filgotinib and Filgotinib Maleate will be combined into "Filgotinib" 
o 
Tofacinitib and Tofacitinib Citrate will be combined into "Tofacitinib" 
 
Concomitant COVID-19 Vaccine 
• 
COVID-19 Vaccines will be derived from the most recent list of terms provided by GSK Medical 
Dictionary at the time of reporting 
 
14.6.3. 
Efficacy 
14.6.3.1. 
ACR20/50/70 
ACR20/50/70 
Proportion of ACR20/50/70 responders 
• 
The American College of Rheumatology’s (ACR) definition for calculating improvement in RA is 
calculated as a 20% improvement (ACR20) in both tender and swollen joint counts and 20% 
improvement in 3 of the 5 remaining ACR-core set measures: patient and physician global 


 
CONFIDENTIAL 
 
 
201790 
 
65 
 
ACR20/50/70 
assessments, patient’s assessment of arthritis pain, disability, and an acute-phase reactant (i.e. CRP 
value).  Similarly, ACR50 and ACR70 are calculated with the respective percent improvement.  This 
efficacy measurement will be made at every post-baseline study assessment time point. 
 
• 
The specific components of the ACR Assessments that will be used in this study are: 
o Tender/Painful Joint count 68 (TJC68) 
o Swollen Joint Count 66 (SJC66) 
o Patient’s Assessment of Arthritis Pain 
o Patient’s Global Assessment of Arthritis Disease Activity 
o Physician’s Global Assessment of Arthritis 
o CRP (mg/L) 
o Health Assessment Questionnaire – Disability Index (HAQ-DI) 
 
• 
Individual components collected outside of a +/- 2 day window from visit date will be considered 
missing for the purpose of the ACR calculation. 
• 
For all visits, if any of the component scores are missing, then those scores will be considered as not 
having met the criteria for improvement.  Therefore, if TJC68 or SJC66 or 3 or more of the 5 
remaining ACR-core set measures are missing, ACR20/ ACR50/ ACR70 will each be considered 
missing.   
• 
For component scores with missing Baseline values or a Baseline value of 0, the percentage 
improvement can’t be calculated, and the component will be considered as missing for all visits.  If 
the baseline value is missing, do not use screening visit data for imputation.    
 
 
14.6.3.2. 
Tender/Painful and Swollen Joint Counts 
Tender/Painful Joint Count (TJC) and Swollen Joint Count (SJC) 
TJC28/68 and SJC28/66 
• 
Four different scores will be calculated to evaluate swelling and tenderness of joints. TJC28 and 
SJC28 will take 28 joints into account, SJC66 and TJC68 will use 66 and 68 joints, respectively.  
• 
The assessment for swelling is the total number of joints with a present swelling and ranges from 0 
to 28 for SJC28 and 0 to 66 for SJC66. 
• 
The assessment for tenderness is the total number of joints with a present tenderness and ranges 
from 0 to 28 for TJC28 and 0 to 68 for TJC68. 
• 
The following 28 joints will be taken into account for TJC28 and SJC28: Shoulder (2 joints), Knee (2), 
Elbow (2), Wrist (2), Fingers (IP, PIP, MCP: 20). 
• 
Additionally, the following joints will be taken into account for SJC66/TJC68: Temporomandibular (2), 
Sternoclavicular (2), Acromioclavicular (2), Fingers (DIP: 8), Ankle (2), Tarsus (2), Toes (IP, PIP, 
MTP: 20), Hip (2, only for TJC). 
• 
Replaced or fused joints are considered non-evaluable in the swelling and tenderness assessment. 
• 
If there are missing observations for tender or swollen joints, then the remaining observations will be 
assessed and weighted by dividing the number presented by number of non-missing and by 
multiplying by 28/66/68 for the joint count. 
• 
If a joint has undergone inter-articular injection of corticosteroid during the course of the study, this 
joint is recorded in the concomitant medication dataset. The joint will be considered to be tender and 
swollen for 8 weeks post IA corticosteroid injection. 
 


 
CONFIDENTIAL 
 
 
201790 
 
66 
 
14.6.3.3. 
Pain VAS 
Patient’s assessment of Arthritis Pain VAS 
Pain VAS 
• 
Subjects will assess the severity of their current arthritis pain using a continuous visual analog scale 
(VAS) with anchors “0” (
) and “100” (
). 
 
14.6.3.4. 
Patient’s/Physician’s Global Assessment of Arthritis Disease Activity 
Patient’s/Physician’s Global Assessment of Arthritis Disease Activity (PtGA/PhGA) 
PtGA 
• 
Subjects will complete a global assessment of disease activity using the patient global assessment 
of disease activity (PtGA) item, a continuous VAS with anchors “0” (
) to “100” (
). 
PhGA 
• 
Physicians will complete a global assessment of disease activity using the physician global 
assessment of disease activity item (PhGA), a continuous VAS with anchors “0” (
) to “100” 
(
). 
 
14.6.3.5. 
HAQ-DI Questionnaire 
HAQ-DI 
HAQ-DI 
• 
The functional status of the subject will be assessed by means of the Disability Index of the Stanford 
Health Assessment Questionnaire (HAQ-DI).  This 20-question instrument assesses the degree of 
difficulty a person has in accomplishing tasks in eight functional areas: 
o Dressing & grooming (HAQ0201, HAQ0202)  
o Arising (HAQ0203, HAQ0204)  
o Eating (HAQ0205, HAQ0206, HAQ0207)  
o Walking (HAQ0208, HAQ0209)  
o Hygiene (HAQ0223, HAQ0224, HAQ0225)  
o Reach (HAQ0226, HAQ0227)  
o Grip (HAQ0228, HAQ0229, HAQ0230) 
o Common daily activities (HAQ0231, HAQ0232, HAQ0233) 
• 
Each functional area contains at least two questions.  For each question, there is a four-level 
response set that is scored from 0 (
) to 3 (
). Each functional area is 
scored as the maximum value of their component activities (0,1,2 or 3).  
• 
If aids/devices or help from another person are used for a specific functional area and the maximum 
response of this functional area is 0 or 1 the according value is increased to a score of 2. If “other” is 
marked as an aid or equipment, then this can be assigned to a group of four functional areas and will 
be handled as an aid or equipment for each of the four functional areas. Therefore, if the maximum 
score of a functional area is 0 or 1 that value is increased to a score of 2 for each of the four 
functional areas: 
Aid/device 
Will be associated with functional area 
Cane (HAQ0210)  
Walker (HAQ0211)  
Crutches (HAQ0212)  
Wheelchair (HAQ0213) 
Walking 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI


 
CONFIDENTIAL 
 
 
201790 
 
67 
 
HAQ-DI 
Devices used for dressing (HAQ0214) 
Dressing and grooming 
Built Up or Special Utensils (HAQ0215) 
Eating 
Special or Built Up Chair (HAQ0216) 
Arising 
Raised toilet seat (HAQ0234)  
Bathtub bar (HAQ0237) 
Bathtub seat (HAQ0235) 
Long-handled appliance in bathroom (HAQ0239) 
Hygiene 
Long-handled appliance for reaching (HAQ0238) 
Reach 
Jar opener (HAQ0236) 
Grip 
Other Aid (Dress/Arising/Eat/Walk) (HAQ0217) 
Dressing & grooming, Arising, Eating, Walking 
Other Aid (Hygiene/Reach/Grip/Act) (HAQ0240) 
Hygiene, Reach, Grip, Common daily activities 
 
Help from another person 
Will be associated with functional area 
Walking (HAQ0222) 
Walking 
Dressing and Grooming (HAQ0219) 
Dressing and grooming 
Eating (HAQ0221) 
Eating 
Arising (HAQ0220) 
Arising 
Hygiene (HAQ0242) 
Hygiene 
Reach (HAQ0243) 
Reach 
Grip (HAQ0244) 
Grip 
Common daily activities (HAQ0245) 
Common daily activities  
• 
After these corrections, the highest response within each functional area determines the final score 
of that specific functional area.  If no questions within a given functional area were answered, no 
score will be provided for that category (even if answers on aids or equipment are available). 
• 
HAQ-DI is only calculated if there are at least 6 functional area scores available. The average of 
these non-missing functional area scores defines the continuous HAQ-DI score ranging from 0 to 3.  
If there are less than 6 functional area scores available, no imputation will be done, and the HAQ-DI 
will be set to missing for the according assessment. 
 
14.6.3.6. 
CDAI 
CDAI 
CDAI Total Score 
• 
The Clinical Disease Activity Index (CDAI) is a composite score consisting of the sum of SJC28, 
TJC28, PtGA and PhGA.  Since PtGA and PhGA are both collected on a VAS scale 0-100, the 
respective scores will be divided by 10 before computing the CDAI total score. 
• 
CDAI ranges from 0 to 76 with higher values representing higher disease activity. 
• 
Individual components collected outside of a +/- 2 day window from visit date will be considered 
missing for the purpose of the CDAI calculation. 
• 
If one of the components is missing at an individual assessment point the CDAI value for that 
assessment will be set to missing. 
CDAI Low disease activity (CDAI-LDA) 
• 
Low Disease Activity is achieved for a non-missing CDAI total score ≤10. 
CDAI Remission 
• 
Remission is achieved for a non-missing CDAI total score ≤2.8. 


 
CONFIDENTIAL 
 
 
201790 
 
68 
 
14.6.3.7. 
DAS28-CRP and DAS28-ESR 
DAS28-CRP 
DAS28-CRP  
• 
The components of the DAS28-CRP arthritis assessment include: 
o Tender Joint Count 28 (TJC28) 
o Swollen Joint Count 28 (SJC28)  
o C-reactive protein (CRP) (in mg/L)  
o Patient’s Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with 
values from 0=
 to 100=
) 
• 
The DAS28-CRP score will be calculated using the following formula: 
DAS28-CRP=0.56*√TJC28+0.28*√SJC28+0.36*ln(CRP+1)+0.014*PtGA+0.96 
• 
Individual components collected outside of a +/- 2 day window from visit date will be considered 
missing for the purpose of the DAS28 calculation. 
• 
If one of the components is missing at an individual assessment point, no imputations will be done 
and the DAS28 value for that assessment will be set to missing. 
DAS28-CRP Low disease activity (LDA) 
• 
Low Disease Activity is achieved for a DAS28-CRP ≤3.2. 
DAS28-CRP Remission 
• 
Remission is achieved for a DAS28-CRP <2.6 
DAS28-ESR 
DAS28-ESR  
• 
The components of the DAS28-ESR arthritis assessment includes: 
o Tender Joint Count 28 (TJC28) 
o Swollen Joint Count 28 (SJC28)  
o Erythrocyte sedimentation rate (ESR) (in mm/hr) 
o Patient’s Global Assessment of Arthritis Disease Activity (PtGA) (visual analogue scale with 
values from 0=
 to 100=
) 
• 
The DAS28-ESR score will be calculated using the following formula: 
DAS28(ESR)=0.56*√TJC28+0.28*√SJC28+0.7*ln(ESR)+0.014*PtGA 
• 
Individual components collected outside of a +/- 2 day window from visit date will be considered 
missing for the purpose of the DAS28 calculation. 
• 
If one of the components is missing at an individual assessment point, no imputations will be done 
and the DAS28 value for that assessment will be set to missing. 
• 
An ESR value of 0 will be substituted with ESR=1 for the calculation of DAS28(ESR). 
DAS28-ESR Low disease activity (LDA) 
• 
Low Disease Activity is achieved for a DAS28-ESR ≤3.2. 
DAS28-ESR Remission 
• 
Remission is achieved for a DAS28-ESR <2.6 
 
14.6.3.8. 
EULAR Response 
EULAR Response 
EULAR Good/Moderate Response 
• 
DAS28-CRP and DAS28-ESR scores will each be categorised using EULAR response criteria.  
Response at a given time point is defined based on the combination of current DAS28 score and the 
CCI
CCI
CCI
CCI


 
CONFIDENTIAL 
 
 
201790 
 
69 
 
improvement in the current DAS28 score relative to baseline.  The definition of no response, 
moderate response and good response is captured in the following table: 
  
• 
If the post-baseline DAS28 value is missing, then the corresponding EULAR category will be set to 
missing. 
 
14.6.3.9. 
ACR/EULAR Remission 
ACR/EULAR Remission 
Boolean-based ACR/EULAR Remission 
• 
Boolean-based remission is achieved if all of the following requirements are met at the same time: 
o TJC68 ≤ 1 
o SJC66 ≤ 1 
o CRP ≤ 1mg/dl 
o PtGA ≤ 10 
• 
Individual components collected outside of a +/- 2 day window from visit date will be considered 
missing for the purpose of the calculation. 
• 
If one of the components is missing at an individual assessment point, the Boolean-based remission 
for that assessment will be set to missing. 
Index-based ACR/EULAR Remission 
• 
The Simple Disease Activity Index (SDAI) is a composite score consisting of the sum of SJC28, 
TJC28, PtGA, PhGA, and CRP (mg/dl).  Since PtGA and PhGA are both collected on a VAS scale 0-
100, the respective scores will be divided by 10 before computing the SDAI total score. 
• 
Index-based remission is achieved if the following requirement is met: 
o SDAI ≤ 3.3 
• 
Individual components collected outside of a +/- 2 day window from visit date will be considered 
missing for the purpose of the calculation. 
• 
If one of the components is missing at an individual assessment point, the Index-based remission for 
that assessment will be set to missing. 
 
 
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected 
by third party copyright laws and therefore have been excluded.


 
CONFIDENTIAL 
 
 
201790 
 
70 
 
14.6.3.10. Van der Heijde Modified Total Sharp Score  
Van der Heijde Modified total Sharp Score (mTSS) 
Multiple Readers  
• 
Since there will be two independent readers who will evaluate each image, the mean score will be 
calculated for the two readers from the individual bone erosion and joint space narrowing (JSN) 
score: 
Bone erosion = (Bone erosion scorereader 1 + Bone erosion scorereader 2)/2 
JSN = (JSN scorereader 1 + JSN scorereader 2)/2 
 
• 
In the instance of large discrepancies between the two independent readers results, a third 
independent adjudication reader may also be required to evaluate the images. In this instance, the 
score of the two closest reads (out of the two primary readers and the adjudicator) will be used. In 
the case of equal distance, the average of the three reads will be used. 
 
Bone Joint Erosion Score 
• 
The joint erosion score is a summary of erosion severity in 16 locations in each hand/wrist (32 
locations in total) and 6 locations in each foot (12 locations in total).  
• 
The 
 is 5 and for a 
 is 10. Thus, the 
 
 is 280 for a timepoint (160 for 
 and 120 for 
). 
• 
Each joint is scored according to the surface area involved from 0 to 5 for hand joints and 0 to 10 for 
the foot joints. The highest score (5 for 
 and 10 for 
) indicates 
 
. A score of 0 in either the 
 
 
 
 
Erosion Grading Scheme of the Foot 
• 
Similar erosion grading method will be used in the foot as previously described for the hand, except 
the scale extends from 0 to 10 per joint. This method gives relatively more weight to the joints of the 
feet, because of the higher maximum erosion score. 
 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected 
by third party copyright laws and therefore have been excluded.


 
CONFIDENTIAL 
 
 
201790 
 
71 
 
Van der Heijde Modified total Sharp Score (mTSS) 
Total Joint Erosion Score 
• 
The total joint erosion score will be calculated using a summation of the scores of all locations (both 
hands and feet) at each time point. 
• 
If an individual location is scored either “Not Assessable” or “Surgically Modified” then the score for 
that location will be set to missing before calculating the total score. 
• 
If an individual location has a missing score, then the score will be imputed using the average score 
across all available evaluable locations. 
• 
If data for more than 50% of locations are missing at the time of a given assessment, then the total 
individual component score will be set to missing for that visit.  
Joint Space Narrowing (JSN) Score 
• 
The JSN score summarizes the severity of JSN in 15 locations in each hand/wrist (30 locations in 
total) and 6 locations in each foot (12 locations in total). 
• 
Assessment of JSN for each hand (15 joints per hand) and foot (6 joints per foot), including 
subluxation, is scored from 0 to 4, with 0 indicating 
 and 4 indicating 
 
. Thus, the 
 is 168 (120 for both hands/ 
wrists and 48 for both feet) at a time point.  
• 
JSN for each hand and foot joint is graded on the following scale: 
o 
o 
o 
o 
o 
o 
o 
Total Joint Space Narrowing Score 
• 
The total joint space narrowing score will be calculated using a summation of the scores of all 
locations (both hands and feet) at each time point. 
• 
If an individual location is scored either “Not Assessable” or “Surgically Modified” then the score for 
that location will be set to missing before calculating the total score. 
• 
If an individual location has a missing score, then the score will be imputed using the average score 
across all available evaluable locations. 
• 
If data for more than 50% of locations are missing at the time of a given assessment, then the total 
individual component score will be set to missing for that visit. 
Modified Total Sharp Score (mTSS) 
• 
The total mTSS score at a time point is the sum of the erosion (maximum of 280) and JSN 
(maximum of 168) scores, for a maximum score of 448. 
• 
The van der Heijde modified sharp scoring method is summarised below: 
 
Joint/Bone 
Erosion 
Joint 
JSN 
Hand 
MCP1 
0-5 
MCP1 
0-4 
MCP2 
0-5 
MCP2 
0-4 
MCP3 
0-5 
MCP3 
0-4 
MCP4 
0-5 
MCP4 
0-4 
MCP5 
0-5 
MCP5 
0-4 
PIP2 
0-5 
PIP2 
0-4 
PIP3 
0-5 
PIP3 
0-4 
PIP4 
0-5 
PIP4 
0-4 
CCI
CCI
CCI
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, 
which are protected by third party copyright laws and therefore have been excluded.


 
CONFIDENTIAL 
 
 
201790 
 
72 
 
Van der Heijde Modified total Sharp Score (mTSS) 
PIP5 
0-5 
PIP5 
0-4 
IP1 
0-5 
CMC3 
0-4 
CMC1 
0-5 
CMC4 
0-4 
Radius 
0-5 
CMC5 
0-4 
Ulna 
0-5 
Trapezium-navicular 
0-4 
Multangular bones 
0-5 
Capitate-navicular 
0-4 
Navicular 
0-5 
Radio-carpal 
0-4 
Lunate 
0-5 
 
 
Foot 
MTP1 
0-10 
MTP1 
0-4 
MTP2 
0-10 
MTP2 
0-4 
MTP3 
0-10 
MTP3 
0-4 
MTP4 
0-10 
MTP4 
0-4 
MTP5 
0-10 
MTP5 
0-4 
IP1 Toe 
0-10 
IP1 Toe 
0-4 
 
 
 
 
 
 
Total score one hand 
0-80 
Total score one hand 
0-60 
 
Total score one foot 
0-60 
Total score one foot 
0-24 
 
 
 
 
 
 
Total score both hands 
0-160 
Total score both hands 
0-120 
 
Total score both feet 
0-120 
Total score both feet 
0-48 
 
 
 
 
 
 
Score range for erosions 
0-280 
Score range for JSN 
0-168 
 
 
 
 
 
 
Score range mTSS 
0-448 
  
 
14.6.3.11. SF-36 
SF-36 
SF-36 
• 
Health-related quality of life will be assessed using the subject-completed Medical Outcomes Study 
Short-Form 36 (SF-36) which is a generic health survey that contains 36 questions covering eight 
domains of health.  The SF-36 yields an eight-scale profile of functional health and well-being scores 
as well as physical and mental component health summary scores.  The version 2, 1-week recall 
questionnaire will be used. Recoding, calculations and standardisation will be done using Quality 
Metrics SF-36 scoring software.  
SF-36 Domain Scores 
• 
Individual question responses will be inputted into the Quality Metrics SF-36 scoring software to 
compute the eight domain scores: 
o Physical functioning (PF) 
o Role function – Physical aspect (RP) 
o Bodily Pain (BP) 
o General health perception (GH)  
o Mental Health (MH) 


 
CONFIDENTIAL 
 
 
201790 
 
73 
 
SF-36 
o Role function – Emotional aspect (RE) 
o Social functioning (SF) 
o Vitality (VT) 
• 
Higher scores represent better health status. 
 
SF-36 Physical and Mental component scores 
• 
Individual question responses will be inputted into the Quality Metrics SF-36 scoring software to 
compute the physical and mental component scores.  
 
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third 
party copyright laws and therefore have been excluded.


 
CONFIDENTIAL 
 
 
201790 
 
74 
 
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third 
party copyright laws and therefore have been excluded.


 
CONFIDENTIAL 
 
 
201790 
 
75 
 
14.6.4. 
Safety 
 
Adverse Events 
AE event rates per 100 patient-years of exposure 
• 
AE event rates per 100 patient-years of exposure will be calculated as: 
(Sum of occurrences of adverse event / Sum of exposure duration [in years]) * 100 
CCI - This section contained Clinical Outcome Assessment data collection questionnaires or indices, which are protected by third 
party copyright laws and therefore have been excluded.


 
CONFIDENTIAL 
 
 
201790 
 
76 
 
Adverse Events of Special Interest (AESI) 
AEs of Special Interest (AESI) 
• 
Adverse events of special interest (AESI) and other important adverse events will be derived using 
MEDRA and Common Terminology Criteria for Adverse Events v5.0 (NCI, 2017) and will include: 
 
AESI 
Programmatical Derivation 
Serious infections and Serious infections 
excluding COVID-19 infections 
Serious infections: Filter on Infections and 
Infestations SOC, limited to serious.  
Serious infections excluding COVID-19 
infections: Filter on Infections and Infestations 
SOC, limited to serious and exclude the 
following PTs:  Suspected COVID-19”, “COVID-
19”, “COVID-19 pneumonia” or “Asymptomatic 
COVID-19”. 
Opportunistic infections  
Opportunistic infections will be derived using the 
“Opportunistic infections” (Broad) SMQ and 
adjudicated by the SRT.  Adjudicated 
opportunistic infections will be summarised. 
Active TB, latent TB and TB reactivation 
Derived from preferred terms of “Tuberculosis”. 
Use HLT: ‘Tuberculous Infections’.  
All tuberculosis infections will be adjudicated by 
SRT. The outcome of the adjudication will be 
Active TB, latent TB, or TB reactivation which 
will be summarised. 
Neutropenia 
Derived using PT of “Neutropenia” and/or 
“neutrophil count decreased” and/or “neutrophil 
percentage decreased”. Only AEs/SAEs of 
neutropenia and/or neutrophil count decreased 
and/or neutrophil percentage decreased where 
the corresponding absolute neutrophil count 
(from laboratory data) are CTCAE grade 3 or 4 
will be reported as AESI. 


 
CONFIDENTIAL 
 
 
201790 
 
77 
 
Persistent Cough 
Cough CTCAE ≥ Grade 2 recorded for 3 
consecutive weeks (≥21 Days). 
 
Identified from: 
Cough ‘Yes’ entered in the pulmonary 
assessment eCRF with Grade determined from 
AE reporting with the following definition: 
      Persistent dyspnoea 
Persistent dyspnoea grade ≥ 2 for three 
consecutive weeks (≥21 days).   
Identified from: 
Dyspnoea rating scale on the pulmonary 
assessment eCRF page with the following 
grading: 
PAP (Pulmonary alveolar proteinosis) 
Derived using preferred term (PT) “alveolar 
proteinosis’.  (LLT of ‘pulmonary alveolar 
proteinosis’ maps to PT of ‘alveolar proteinosis’). 
All cases adjudicated by Pulmonary Adjudication 
Committee (PAC).  
The adjudicated PAP outcome will be 
summarised. 
Serious Hypersensitivity reactions, 
including anaphylaxis 
Serious hypersensitivity reactions will be 
adjudicated using “Hypersensitivity” (Broad) 
SMQ, “Anaphylactic reaction” (Broad) SMQ and 
“anaphylactic/anaphylactoid shock condition” 
(Broad) SMQ based on SAE listings.  
CCI - This section contained Clinical Outcome 
Assessment data collection questionnaires or indices, 
which are protected by third party copyright laws and 
therefore have been excluded.
CCI - This section contained Clinical Outcome 
Assessment data collection questionnaires or indices, 
which are protected by third party copyright laws and 
therefore have been excluded.


 
CONFIDENTIAL 
 
 
201790 
 
78 
 
 
Other Important AEs 
Protocol defined cardiovascular (CV) events and adjudicated CV events 
• 
CV Events 
CV events as reported in the database will be included in the summary table for all AEs.  
• 
Adjudicated CV Events 
Endpoints of interest: cardiovascular (CV) death, myocardial infarction (MI), hospitalisation for 
unstable angina, stroke, hospitalisation for heart failure, deep vein thrombosis (DVT) and pulmonary 
embolism (PE). These will be derived using PT terms listed in clinical events classification (CEC) 
Charter and adjudicated by Duke Clinical Research Institute (DCRI) CEC group. Adjudicated CV 
endpoints will be summarised.  
Adjudicated CV Events will also be reported as the following categories: 
o MACE: CV death, non-fatal MI, non-fatal stroke 
o Broad MACE: CV death, MI, hospitalisation for unstable angina, stroke and hospitalisation 
for heart failure 
o VTE (DVT and/or PE) 
o DVT only 
o PE only 
Note: 
▪ 
CV categories include both fatal and non-fatal events. 
▪ 
Fatal CV events will be captured in two categories, respective CV category and CV death.  
▪ 
A subject can have an event in more than one category.   
▪ 
CV death includes death due to CV causes (cardiogenic shock, HF, arrhythmia/sudden death, 
MI, cardiac rupture, ischemic stroke, PE, venous/arterial thrombotic events) and any other 
unobserved deaths for which an alternative cause has not been identified 
▪ 
In the broad MACE category, if a subject has a CV event that resulted in death, it will only be 
counted as one MACE event. This will be derived by cross referencing the adjudication 
outcomes with the outcomes of the CV event reported by the investigator. 
GI Perforation and Adjudicated GI perforation 
• 
GI perforation Events 
GI perforation events as reported in the database will be included in the summary table for all AEs.  
• 
Adjudicated GI perforation 
This will be adjudicated by CEC. Data reported in EDC and the adjudicated GI Perforation will be 
used in the outputs.  
Malignancy 
• 
Malignancies will be reported as the following categories:  
o Any Malignancy – derived from the preferred terms in the below SMQs. 
Final adjudication will be conducted by SRT and 
the adjudicated hypersensitivity reactions will be 
summarised. 
Injection site reactions 
Derived from HLT term “injection site reactions”, 
HLT term “administration site reaction NEC” and 
PT term “injection related reaction”. 
  


 
CONFIDENTIAL 
 
 
201790 
 
79 
 
Other Important AEs 
o Solid, excluding non-melanoma skin cancer (NMSC) – derived from Non-haematological 
malignant tumours (SMQ) and Non-haematological tumours of unspecified malignancy 
(SMQ) and excluding NMSC terms identified below 
o NMSC– PTs derived from Skin neoplasms, malignant and unspecified (SMQ): 
▪ 
Atypical fibroxanthoma 
▪ 
Basal cell carcinoma 
▪ 
Basosquamous carcinoma of skin 
▪ 
Bowen’s disease 
▪ 
Carcinoma in situ of skin 
▪ 
Keratoacanthoma 
▪ 
Marjolin’s ulcer 
▪ 
Skin squamous cell carcinoma metastatic 
▪ 
Skin squamous cell carcinoma recurrent 
▪ 
Squamous cell carcinoma of skin  
o Hematologic – derived from Haematological malignant tumours (SMQ) and Haematological 
tumours of unspecified malignancy (SMQ) 
o Lymphoma – derived from Malignant Lymphomas (broad SMQ) 
Herpes Infections 
• 
Derived from HLT term “Herpes Viral Infections” excluding the following terms: Human herpesvirus 6 
encephalitis, Human herpesvirus 6 infection, Human herpesvirus 7 infection, Human herpesvirus 8 
infection, Exanthema subitum 
• 
They will be further categorised as Herpes Zoster, Herpes Simplex and Non-Specific using preferred 
terms from the most recent version of MedDRA at the time of reporting. 
All-Cause Mortality 
• 
Any SAE with a fatal outcome 
Serious Pulmonary infections 
• 
Any SAE in  HLGT “respiratory tract infections” 
Serious Pulmonary infections excluding COVID-19 Infections 
• 
Any SAE in HLGT “respiratory tract infections” excluding the following PTs:  Suspected COVID-19”, 
“COVID-19”, “COVID-19 pneumonia” or “Asymptomatic COVID-19”. 
Pneumonia (serious and non-serious)  
• 
Derived from Infective pneumonia (narrow SMQ) 
Pneumonia (serious and non-serious) excluding COVID-19 Infections 
• 
Derived from Infective pneumonia (narrow SMQ) excluding the following PTs:  Suspected COVID-
19”, “COVID-19”, “COVID-19 pneumonia” or “Asymptomatic COVID-19”. 
Hepatitis B and Hepatitis B Reactivation  
• 
AEs and SAEs using PTs ‘hepatitis B’ and ‘hepatitis B reactivation’ 
Thromboembolic events  
• 
AEs and SAEs using ‘Embolic and thrombotic events’ (Broad) SMQ 
COVID-19 Infections and Adjudicated COVID-19 Infections 
• 
COVID-19 Infections 
COVID-19 infections will be derived from the following PTs: “Suspected COVID-19”, “COVID-19”, 
“COVID-19 pneumonia” or “Asymptomatic COVID-19”.  
All events will be split into serious or non-serious based on how they are reported i.e. all COVID-19 
SAEs will be categorised as serious and all COVID-19 AEs will be categorised as non-serious.   


 
CONFIDENTIAL 
 
 
201790 
 
80 
 
Other Important AEs 
Non-serious cases of COVID-19 will be split into confirmed, suspected or probable cases based on 
the eCRF and cases for each category will be displayed. 
The serious adverse events of COVID-19 will be adjudicated by PAC and only the adjudicated 
events summarised.  
• 
Adjudicated COVID-19 Infections 
Each case that is adjudicated to confirmed case of COVID-19 or probable case of COVID-19 will 
also be assigned a grade based on World Health Organisation (WHO) original scale.  
All adjudicated confirmed cases of COVID-19 and all adjudicates probable cases of COVID-19 will 
be split into 3 categories (see the categorisation below) and cases for each category will be 
summarised: 
• 
Non hospitalised includes the following WHO grades: grade 1-no limitation of activity and grade 
2-limation of activity.  
• 
Hospitalised includes the following WHO grades: grade 3-no oxygen therapy; grade 4-low-flow 
oxygen by mask or nasal prongs; grade 5-high-flow oxygen (≥15L/min), CPAP, BIPAP, non-
invasive ventilation; grade 6- intubation and mechanical ventilation and grade 7- mechanical 
ventilation plus additional organ support (ECMO and vasopressors). 
• 
Death 
 
 
Laboratory Parameters 
eGFR 
• 
This will be provided in the dataset by Q2 
Laboratory Results 
If a laboratory value which is expected to have a numeric value for summary purposes,  
has a non-detectable level reported in the database, where the numeric value is missing,  
but typically a character value starting with ‘<x’ or ‘>x’ (or indicated as less than x or  
greater than x in the comment field) is present, the number of significant digits in the  
observed values will be used to determine how much to add or subtract in order to impute  
the corresponding numeric value.  
• 
Example 1: 2 Decimal Places=  ‘< x ‘ becomes x – 0.01 
• 
Example 2: 1 Decimal Place=  ‘> x’ becomes x + 0.1 
• 
Example 3: 0 Decimal Places= ‘< x’ becomes x – 1  
Immunogenicity 
• 
Positive binding antibody assay results are to be categorised as transient positive or persistent 
positive accordingly to the following definitions: 
• 
For all post-baseline visits, other than final study assessment 
o Transient positive = a single positive immunogenic response at a visit, where the previous 
visit was negative 
o Persistent positive = a positive immunogenic response at a visit, where the previous visit 
was also positive 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
81 
 
14.7. 
Appendix 7: Reporting Standards for Missing Data 
14.7.1. 
Premature Withdrawals 
Element 
Reporting Detail 
General 
• 
Participant study completion (i.e. as specified in the protocol) was defined as 
completion of all phases of the study including the follow up.  
• 
Withdrawn participants will not be replaced in the study. 
• 
All available data from participants who were withdrawn from the study will be listed 
and all available planned data will be included in summary tables and figures, unless 
otherwise specified.  
• 
Withdrawal visits will be slotted as per Appendix 3: Assessment Windows or will be 
summarised as withdrawal visits. 
• 
If a scheduled visit and an EW visit occur within the same visit window and are both 
available, the scheduled visit will be used for any summaries/analyses. The EW visit 
will appear in listing only. 
• 
For efficacy analyses, if an EW visit is assigned to a non-standard efficacy visit, i.e., a 
visit at which efficacy assessments are not scheduled per the Time and Events Table, 
then these EW data will be ignored in the statistical analysis, but all data will be listed. 
14.7.2. 
Handling of Missing Data 
Element 
Reporting Detail 
General 
• 
Missing data occurs when any requested data is not provided, leading to blank fields 
on the collection instrument: 
o These data will be indicated by the use of a “blank” in subject listing displays. 
Unless all data for a specific visit are missing in which case the data is excluded 
from the table.  
o Answers such as “Not applicable” and “Not evaluable” are not considered to be 
missing data and should be displayed as such. 
Outliers 
• 
Any participants excluded from the summaries and/or statistical analyses will be 
documented along with the reason for exclusion in the clinical study report. 
Adverse 
Events 
• 
AEs with missing intensity will be considered as severe. 
14.7.2.1. 
Handling of Missing and Partial Dates 
Element 
Reporting Detail 
General 
• 
Partial dates will be displayed as captured in subject listing displays. 
Adverse 
Events 
• 
Although every effort will be made to prevent and eliminate partial dates, the eCRF 
allows for the possibility of partial dates (i.e., only month and year) to be recorded for 
AE start and end dates; that is, the day of the month may be missing. In such a case, 
the following conventions will be applied for calculating the time to onset and the 
duration of the event: 
o Missing Start Day: First of the month will be used unless this is before the start 
date of study treatment; in this case the study treatment start date will be used 
and hence the event is considered On-treatment as per Appendix 4: Study 
Phases and Treatment Emergent Adverse Events. 


 
CONFIDENTIAL 
 
 
201790 
 
82 
 
Element 
Reporting Detail 
o Missing Stop Day: Last day of the month will be used, unless this is after the stop 
date of study treatment; in this case the study treatment stop date will be used. 
• 
Completely missing start or end dates will remain missing, with no imputation applied. 
Consequently, time to onset and duration of such events will be missing. 
Concomitant 
Medications/ 
Medical 
History 
• 
Partial dates for any concomitant medications recorded in the CRF will be imputed 
using the following convention: 
o If the partial date is a start date, a '01' will be used for the day and 'Jan' will be 
used for the month 
o If the partial date is a stop date, a '28/29/30/31' will be used for the day 
(dependent on the month and year) and 'Dec' will be used for the month. 
• 
The recorded partial date will be displayed in listings. 
RA diagnosis 
and symptom 
onset 
• 
Missing day, but month and year present: 
o Date is set to the first day of the month (e.g., XX-Sep-2010 is considered as 01-
Sep-2010). 
• 
Missing day and month, but year present:  
o Date is set to 01 January (e.g., XX-XXX-2010 is considered as 01-Jan-2010) 
 
 
14.7.2.2. 
Handling of Missing Efficacy Data 
Unless otherwise stated, apply the missing data imputation strategies detailed in Section 
7.1.1.6 and Section 7.2.1.6. 
 


 
CONFIDENTIAL 
 
 
201790 
 
83 
 
14.8. 
Appendix 8: Laboratory Parameters of  Interest 
14.8.1. 
Laboratory Values Gradings 
Laboratory value gradings will be derived using the most recent version of CTCAE at the 
time of reporting. 
14.8.2. 
Laboratory Values of Potential Clinical Importance 
Hematology 
Laboratory Parameter 
 
Units 
Category 
Clinical Concern Range 
Low Flag (< x) 
High Flag (>x) 
Hematocrit  
Ratio of 
1 
Male 
0.2 
0.6 
Female 
0.2 
0.6 
Change 
from 
baseline 
↓0.075 
 
Hemoglobin  
g/L 
 
Male 
80 
180 
Female 
80 
180 
Change 
from 
baseline 
↓20 
 
Lymphocytes  
x109/ L 
 
 0.75 
 
Neutrophil Count  
x109/ L 
 
1.0 
16 
Platelet Count  
x109/ L 
 
100 
550 
While Blood Cell Count 
(WBC) 
x109/ L 
 
2.0 
20 
Eosinophils 
x109/ L 
 
 
1 
 
Clinical Chemistry 
Laboratory Parameter 
Units 
Category 
Clinical Concern Range 
Low Flag (< x) 
High Flag (>x) 
Albumin  
g/L 
 
30 
55 
Calcium 
mmol/L 
 
2 
2.75 
Creatinine 
µmol/L 
 
 
150 
µmol/L 
Change 
from 
baseline 
 
↑ 44.2 
Glucose 
mmol/L 
 
3 
11 
Potassium 
mmol/L 
 
3 
5.5 
Sodium 
mmol/L 
 
130 
160 


 
CONFIDENTIAL 
 
 
201790 
 
84 
 
Clinical Chemistry 
Laboratory Parameter 
Units 
Category 
Clinical Concern Range 
Low Flag (< x) 
High Flag (>x) 
GFR from Creatinine 
Adjusted for BSA 
mL/min/1.73 
m2 
 
60 
 
Cholesterol 
mmol/L 
 
 
 6.5 
Triglycerides 
mmol/L 
 
 
 2.3 
Urea 
mmol/L 
 
 
10.5 
 
Liver Function 
Test Analyte 
Units 
Category 
Clinical Concern Range 
ALT/SGPT  
U/L 
High 
 2x ULN 
AST/SGOT  
U/L 
High 
 2x ULN 
AlkPhos  
U/L 
High 
 2x ULN 
T Bilirubin  
µmol/L 
High 
 1.5xULN 
Creatinine Kinase 
U/L 
High 
 2x ULN 
Gamma Glutamyl Transferase 
U/L 
High 
 2x ULN 
Lactate Dehydrogenase 
U/L 
High 
 2x ULN 
 
Urinalysis 
Test Analyte 
Clinical Concern Range 
Bacteria 
Moderate 
Many 
Squamous Epithelial Cells 
Moderate (6-20)  
Many (21 or greater) 
Glucose 
1+ OR 1/4 G/DL (%)  
2+ OR 1/4 G/DL (%)  
3+ OR 1/4 G/DL (%) 
Protein 
1+  
2+  
3+  
Erythrocytes 
10-15 
12-25 
25-50 
50-100 
>100 
Leukocytes 
10-15 
12-25 
25-50 


 
CONFIDENTIAL 
 
 
201790 
 
85 
 
Urinalysis 
Test Analyte 
Clinical Concern Range 
50-100 
>100 
Yeast Cells 
Moderate 
Many 
 
For the listing of Laboratory Data for Subjects with any value of Potential Clinical 
Important, only include the following laboratory data: 
• Alanine Aminotransferase 
• Albumin 
• Albumin/Globulin 
• Alkaline Phosphate 
• Aspartate Aminotransferase 
• Basophils 
• Bilirubin 
• C Reactive Protein 
• Calcium 
• Cholesterol 
• Creatinine Kinase 
• Creatinine 
• Cyclic Citrullinated Peptide Antibody 
• Direct Bilirubin 
• Eosinophils 
• Erythrocyte Sedimentation Rate 
• Erythrocytes 
• GFR from Creatinine Adjusted for BSA 
• Gamma Glutamyl Transferase 
• Glucose 
• HDL Cholesterol, Direct 
• Hematocrit 
• Hemoglobin 
• Hepatitis B Core Antibody Total, Qual 
• Hepatitis B Virus DNA 
• Hepatitis B Virus DNA, copies 
• Hepatitis B Virus DNA, log 
• Hepatitis B Virus Surface Antibody, Qual 
• Hepatitis B Virus Surface Antigen, Qual 
• Hepatitis C Antibody, Qual 
• Hepatitis C Virus RNA 
• Hepatitis C Virus RNA, log 
• Interferon Gamma, Qualitative 
• LDL Cholesterol 
• Lactate Dehydrogenase 


 
CONFIDENTIAL 
 
 
201790 
 
86 
 
• Leukocytes 
• Lymphocytes 
• Monocytes 
• Neutrophils 
• Platelets 
• Potassium 
• Protein 
• Prothrombin Intl. Normalized Ratio 
• Reticulocytes/Erythrocytes 
• Rheumatoid Factor 
• Theophylline 
• Triglycerides 
• Urea 
14.8.3. 
ECG Values of Potential Clinical Importance 
ECG Parameter 
Units 
Clinical Concern Range 
 
 
Lower 
Upper 
Absolute 
Absolute QTc Interval 
msec 
 
>450 
Absolute PR Interval 
msec 
< 110 
> 220  
Absolute QRS Interval 
msec 
< 75  
> 110  
Change from Baseline 
Increase from Baseline QTc 
msec 
 
>30↑ 
14.8.4. 
Vital Signs Values of Potential Clinical Importance 
Vital Sign Parameter 
 
Units 
Clinical Concern Range 
Lower 
Upper 
Absolute 
Systolic Blood Pressure 
mmHg 
< 85 
> 160 
Diastolic Blood Pressure 
mmHg 
< 45 
> 100 
Heart Rate 
bpm 
< 40 
> 110 
Change from Baseline 
Systolic Blood Pressure 
mmHg 
≥ 20↓ 
≥ 20↑ 
Diastolic Blood Pressure 
mmHg 
≥ 10↓ 
≥ 10↑ 
Heart Rate 
bpm 
≥ 15↓ 
≥ 15↑ 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
87 
 
14.9. 
Appendix 9: List of Preferred Terms 
14.9.1. 
Herpes Zoster 
 Adjudication by GSK SRT will identify events that are recurrent or disseminated. Herpes 
Zoster is considered disseminated if there is involvement of other organs other than the 
skin or if skin lesions (1) cross the midline of the body or (2) are in non-adjacent 
dermatomes or (3) are located in more than three adjacent dermatomes.  Herpes zoster is 
considered an opportunistic infection if it is adjudicated as recurrent or 
disseminated.  However, there may be some uncommon occurrences of a herpes zoster 
case that is adjudicated as an OI but is neither recurrent nor disseminated. 
14.9.2. 
Mycobacterium Tuberculosis 
Tuberculosis (TB) cases are reviewed by the GSK SRT to determine if a case is an OI. 
The following principles are applied: Pulmonary TB in an endemic area is not considered 
an OI. Pulmonary TB in a non-endemic area would be considered an OI unless the 
participant had close contact with a person infected with TB. Extra pulmonary TB is 
generally considered an OI unless the affected extra pulmonary area followed a wound or 
trauma. 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
88 
 
14.10. 
Appendix 10: Missing Data Imputation Strategies 
14.10.1. 
Primary Estimand Strategy 
14.10.1.1. Multiple Imputation using off-treatment data within treatment arm 
1. Exclude week 1 data and participants with missing baseline values. 
2. Generate 1000 multiply imputed datasets using a monotone logistic imputation 
with augmentation (binary endpoints) or monotone regression imputation 
(continuous endpoints) including terms for baseline value, all previous visit 
values, treatment group, treatment discontinuation and treatment group-by-
treatment discontinuation interaction, i.e. a model of the form 
𝑦𝑖= 𝛼1𝑖+ 𝛼2𝑖𝑏𝑎𝑠𝑒+ 𝛼3𝑖𝑇𝐷𝑖+ 𝛼4𝑖𝑡𝑟𝑡+ 𝛼5𝑖(𝑡𝑟𝑡∗𝑇𝐷𝑖) + 𝛽𝑖−1𝑦𝑖−1 + ⋯+ 𝛽1𝑦1 
where 𝑦𝑖 is the result at visit i and 𝑇𝐷𝑖 is the treatment discontinuation indicator at 
visit i. 
3. Perform statistical analysis as detailed in Section 7.1.3 and Section 7.2.3. 
14.10.1.2. Multiple Imputation using off-treatment data across all treatment arms 
1. Exclude week 1 data and participants with missing baseline values. 
2. Generate 1000 multiply imputed datasets using a monotone logistic imputation 
with augmentation (binary endpoints) or monotone regression imputation 
(continuous endpoints) including terms for baseline value, all previous visit 
values, treatment group and treatment discontinuation, i.e. a model of the form 
𝑦𝑖= 𝛼1𝑖+ 𝛼2𝑖𝑏𝑎𝑠𝑒+ 𝛼3𝑖𝑇𝐷𝑖+ 𝛼4𝑖𝑡𝑟𝑡+ 𝛽𝑖−1𝑦𝑖−1 + ⋯+ 𝛽1𝑦1 
where 𝑦𝑖 is the result at visit i and 𝑇𝐷𝑖 is the treatment discontinuation indicator at 
visit i. 
3. Perform statistical analysis as detailed in Section 7.1.3 and Section 7.2.3. 
14.10.1.3. Multiple imputation under MAR assumption 
1. Exclude week 1 data and participants with missing baseline values. 
2. Generate 1000 multiply imputed datasets using a monotone logistic imputation 
with augmentation (binary endpoints) or monotone regression imputation 
(continuous endpoints) including terms for baseline value, all previous visit 
values and treatment group, to impute any missing data post study withdrawal, i.e. 
a model of the form 
𝑦𝑖= 𝛼1𝑖+ 𝛼2𝑖𝑏𝑎𝑠𝑒+ 𝛼3𝑖𝑡𝑟𝑡+ 𝛽𝑖−1𝑦𝑖−1 + ⋯+ 𝛽1𝑦1 
where 𝑦𝑖 is the result at visit i. 
3. Perform statistical analysis as detailed in Section 7.1.3 and Section 7.2.3. 
14.10.2. 
Supplemental Estimand 1 Strategy 
1. Impute all data for each visit following the intercurrent event for categorical 
variables to be non-response. 
2. Exclude week 1 data and participants with missing baseline values. 
3. In order to impute intermittent missing data, generate 1000 multiply imputed 
datasets using a monotone logistic imputation with augmentation (binary 
endpoints) or monotone regression imputation (continuous endpoints) including 


 
CONFIDENTIAL 
 
 
201790 
 
89 
 
terms for baseline value, all previous visit values, and treatment group, i.e. a 
model of the form 
𝑦𝑖= 𝛼1𝑖+ 𝛼2𝑖𝑏𝑎𝑠𝑒+ 𝛼3𝑖𝑡𝑟𝑡+ 𝛽𝑖−1𝑦𝑖−1 + ⋯+ 𝛽1𝑦1 
where 𝑦𝑖 is the result at visit i 
4. Perform statistical analysis as detailed in Section 7.1.3 and Section 7.2.3. 
14.10.3. 
Supplemental Estimand 2 Strategy 
1. Set all data at each visit following the intercurrent event to missing. 
2. Exclude week 1 data and participants with missing baseline values. 
3. Generate 1000 multiply imputed datasets using a monotone logistic imputation 
with augmentation (binary endpoints) or monotone regression imputation 
(continuous endpoints) including terms for baseline value, all previous visit 
values, and treatment group, i.e. a model of the form 
𝑦𝑖= 𝛼1𝑖+ 𝛼2𝑖𝑏𝑎𝑠𝑒+ 𝛼3𝑖𝑡𝑟𝑡+ 𝛽𝑖−1𝑦𝑖−1 + ⋯+ 𝛽1𝑦1 
where 𝑦𝑖 is the result at visit i 
4. Perform statistical analysis as detailed in Section 7.1.3 and Section 7.2.3. 
14.10.4. 
Intermittent Missing Data Multiple Imputation 
Under the primary estimand strategy detailed in Section 14.10.1, in the absence of a 
treatment discontinuation flag at a particular visit, the models will all reduce to a model 
of the form: 
𝑦𝑖= 𝛼1𝑖+ 𝛼2𝑖𝑏𝑎𝑠𝑒+ 𝛼3𝑖𝑡𝑟𝑡+ 𝛽𝑖−1𝑦𝑖−1 + ⋯+ 𝛽1𝑦1 
where 𝑦𝑖 is the result at visit i, which will satisfy an MAR assumption for intermittent 
missing data. 
Under the supplemental estimand 1 strategy detailed in Section 14.10.2, intermittent 
missing data will be imputed separately under an MAR assumption. 
Under the hypothetical estimand strategy detailed in Section 14.10.3, all data, including 
intermittent missing data, is imputed under an MAR assumption. 
 


 
CONFIDENTIAL 
 
 
201790 
 
90 
 
14.11. 
Appendix 11: Abbreviations & Trade Marks 
14.11.1. 
Abbreviations 
Abbreviation 
Description 
AAC 
All Analysis Complete 
ACR 
American College of Rheumatology 
ADA 
Anti-Drug Antibodies 
ADaM 
Analysis Data Model 
AE 
Adverse Event 
AESI 
Adverse Event of Special Interest 
ANCOVA 
Analysis of Covariance 
bDMARD 
Biologic Disease-Modifying Anti-Rheumatic Drug 
BID 
Twice a day 
BMI 
Body Mass Index 
boDMARD 
Biological Originator Disease-Modifying Antirheumatic Drug 
bsDMARD 
Biosimilar Disease-Modifying Antirheumatic Drug 
CDAI 
Clinical Disease Activity Index 
CDISC 
Clinical Data Interchange Standards Consortium 
CI 
Confidence Interval 
CIRT 
Cenduit Interactive Response Technology 
CRP 
C-Reactive Protein 
csDMARD 
Conventional Synthetic Disease Modifying Antirheumatic Drug 
CSR 
Clinical Study Report 
CTCAE 
Common Terminology Criteria for Adverse Events 
CV 
Cardiovascular 
CVb / CVw 
Coefficient of Variation (Between) / Coefficient of Variation (Within) 
DAS 
Disease Activity Score 
DBF 
Database Freeze 
DBR 
Database Release 
DMARD 
Disease-Modifying Antirheumatic Drug 
DOB 
Date of Birth 
DP 
Decimal Places 
eCRF 
Electronic Case Record Form 
EMA 
European Medicines Agency 
ESR 
Erythrocyte Sedimentation Rate 
EULAR 
European League Against Rheumatism 
EW 
Early Withdrawal 
FACIT 
Functional Assessment of Chronic Illness Therapy - Fatigue 
FDA 
Food and Drug Administration 
FDAAA 
Food and Drug Administration Clinical Results Disclosure Requirements 
GM-CSF 
Granulocyte-Macrophage Colony-Stimulating Factor 
GSK 
GlaxoSmithKline 
HAQ-DI 
Health Assessment Questionnaire Disability Index 
HDL 
Headline Results 
ICH 
International Conference on Harmonization 


 
CONFIDENTIAL 
 
 
201790 
 
91 
 
Abbreviation 
Description 
IDMC 
Independent Data Monitoring Committee  
IDSL 
Integrated Data Standards Library 
IE 
Intercurrent Event 
IP 
Investigational Product 
ITT 
Intent-To-Treat 
IWRS 
Interactive Web Response System 
JAKi 
Janus Kinase Inhibitor 
LDA 
Low Disease Activity 
LLOQ 
Lower Limit of Quantification 
LS 
Least Squares 
MACE 
Major Adverse Cardiovascular Event 
MAR 
Missing at Random 
MCID 
Minimum Clinically Important Different 
MCMC 
Markov Chain Monte Carlo 
MCS 
Mental Component Score 
MedDRA 
Medical Dictionary for Regulatory Activities 
MI 
Multiple Imputation 
MMRM 
Mixed Model Repeated Measures 
mTSS 
Modified Total Sharp Score 
MTX 
Methotrexate 
NQ 
Non-quantifiable 
NRS 
Numerical Rating Scale 
OR 
Odds Ratio 
PAP 
Pulmonary Alveolar Proteinosis 
PCI 
Potential Clinical Importance  
PCS 
Physical Component Score 
PD 
Pharmacodynamic 
PDMP 
Protocol Deviation Management Plan 
PhGA 
Physician’s Global Assessment of Arthritis Disease Activity  
PK 
Pharmacokinetic 
PP 
Per Protocol 
PopPK 
Population PK 
PRO 
Patient Reported Outcome 
PT 
Preferred Term 
PtGA 
Patient’s Global Assessment of Arthritis Disease Activity  
QC 
Quality Control 
QTcF 
Frederica’s QT Interval Corrected for Heart Rate 
QTcB 
Bazett’s QT Interval Corrected for Heart Rate 
QW 
Every Week 
Q2W 
Every 2 Weeks 
RA 
Rheumatoid Arthritis 
RAP 
Reporting & Analysis Plan 
RF 
Rheumatoid Factor 
CCI
CCI


 
CONFIDENTIAL 
 
 
201790 
 
92 
 
Abbreviation 
Description 
SAC 
Statistical Analysis Complete 
SAE 
Serious Adverse Events 
SC 
Subcutaneous 
SDTM 
Study Data Tabulation Model 
SF-36 
36-Item Short Form Survey 
SJC 
Swollen Joint Count 
SMQ 
Standardised MedDRA Query 
SOC 
System Organ Class 
SOP 
Standard Operation Procedure 
SRT 
Safety Review Team 
TA 
Therapeutic Area 
TB 
Mycobacterium Tuberculosis 
TEAE 
Treatment Emergent Adverse Event 
TFL 
Tables, Figures & Listings  
TJC 
Tender Joint Count 
tsDMARD 
Targeted Synthetic Disease Modifying Antirheumatic Drug 
VAS 
Visual Analog Scale 
WOCBP 
Woman of Childbearing Potential 
WPMI 
Within Patient Meaningful Improvement 
14.11.2. 
Trademarks 
Trademarks of the GlaxoSmithKline 
Group of Companies 
 
Trademarks not owned by the 
GlaxoSmithKline Group of Companies 
NONE 
 
 
 
 
 
SAS 
 
 
SF-36 
 
 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
93 
 
14.12. 
Appendix 12: List of Data Displays 
All data displays will use the term “subject” rather than “participant” in accordance with 
CDSIC and GSK Statistical Display Standards. 
14.12.1. 
Data Display Numbering 
The following numbering will be applied for RAP generated displays: 
Section 
Tables 
Figures 
Study Population 
1.1 to 1.30 
1.1 to 1.2 
Efficacy 
2.1 to 2.92 
2.1 to 2.77 
Safety 
3.1 to 3.137 
3.1 to 3.7 
Section 
Listings 
ICH Listings 
1 to 14 
Other Listings 
15 to 45 
 
14.12.2. 
Mock Example Shell Referencing 
Non IDSL specifications will be referenced as indicated and if required example mock-up 
displays provided in the final version of this document. 
14.12.3. 
Deliverables 
Delivery [Priority] [1] 
Description 
HDL [1] 
Headline Results Complete 
SAC [2] 
Statistical Analysis Complete 
AAC [3] 
All Analysis Complete 
NOTES:  
1. 
Indicates priority (i.e. order) in which displays will be generated for the reporting effort 
 
 
 
 
 
 
 
 
 
 
 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
94 
 
   Study Population Tables 
Study Population Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Subject Disposition 
1.1. 
Randomised 
Non-
Standard 
POP_T1 
(Based on 
ES1) 
Summary of Subject Disposition for the Subject Conclusion 
Record 
ICH E3, FDAAA, EudraCT 
 
Include Total Column 
SAC[2] 
1.2. 
Randomised 
Non-
Standard 
POP_T1 
(Based on 
ES1) 
Summary of Subject Status and Subject Disposition for 
Withdrawals due to COVID-19 Pandemic 
Only include: 
• 
Related to COVID-19 
Pandemic 
This information should be gathered 
from COVID-19 impact form in eCRF. 
Include Total Column 
SAC[2] 
1.3. 
Randomised 
Non-
Standard 
POP_T2 
(Based on 
SD1) 
Summary of Treatment Status and Reasons for 
Discontinuation of Study Treatment 
ICH E3 
 
Include Total Column 
SAC[2] 
1.4. 
Randomised 
Non-
Standard 
POP_T2 
(Based on 
SD1) 
Summary of Treatment Status and Reasons for 
Discontinuation of Study Treatment due to COVID-19 
Pandemic 
Only include: 
• 
Related to COVID-19 
Pandemic 
This information should be gathered 
from COVID-19 impact form in eCRF. 
Include Total Column 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
95 
 
Study Population Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
1.5. 
Screened 
ES6 
Summary of Screening Status and Reasons for Screen 
Failure 
Journal Requirements 
SAC[2] 
1.6. 
Enrolled 
NS1 
Summary of Number of Subjects by Country and Site ID by 
Implementation of Pandemic Measures 
EudraCT/Clinical Operations 
Summarise by: 
• 
Overall 
• 
Before Implementation of 
Pandemic Measures 
• 
After Implementation of 
Pandemic Measures 
SAC[2] 
Protocol Deviation 
1.7. 
ITT 
DV1 
Summary of Important Protocol Deviations 
ICH E3 
Only categories are to be reported in 
the table. 
SAC[2] 
1.8. 
ITT 
DV1 
Summary of Important Protocol Deviations Related to the 
COVID-19 Pandemic 
Only include: 
• 
Important related to COVID-
19 Pandemic 
Only categories are to be 
reported in the table. 
SAC[2] 
Population Analysed 
1.9. 
Screened 
SP1  
Summary of Study Populations  
IDSL 
 
SAC[2] 
1.10. 
Enrolled 
SP2  
 
Summary of Protocol Deviations Leading to Exclusion from 
the Per Protocol Population(s) 
IDSL 
Include total column. 
Only categories are to be reported in 
the table. 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
96 
 
Study Population Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Demographic and Baseline Characteristics 
1.11. 
ITT 
DM1 
Summary of Demographic Characteristics 
ICH E3, FDAAA, EudraCT 
Add BMI to the output. 
HDL[1] 
1.12. 
Enrolled 
DM11 
Summary of Age Ranges 
EudraCT 
SAC[2] 
1.13. 
ITT 
DM6 
Summary of Race and Racial Combinations 
ICH E3, FDA, FDAAA, EudraCT 
SAC[2] 
1.14. 
ITT 
Non-
Standard 
POP_T3 
Summary of Baseline Efficacy Parameters 
Include all efficacy endpoints 
HDL[1] 
1.15. 
ITT 
Non-
Standard 
POP_T4 
Summary of Rheumatoid Arthritis Disease History 
 
HDL[1] 
1.16. 
ITT 
Non-
Standard 
POP_T5 
Summary of History of Tobacco Use and Family History of 
Cardiovascular Risk Factors 
Display by Overall, Age <50 and 
Age>=50 
SAC[2] 
Prior and Concomitant Medications 
1.17. 
ITT 
AE1 
Summary of Medical Conditions 
ICH E3  
Include Preferred Terms. 
SAC[2] 
1.18. 
ITT 
Non-
Standard 
POP_T6  
Summary of RA Concomitant Medications  
Include Total Column. 
 
SAC[2] 
1.19. 
ITT  
CM1 
Summary of All Concomitant Medications 
ICH E3 
Include Total Column. 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
97 
 
Study Population Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
1.20. 
ITT 
Non-
Standard 
POP_T7 
Summary of RA Prior Medications  
Include Total Column. 
SAC[2] 
1.21. 
ITT 
CM1 
Summary of All Prior Medications 
Include Total Column. 
SAC[2] 
1.22. 
ITT 
Non-
Standard 
POP_T8 
Summary of RA Medications taken at Baseline (Day 1)  
Include Total Column. 
SAC[2] 
1.23. 
ITT 
Non-
Standard 
POP_T9 
Summary of Concomitant COVID-19 Vaccines 
Include Total Column. 
SAC[2] 
Exposure and Treatment Compliance 
1.24. 
Safety 
Non-
Standard 
POP_T10 
Summary of Exposure to Study Treatment 
ICH E3 
Include Total Column. 
SAC[2] 
1.25. 
Safety 
Non-
Standard 
POP_T11 
Summary of Overall Compliance Based on Exposure 
Display for compliance with both 
injections and capsules 
Include Total Column. 
SAC[2] 
COVID-19 
1.26. 
ITT 
PAN4 
Summary of COVID-19 Visit Impacts 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
98 
 
Study Population Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
1.27. 
ITT 
DM1 
Summary of Demographic Characteristics by Pre and Post 
Pandemic Measures 
Summarise by: 
• 
Before Implementation of 
Pandemic Measures 
• 
After Implementation of 
Pandemic Measures 
SAC[2] 
Tables for Disclosure 
1.29. Randomised 
Non-
Standard 
POP_T1 
Summary of Subject Disposition for the Subject Conclusion 
Record (by Randomised Treatment Arm) 
Display by randomised treatment arm 
(i.e. all 6 treatment arms) 
AAC[3] 
1.30. 
ITT 
DM1 
Summary of Demographic Characteristics (by Randomised 
Treatment Arm) 
Display by randomised treatment arm 
(i.e. all 6 treatment arms) 
AAC[3] 
 
 
 
 
 
 
 
 
 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
99 
 
Study Population Figures 
Study Population Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Subject Disposition 
1.1. 
Randomised 
PAN6 
Plot of Recruitment over time by Country Relative to 
COVID-19 Pandemic Measures 
 
SAC[2] 
COVID-19 
1.2. 
ITT 
PAN8 
Plot of Visits Impacted by COVID-19 Pandemic 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
100 
 
Efficacy Tables 


 
CONFIDENTIAL 
 
 
201790 
 
101 
 
Efficacy: Tables 
No. 
Population 
IDSL /  
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
ACR20 
2.1. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of ACR20 Response at Each 
Assessment Visit (Primary Estimand) 
 
HDL[1] 
2.2. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of ACR20 Response at Each 
Assessment Visit (Supplemental Estimand 1) 
 
SAC[2] 
2.3. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of ACR20 Response at Each 
Assessment Visit (Supplemental Estimand 2) 
 
AAC[3] 
2.4. 
ITT 
Non-Standard 
EFF_T2 
Summary of Observed ACR20 Response at Each 
Assessment Visit 
 
SAC[2] 
CDAI-LDA 
2.5. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of CDAI-LDA Response (CDAI 
≤10) at Each Assessment Visit (Primary Estimand) 
 
HDL[1] 
2.6. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of CDAI-LDA Response (CDAI 
≤10) at Each Assessment Visit (Supplemental Estimand 1) 
 
SAC[2] 
2.7. 
ITT 
Non-Standard 
EFF_T2 
Summary of Observed CDAI-LDA Response (CDAI ≤10)  
at Each Assessment Visit 
 
SAC[2] 
HAQ-DI 
2.8. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in HAQ-DI Score at 
Each Assessment Visit (Primary Estimand) 
 
HDL[1] 


 
CONFIDENTIAL 
 
 
201790 
 
102 
 
Efficacy: Tables 
No. 
Population 
IDSL /  
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
2.9. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in HAQ-DI 
Score and in Functional Areas of the HAQ-DI Score at 
Each Assessment Visit 
 
SAC[2] 
CDAI Total Score 
2.10. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in CDAI Total score at 
Each Assessment Visit  (Primary Estimand) 
 
HDL[1] 
2.11. 
ITT 
Non-Standard 
EFF_T3  
Analysis of Change from Baseline in CDAI Total score at 
Each Assessment Visit (Supplemental Estimand 2) 
 
AAC[3] 
2.12. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in CDAI 
Total Score at Each Assessment Visit 
 
SAC[2] 
FACIT-Fatigue 
2.13. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in FACIT-Fatigue at 
Each Assessment Visit (Primary Estimand) 
 
HDL[1] 
2.14. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in FACIT-
Fatigue at Each Assessment Visit 
 
SAC[2] 
Arthritis Pain VAS 
2.15. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in Arthritis Pain VAS 
Score at Each Assessment Visit (Primary Estimand) 
 
HDL[1] 
2.16. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in Arthritis Pain VAS 
Score at Each Assessment Visit (Supplemental Estimand 
2) 
 
AAC[3] 


 
CONFIDENTIAL 
 
 
201790 
 
103 
 
Efficacy: Tables 
No. 
Population 
IDSL /  
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
2.17. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in Arthritis 
Pain VAS Score at Each Assessment Visit 
 
SAC[2] 
ACR50/70  
2.18. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of ACR50 Response at Each 
Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.19. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of ACR70 Response at Each 
Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.20. 
ITT 
Non-Standard 
EFF_T2 
Summary of Observed ACR50/70 Response at Each 
Assessment Visit 
Page by ACR50 and ACR70 
SAC[2] 
CDAI Remission 
2.21. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of CDAI Remission Response 
(CDAI≤2.8) at Each Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.22. 
ITT 
Non-Standard 
EFF_T2 
Summary of Observed CDAI Remission (CDAI≤2.8) at 
Each Assessment Visit 
 
SAC[2] 
DAS28-CRP LDA 
2.23. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of DAS28-CRP LDA Response 
(DAS28-CRP≤3.2) at Each Assessment Visit (Primary 
Estimand) 
 
SAC[2] 
2.24. 
ITT 
Non-Standard 
EFF_T2 
Summary of Observed DAS28-CRP LDA Response 
(DAS28-CRP≤3.2) at Each Assessment Visit 
 
SAC[2] 
 


 
CONFIDENTIAL 
 
 
201790 
 
104 
 
Efficacy: Tables 
No. 
Population 
IDSL /  
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
DAS28-CRP Remission 
2.25. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of DAS28-CRP Remission 
Response (DAS28-CRP<2.6) at Each Assessment Visit 
(Primary Estimand) 
 
SAC[2] 
2.26. 
ITT 
Non-Standard 
EFF_T2 
Summary of Observed DAS28-CRP Remission Response 
(DAS28-CRP<2.6) at Each Assessment Visit 
 
SAC[2] 
DAS28-ESR LDA 
2.27. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of DAS28-ESR LDA Response 
(DAS28-ESR≤3.2) at Each Assessment Visit (Primary 
Estimand) 
 
SAC[2] 
2.28. 
ITT 
Non-Standard 
EFF_T2 
Summary of Observed DAS28-ESR LDA Response 
(DAS28-ESR≤3.2) at Each Assessment Visit 
 
SAC[2] 
DAS28-ESR Remission 
2.29. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of DAS28-ESR Remission 
Response (DAS28-ESR<2.6) at Each Assessment Visit 
(Primary Estimand) 
 
SAC[2] 
2.30. 
ITT 
Non-Standard 
EFF_T2 
Summary of Observed DAS28-ESR Remission Response 
(DAS28-ESR<2.6) at Each Assessment Visit 
 
SAC[2] 
Good/Moderate EULAR Response 
2.31. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of Good/Moderate EULAR 
Response (based on DAS28-CRP) at Each Assessment 
Visit (Primary Estimand) 
  
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
105 
 
Efficacy: Tables 
No. 
Population 
IDSL /  
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
2.32. 
ITT 
Non-Standard 
EFF_T2 
Summary of Observed Good/Moderate EULAR Response 
(based on DAS28-CRP) at Each Assessment Visit 
 
SAC[2] 
ACR/EULAR Remission Boolean-based and Index-based 
2.33. 
ITT 
Non-Standard 
EFF_T2 
Summary of Observed Index-based ACR/EULAR 
Remission Response at Each Assessment Visit 
 
SAC[2] 
2.34. 
ITT 
Non-Standard 
EFF_T2 
Summary of Observed Boolean-based ACR/EULAR 
Remission Response at Each Assessment Visit 
 
SAC[2] 
Radiographic Progression (change from baseline in van der Heijde mTSS score) 
2.35. 
ITT 
Non-Standard 
EFF_T2 
Summary of Observed Proportion of Subjects with Change 
from Baseline in Van der Heijde mTSS of ≤0 and ≤0.5 at 
Each Assessment Visit 
Page by ≤0 and ≤0.5 
SAC[2] 
2.36. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in Van der 
Heijde mTSS at Each Assessment Visit 
 
SAC[2] 
Tender Joint Counts 
2.37. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in TJC28 at Each 
Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.38. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in TJC68 at Each 
Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.39. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in TJC28 
and TJC68 at Each Assessment Visit 
 
SAC[2] 
 


 
CONFIDENTIAL 
 
 
201790 
 
106 
 
Efficacy: Tables 
No. 
Population 
IDSL /  
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Swollen Joint Counts 
2.40. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in SJC28 at Each 
Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.41. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in SJC66 at Each 
Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.42. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in SJC28 
and SJC66 at Each Assessment Visit 
 
SAC[2] 
CRP/ESR 
2.43. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in CRP (mg/L) at Each 
Assessment Visit (Primary Estimand)  
 
SAC[2] 
2.44. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in CRP 
(mg/L) and ESR (mm/h) at Each Assessment Visit 
 
SAC[2] 
2.45. 
ITT 
Non-Standard 
EFF_T5 
Summary of Ratio to Baseline in CRP (mg/L) and ESR 
(mm/h) at Each Assessment Visit (Log Transformed) 
 
SAC[2] 
Patient’s Global Assessment 
2.46. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in Patient’s Global 
Assessment of Arthritis at Each Assessment Visit (Primary 
Estimand) 
 
SAC[2] 
2.47. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in Patient’s 
Global Assessment of Arthritis at Each Assessment Visit 
 
SAC[2] 
 


 
CONFIDENTIAL 
 
 
201790 
 
107 
 
Efficacy: Tables 
No. 
Population 
IDSL /  
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Physician’s Global Assessment 
2.48. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in Physician’s Global 
Assessment of Arthritis at Each Assessment Visit (Primary 
Estimand) 
 
SAC[2] 
2.49. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in 
Physician’s Global Assessment of Arthritis at Each 
Assessment Visit 
 
SAC[2] 
DAS28-CRP 
2.50. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in DAS28-CRP at Each 
Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.51. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in DAS28-
CRP at Each Assessment Visit 
 
SAC[2] 
DAS28-ESR 
2.52. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in DAS28-ESR at Each 
Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.53. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in DAS28-
ESR at Each Assessment Visit 
 
SAC[2] 
SF-36 (Physical, Mental and Individual Components) 
2.54. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in Physical Component 
Score (PCS) of SF-36 at Each Assessment Visit (Primary 
Estimand) 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
108 
 
Efficacy: Tables 
No. 
Population 
IDSL /  
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
2.55. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in Physical 
Component Score (PCS) of SF-36 at Each Assessment 
Visit 
 
SAC[2] 
2.56. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in Mental Component 
Score (MCS) of SF-36 at Each Assessment Visit (Primary 
Estimand) 
 
SAC[2] 
2.57. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in Mental 
Component Score (MCS) of SF-36 at Each Assessment 
Visit 
 
SAC[2] 
2.58. 
ITT 
Non-Standard 
EFF_T4 
Summary of Observed Change from Baseline in Domain 
Scores of SF-36 at Each Assessment Visit 
 
SAC[2] 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
109 
 
Efficacy: Tables 
No. 
Population 
IDSL /  
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
110 
 
Efficacy: Tables 
No. 
Population 
IDSL /  
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
111 
 
Efficacy: Tables 
No. 
Population 
IDSL /  
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
112 
 
Efficacy: Tables 
No. 
Population 
IDSL /  
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
113 
 
Efficacy: Tables 
No. 
Population 
IDSL /  
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Sensitivity Analyses 
2.92. 
Per 
Protocol 
Non-Standard  
EFF_T1 
Summary and Analysis of ACR20 Response at Each 
Assessment Visit (Primary Estimand) (Per Protocol 
Population) 
 
AAC[3] 
Radiographic Progression (change from baseline in van der Heijde mTSS score) 
2.93. 
ITT 
Non-Standard 
EFF_T3 
Analysis of Change from Baseline in Van der Heijde mTSS 
Score at Each Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.94. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of the Proportion of Subjects with 
Change from Baseline in Van der Heijde mTSS ≤ 0 at 
Each Assessment Visit (Primary Estimand) 
  
SAC[2] 
2.95. 
ITT 
Non-Standard  
EFF_T1 
Summary and Analysis of the Proportion of Subjects with 
Change from Baseline in Van der Heijde mTSS ≤ 0.5 at 
Each Assessment Visit (Primary Estimand) 
  
SAC[2] 
 
Efficacy Figures 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
114 
 
Efficacy: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
ACR20 
2.1. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving ACR20 Response at 
Each Assessment Visit (Primary Estimand) 
 
HDL[1] 
2.2. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving ACR20 Response at 
Each Assessment Visit (Supplemental Estimand 1) 
 
SAC[2] 
2.3. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving ACR20 Response at 
Each Assessment Visit (Supplemental Estimand 2) 
 
AAC[3] 
CDAI-LDA 
2.4. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving CDAI-LDA (CDAI ≤10) at 
Each Assessment Visit (Primary Estimand) 
 
HDL[1] 
2.5. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving CDAI-LDA (CDAI ≤10) at 
Each Assessment Visit (Supplemental Estimand 1) 
 
SAC[2] 
HAQ-DI 
2.6. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
HAQ-DI Score at Each Assessment Visit (Primary 
Estimand)  
 
HDL[1] 
CDAI Total Score 
2.7. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
CDAI Total Score at Each Assessment Visit (Primary 
Estimand) 
 
HDL[1] 


 
CONFIDENTIAL 
 
 
201790 
 
115 
 
Efficacy: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
2.8. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
CDAI Total Score at Each Assessment Visit (Supplemental 
Estimand 2) 
 
AAC[3] 
FACIT-Fatigue 
2.9. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
FACIT-Fatigue at Each Assessment Visit (Primary 
Estimand) 
 
HDL[1] 
Arthritis Pain VAS 
2.10. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
Arthritis Pain VAS at Each Assessment Visit (Primary 
Estimand) 
 
HDL[1] 
2.11. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
Arthritis Pain VAS at Each Assessment Visit (Supplemental 
Estimand 2) 
 
AAC[3] 
ACR50/70 
2.12. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving ACR50 Response at 
Each Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.13. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving ACR70 Response at 
Each Assessment Visit (Primary Estimand) 
 
SAC[2] 
CDAI Remission 
2.14. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving CDAI Remission 
(CDAI≤2.8) at Each Assessment Visit (Primary Estimand) 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
116 
 
Efficacy: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
DAS28-CRP LDA 
2.15. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving DAS28-CRP LDA 
(DAS28-CRP≤3.2) at Each Assessment Visit (Primary 
Estimand) 
 
SAC[2] 
DAS28-CRP Remission 
2.16. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving DAS28-CRP Remission 
(DAS28-CRP<2.6) at Each Assessment Visit (Primary 
Estimand) 
 
SAC[2] 
DAS28-ESR LDA 
2.17. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving DAS28-ESR LDA 
(DAS28-ESR≤3.2) at Each Assessment Visit (Primary 
Estimand) 
 
SAC[2] 
DAS28-ESR Remission 
2.18. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving DAS28-ESR Remission 
(DAS28-ESR<2.6) at Each Assessment Visit (Primary 
Estimand) 
 
SAC[2] 
Good/Moderate EULAR Response 
2.19. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving Good/Moderate EULAR 
Response (based on DAS28-CRP) at Each Assessment 
Visit (Primary Estimand) 
 
SAC[2] 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
117 
 
Efficacy: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Radiographic Progression (change from baseline in van der Heijde mTSS score) 
2.20. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving Change from Baseline in 
mTSS of ≤0 and ≤0.5 at Each Assessment Visit 
 
SAC[2] 
2.21. 
ITT 
Non-Standard 
EFF_F2 
Plot of Change from Baseline in mTSS at Each 
Assessment Visit 
 
SAC[2] 
2.22. 
ITT 
Non-Standard 
EFF_F7 
Cumulative Probability Plots of Individual Subject Changes 
from Baseline in mTSS at Each Assessment Visit 
 
SAC[2] 
Tender Joint Counts 
2.23. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
TJC28 at Each Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.24. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
TJC68 at Each Assessment Visit (Primary Estimand) 
 
SAC[2] 
Swollen Joint Counts 
2.25. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
SJC28 at Each Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.26. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
SJC66 at Each Assessment Visit (Primary Estimand) 
 
SAC[2] 
CRP 
2.27. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
CRP (mg/L) at Each Assessment Visit (Primary Estimand) 
 
SAC[2] 
 


 
CONFIDENTIAL 
 
 
201790 
 
118 
 
Efficacy: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Patient’s Global Assessment 
2.28. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
Patient’s Global Assessment at Each Assessment Visit 
(Primary Estimand) 
 
SAC[2] 
Physician’s Global Assessment 
2.29. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
Physician’s Global Assessment at Each Assessment Visit 
(Primary Estimand) 
 
SAC[2] 
DAS28-CRP 
2.30. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
DAS28-CRP at Each Assessment Visit (Primary Estimand) 
 
SAC[2] 
DAS28-ESR 
2.31. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
DAS28-ESR at Each Assessment Visit (Primary Estimand) 
 
SAC[2] 
SF-36 (Physical, Mental and Individual Components) 
2.32. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
Physical Component Score (PCS) of SF-36 at Each 
Assessment Visit (Primary Estimand) 
 
SAC[2] 
2.33. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means Change from Baseline in 
Mental Component Score (MCS) of SF-36 at Each 
Assessment Visit (Primary Estimand) 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
119 
 
Efficacy: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
2.34. 
ITT 
Non-Standard 
EFF_F3 
Spydergram of Individual Domain Scores of SF-36 at Each 
Assessment Visit  
 
SAC[2] 
Subgroup: ACR20 
2.35. 
ITT 
Non-Standard 
EFF_F4 
Forest Plot of Demographic Subgroup Results for ACR20 – 
Comparison to Placebo at Week 12 
 
SAC[2] 
2.36. 
ITT 
Non-Standard 
EFF_F4 
Forest Plot of Demographic Subgroup Results for ACR20 – 
Comparison to Tofacitinib at Week 24 
 
SAC[2] 
2.37. 
ITT 
Non-Standard 
EFF_F4 
Forest Plot of Disease Characteristic Subgroup Results for 
ACR20 – Comparison to Placebo at Week 12 
 
SAC[2] 
2.38. 
ITT 
Non-Standard 
EFF_F4 
Forest Plot of Disease Characteristic Subgroup Results for 
ACR20 – Comparison to Tofacitinib at Week 24 
 
SAC[2] 
Subgroup: CDAI-LDA 
2.39. 
ITT 
Non-Standard 
EFF_F4 
Forest Plot of Demographic Subgroup Results for CDAI-
LDA – Comparison to Placebo at Week 12 
 
SAC[2] 
2.40. 
ITT 
Non-Standard 
EFF_F4 
Forest Plot of Demographic Subgroup Results for CDAI-
LDA – Comparison to Tofacitinib at Week 24 
 
SAC[2] 
2.41. 
ITT 
Non-Standard 
EFF_F4 
Forest Plot of Disease Characteristic Subgroup Results for 
CDAI-LDA – Comparison to Placebo at Week 12 
 
SAC[2] 
2.42. 
ITT 
Non-Standard 
EFF_F4 
Forest Plot of Disease Characteristic Subgroup Results for 
CDAI-LDA – Comparison to Tofacitinib at Week 24 
 
SAC[2] 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
120 
 
Efficacy: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Subgroup: HAQ-DI 
2.43. 
ITT 
Non-Standard 
EFF_F5 
Forest Plot of Demographic Subgroup Results for Change 
from Baseline in HAQ-DI – Comparison to Placebo at 
Week 12 
 
SAC[2] 
2.44. 
ITT 
Non-Standard 
EFF_F5 
Forest Plot of Demographic Subgroup Results for Change 
from Baseline in HAQ-DI – Comparison to Tofacitinib at 
Week 24 
 
SAC[2] 
2.45. 
ITT 
Non-Standard 
EFF_F5 
Forest Plot of Disease Characteristic Subgroup Results for 
Change from Baseline in HAQ-DI – Comparison to Placebo 
at Week 12 
 
SAC[2] 
2.46. 
ITT 
Non-Standard 
EFF_F5 
Forest Plot of Disease Characteristic Subgroup Results for 
Change from Baseline in HAQ-DI – Comparison to 
Tofacitinib at Week 24 
 
SAC[2] 
Subgroup: CDAI Total 
2.47. 
ITT 
Non-Standard 
EFF_F5 
Forest Plot of Demographic Subgroup Results for Change 
from Baseline in CDAI Total Score – Comparison to 
Placebo at Week 12 
 
SAC[2] 
2.48. 
ITT 
Non-Standard 
EFF_F5 
Forest Plot of Demographic Subgroup Results for Change 
from Baseline in CDAI Total Score – Comparison to 
Tofacitinib at Week 24 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
121 
 
Efficacy: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
2.49. 
ITT 
Non-Standard 
EFF_F5 
Forest Plot of Disease Characteristic Subgroup Results for 
Change from Baseline in CDAI Total Score – Comparison 
to Placebo at Week 12 
 
SAC[2] 
 
 
2.50. 
ITT 
Non-Standard 
EFF_F5 
Forest Plot of Disease Characteristic Subgroup Results for 
Change from Baseline in CDAI Total Score – Comparison 
to Tofacitinib at Week 24 
 
SAC[2] 
Subgroup: Arthritis Pain VAS 
2.51. 
ITT 
Non-Standard 
EFF_F5 
Forest Plot of Demographic Subgroup Results for Change 
from Baseline in Arthritis Pain VAS – Comparison to 
Placebo at Week 12 
 
AAC[3] 
2.52. 
ITT 
Non-Standard 
EFF_F5 
Forest Plot of Demographic Subgroup Results for Change 
from Baseline in Arthritis Pain VAS – Comparison to 
Tofacitinib at Week 24 
 
AAC[3] 
2.53. 
ITT 
Non-Standard 
EFF_F5 
Forest Plot of Disease Characteristic Subgroup Results for 
Change from Baseline in Arthritis Pain VAS – Comparison 
to Placebo at Week 12 
 
AAC[3] 
2.54. 
ITT 
Non-Standard 
EFF_F5 
Forest Plot of Disease Characteristic Subgroup Results for 
Change from Baseline in Arthritis Pain VAS – Comparison 
to Tofacitinib at Week 24 
 
AAC[3 
 
 
 
] 


 
CONFIDENTIAL 
 
 
201790 
 
122 
 
Efficacy: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Additional Figures Splitting out Pooled Placebo Post Week 12 
2.55. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving ACR20 Response at 
Each Assessment Visit (Primary Estimand) Splitting out 
Pooled Placebo Post Week 12 
Display pooled placebo arm split out 
after week 12 
AAC[3] 
2.56. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving CDAI-LDA (CDAI≤10) at 
Each Assessment Visit (Primary Estimand) Splitting out 
Pooled Placebo Post Week 12 
Display pooled placebo arm split out 
after week 12 
AAC[3] 
2.57. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
HAQ-DI Score at Each Assessment Visit (Primary 
Estimand) Splitting out Pooled Placebo Post Week 12 
Display pooled placebo arm split out 
after week 12 
AAC[3] 
2.58. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
CDAI Total Score at Each Assessment Visit (Primary 
Estimand) Splitting out Pooled Placebo Post Week 12 
Display pooled placebo arm split out 
after week 12 
AAC[3] 
2.59. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
Arthritis Pain VAS at Each Assessment Visit (Primary 
Estimand) Splitting out Pooled Placebo Post Week 12 
Display pooled placebo arm split out 
after week 12 
AAC[3] 
2.60. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving ACR50 Response at 
Each Assessment Visit (Primary Estimand) Splitting out 
Pooled Placebo Post Week 12 
Display pooled placebo arm split out 
after week 12 
AAC[3] 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
123 
 
Efficacy: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
124 
 
Efficacy: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Radiographic Progression (change from baseline in van der Heijde mTSS score) 
2.78. 
ITT 
Non-Standard 
EFF_F2 
Plot of Least Squares Means of Change from Baseline in 
Van der Heijde mTSS at Each Assessment Visit (Primary 
Estimand) 
 
SAC[2] 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
125 
 
Efficacy: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
2.79. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving Change from Baseline in 
Van der Heijde mTSS ≤ 0 at Each Assessment Visit 
(Primary Estimand) 
 
SAC[2] 
2.80. 
ITT 
Non-Standard 
EFF_F1 
Proportion of Subjects Achieving Change from Baseline in 
Van der Heijde mTSS ≤ 0.5 at Each Assessment Visit 
(Primary Estimand) 
 
SAC[2] 
 
Safety Tables 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Adverse Events (AEs) 
3.1. 
Safety 
AE13 
Overall Summary of Adverse Events (Period 1) 
 
SAC[2] 
3.2. 
Safety - 
Subjects 
who 
Entered 
Period 2 
AE13 
Overall Summary of Adverse Events (Period 2) 
 
SAC[2] 
3.3. 
Safety 
AE13 
Overall Summary of Adverse Events (Period 1+2) 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
126 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.4. 
Safety 
AE1 
Summary of All Adverse Events by System Organ Class 
and Preferred Term (Period 1) 
ICH E3 
 
SAC[2] 
3.5. 
Safety - 
Subjects 
who 
Entered 
Period 2 
AE1 
Summary of All Adverse Events by System Organ Class 
and Preferred Term (Period 2) 
ICH E3 
 
SAC[2] 
3.6. 
Safety 
AE1 
Summary of All Adverse Events by System Organ Class 
and Preferred Term (Period 1+2) 
ICH E3 
 
SAC[2] 
3.7. 
Safety 
AE1 
Summary of All Drug-Related Adverse Events by System 
Organ Class and Preferred Term (Period 1) 
ICH E3 
SAC[2] 
3.8. 
Safety - 
Subjects 
who 
Entered 
Period 2 
AE1 
Summary of All Drug-Related Adverse Events by System 
Organ Class and Preferred Term (Period 2) 
ICH E3 
SAC[2] 
3.9. 
Safety 
AE1 
Summary of All Drug-Related Adverse Events by System 
Organ Class and Preferred Term (Period 1+2) 
ICH E3 
SAC[2] 
3.10. 
Safety 
AE1 
Summary of Serious Adverse Events by System Organ 
Class and Preferred Term (Period 1) 
ICH E3 
HDL[1] 


 
CONFIDENTIAL 
 
 
201790 
 
127 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.11. 
Safety - 
Subjects 
who 
Entered 
Period 2 
AE1 
Summary of Serious Adverse Events by System Organ 
Class and Preferred Term (Period 2) 
ICH E3 
SAC[2] 
3.12. 
Safety 
AE1 
Summary of Serious Adverse Events by System Organ 
Class and Preferred Term (Period 1+2) 
ICH E3 
HDL[1] 
3.13. 
Safety 
AE1  
 
Summary of Adverse Events Leading to Permanent 
Discontinuation of Study Treatment by System Organ 
Class and Preferred Term (Period 1) 
IDSL 
 
SAC[2] 
3.14. 
Safety - 
Subjects 
who 
Entered 
Period 2 
AE1  
 
Summary of Adverse Events Leading to Permanent 
Discontinuation of Study Treatment by System Organ 
Class and Preferred Term (Period 2) 
IDSL 
 
SAC[2] 
3.15. 
Safety 
AE1  
 
Summary of Adverse Events Leading to Permanent 
Discontinuation of Study Treatment by System Organ 
Class and Preferred Term (Period 1+2) 
IDSL 
 
SAC[2] 
3.16. 
Safety 
AE3 
Summary of Common (>=5%) Adverse Events by Overall 
Frequency (Period 1) 
ICH E3 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
128 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.17. 
Safety - 
Subjects 
who 
Entered 
Period 2 
AE3 
Summary of Common (>=5%) Adverse Events by Overall 
Frequency (Period 2) 
ICH E3 
 
SAC[2] 
3.18. 
Safety 
AE3 
Summary of Common (>=5%) Adverse Events by Overall 
Frequency (Period 1+2) 
ICH E3 
 
SAC[2] 
3.19. 
Safety 
AE15 
Summary of Common (>=5%) Non-Serious Adverse 
Events by System Organ Class and Preferred Term 
(Number of Subject and Occurrences) (Period 1) 
FDAAA, EudraCT 
 
SAC[2] 
3.20. 
Safety - 
Subjects 
who 
Entered 
Period 2 
AE15 
Summary of Common (>=5%) Non-Serious Adverse 
Events by System Organ Class and Preferred Term 
(Number of Subject and Occurrences) (Period 2) 
FDAAA, EudraCT 
 
SAC[2] 
3.21. 
Safety 
AE15 
Summary of Common (>=5%) Non-Serious Adverse 
Events by System Organ Class and Preferred Term 
(Number of Subject and Occurrences) (Period 1+2) 
FDAAA, EudraCT 
 
SAC[2] 
3.22. 
Safety 
AE16 
Summary of Serious Adverse Events by System Organ 
Class and Preferred Term (Number of Subjects and 
Occurrences) (Period 1) 
FDAAA, EudraCT 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
129 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.23. 
Safety - 
Subjects 
who 
Entered 
Period 2 
AE16 
Summary of Serious Adverse Events by System Organ 
Class and Preferred Term (Number of Subjects and 
Occurrences) (Period 2) 
FDAAA, EudraCT 
 
SAC[2] 
3.24. 
Safety 
AE16 
Summary of Serious Adverse Events by System Organ 
Class and Preferred Term (Number of Subjects and 
Occurrences) (Period 1+2) 
FDAAA, EudraCT 
 
SAC[2] 
3.25. 
Safety 
AE5A 
Summary of All Adverse Events by Maximum Intensity by 
System Organ Class and Preferred Term (Period 1) 
ICH E3 
SAC[2] 
3.26. 
Safety - 
Subjects 
who 
Entered 
Period 2 
AE5A 
Summary of All Adverse Events by Maximum Intensity by 
System Organ Class and Preferred Term (Period 2) 
ICH E3 
SAC[2] 
3.27. 
Safety 
AE5A 
Summary of All Adverse Events by Maximum Intensity by 
System Organ Class and Preferred Term (Period 1+2) 
ICH E3 
SAC[2] 
3.28. 
Safety 
AE5A 
Summary of All Drug-Related Adverse Events by Maximum 
Intensity by System Organ Class and Preferred Term 
(Period 1) 
ICH E3 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
130 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.29. 
Safety - 
Subjects 
who 
Entered 
Period 2 
AE5A 
Summary of All Drug-Related Adverse Events by Maximum 
Intensity by System Organ Class and Preferred Term 
(Period 2) 
ICH E3 
SAC[2] 
3.30. 
Safety 
AE5A 
Summary of All Drug-Related Adverse Events by Maximum 
Intensity by System Organ Class and Preferred Term 
(Period 1+2) 
ICH E3 
SAC[2] 
3.31. 
Safety 
AE3 
Summary of Non-Serious Drug-Related Adverse Events by 
Overall Frequency (Period 1) 
PLS Requirements 
SAC[2] 
3.32. 
Safety - 
Subjects 
who 
Entered 
Period 2 
AE3 
Summary of Non-Serious Drug-Related Adverse Events by 
Overall Frequency (Period 2) 
PLS Requirements 
SAC[2] 
3.33. 
Safety 
AE3 
Summary of Non-Serious Drug-Related Adverse Events by 
Overall Frequency (Period 1+2) 
PLS Requirements 
SAC[2] 
3.34. 
Safety 
AE20 
Summary of Serious Fatal and Non-Fatal Drug-Related 
Adverse Events by Overall Frequency (Period 1) 
PLS Requirements 
SAC[2] 
3.35. 
Safety - 
Subjects 
who 
Entered 
Period 2 
AE20 
Summary of Serious Fatal and Non-Fatal Drug-Related 
Adverse Events by Overall Frequency (Period 2) 
PLS Requirements 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
131 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.36. 
Safety 
AE20 
Summary of Serious Fatal and Non-Fatal Drug-Related 
Adverse Events by Overall Frequency (Period 1+2) 
PLS Requirements 
SAC[2] 
3.37. 
Safety 
Non-Standard 
SAFE_T1 
Summary of Exposure Adjusted Event Rates per 100 
Person Years for All Adverse Events (Period 1) 
 
SAC[2] 
3.38. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard 
SAFE_T1 
Summary of Exposure Adjusted Event Rates per 100 
Person Years for All Adverse Events (Period 2) 
 
SAC[2] 
3.39. 
Safety 
Non-Standard 
SAFE_T1 
Summary of Exposure Adjusted Event Rates per 100 
Person Years for All Adverse Events (Period 1+2) 
 
SAC[2] 
Adverse Events of Special Interest (AESI) and Other Important AEs 
3.40. 
Safety 
Non-Standard 
SAFE_T2 
Summary of Adverse Events of Special Interest (AESI) 
(Period 1) 
 
HDL[1] 
3.41. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard 
SAFE_T2 
Summary of Adverse Events of Special Interest (AESI) 
(Period 2) 
 
SAC[2] 
3.42. 
Safety 
Non-Standard 
SAFE_T2 
Summary of Adverse Events of Special Interest (AESI) 
(Period 1+2) 
 
HDL[1] 


 
CONFIDENTIAL 
 
 
201790 
 
132 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.43. 
Safety 
Non-Standard 
SAFE_T1 
Summary of Exposure Adjusted Event Rates per 100 
Person Years for Adverse Events of Special Interest 
(Period 1) 
 
SAC[2] 
3.44. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard 
SAFE_T1 
Summary of Exposure Adjusted Event Rates per 100 
Person Years for Adverse Events of Special Interest 
(Period 2) 
 
SAC[2] 
3.45. 
Safety 
Non-Standard 
SAFE_T1 
Summary of Exposure Adjusted Event Rates per 100 
Person Years for Adverse Events of Special Interest 
(Period 1+2) 
 
SAC[2] 
3.46. 
Safety 
Non-Standard 
SAFE_T3 
Summary of Other Important Adverse Events (Period 1) 
 
SAC[2] 
3.47. 
Safety 
Non-Standard 
SAFE_T3 
Summary of Other Important Adverse Events (Period 2) 
 
SAC[2] 
3.48. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard 
SAFE_T3 
Summary of Other Important Adverse Events (Period 1+2) 
 
SAC[2] 
3.49. 
Safety 
Non-Standard 
SAFE_T1 
Summary of Exposure Adjusted Event Rates per 100 
Person Years for Other Important Adverse Events (Period 
1) 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
133 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.50. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard 
SAFE_T1 
Summary of Exposure Adjusted Event Rates per 100 
Person Years for Other Important Adverse Events (Period 
2) 
 
SAC[2] 
3.51. 
Safety 
Non-Standard 
SAFE_T1 
Summary of Exposure Adjusted Event Rates per 100 
Person Years for Other Important Adverse Events (Period 
1+2) 
 
SAC[2] 
3.52. 
Safety 
Non-Standard 
SAFE_T4 
Summary of Adjudicated Cardiovascular Event Categories 
(Period 1) 
 
SAC[2] 
3.53. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard 
SAFE_T4 
Summary of Adjudicated Cardiovascular Event Categories 
(Period 2) 
 
SAC[2] 
3.54. 
Safety 
Non-Standard 
SAFE_T4 
Summary of Adjudicated Cardiovascular Event Categories 
(Period 1+2) 
 
SAC[2] 
3.55. 
Safety 
ESI1 
(modified) 
Summary of Characteristics of Injection Site Reactions 
(Period 1)  
 
SAC[2] 
3.56. 
Safety - 
Subjects 
who 
Entered 
Period 2 
ESI1 
(modified) 
Summary of Characteristics of Injection Site Reactions 
(Period 2)  
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
134 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.57. 
Safety 
ESI1 
(modified) 
Summary of Characteristics of Injection Site Reactions 
(Period 1+2)  
 
SAC[2] 
3.58. 
Safety 
Non-Standard 
SAFE_T5 
Summary of Injection Site Reactions (Period 1) 
 
SAC[2] 
3.59. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard 
SAFE_T5 
Summary of Injection Site Reactions (Period 2) 
 
SAC[2] 
3.60. 
Safety 
Non-Standard 
SAFE_T5 
Summary of Injection Site Reactions (Period 1+2) 
 
SAC[2] 
3.61. 
Safety 
Non-Standard 
SAFE_T6 
Summary of Serious or Adjudicated Opportunistic 
Infections (Period 1) 
 
SAC[2] 
3.62. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard 
SAFE_T6 
Summary of Serious or Adjudicated Opportunistic 
Infections (Period 2) 
 
SAC[2] 
3.63. 
Safety 
Non-Standard 
SAFE_T6 
Summary of Serious or Adjudicated Opportunistic 
Infections (Period 1+2) 
 
SAC[2] 
3.64. 
Safety 
Non-Standard 
SAFE_T7 
Summary of Adjudicated Serious Hypersensitivity 
Reactions (Period 1) 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
135 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.65. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard 
SAFE_T7 
Summary of Adjudicated Serious Hypersensitivity 
Reactions (Period 2) 
 
SAC[2] 
3.66. 
Safety 
Non-Standard 
SAFE_T7 
Summary of Adjudicated Serious Hypersensitivity 
Reactions (Period 1+2) 
 
SAC[2] 
Pulmonary Findings 
3.67. 
Safety 
Non-Standard 
SAFE_T8 
Summary of Pulmonary Findings (Period 1) 
 
SAC[2] 
3.68. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard 
SAFE_T8 
Summary of Pulmonary Findings (Period 2) 
 
SAC[2] 
3.69. 
Safety 
Non-Standard 
SAFE_T8 
Summary of Pulmonary Findings (Period 1+2) 
 
SAC[2] 
3.70. 
Safety 
Non-Standard  
SAFE_T9 
Summary of Pulse Oximetry Results (Period 1) 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
136 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.71. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard  
SAFE_T9 
Summary of Pulse Oximetry Results (Period 2) 
 
SAC[2] 
3.72. 
Safety 
Non-Standard  
SAFE_T9 
Summary of Pulse Oximetry Results (Period 1+2) 
 
SAC[2] 
Laboratory: Chemistry, Hematology & Fasting Lipids  
3.73. 
Safety 
LB1 
Summary of Chemistry Changes from Baseline (Period 1) 
ICH E3 
Exclude CRP 
 
SAC[2] 
3.74. 
Safety - 
Subjects 
who 
Entered 
Period 2 
LB1 
Summary of Chemistry Changes from Baseline (Period 2) 
ICH E3 
Exclude CRP 
 
SAC[2] 
3.75. 
Safety 
LB1 
Summary of Chemistry Changes from Baseline (Period 
1+2) 
ICH E3 
Exclude CRP 
 
SAC[2] 
3.76. 
Safety 
LB16A 
(modified) 
Summary of Worst Case Chemistry Results by Maximum 
Grade Shift Post-Baseline Relative to Baseline (Period 1) 
ICH E3 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
137 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.77. 
Safety - 
Subjects 
who 
Entered 
Period 2 
LB16A 
(modified) 
Summary of Worst Case Chemistry Results by Maximum 
Grade Shift Post-Baseline Relative to Baseline (Period 2) 
ICH E3 
 
SAC[2] 
3.78. 
Safety 
LB16A 
(modified) 
Summary of Worst Case Chemistry Results by Maximum 
Grade Shift Post-Baseline Relative to Baseline (Period 
1+2) 
ICH E3 
 
SAC[2] 
3.79. 
 Safety 
LB1 
Summary of Hematology Changes from Baseline (Period 
1) 
ICH E3 
Exclude ESR 
 
SAC[2] 
3.80. 
Safety - 
Subjects 
who 
Entered 
Period 2 
LB1 
Summary of Hematology Changes from Baseline (Period 
2) 
ICH E3 
Exclude ESR 
 
SAC[2] 
3.81. 
 Safety 
LB1 
Summary of Hematology Changes from Baseline (Period 
1+2) 
ICH E3 
Exclude ESR 
 
SAC[2] 
3.82. 
Safety 
LB16A 
(modified) 
Summary of Worst Case Hematology Results by Maximum 
Grade Shift Post-Baseline Relative to Baseline (Period 1) 
ICH E3 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
138 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.83. 
Safety - 
Subjects 
who 
Entered 
Period 2 
LB16A 
(modified) 
Summary of Worst Case Hematology Results by Maximum 
Grade Shift Post-Baseline Relative to Baseline (Period 2) 
ICH E3 
 
SAC[2] 
3.84. 
Safety 
LB16A 
(modified) 
Summary of Worst Case Hematology Results by Maximum 
Grade Shift Post-Baseline Relative to Baseline (Period 
1+2) 
ICH E3 
 
SAC[2] 
3.85. 
Safety 
LB1 
Summary of Fasting Lipids Changes from Baseline (Period 
1) 
 
SAC[2] 
3.86. 
Safety - 
Subjects 
who 
Entered 
Period 2 
LB1 
Summary of Fasting Lipids Changes from Baseline (Period 
2) 
 
SAC[2] 
3.87. 
Safety 
LB1 
Summary of Fasting Lipids Changes from Baseline (Period 
1+2) 
 
SAC[2] 
3.88. 
Safety 
LB18 
Summary of Laboratory Parameters of Interest CTCAE 
Worst Grade Shift from Baseline Grade (Period 1) 
 
SAC[2] 
3.89. 
Safety – 
Subjects 
who 
Entered 
Period 2 
LB18 
Summary of Laboratory Parameters of Interest CTCAE 
Worst Grade Shift from Baseline Grade (Period 2) 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
139 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.90. 
Safety  
LB18 
Summary of Laboratory Parameters of Interest CTCAE 
Worst Grade Shift from Baseline Grade (Period 1+2) 
 
SAC[2] 
3.91. 
Safety 
UR1 
Summary of Worst Case Urinalysis Results (Discrete or 
Character Values) Post-Baseline Relative to Baseline 
(Period 1) 
ICH E3 
 
SAC[2] 
3.92. 
Safety – 
Subjects 
who 
Entered 
Period 2 
UR1 
Summary of Worst Case Urinalysis Results (Discrete or 
Character Values) Post-Baseline Relative to Baseline 
(Period 2) 
ICH E3 
 
SAC[2] 
3.93. 
Safety  
UR1 
Summary of Worst Case Urinalysis Results (Discrete or 
Character Values) Post-Baseline Relative to Baseline 
(Period 1+2) 
ICH E3 
 
SAC[2] 
Laboratory: Hepatobiliary (Liver) 
3.94. 
 Safety 
LIVER1 
Summary of Liver Monitoring/Stopping Event Reporting 
(Period 1) 
IDSL 
SAC[2] 
3.95. 
Safety - 
Subjects 
who 
Entered 
Period 2 
LIVER1 
Summary of Liver Monitoring/Stopping Event Reporting 
(Period 2) 
IDSL 
SAC[2] 
3.96. 
 Safety 
LIVER1 
Summary of Liver Monitoring/Stopping Event Reporting 
(Period 1+2) 
IDSL 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
140 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.97. 
 Safety 
LIVER10 
Summary of Hepatobiliary Laboratory Abnormalities 
(Period 1) 
IDSL 
 
SAC[2] 
3.98. 
Safety - 
Subjects 
who 
Entered 
Period 2 
LIVER10 
Summary of Hepatobiliary Laboratory Abnormalities 
(Period 2) 
IDSL 
 
SAC[2] 
3.99. 
Safety 
LIVER10 
Summary of Hepatobiliary Laboratory Abnormalities 
(Period 1+2) 
IDSL 
 
SAC[2] 
ECG 
3.100. 
 Safety 
EG1 
Summary of ECG Findings  
IDSL 
 
SAC[2] 
3.101. 
Safety 
EG2 
Summary of Change from Baseline in ECG Values by Visit 
(Period 1) 
IDSL 
 
SAC[2] 
3.102. 
Safety - 
Subjects 
who 
Entered 
Period 2 
EG2 
Summary of Change from Baseline in ECG Values by Visit 
(Period 2) 
IDSL 
 
SAC[2] 
3.103. 
Safety 
EG2 
Summary of Change from Baseline in ECG Values by Visit 
(Period 1+2) 
IDSL 
 
SAC[2] 
3.104. 
Safety 
EG10 
Summary of Maximum QTc Values Post-Baseline Relative 
to Baseline by Category (Period 1) 
IDSL 
  
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
141 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.105. 
Safety – 
Subjects 
who 
Entered 
Period 2 
EG10 
Summary of Maximum QTc Values Post-Baseline Relative 
to Baseline by Category (Period 2) 
IDSL 
 
SAC[2] 
3.106. 
Safety 
EG10 
Summary of Maximum QTc Values Post-Baseline Relative 
to Baseline by Category (Period 1+2) 
IDSL 
 
SAC[2] 
3.107. 
Safety 
EG11 
Summary of Maximum Increase in QTc Values Post-
Baseline Relative to Baseline by Category (Period 1) 
IDSL 
  
SAC[2] 
3.108. 
Safety – 
Subjects 
who 
Entered 
Period 2 
EG11 
Summary of Maximum Increase in QTc Values Post-
Baseline Relative to Baseline by Category (Period 2) 
IDSL 
 
SAC[2] 
3.109. 
Safety 
EG11 
Summary of Maximum Increase in QTc Values Post-
Baseline Relative to Baseline by Category (Period 1+2) 
IDSL 
 
SAC[2] 
Vital Signs 
3.110. 
Safety 
VS1 
Summary of Change from Baseline in Vital Signs (Period 
1) 
ICH E3 
 
SAC[2] 
3.111. 
Safety - 
Subjects 
who 
Entered 
Period 2 
VS1 
Summary of Change from Baseline in Vital Signs (Period 
2) 
ICH E3 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
142 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.112. 
Safety 
VS1 
Summary of Change from Baseline in Vital Signs (Period 
1+2) 
ICH E3 
 
SAC[2] 
3.113. 
Safety 
VS3 
 
Summary of Worst Case Vital Signs Results Relative to 
Normal Range Post-Baseline Relative to Baseline (Period 
1) 
IDSL 
SAC[2] 
3.114. 
Safety – 
Subjects 
who 
Entered 
Period 2 
VS3 
 
Summary of Worst Case Vital Signs Results Relative to 
Normal Range Post-Baseline Relative to Baseline (Period 
1) 
IDSL 
SAC[2] 
3.115. 
Safety  
VS3 
 
Summary of Worst Case Vital Signs Results Relative to 
Normal Range Post-Baseline Relative to Baseline (Period 
1+2) 
IDSL 
SAC[2] 
Safety Biomarkers (Immunogenicity) 
3.116. 
Safety 
Non-Standard 
SAFE_T10 
Summary of Anti-GSK3196165 Antibodies (ADA) 
 
AAC[3] 
3.117. 
Safety 
Non-Standard 
SAFE_T11 
Summary of Binding Antibody at Each Assessment Visit 
 
AAC[3] 
3.118. 
Safety 
Non-Standard 
SAFE_T12 
Summary of Neutralising Antibody at Each Assessment 
Visit 
 
AAC[3] 


 
CONFIDENTIAL 
 
 
201790 
 
143 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
COVID-19 
3.119. 
Safety 
PAN1 
Summary of COVID-19 Assessments for Subjects with 
COVID-19 Adverse Events (Period 1) 
 
SAC[2] 
3.120. 
Safety - 
Subjects 
who 
Entered 
Period 2 
PAN1 
Summary of COVID-19 Assessments for Subjects with 
COVID-19 Adverse Events (Period 2) 
 
SAC[2] 
3.121. 
Safety 
PAN1 
Summary of COVID-19 Assessments for Subjects with 
COVID-19 Adverse Events (Period 1+2) 
 
SAC[2] 
3.122. 
Safety 
PAN2 
Summary of COVID-19 Additional Assessments for 
Subjects with COVID-19 Adverse Events (Period 1) 
 
SAC[2] 
3.123. 
Safety - 
Subjects 
who 
Entered 
Period 2 
PAN2 
Summary of COVID-19 Additional Assessments for 
Subjects with COVID-19 Adverse Events (Period 2) 
 
SAC[2] 
3.124. 
Safety 
PAN2 
Summary of COVID-19 Additional Assessments for 
Subjects with COVID-19 Adverse Events (Period 1+2) 
 
SAC[2] 
3.125. 
Safety 
PAN3 
Summary of COVID-19 Symptoms for Subjects with 
COVID-19 Adverse Events (Period 1) 
Remove “no” and “unknown” rows 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
144 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.126. 
Safety - 
Subjects 
who 
Entered 
Period 2 
PAN3 
Summary of COVID-19 Symptoms for Subjects with 
COVID-19 Adverse Events (Period 2) 
 
 
Remove “no” and “unknown” rows 
SAC[2] 
3.127. 
Safety 
PAN3 
Summary of COVID-19 Symptoms for Subjects with 
COVID-19 Adverse Events (Period 1+2) 
Remove “no” and “unknown” rows 
SAC[2] 
3.128. 
Safety 
Non-Standard 
SAFE_T13 
Summary of Adjudicated Serious Cases of COVID-19 
Infections (Period 1) 
 
SAC[2] 
3.129. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard 
SAFE_T13 
Summary of Adjudicated Serious Cases of COVID-19 
Infections (Period 2) 
 
SAC[2] 
3.130. 
Safety 
Non-Standard 
SAFE_T13 
Summary of Adjudicated Serious Cases of COVID-19 
Infections (Period 1+2) 
 
SAC[2] 
3.131. 
Safety 
Non-Standard 
SAFE_T15 
Summary of COVID-19 Infections (Period 1) 
 
SAC[2] 
3.132. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard 
SAFE_T15 
Summary of COVID-19 Infections (Period 2) 
 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
145 
 
Safety: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
3.133. 
Safety 
Non-Standard 
SAFE_T15 
Summary of COVID-19 Infections (Period 1+2) 
 
SAC[2] 
Additional Adverse Events 
3.134. 
Safety 
Non-Standard 
SAFE_T14 
Summary of Common (>=2%) Adverse Events by Time 
from Randomisation 
 
AAC[3] 
Exposure Adjusted SAEs 
3.135. 
Safety 
Non-Standard 
SAFE_T1 
Summary of Exposure Adjusted Event Rates per 100 
Person Years for Serious Adverse Events (Period 1) 
 
SAC[2] 
3.136. 
Safety - 
Subjects 
who 
Entered 
Period 2 
Non-Standard 
SAFE_T1 
Summary of Exposure Adjusted Event Rates per 100 
Person Years for Serious Adverse Events (Period 2) 
 
SAC[2] 
3.137. 
Safety 
Non-Standard 
SAFE_T1 
Summary of Exposure Adjusted Event Rates per 100 
Person Years for Serious Adverse Events (Period 1+2) 
 
SAC[2] 
 


 
CONFIDENTIAL 
 
 
201790 
 
146 
 
Safety Figures 
Safety: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Adverse Events 
3.1. 
Safety 
AE10 
Plot of Relative Risks for Common (>= 5%) Adverse 
Events  
 
SAC[2] 
3.2. 
Safety 
AE10 
Plot of Relative Risks for Adverse Events of Special 
Interest 
 
SAC[2] 
Laboratory: Chemistry, Hematology & Fasting Lipids 
3.3. 
Safety 
LB9 
Distribution of Laboratory Parameters of Interest by Time 
and Treatment with Maximum over Time 
 
SAC[2] 
Laboratory: Hepatobiliary (Liver) 
3.4. 
Safety 
LIVER14 
Scatter Plot of Maximum vs Baseline for ALT 
 
SAC[2] 
3.5. 
Safety 
LIVER9 
Scatter Plot of Maximum Total Bilirubin vs Maximum ALT 
 
SAC[2] 
Adverse Events (Treatment Policy Handling Strategy) 
3.6. 
Safety 
AE10 
Plot of Relative Risks for Common (>= 5%) Adverse 
Events (Treatment Policy Handling Strategy) 
 
AAC[3] 
3.7. 
Safety 
AE10 
Plot of Relative Risks for Adverse Events of Special 
Interest (Treatment Policy Handling Strategy) 
 
AAC[3] 
 


 
CONFIDENTIAL 
 
 
201790 
 
147 
 
Pharmacokinetic Tables 
Pharmacokinetic: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
148 
 
Biomarker Tables 
 Biomarker: Tables 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
149 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
150 
 
Biomarker Figures 
 Biomarker: Figures 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
151 
 
ICH Listings 
ICH: Listings 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Subject Disposition 
1.  
Randomised 
ES2  
Listing of Reasons for Study Withdrawal 
ICH E3 
SAC[2] 
2.  
Randomised 
SD2 
Listing of Reasons for Study Treatment Discontinuation 
ICH E3 
 
SAC[2] 
3.  
ITT 
BL1 
Listing of Subjects for Whom the Treatment Blind was 
Broken 
ICH E3 
 
SAC[2] 
Protocol Deviations 
4.  
ITT 
DV2 
Listing of Important Protocol Deviations  
ICH E3 
 
SAC[2] 
5.  
ITT 
IE3 
Listing of Subjects with Inclusion/Exclusion Criteria 
Deviations 
ICH E3 
SAC[2] 
Populations Analysed 
6.  
Enrolled 
SP3 
Listing of Subjects Excluded from Per Protocol Population 
ICH E3 
 
SAC[2] 
Demographic and Baseline Characteristics 
7.  
ITT 
DM2 
Listing of Demographic Characteristics 
ICH E3 
Include BMI in output. 
SAC[2] 
8.  
ITT 
DM9  
Listing of Race 
ICH E3 
SAC[2] 
Exposure and Treatment Compliance 
9.  
Safety 
EX3  
Listing of Exposure Data 
ICH E3 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
152 
 
ICH: Listings 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Adverse Events 
10.  
Safety 
AE8  
Listing of All Adverse Events 
ICH E3 
SAC[2] 
11.  
Safety 
AE14 
Listing of Reasons for Considering as a Serious Adverse 
Event 
ICH E3 
SAC[2] 
12.  
Safety 
DD3 
Death Subject Profile 
ICH E3 
SAC[2] 
All Laboratory 
13.  
Safety 
 
LB5A 
Listing of All Laboratory Data for Subjects with Any Value 
of Potential Clinical Importance 
ICH E3 
 
SAC[2] 
14.  
Safety 
UR2 
Listing of Urinalysis Data for Subjects with Any Value of 
Potential Clinical Importance 
ICH E3 
SAC[2] 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
153 
 
Non-ICH Listings 
Non-ICH: Listings 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Subject Disposition 
15.  
Screened 
ES7 
Listing of Reasons for Screen Failure 
BIMO Requirements 
SAC[2] 
Protocol Deviations 
16.  
ITT 
DV2 
Listing of Non-Important COVID-19 related Protocol 
Deviations 
COVID Requirements 
SAC[2] 
Prior and Concomitant Medications 
17.  
ITT 
CM3  
Listing of Prior and Concomitant Medications 
BIMO Requirements 
Include “medication taken for pain” 
SAC[2] 
18.  
ITT 
CM3 
Listing of Intra-Articular Corticosteroids 
Add columns for: 
• 
“medication taken for pain” 
• 
“Location of dose 
administration” 
• 
“Laterality” 
SAC[2] 
Adverse Events 
19.  
Safety 
AE7 
Listing of Subject Numbers for Individual Adverse Events 
Non-ICH Required 
SAC[2] 
20.  
Safety 
AE8XO  
Listing of Non-Fatal Serious Adverse Events 
Non-ICH Required 
Include “Action Taken with 
Background Therapy” 
SAC[2] 
21.  
Safety 
AE8XO 
Listing of Adverse Events Leading to Permanent 
Discontinuation of Study Treatment or Withdrawal from 
Study  
Non-ICH Required 
Include “Action Taken with 
Background Therapy” 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
154 
 
Non-ICH: Listings 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
22.  
Safety 
AE8XO  
Listing of Other Significant Adverse Events 
Non-ICH Required 
Include “Action Taken with 
Background Therapy” 
SAC[2] 
23.  
Safety 
AE8XO 
Listing of Adverse Events of Special Interest (AESI) 
Include “Action Taken with 
Background Therapy” 
SAC[2] 
24.  
Safety 
AE2 
Listing of Relationship Between Adverse Event System 
Organ Classes, Preferred Terms, and Verbatim Text 
BIMO Requirements 
SAC[2] 
25.  
Safety 
Non-Standard 
SAFE_L1 
Listing of Neutrophils and Associated Infections 
Select the following subgroup and add 
under the title: 
“Subset of Subjects who experienced 
grade 3 or 4 Neutropenia” 
SAC[2] 
26.  
Safety 
Non-Standard 
SAFE_L1 
Listing of Lymphocytes and Associated Infections 
Select the following subgroup and add 
under the title: 
“Subset of Subjects who experienced 
grade 3 or 4 Lymphopenia” 
SAC[2] 
Hepatobiliary (Liver) 
27.  
Safety 
LIVER15 
Listing of Liver Event Stopping Profile 
Non-ICH Required 
SAC[2] 
All Laboratory 
28.  
Safety 
LB5A 
Listing of All Local Laboratory Data 
COVID Requirements 
SAC[2] 


 
CONFIDENTIAL 
 
 
201790 
 
155 
 
Non-ICH: Listings 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
ECG 
29.  
Safety 
EG5 
Listing of All ECG Findings for Subjects with an Abnormal 
ECG Finding 
BIMO Requirements 
SAC[2] 
30.  
Safety 
EG3 
Listing of All ECG Values for Subjects with Any Value of 
Potential Clinical Importance 
BIMO Requirements 
SAC[2] 
Vital Signs 
31.  
Safety 
VS4 
Listing of All Vital Signs for Subjects with any Value of 
Potential Clinical Importance 
BIMO Requirements 
SAC[2] 
32.  
Safety 
PREG1 
Listing of Subjects Who Became Pregnant During the 
Study 
Non-ICH Required 
SAC[2] 
COVID-19 
34.  
ITT 
PAN7 
Listing of All Subjects with Visits and Assessments 
Impacted by COVID-19 Pandemic 
COVID Requirements 
SAC[2] 
35.  
Safety 
PAN12 
Listing of COVID-19 Assessments and Symptom 
Assessments for Subjects with COVID-19 Adverse 
Events 
COVID Requirements 
Include “Serious Event” 
SAC[2] 
36.  
Screened 
PAN5 
Listing of Start Dates of COVID-19 Pandemic Measures 
by Country  
COVID Requirements 
SAC[2] 
CCI


 
CONFIDENTIAL 
 
 
201790 
 
156 
 
Non-ICH: Listings 
No. 
Population 
IDSL / 
Example 
Shell 
Title  
Programming Notes 
Deliverable 
[Priority] 
Cardiovascular Event Listings (Conditionally required) 
37.  
Safety 
ARR1 
Arrhythmia Subject Profile 
Non-ICH Required 
AAC[3] 
38.  
Safety 
CHF1 
Congestive Heart Failure Subject Profile 
Non-ICH Required 
AAC[3] 
39.  
Safety 
CVATIA1 
Cerebrovascular Events/Stroke Subject Profile 
Non-ICH Required 
AAC[3] 
40.  
Safety 
DVT1 
Deep venous Thrombosis/ Pulmonary Embolism Subject 
Profile 
Non-ICH Required 
AAC[3] 
41.  
Safety 
MI1 
Myocardial Infarction /Unstable Angina Subject Profile 
Non-ICH Required 
AAC[3] 
42.  
Safety 
PATE1 
Peripheral Arterial Thrombosis Embolism Subject Profile 
Non-ICH Required 
AAC[3] 
43.  
Safety 
PUL1 
Pulmonary Hypertension Subject Profile 
Non-ICH Required 
AAC[3] 
44.  
Safety 
REV1 
Revascularization Subject Profile 
Non-ICH Required 
AAC[3] 
45.  
Safety 
VAL1 
Valvulopathy Subject Profile 
Non-ICH Required 
AAC[3] 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
157 
 
14.13. 
Appendix 13: Example Mock Shells for Data Displays 
Example: POP_T1 
Protocol: 201790                                                                                            Page 1 of n 
Population: Safety 
Table 1.1 
Summary of Subject Status and Subject Disposition for the Study Conclusion Record 
 
___________________________________________________________________________________________________________________________ 
                                       
Treatment 1   Treatment 2   Treatment 3   Treatment 4   Treatment 5  Treatment 6 
                                         
(N=xx)        (N=xx)        (N=xx)        (N=xx)        (N=xx)         (N=xx) 
Subject Status 
  Completed                               xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
    Completed Safety Follow up            xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
    Entered Long Term Extension           xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
     
  Withdrawn                               xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
    Withdrawn in Period 1 [1]      
  xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
    Withdrawn in Period 2 [2]      
xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
 
Primary Reason [3] for Study  
Withdrawal in Period 1 [1]      
  ADVERSE EVENT                           xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  LACK OF EFFICACY                        xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
  PROTOCOL DEVIATION                      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  PROTOCOL-SPECIFIED WITHDRAWAL           xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
  CRITERION MET 
  STUDY TERMINATED BY SPONSOR             xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  LOST TO FOLLOW-UP                       xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  PHYSICIAN DECISION                      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  INFORMED CONSENT WITHDRAWN              xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)  
  INVESTIGATOR SITE CLOSED                xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
   
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
158 
 
Example: POP_T1 (cntd.) 
Protocol: 201790                                                                                                Page 1 of n 
Population: Safety 
Table 1.1 
Summary of Subject Status and Subject Disposition for the Study Conclusion Record 
 
___________________________________________________________________________________________________________________________ 
                                         Treatment 1   Treatment 2   Treatment 3   Treatment 4   Treatment 5   Treatment 6 
                                           (N=xx)        (N=xx)        (N=xx)        (N=xx)        (N=xx)         (N=xx) 
 
Primary Reason [3] for Study  
Withdrawal in Period 2 [2]      
  ADVERSE EVENT                           xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  LACK OF EFFICACY                        xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
  PROTOCOL DEVIATION                      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  PROTOCOL-SPECIFIED WITHDRAWAL           xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
  CRITERION MET 
  STUDY TERMINATED BY SPONSOR             xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  LOST TO FOLLOW-UP                       xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  PHYSICIAN DECISION                      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  INFORMED CONSENT WITHDRAWN              xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)  
  INVESTIGATOR SITE CLOSED                xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
 
Outcome of Adverse Events Which 
Led to Study Withdrawal in Period 1 [1]  
  NON-FATAL                               xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  FATAL                                   xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
Outcome of Adverse Events Which 
Led to Study Withdrawal in Period 2 [2]  
  NON-FATAL                               xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  FATAL                                   xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
 
[1] Period 1 - up to 12 weeks, defined as time from randomisation and first dose of treatment up to dosing of Period 2 
treatment (Week 12) or date of study withdrawal or date of treatment withdrawal plus safety follow up whichever is earlier.  
[2] Period 2 – post week 12,  defined as time from first dose of treatment of period 2 (week 12) until date of study 
completion or date of study withdrawal or date of treatment withdrawal plus safety follow up whichever is earlier. 
[3] Subjects may have only one primary reason. 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
159 
 
Example: POP_T2 
Protocol: 201790                                                                                                Page 1 of n 
Population: Safety 
Table 1.x 
Summary of Treatment Status and Reasons for Discontinuation of Study Treatment 
 
___________________________________________________________________________________________________________________________ 
                                         Treatment 1   Treatment 2   Treatment 3   Treatment 4   Treatment 5   Treatment 6 
                                           (N=xx)        (N=xx)        (N=xx)        (N=xx)        (N=xx)         (N=xx) 
Treatment Status 
  Prematurely Discontinued Treatment      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
      Prematurely Discontinued Treatment  xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
      in Period 1 [1]         
      Prematurely Discontinued Treatment  xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
      in Period 2 [2]         
 
Primary Reason [3] for Treatment  
Discontinuation in Period 1 [1]      
  ADVERSE EVENT                           xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  LACK OF EFFICACY                        xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
  PROTOCOL DEVIATION                      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  PROTOCOL-SPECIFIED WITHDRAWAL           xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
  CRITERION MET 
  STUDY TERMINATED BY SPONSOR             xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  LOST TO FOLLOW-UP                       xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  PHYSICIAN DECISION                      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  WITHDRAWAL BY SUBJECT                   xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  SPONSOR TERMINATED STUDY                xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  TREATMENT 
  INVESTIGATOR SITE CLOSED                xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
160 
 
Example: POP_T2 (cntd.) 
Protocol: 201790                                                                                                Page 1 of n 
Population: Safety 
Table 1.x 
Summary of Treatment Status and Reasons for Discontinuation of Study Treatment 
 
___________________________________________________________________________________________________________________________ 
                                         Treatment 1   Treatment 2   Treatment 3   Treatment 4   Treatment 5   Treatment 6 
                                           (N=xx)        (N=xx)        (N=xx)        (N=xx)        (N=xx)         (N=xx) 
 
Primary Reason [3] for Treatment  
Discontinuation in Period 2 [2]      
  ADVERSE EVENT                           xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  LACK OF EFFICACY                        xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
  PROTOCOL DEVIATION                      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  PROTOCOL-SPECIFIED WITHDRAWAL           xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%) 
  CRITERION MET 
  STUDY TERMINATED BY SPONSOR             xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  LOST TO FOLLOW-UP                       xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  PHYSICIAN DECISION                      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  WITHDRAWAL BY SUBJECT                   xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  SPONSOR TERMINATED STUDY                xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
  TREATMENT 
  INVESTIGATOR SITE CLOSED                xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)      xx (xx%)       xx (xx%)    
 
 
[1] Treatment Discontinuation in Period 1- defined as time from first dose of treatment up to date of 
treatment withdrawal prior to week 12 dosing. 
[2] Treatment Discontinuation in Period 2- defined as time from first dose of treatment period 2 (week 12) 
until date of treatment withdrawal post week 12. 
[3] Subjects may have only one primary reason for treatment discontinuation. 
 


 
CONFIDENTIAL 
 
 
201790 
 
161 
 
Example: POP_T3 
Protocol: 201790                                                                                              Page 1 of n 
Population: Intent-to-Treat 
Table 1.x    
Baseline Efficacy Parameters 
 
 
 
Statistic 
Treatment 1 
(N=xx) 
Treatment 2  
(N=xx) 
Treatment 3 
(N=xx) 
Treatment 4 
(N=xx) 
 
 
 
 
 
 
Swollen Joint Count 28 
n 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
 
Minimum 
xx 
xx 
xx 
xx 
 
Maximum 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
Swollen Joint Count 66 
n 
xx 
xx 
xx 
xx 
 
Mean 
xx.x 
xx.x 
xx.x 
xx.x 
 
SD 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
Median 
xx.x 
xx.x 
xx.x 
xx.x 
 
Minimum 
xx 
xx 
xx 
xx 
 
Maximum 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
Tender Joint Count 28 
n 
xx 
xx 
xx 
xx 
 
… 
… 
… 
… 
… 
Tender Joint Count 68 
n 
xx 
xx 
xx 
xx 
 
… 
… 
… 
… 
… 
… 
n 
xx 
xx 
xx 
xx 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
162 
 
 
Example: POP_T4 
Protocol: 201790 Confidential                                                                                  Page 1 of n 
Population: Intent-to-Treat  
Table 1.x 
Summary of Rheumatoid Arthritis Disease History 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
Time since RA diagnosis (years) 
  n 
xx 
xx 
xx 
xx 
xx 
xx 
  Mean 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
  SD 
 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
  Median  
 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
  Min. 
 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
  Max. 
 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
Time since RA diagnosis 
  n 
 
xx 
xx 
xx 
xx 
xx 
xx 
  <= 2 years 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  >2-5 years 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  >5-10 years 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  >10 years 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  Missing 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 
RA functional class 
  n 
 
xx 
xx 
xx 
xx 
xx 
xx 
  I 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  II 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  III 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 
Time since start of RA symptoms (years) 
  n 
 
xx 
xx 
xx 
xx 
xx 
xx 
  Mean 
 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
  SD 
 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
  Median  
 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
  Min. 
 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
  Max. 
 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
Note: Time since RA diagnosis and start of RA symptoms is calculated up to date of first study medication administration. 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
163 
 
Example: POP_T4 (continued) 
Protocol: 201790 Confidential                                                                                  Page 2 of n 
Population: Intent-to-Treat  
Table 1.x 
Summary of Rheumatoid Arthritis Disease History 
 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
 
 
 
 
 
 
 
 
Baseline Anti-CCP Status 
  n 
 
xx 
xx 
xx 
xx 
xx 
xx 
  Positive  
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  Negative 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  Missing 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 
Baseline RF Status 
  n 
 
xx 
xx 
xx 
xx 
xx 
xx 
  Positive  
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  Negative 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  Missing 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 
Baseline Anti-CCP and RF Status 
  n 
 
xx 
xx 
xx 
xx 
xx 
xx 
  At Least one Positive  
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  Both Negative 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 
Note: Time since RA diagnosis and start of RA symptoms is calculated up to date of first study medication administration. 
 
 
 
 
 
 
 
 
 
 
 
Example: POP_T5 


 
CONFIDENTIAL 
 
 
201790 
 
164 
 
Protocol: 201790                                                                                              Page 1 of n 
Population: Intent-to-Treat 
Table 1.x 
Summary of Cardiovascular Risk Factors 
 
Age group: xxxxxx 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
 
 
 
 
 
 
 
 
History of Tobacco Use  
 
 
 
 
 
 
 
  n 
 
 xx 
 xx 
 xx 
 xx 
 xx 
 xx 
  Never smoked 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  Current Smoker 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  Former Smoker 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  Unknown 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 
 
 
 
 
 
 
 
If former smoker: Time between last  
smoking and assessment date (years) 
  n 
 
 xx 
 xx 
 xx 
 xx 
 xx 
 xx 
  Mean 
 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
  SD 
 
  x.xx 
  x.xx 
  x.xx 
  x.xx 
  x.xx 
  x.xx 
  Median  
 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
  Min. 
 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
  Max. 
 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
 
Family history of cardiovascular  
risk factors [1] 
  n 
 
 xx 
 xx 
 xx 
 xx 
 xx 
 xx 
  Yes 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  No 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  Unknown 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 
 
 
 
 
 
 
 
Angina Pectoris 
  n 
 
 xx 
 xx 
 xx 
 xx 
 xx 
 xx 
  Current 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  Past 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  No Medical History 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Note: [1] Family history of premature coronary artery disease in women <65 years or men < 55 years in first degree relatives 
only. 
Example: POP_T5 (continued) 


 
CONFIDENTIAL 
 
 
201790 
 
165 
 
Protocol: 201790                                                                                              Page 2 of n 
Population: Intent-to-Treat 
Table 1.x 
Summary of Cardiovascular Risk Factors 
Age group: xxxxxx 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
Diabetes mellitus 
  n 
 
 xx 
 xx 
 xx 
 xx 
 xx 
 xx 
  Current 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  Past 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  No Medical History 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 
 
 
 
 
 
 
 
Hyperlipidemia 
 
 
 
 
 
 
 
  n 
 
 xx 
 xx 
 xx 
 xx 
 xx 
 xx 
  Current 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  Past 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  No Medical History 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 
 
 
 
 
 
 
 
Hypertension 
  n 
 
 xx 
 xx 
 xx 
 xx 
 xx 
 xx 
  Current 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  Past 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  No Medical History 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 
 
 
 
 
 
 
 
Myocardial Infarction 
 
 
 
 
 
 
 
  n 
 
 xx 
 xx 
 xx 
 xx 
 xx 
 xx 
  Current 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  Past 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  No Medical History 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 
 
 
 
 
 
 
 
Stroke 
  n 
 
 xx 
 xx 
 xx 
 xx 
 xx 
 xx 
  Current 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  Past 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
  No Medical History 
 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
 xx (xx%) 
Note: [1] Family history of premature coronary artery disease in women < 65 years or men < 55 years in 
first degree relatives only. 
 
 
 
Example: POP_T6  


 
CONFIDENTIAL 
 
 
201790 
 
166 
 
Protocol: 201790                                                                                               Page 1 of n 
Population: Intent-to-Treat 
Table 1.x 
Summary of RA Concomitant Medications  
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
ANY MEDICATION 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
DMARDs 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  Methotrexate 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  Other csDMARDs (not methotrexate) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  csDMARDs >1 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  bsDMARDs/boDMARDs/tsDMARDs 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
Corticosteroids  
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  Oral 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  Intra-Articular 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
Other RA medications 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
Note: Concomitant medication is defined as any medication taken after the first dose of study treatment, regardless of whether 
it was started  prior to the first dose of study treatment or not.  
Note: For subjects that discontinued treatment, medications taken after the date of treatment discontinuation up to the end 
of safety follow up are also presented in this table.  
 
Example: POP_T7  


 
CONFIDENTIAL 
 
 
201790 
 
167 
 
Protocol: 201790                                                                                               Page 1 of n 
Population: Intent-to-Treat 
Table 1.x 
Summary of RA Prior Medications 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
ANY MEDICATION 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
DMARDs 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  Methotrexate 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  Other csDMARDs (not methotrexate) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  csDMARDs >1 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  bsDMARDs/boDMARDs/tsDMARDs 
 
 
 
 
    >=1 of bs/bo/tsDMARDs 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    =1 of bs/bo/tsDMARDs 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    >1 of bs/bo/tsDMARDs 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    Inadequate response to >=1 bs/boDMARD  
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    Inadequate response to >=1 tsDMARD  
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    Inadequate response to >1 bs/bo/tsDMARD 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
Oral corticosteroids  
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
Other RA medications 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
Note: Prior medication is defined as any medication that started before first dose of study treatment. 


 
CONFIDENTIAL 
 
 
201790 
 
168 
 
Example: POP_T8  
Protocol: 201790                                                                                               Page 1 of n 
Population: Intent-to-Treat 
Table 1.x 
Summary of RA Medications taken at Baseline (Day 1) 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
  Methotrexate 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  Other csDMARDs (not methotrexate) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
  csDMARDs >1 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
Methotrexate dose at baseline 
 
 
 
 
 
 
  n 
xx 
xx 
xx 
xx 
xx 
xx 
  No Methotrexate 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  <10mg/week 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
  >=10mg/week 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
Methotrexate dose at baseline (mg/week) 
 
 
 
 
 
 
  n 
xx 
xx 
xx 
xx 
xx 
xx 
  Mean 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
  SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
  Median  
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
  Min. 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
  Max. 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
 
 
 
 
 
 
 
Corticosteroids [1] 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
Corticosteroid dose at baseline 
(mg/day) [1] 
 
 
 
 
 
 
  n 
xx 
xx 
xx 
xx 
xx 
xx 
  Mean 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
  SD 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
x.xx 
  Median  
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
xxx.x 
  Min. 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
  Max. 
xxx 
xxx 
xxx 
xxx 
xxx 
xxx 
[1] Only includes subjects who have taken oral corticosteroids for at least 4 weeks prior to baseline 


 
CONFIDENTIAL 
 
 
201790 
 
169 
 
Example: POP_T9  
Protocol: 201790                                                                                               Page 1 of n 
Population: Intent-to-Treat 
Table 1.x 
Summary of Concomitant COVID-19 Vaccines 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
 Any Medication 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 PFIZER BIONTECH COVID-19 VACCINE 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 MODERNA COVID-19 VACCINE 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
170 
 
Example: POP_T10 
Protocol: 201790                                                                                                Page 1 of n 
Population: Safety 
Table 1.x 
Summary of Exposure to Study Treatment 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
 
 
 
 
 
 
 
Duration of drug exposure [injections] (days) 
 
 
  Period 1 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
  Period 2 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
 
 
 
 
 Period 1+2 
 
 
 
 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
171 
 
Example: POP_T10 (cntd.) 
Protocol: 201790                                                                                                Page 2 of n 
Population: Safety 
Table 1.x 
Summary of Exposure to Study Treatment 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
 
 
 
 
 
 
 
Number of injections 
 
 
  Period 1 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
  Period 2 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
 
 
 
 
  Period 1+2 
 
 
 
 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
172 
 
Example: POP_T10 (cntd.) 
Protocol: 201790                                                                                                Page 3 of n 
Population: Safety 
Table 1.x 
Summary of Exposure to Study Treatment 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
 
Number of injections 
  Period 1+2 
    1 - 12 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    13 - 24 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    25 - 40 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    > 40 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
 
Number of missed injections 
  Period 1 
 
 
    0 missed injections 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    1 missed injection 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    >1 missed injection 
    xx (xx% 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
 
  Period 2 
    0 missed injections 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    1 missed injection 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    >1 missed injection 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
 
 
 
 
 
 
 
  Period 1+2 
 
 
 
 
 
 
    0 missed injections 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    1 missed injection 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    >1 missed injection 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
173 
 
Example: POP_T10 (cntd.) 
Protocol: 201790                                                                                                Page 4 of n 
Population: Safety 
Table 1.x 
Summary of Exposure to Study Treatment 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
 
 
 
Duration of drug exposure [capsules] (days) 
 
 
  Period 1 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
  Period 2 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
 
 
 
 
  Period 1+2 
 
 
 
 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
174 
 
Example: POP_T10 (cntd.) 
Protocol: 201790                                                                                                Page 5 of n 
Population: Safety 
Table 1.x 
Summary of Exposure to Study Treatment 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
 
 
 
Number of capsules 
 
 
  Period 1 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
  Period 2 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
 
 
 
 
  Period 1+2 
 
 
 
 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
175 
 
Example: POP_T11 
Protocol: 201790                                                                                                Page 1 of n 
Population: Safety 
Table 1.x 
Summary of Overall Compliance Based on Exposure 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
Percent Overall Compliance [injections]  
 
 
  Period 1 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
  Period 2 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
  Period 1+2 
 
 
 
 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
 
 
 
 
 
Percent Overall Compliance [injections]=(Number of Actual Doses/Planned Treatment Duration in Weeks)*100. 
Percent Overall Compliance [capsules]=Number of Actual Doses/(Planned Treatment Duration in Weeks*14)*100. 
Planned Treatment Duration is 52 weeks, adjusted for early treatment discontinuation subjects. 
 


 
CONFIDENTIAL 
 
 
201790 
 
176 
 
Example: POP_T11 (cntd.) 
Protocol: 201790                                                                                                Page 2 of n 
Population: Safety 
Table 1.x 
Summary of Overall Compliance Based on Exposure 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
 
Overall Compliance Categories [injections] 
  Period 1 
    <80% 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    80-105% 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    >105% 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
  Period 2 
 
 
    <80% 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
    80-105% 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
    >105% 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
  Period 1+2 
    <80% 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
    80-105% 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
    >105% 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
 
 
 
 
 
 
 
 
Percent Overall Compliance [injections]=(Number of Actual Doses/Planned Treatment Duration in Weeks)*100. 
Percent Overall Compliance [capsules]=Number of Actual Doses/(Planned Treatment Duration in Weeks*14)*100. 
Planned Treatment Duration is 52 weeks, adjusted for early treatment discontinuation subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
177 
 
Example: POP_T11 (cntd.) 
Protocol: 201790                                                                                                Page 3 of n 
Population: Safety 
Table 1.x 
Summary of Overall Compliance Based on Exposure 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
Percent Overall Compliance [capsules]  
 
 
  Period 1 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
  Period 2 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
  Period 1+2 
 
 
 
 
 
 
    n 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Mean 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    SD 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    xx.xx 
    Median 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    xx.x 
    Min. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
    Max. 
    xx 
    xx 
    xx 
    xx 
    xx 
    xx 
 
 
 
 
 
 
 
 
Percent Overall Compliance [injections]=(Number of Actual Doses/Planned Treatment Duration in Weeks)*100. 
Percent Overall Compliance [capsules]=Number of Actual Doses/(Planned Treatment Duration in Weeks*14)*100. 
Planned Treatment Duration is 52 weeks, adjusted for early treatment discontinuation subjects. 
 


 
CONFIDENTIAL 
 
 
201790 
 
178 
 
Example: POP_T11 (cntd.) 
Protocol: 201790                                                                                                Page 4 of n 
Population: Safety 
Table 1.x 
Summary of Overall Compliance Based on Exposure 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
 
Overall Compliance Categories [capsules] 
  Period 1 
    <80% 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    80-105% 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    >105% 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
  Period 2 
 
 
    <80% 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
    80-105% 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
    >105% 
    xx(xx% 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
  Period 1+2 
    <80% 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
    80-105% 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
    >105% 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
 
 
 
 
 
 
 
 
Percent Overall Compliance [injections]=(Number of Actual Doses/Planned Treatment Duration in Weeks)*100. 
Percent Overall Compliance [capsules]=Number of Actual Doses/(Planned Treatment Duration in Weeks*14)*100. 
Planned Treatment Duration is 52 weeks, adjusted for early treatment discontinuation subjects. 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
179 
 
 
Example: POP_T11 (cntd.) 
Protocol: 201790                                                                                                Page 5 of n 
Population: Safety 
Table 1.x 
Summary of Overall Compliance Based on Exposure 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
 
Overall Compliance [injections and capsules] >=80% 
  Period 1 
    Yes 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
    No 
    xx (xx%) 
    xx (xx%) 
    xx (xx%) 
   xx (xx%) 
    xx (xx%)   xx (xx%) 
  Period 2 
 
 
    Yes 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
    No 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
  Period 1+2 
    Yes 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
    No 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
    xx(xx%) 
  xx(xx%) 
 
 
 
 
 
 
 
 
Percent Overall Compliance [injections]=(Number of Actual Doses/Planned Treatment Duration in Weeks)*100. 
Percent Overall Compliance [capsules]=Number of Actual Doses/(Planned Treatment Duration in Weeks*14)*100. 
Planned Treatment Duration is 52 weeks, adjusted for early treatment discontinuation subjects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
180 
 
Example: POP_T12 
Protocol: 201790                                                                                                Page 1 of n 
Population: Intent-to-Treat 
Table 1.x 
Summary of Neuropathic Pain Component as Identified by the Pain DETECT Questionnaire 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
Total 
N=xx 
 
 
Screening Result 
 
 
 
 
 
 
 
   n 
   xx 
   xx 
   xx 
   xx 
   xx 
   xx 
   xx 
   Neuropathic 
   xx (xx%) 
   xx (xx%) 
   xx (xx%) 
   xx (xx%) 
   xx (xx%) 
   xx (xx%)    xx (xx%) 
   Nociceptive 
   xx (xx%) 
   xx (xx%) 
   xx (xx%) 
   xx (xx%) 
   xx (xx%) 
   xx (xx%)    xx (xx%) 
   Unclear 
   xx (xx%) 
   xx (xx%) 
   xx (xx%) 
   xx (xx%) 
   xx (xx%) 
   xx (xx%)    xx (xx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
181 
 
Example: EFF_T1 
Protocol: 201790 Confidential                                                                   Page 1 of n 
Population: Intent-To-Treat                                     
Table 2.x  
Summary and Analysis of the Proportion of Subjects Achieving [ACR20/CDAI-LDA/…] at Each Assessment Visit 
Visit: Week X 
Statistic 
Pooled PBO 
(N=xx) 
OTI 90mg QW 
(N=xx) 
OTI 150mg QW 
(N=xx) 
TOFA 5mg BID 
(N=xx) 
PBO to OTI 
90mg QW 
(N=xx) 
PBO to OTI 
150mg QW 
(N=xx) 
PBO to TOFA 
5mg BID 
(N=xx) 
 
 
 
 
 
 
 
 
%Responders  
xx.x 
xx.x 
xx.x 
xx.x 
 
 
 
SE %Responders 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
 
 
 
 
 
 
 
 
 
 
Difference vs. 
Pooled PBO (%) 
 
xx.x 
xx.x 
xx.x 
 
 
 
  95% CI (%) 
 
(xx.x, xx.x) 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
 
 
 
 
 
 
 
 
 
Difference vs. 
TOFA(%) 
xx.x 
xx.x 
xx.x 
 
 
 
 
  95% CI (%) 
(xx.x, xx.x) 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
 
 
 
 
 
 
 
 
 
 
Odds Ratio vs. 
Pooled PBO 
 
xx.x 
xx.x 
xx.x 
 
 
 
  95% CI (%) 
 
(xx.x, xx.x) 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
 
  p-value 
 
0.xxxx 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
 
 
 
 
 
Odds Ratio vs. 
TOFA 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
 
   95% CI (%) 
(xx.x, xx.x) 
(xx.x, xx.x) 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
 
   p-value 
0.xxxx 
0.xxxx 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
 
 
 
 
 
Note: All estimates are produced following multiple imputation specified for the [primary estimand/supplemental estimand 
1/supplemental estimand 2]. 
Note: Positive differences and Odds Ratios >1 indicate an improvement of treatment over placebo or tofacitinib. 
Note: 95% confidence intervals for the difference to placebo and tofacitinib are constructed using asymptotic Wald confidence 
limits without correction. 
Note: Odds Ratios and corresponding 95% confidence intervals for odds ratios are generated from the logistic regression 
model  adjusted for [Baseline Value] and Treatment Group. 
Note: Placebo switch treatment arms will only be displayed after Week 12. 
 


 
CONFIDENTIAL 
 
 
201790 
 
182 
 
Example: EFF_T2 
Protocol: 201790 Confidential                                                                    Page 1 of n 
Population: Intent-To-Treat                                     
Table 2.x  
Summary of Observed [ACR20] Response at Each Assessment Visit 
Parameter: XXX [optional] 
 
Note: N is the number of subjects with non-missing data at that visit 
 
 
 
 
 
Pooled PBO 
(N=xx) 
OTI 90mg QW 
(N=xx) 
OTI 150mg QW 
(N=xx) 
TOFA 5mg BID 
(N=xx) 
PBO to OTI 
90mg QW 
(N=xx) 
PBO to OTI 
150mg QW 
(N=xx) 
PBO to TOFA 
5mg BID 
(N=xx) 
 
 
 
 
 
 
 
 
Week 1 
 
 
 
 
 
 
 
   N 
xx 
xx 
xx 
xx 
 
 
 
   n(%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 
 
 
 
Week 2 
 
 
 
 
 
 
 
   N 
xx 
xx 
xx 
xx 
 
 
 
   n(%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 
 
 
 
Week 3 
 
 
 
 
 
 
 
   N 
xx 
xx 
xx 
xx 
 
 
 
   n(%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 
 
 
 
… 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Week 13 
 
 
 
 
 
 
 
   N 
 
xx 
xx 
xx 
xx 
xx 
xx 
n(%) 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 
… 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
183 
 
Example: EFF_T3 
Protocol: 201790 Confidential                                                                    Page 1 of n 
Population: Intent-To-Treat                                     
Table 2.x  
Analysis of Change from Baseline in [HAQ-DI/CDAI Total/…] at Each Assessment Visit [(Primary Estimand)] 
 
 
 
 
Visit: Week X 
Statistic 
Pooled PBO 
(N=xx) 
OTI 90mg QW 
(N=xx) 
OTI 150mg QW 
(N=xx) 
TOFA 5mg BID 
(N=xx) 
PBO to OTI 
90mg QW 
(N=xx) 
PBO to OTI 
150mg QW 
(N=xx) 
PBO to TOFA 
5mg BID 
(N=xx) 
 
 
 
 
 
 
 
 
LS Mean Change 
xx.x 
xx.x 
xx.x 
xx.x 
 
 
 
Standard Error 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
 
 
 
 
 
 
 
 
 
 
LS Mean Difference 
from Pooled PBO 
 
xx.x 
xx.x 
xx.x 
 
 
 
  95% CI  
 
(xx.x, xx.x) 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
 
  p-value 
 
0.xxxx 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
 
 
 
 
 
LS Mean Difference 
from TOFA 
xx.x 
xx.x 
xx.x 
 
 
 
 
   95% CI  
(xx.x, xx.x) 
(xx.x, xx.x) 
(xx.x, xx.x) 
 
 
 
 
   p-value 
0.xxxx 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
 
 
 
 
 
 
Note: All estimates are produced following multiple imputation specified for the [primary estimand/supplemental estimand 
1/supplemental estimand 2] 
Note: All estimates are obtained from an ANCOVA analysis adjusted for Baseline Value and Treatment Group. 
Note: Placebo switch treatment arms will only be displayed after Week 12. 


 
CONFIDENTIAL 
 
 
201790 
 
184 
 
Example: EFF_T4 
Protocol: 201790 Confidential                                                                   Page 1 of n 
Population: Intent-To-Treat                                     
Table 2.x  
Summary of Observed [Result/Change from Baseline] in [HAQ-DI/CDAI Total/…] at Each Assessment Visit 
 
Parameter: XXXX [optional] 
 
 
 
 
 
Treatment 
Visit 
n 
Mean 
SD 
95% CI 
Median 
Min. 
Max. 
Pooled PBO (N=xx) 
Baseline 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
Week 1 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
… 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
 
OTI 90mg QW 
(N=xx) 
Baseline 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
Week 1 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
… 
… 
… 
… 
… 
… 
… 
… 
 
Week 13 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
Week 16 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
… 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
 
… 
… 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
 
PBO to OTI 90mg QW 
(N=xx) 
Baseline 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
Week 13 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
Week 16 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
… 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
 
… 
… 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
185 
 
Example: EFF_T5 
Protocol: 201790 Confidential                                                                    Page 1 of n 
Population: Intent-To-Treat                                     
Table 2.x  
Summary of Ratio to Baseline in [CRP] at Each Assessment Visit (Log Transformed) 
 
Parameter: XXXX 
 
 
 
Treatment 
Visit 
n 
Geometric Mean 
%CVb 
95% CI 
Median 
Min. 
Max. 
Pooled PBO (N=xx) 
Baseline 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
Week 1 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
 
 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
… 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
 
OTI 90mg QW 
(N=xx) 
Baseline 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
Week 1 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
 
 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
… 
… 
… 
… 
… 
… 
… 
… 
 
Week 13 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
 
 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
 
 
 
 
 
 
 
 
 
Week 16 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
 
 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
… 
… 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
 
PBO to OTI 90mg 
QW (N=xx) 
Baseline 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
Week 13 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
 
 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
 
 
 
 
 
 
 
 
 
Week 16 
xx 
xx.x 
xx.xx 
(xx.x,xx.x) 
xx.x 
xx 
xx 
 
… 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
186 
 
Example: EFF_T6 
Protocol: 201790 Confidential                                                                    Page 1 of n 
Population: Intent-To-Treat                                     
Table 2.x  
Summary of Observed [ACR20] Response Within 4/8/12/16/24/>24 Weeks Post Baseline 
 
 
 
 
 
 
Achieved Response 
Pooled PBO 
(N=xx) 
OTI 90mg QW 
(N=xx) 
OTI 150mg QW 
(N=xx) 
TOFA 5mg BID 
(N=xx) 
 
 
 
 
 
Within 4 weeks 
 
 
 
 
   n(%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
Within 8 weeks 
 
 
 
 
   n(%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
Within 12 weeks 
 
 
 
 
   n(%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
Within 16 weeks 
 
 
 
 
n(%) 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
Within 24 weeks 
 
 
 
 
   n(%) 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
Within >24 weeks 
 
 
 
 
   n(%) 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
187 
 
 
 
Example: EFF_T7 
Protocol: 201790 Confidential                                                                    Page 1 of n 
Population: Intent-To-Treat                                     
Table 2.x  
Summary of Observed Maintained [ACR20] Response for 12/24/36 Weeks After the First Occurrence 
 
 
 
 
 
 
 
 
 
Note: If a subject has at most two non-consecutive visits with missing response data within the 12 week window after first 
occurrence of response and the subject was in response for all other visits, then the subject will be considered to have 
maintenance of response. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Maintained Response 
OTI 90mg QW 
(N=xx) 
OTI 150mg QW 
(N=xx) 
TOFA 5mg BID 
(N=xx) 
 
 
 
 
For 12 weeks 
 
 
 
   n(%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
For 24 weeks 
 
 
 
   n(%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
For 36 weeks 
 
 
 
   n(%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
188 
 
Example: EFF_T8 
Protocol: 201790 Confidential                                                                    Page 1 of n 
Population: Intent-To-Treat                                     
Table 2.x  
 Analysis of Time to Onset of [ACR20] Response 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[1] Statistics will be missing when the number of events is too low to estimate the values from the 
survival function. 
[2] A hazard ratio <1 indicates a lower risk with this treatment compared with tofacitinib. Hazard Ratio is 
adjusted for [Baseline Value]. 
[3] Among subjects achieving response. 
 
 
 
 
OTI 90mg QW 
(N=xx) 
OTI 150mg QW 
(N=xx) 
TOFA 5mg BID 
(N=xx) 
 
 
 
 
Number of Subjects 
 
 
 
   n 
xx  
xx  
xx  
   Endpoint (ACR20) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
   Censored 
xx (xx%) 
xx (xx%) 
xx (xx%) 
      Early Study Withdrawal 
xx (xx%) 
xx (xx%) 
xx (xx%) 
      Study Completion 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
Estimate for Time to ACR20 (Weeks) [1] 
 
 
 
   1st Quartile 
xx.x 
xx.x 
xx.x 
   Median 
xx.x 
xx.x 
xx.x 
   3rd Quartile 
xx.x 
xx.x 
xx.x 
 
 
 
 
Adjusted Hazard Ratio [2] 
 
 
 
   Estimate 
x.xx 
x.xx 
x.xx 
   95% CI 
(x.xx, x.xx) 
(x.xx, x.xx) 
(x.xx, x.xx) 
   p-value 
0.xxx 
0.xxx 
0.xxx 
 
 
 
 
Estimate for Time to ACR20 (Weeks) [3] 
 
 
 
   1st Quartile 
xx.x 
xx.x 
xx.x 
   Median 
xx.x 
xx.x 
xx.x 
   3rd Quartile 
xx.x 
xx.x 
xx.x 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
189 
 
Example: EFF_F1 
Protocol: 201790 Confidential                                                                       Page 1 of n 
Population: Intent-to-Treat                                     
Figure 2.x  
Proportion of Subjects Achieving [ACR20/50/70 Response] at Each Assessment Visit [(Primary Estimand)] 
 
Note: All estimates are produced following multiple imputation specified for the [primary estimand/supplemental estimand 
1/supplemental estimand 2] 
 


 
CONFIDENTIAL 
 
 
201790 
 
190 
 
Example: EFF_F2 
Protocol: 201790 Confidential                                                                       Page 1 of n 
Population: Intent-to-Treat                                     
Figure 2.x  
Plot of Least Squares Means of Change from Baseline in [HAQ-DI/CDAI Total Score/…] at Each Assessment Visit 
[(Primary Estimand)] 
 
Note: All estimates are produced following multiple imputation specified for the [primary estimand/supplemental estimand 
1/supplemental estimand 2] 
Note: All estimates are obtained from an ANCOVA analysis adjusted for Baseline Value and Treatment Group. 
 


 
CONFIDENTIAL 
 
 
201790 
 
191 
 
Example: EFF_F3 
Protocol: 201790 Confidential                                                                       Page 1 of n 
Population: Intent-to-Treat                                     
Figure 2.x  
Spydergram of Individual Domain Scores of SF-36 at Each Assessment Visit 
 


 
CONFIDENTIAL 
 
 
201790 
 
192 
 
Example: EFF_F4 
Protocol: 201790 Confidential                                                                       Page 1 of n 
Population: Intent-to-Treat                                     
Figure 2.x  
Forest Plot of [Demographic] Subgroup Results for [ACR20] – Comparison to [Placebo at Week 12] 
 
Note: Odds Ratios (OR) >1 indicate an improvement of treatment over [placebo]. 
Note: All estimates are produced following multiple imputation specified for the primary estimand. 
Note: Odds Ratios and corresponding 95% confidence intervals for odds ratios are generated from the logistic 
regression model adjusted for [Baseline Value] and Treatment Group. 
 


 
CONFIDENTIAL 
 
 
201790 
 
193 
 
Example: EFF_F5 
Protocol: 201790 Confidential                                                                       Page 1 of n 
Population: Intent-to-Treat                                     
Figure 2.x  
Forest Plot of [Demographic] Subgroup Results for Change from Baseline in [HAQ-DI] – Comparison to [Placebo at 
Week 12] 
 
Note: LSM= Least Squares Means, SE= Standard Error. 
Note: All estimates are produced following multiple imputation specified for the primary estimand. 
Note: All estimates are obtained from an ANCOVA analysis adjusted for Baseline Value and Treatment Group. 
 


 
CONFIDENTIAL 
 
 
201790 
 
194 
 
 
Example: EFF_F6 
Protocol: 201790 Confidential                                                                       Page 1 of n 
Population: Intent-to-Treat                                     
Figure 2.x  
Proportion of Subjects Achieving Maintained [ACR50 Response] for At Least 12/24/36 Weeks After the First 
Occurrence 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
195 
 
 
 
Example: EFF_F7 
Protocol: 201790 Confidential                                                                       Page 1 of n 
Population: Intent-to-Treat                                     
Figure 2.x  
Cumulative Probability Plots of Individual Subject Changes from Baseline in [mTSS] at Each Assessment Visit 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
196 
 
 
 
Example: BIOM_T1 
Protocol: 201790 Confidential                                                                       Page 1 of n 
Population: Intent-to-Treat                                     
Table 5.x  
Summary of Observed [Result/Change from Baseline] in [Pharmacodynamic Biomarkers/…] at Each Assessment Visit 
 
Parameter: XXXX 
Note: Values reported below lower limit of quantification were replaced by one-half the limit of quantification. 
 
 
 
 
 
 
 
Treatment 
Visit 
n 
Mean 
SD 
Median 
(Q1, Q3) 
Min 
Max 
Pooled PBO (N=xx) 
Baseline 
xx 
xx.x 
xx.xx 
xx.x 
(xx.x,xx.x) 
xx 
xx 
 
Week 1 
xx 
xx.x 
xx.xx 
xx.x 
(xx.x,xx.x) 
xx 
xx 
 
… 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
 
OTI 90mg QW 
(N=xx) 
Baseline 
xx 
xx.x 
xx.xx 
xx.x 
(xx.x,xx.x) 
xx 
xx 
 
Week 1 
xx 
xx.x 
xx.xx 
xx.x 
(xx.x,xx.x) 
xx 
xx 
 
… 
… 
… 
… 
… 
… 
… 
… 
 
Week 13 
xx 
xx.x 
xx.xx 
xx.x 
(xx.x,xx.x) 
xx 
xx 
 
Week 16 
xx 
xx.x 
xx.xx 
xx.x 
(xx.x,xx.x) 
xx 
xx 
 
… 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
 
… 
… 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
 
PBO to OTI 90mg QW 
(N=xx) 
Baseline 
xx 
xx.x 
xx.xx 
xx.x 
(xx.x,xx.x) 
xx 
xx 
 
Week 13 
xx 
xx.x 
xx.xx 
xx.x 
(xx.x,xx.x) 
xx 
xx 
 
Week 16 
xx 
xx.x 
xx.xx 
xx.x 
(xx.x,xx.x) 
xx 
xx 
 
… 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
 
… 
… 
… 
… 
… 
… 
… 
… 
… 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
197 
 
Example: BIOM_T2 
Protocol: 201790 Confidential                                                                       Page 1 of n 
Population: Intent-to-Treat                                     
Table 5.x  
Repeated Measures Analysis of Change from Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit 
([Placebo/Tofacitinib] Comparison) 
 
 
 
 
 
 
 
 
[1] Number of subjects with analysable data at the given timepoint. 
Note: All estimates are obtained from an MMRM analysis adjusted for Baseline Value, Treatment Group, Visit and Treatment 
Group by Visit. 
 
 
 
 
 
Biomarker: [Chemokine (C-C Motif) Ligand 17] 
Visit: Week 1 
Statistic 
Pooled PBO 
N=xx 
OTI 90mg QW 
N=xx 
OTI 150mg QW 
N=xx 
TOFA 5mg BID 
N=xx 
 
 
 
 
 
n [1] 
      xx 
      xx 
      xx 
     xx 
 
 
 
 
 
LS Mean Change 
xx.x 
xx.x 
xx.x 
xx.x 
Standard Error 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
 
 
 
 
LS Mean Difference from 
Pooled PBO 
 
xx.x 
xx.x 
xx.x 
  95% CI  
 
(xx.x, xx.x) 
(xx.x, xx.x) 
(xx.x, xx.x) 
  p-value 
 
0.xxxx 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
198 
 
 
Example: BIOM_T3 
Protocol: 201790 Confidential                                                                       Page 1 of n 
Population: Intent-to-Treat                                     
Table 5.x  
Repeated Measures Analysis of Change from Baseline in Pharmacodynamic Biomarkers at Each Assessment Visit 
([Placebo/Tofacitinib] Comparison) (Log Transformed) 
 
 
 
 
 
 
 
 
[1] Number of subjects with analysable data at the given timepoint. 
Note: All estimates are obtained from an MMRM analysis adjusted for Baseline Value, Treatment Group, Visit and Treatment 
Group by Visit. 
 
 
 
 
 
Biomarker: [Chemokine (C-C Motif) Ligand 17] 
Visit: Week 1 
Statistic 
Pooled PBO 
N=xx 
OTI 90mg QW 
N=xx 
OTI 150mg QW 
N=xx 
TOFA 5mg BID 
N=xx 
 
 
 
 
 
n [1] 
      xx 
      xx 
      xx 
     xx 
 
 
 
 
 
LS Geometric Mean 
xx.x 
xx.x 
xx.x 
xx.x 
%CVb 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
 
 
 
 
Ratio to Pooled PBO 
 
xx.x 
xx.x 
xx.x 
  95% CI  
 
(xx.x, xx.x) 
(xx.x, xx.x) 
(xx.x, xx.x) 
  p-value 
 
0.xxxx 
0.xxxx 
0.xxxx 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
199 
 
 
Example: AE13 (modified) 
Protocol: 201790                                                                                                Page 1 of n 
Population: Safety 
                                                              
Table 3.x 
Overall Summary of Adverse Events (Period X) 
 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
 
 
 
 
 
Any AE 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
AEs related to study treatment 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    AEs leading to discontinuation of 
study treatment only 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
AEs leading to discontinuation of 
background therapy only 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
AEs leading to discontinuation of 
both study treatment and background 
therapy  
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
AEs leading to dose 
interruption/delay of study treatment 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
AEs leading to dose 
interruption/delay of background 
therapy 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
AEs leading to dose reduction of 
background therapy 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
Any SAE 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
SAEs related to study treatment 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
Fatal SAEs 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
Fatal SAEs related to study treatment 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
Any SAE excluding COVID-19 Infections 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
SAEs excluding COVID-19 Infections 
related to study treatment 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
Fatal SAEs excluding COVID-19 
Infections 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
Fatal SAEs excluding COVID-19 
Infections related to study treatment 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
200 
 
Example: SAFE_T1 
Protocol: 201790                                                                                                Page 1 of n 
Population: Safety 
                                                              
Table 3.x 
Summary of Exposure Adjusted Event Rates per 100 years for All Adverse Events (Period X) 
 
 
System Organ Class 
  Preferred Term 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Treatment 4 
N=xx 
 
 
 
 
 
Total Treatment Exposure (person-years) 
xx.xx 
xx.xx 
xx.xx 
xx.xx 
 
 
 
 
 
Any Adverse Event 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
 
 
 
 
 
Infections and Infestations 
  Any Adverse Event 
  Nasopharyngitis 
  Upper Respiratory Tract 
  Infection 
  Bronchitis 
  Pharyngitis 
  Rhinitis 
  Oral Herpes 
  Viral Infection 
 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
 
 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
xx.x [xx] 
 
Note: The rate and number of events "Rate [#]" are reported in this table. #= Number of events. 
Note: Rate is event rate per 100 person-years, calculated as the number of events multiplied by 100, divided by the total 
treatment exposure in years. 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
201 
 
 
Example: SAFE_T2 
Protocol: 201790                                                                                                Page 1 of n 
Population: Safety 
                                                              
Table 3.x 
Summary of Adverse Events of Special Interest (AESI) (Period X)  
 
 
Treatment 1 
N=xx 
 n (%) [#] 
Treatment 2 
N=xx 
 n (%) [#] 
Treatment 3 
N=xx 
 n (%) [#] 
Treatment 4 
N=xx 
 n (%) [#] 
Treatment 5 
N=xx 
 n (%) [#] 
Treatment 6 
N=xx 
 n (%) [#] 
 
Any AESI 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
x (x) [x] 
x (x) [x] 
 
Serious infections 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
x (x) [x] 
x (x) [x] 
Serious infections excluding 
COVID-19 Infections 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
x (x) [x] 
x (x) [x] 
Opportunistic infections 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
x (x) [x] 
x (x) [x] 
  Active TB   
  Latent TB 
TB reactivation 
  x (x) [x]   
  x (x) [x] 
  x (x) [x]    
  x (x) [x]   
  x (x) [x] 
  x (x) [x] 
  x (x) [x]   
  x (x) [x] 
  x (x) [x] 
  x (x) [x]   
  x (x) [x] 
  x (x) [x] 
x (x) [x] 
x (x) [x] 
x (x) [x] 
x (x) [x] 
x (x) [x] 
x (x) [x] 
Neutropenia 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
x (x) [x] 
x (x) [x] 
Persistent cough 
Persistent dyspnoea  
Pulmonary alveolar proteinosis 
Serious Hypersensitivity 
reactions 
Injection site reaction 
  x (x) [x] 
  x (x) [x] 
  x (x) [x]   
  x (x) [x] 
 
  x (x) [x] 
  x (x) [x] 
  x (x) [x]    
  x (x) [x] 
  x (x) [x] 
 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x]   
  x (x) [x] 
 
  x (x) [x] 
x (x) [x] 
x (x) [x] 
x (x) [x] 
x (x) [x] 
 
x (x) [x] 
x (x) [x] 
x (x) [x] 
x (x) [x] 
x (x) [x] 
 
x (x) [x] 
 
Note: n=number of subjects with at least one event. #=number of individual occurrences.  
Note: Persistent cough or persistent dyspnoea defined as a cough (CTACE Grade >= 2) or a dyspnoea (dyspnoea scale Grade >= 
2) for three consecutive weeks (>=21 days). 
Note: Neutropenia is defined as AEs/SAEs of neutropenia where the corresponding absolute neutrophil counts are grade 3 or 4 
(<1.0 X 10^9/L). 
Note: Opportunistic infections, Active TB, Latent TB, TB reactivation events, serious hypersensitivity reactions and 
pulmonary alveolar proteinosis have been adjudicated and only adjudicated events displayed in the summary table. 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
202 
 
 
Example: SAFE_T3 
Protocol: 201790                                                                                                Page 1 of n 
Population: Safety                                        Table 3.x 
Summary of Other Important Adverse Events (Period X) 
 
 
Treatment 1 
N=xx 
 n (%) [#] 
Treatment 2 
N=xx 
 n (%) [#] 
Treatment 3 
N=xx 
 n (%) [#] 
Treatment 4 
N=xx 
 n (%) [#] 
 
 
Any Other Important AEs 
 
Adjudicated GI Perforation 
 
Adjudicated CV Events 
 
  CV Death             
 
  Myocardial Infarction 
 
  Hospitalisation for Unstable Angina 
 
  Stroke 
 
  Hospitalisation for Heart Failure   
 
  Deep Vein Thrombosis 
 
  Pulmonary Embolism 
 
Any Malignancy 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
  
 
   Solid, Excluding Non-melanoma Skin Cancer   x (x) [x]     x (x) [x] 
x (x) [x] 
x (x) [x] 
 
    Non-melanoma Skin Cancer 
x (x) [x] 
x (x) [x] 
x (x) [x] 
 x (x) [x] 
 
 
Hematologic                                 x (x) [x]     x (x) [x]       x (x) [x]      x (x) [x] 
 
    Lymphoma 
x (x) [x]     x (x) [x]       x (x) [x] 
x (x) [x] 
 
Note: n=number of subjects with at least one event. #=number of individual occurrences. 
Note: A subject can have an event in more than one category. 


 
CONFIDENTIAL 
 
 
201790 
 
203 
 
Note: Fatal CV events are captured in two categories, respective CV category and CV death. 
Example: SAFE_T3 (continued) 
Protocol: 201790                                                                                                Page 2 of n 
Population: Safety                                          Table 3.x 
Summary of Other Important Adverse Events (Period X)  
 
 
Treatment 1 
N=xx 
 n (%) [#] 
Treatment 2 
N=xx 
 n (%) [#] 
Treatment 3 
N=xx 
 n (%) [#] 
Treatment 4 
N=xx 
 n (%) [#] 
 
 
 
 Any malignancy, Excluding Non-melanoma Skin  
Cancer 
 
 Any Herpes Infection 
 
  Herpes Zoster 
 
  Herpes Simplex 
 
  Non-Specific Herpes Infection             
 
All-Cause Mortality 
 
Serious Pulmonary Infections 
 
Serious Pulmonary Infections excluding 
COVID-19 Infections 
 
Pneumonia (Serious and Non-Serious) 
 
Pneumonia (Serious and Non-Serious) 
excluding COVID-19 Infections 
 
Hepatitis B and Hepatitis B Reactivation   
 
  Thromboembolic Events 
 
 
x (x) [x] 
 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
 
x (x) [x] 
 
  x (x) [x] 
 
 
x (x) [x] 
 
  x (x) [x] 
 
x (x) [x] 
x (x) [x] 
 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
 
x (x) [x] 
 
x (x) [x] 
 
 
x (x) [x] 
 
   x (x) [x] 
 
x (x) [x] 
x (x) [x] 
 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
 
x (x) [x] 
 
x (x) [x] 
 
 
x (x) [x] 
 
   x (x) [x] 
 
x (x) [x] 
x (x) [x] 
 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
 
x (x) [x] 
 
x (x) [x] 
 
 
x (x) [x] 
 
   x (x) [x] 
 
x (x) [x] 
  
Note: n=number of subjects with at least one event. #=number of individual occurrences. 
Note: A subject can have an event in more than one category. 


 
CONFIDENTIAL 
 
 
201790 
 
204 
 
Note: Fatal CV events are captured in two categories, respective CV category and CV death. 
 
Example: SAFE_T4 
Protocol: 201790                                                                                                Page 1 of n 
Population: Safety 
Table 3.x 
Summary of Adjudicated Cardiovascular Event Categories (Period X) 
 
 
Treatment 1 
N=xx 
 n (%) [#] 
Treatment 2 
N=xx 
 n (%) [#] 
Treatment 3 
N=xx 
 n (%) [#] 
Treatment 4 
N=xx 
 n (%) [#] 
 
 
 
Any Adjudicated CV Event 
 
MACE 
 
Broad MACE 
 
VTE (DVT and/or PE) 
 
DVT only 
 
  PE only 
 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
x (x) [x] 
 
 
  
 
 
Note: n=number of subjects with at least one event. #=number of individual occurrences. 
Note: MACE=Major Adverse Cardiovascular Event, DVT=Deep Vein Thrombosis, PE= Pulmonary Embolism, VTE=Venous 
Thromboembolism. 
Note: MACE is defined reported as the following categories - CV death, non-fatal MI and non-fatal stroke. 
Note: Broad MACE is defined as reported as the following categories – CV death, MI, hospitalisation for unstable angina, 
stroke and hospitalisation for heart failure. A CV event resulting in death is reported as one MACE event. 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
205 
 
 
Example ESI1 (modified) 
Protocol: 201790                                                                                             Page 1 of n 
Population: Safety 
Table 3.x 
Summary of Characteristics of Injection Site Reaction 
Period: Period X 
 
Treatment 1 
(N=100)  
Treatment 2 
(N=100) 
Treatment 3 
(N=100) 
 
 
 
 
Number of Subjects with the Event 
   50     (50%) 
   40     (40%) 
   40     (40%) 
Number of Events 
   60 
   65 
   55 
 
 
 
 
Event Characteristics (% based on all subjects)[1] 
 
 
 
Serious 
   10/100 (10%) 
   16/100 (16%) 
    8/100  (8%) 
Study treatment related 
 
   25/100 (25%) 
     
   10/100 (10%) 
     
   20/100 (20%) 
     
Led to study withdrawal 
    5/100  (5%) 
    4/100  (4%) 
    2/100  (2%) 
 
 
 
 
Event Characteristics (% based on subjects with the 
Event)[1] 
 
 
 
Serious 
   10/50  (20%) 
   16/40  (40%) 
    8/40  (20%) 
Study treatment related 
 
   25/50  (50%) 
     
   10/40  (25%) 
 
   20/40  (50%) 
 
Led to study withdrawal 
    5/50  (10%) 
    4/40  (10%) 
    2/40   (5%) 
 
 
 
 
 
 
Note: [1] Subjects may be included in more than one category for ‘Event Characteristics’. 
Note: [2] Outcome worst case hierarchy: Fatal > Not Recovered/Not Resolved > Recovered/Resolved with sequelae > 
Recovering/Resolving > Recovered/Resolved 
Note: [3] Subjects are counted once under each action that was taken. 
Note: [4] Background therapy is methotrexate. 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
206 
 
 
 
Example ESI1 (modified) 
Protocol: 201790                                                                                             Page 2 of n 
Population: Safety 
Table 3.x 
Summary of Characteristics of Injection Site Reaction  
Study: Period X 
 
Treatment 1  
(N=100) 
Treatment 2 
(N=100) 
Treatment 3 
(N=100) 
 
 
 
 
Number of occurrences (% based on all subjects) 
 
 
 
One 
   30/100 (30%) 
   20/100 (20%) 
    8/100  (8%) 
Two 
   15/100 (15%) 
   10/100 (10%) 
   30/100 (30%) 
Three or more 
    5/100  (5%) 
   10/100 (10%) 
    2/100  (2%) 
 
 
 
 
Number of occurrences (% based on subjects with the Event) 
 
 
 
One 
   30/50  (60%) 
   20/40  (50%) 
    8/40  (20%) 
Two 
   15/50  (30%) 
   10/40  (25%) 
   30/40  (75%) 
Three or more 
    5/50  (10%) 
   10/40  (25%) 
    2/40   (5%) 
 
 
 
 
Outcome (% based on all subjects)[2] 
 
 
 
Recovered/Resolved 
   20/100 (20%) 
   10/100 (10%) 
    8/100  (8%) 
Recovering/Resolving 
   10/100 (10%) 
   20/100 (20%) 
   30/100 (30%) 
Not Recovered/Not Resolved 
   10/100 (10%) 
    5/100  (5%) 
    0/100   
Recovered/Resolved with sequelae 
    5/100  (5%) 
    0/100 
    0/100 
Fatal 
    5/100  (5%) 
    5/100  (5%) 
    2/100  (2%) 
 
 
 
 
Outcome (% based on subjects with the Event)[2] 
 
 
 
Recovered/Resolved 
   20/50  (40%) 
   10/40 (25%) 
    8/40 (20%) 
Recovering/Resolving 
   10/50  (20%) 
   20/40 (50%) 
   30/40 (75%) 
Not Recovered/Not Resolved 
   10/50  (20%) 
    5/40 (13%) 
    0/40   
Recovered/Resolved with sequelae 
    5/50  (10%) 
    0/40 
    0/40 
Fatal 
    5/50  (10%) 
    5/40 (13%) 
    2/40  (5%) 
 
Note: [1] Subjects may be included in more than one category for ‘Event Characteristics’. 
Note: [2] Outcome worst case hierarchy: Fatal > Not Recovered/Not Resolved > Recovered/Resolved with sequelae > 
Recovering/Resolving > Recovered/Resolved 
Note: [3] Subjects are counted once under each action that was taken. 
Note: [4] Background therapy is methotrexate. 
 


 
CONFIDENTIAL 
 
 
201790 
 
207 
 
Example ESI1 (modified) 
Protocol: 201790                                                                                             Page 3 of n 
Population: Safety 
Table 3.x 
Summary of Characteristics of Injection Site Reaction  
Period: Period X 
 
Treatment 1  
(N=100) 
Treatment 2 
(N=100) 
Treatment 3 
(N=100) 
 
 
 
 
Maximum Intensity (% based on all subjects) 
 
 
 
Mild 
   30/100 (30%) 
   20/100 (20%) 
    8/100  (8%) 
Moderate 
   15/100 (15%) 
   10/100 (10%) 
   30/100 (30%) 
Severe 
    5/100  (5%) 
   10/100 (10%) 
    2/100  (2%) 
 
 
 
 
Maximum Intensity (% based on subjects with the Event) 
 
 
 
Mild 
   30/50  (60%) 
   20/40  (50%) 
    8/40  (20%) 
Moderate 
   15/50  (30%) 
   10/40  (25%) 
   30/40  (75%) 
Severe 
    5/50  (10%) 
   10/40  (25%) 
    2/40   (5%) 
 
 
 
 
 
Note: [1] Subjects may be included in more than one category for ‘Event Characteristics’. 
Note: [2] Outcome worst case hierarchy: Fatal > Not Recovered/Not Resolved > Recovered/Resolved with sequelae > 
Recovering/Resolving > Recovered/Resolved 
Note: [3] Subjects are counted once under each action that was taken. 
Note: [4] Background therapy is methotrexate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
208 
 
Example ESI1 (modified) 
Protocol: 201790                                                                                             Page 4 of n 
Population: Safety 
Table 3.x 
Summary of Characteristics of Injection Site Reaction  
Period: Period X 
 
Treatment 1 
(N=100)   
Treatment 2 
(N=100) 
Treatment 3 
(N=100) 
 
 
 
 
Action Taken (% based on all subjects)[3] 
 
 
 
Study treatment withdrawn 
   20/100 (20%) 
   10/100 (10%) 
    8/100  (8%) 
Dose not changed 
    5/100  (5%) 
    0/100 
    0/100 
Dose interrupted/delayed 
    0/100 
    5/100  (5%) 
    2/100  (2%) 
Not applicable 
    5/100 (10%) 
    0/100 
    0/100 
 
 
 
 
Action Taken (% based on subjects with the Event)[3] 
 
 
 
Study treatment withdrawn 
   20/50  (40%) 
   10/40 (25%) 
    8/40 (20%) 
Dose not changed 
    5/50  (10%) 
    0/40 
    0/40 
Dose interrupted/delayed 
    0/50   
    5/40 (13%) 
    2/40  (5%) 
Not applicable 
    5/50  (10%) 
    0/40 
    0/40 
 
 
 
 
Action 
Taken 
with 
Background 
Therapy(% 
based 
on 
all 
subjects)[3] [4] 
 
 
 
Drug withdrawn 
   20/100 (20%) 
   10/100 (10%) 
    8/100  (8%) 
Dose reduced 
   10/100 (10%) 
   20/100 (20%) 
   30/100 (30%) 
Dose not changed 
    5/100  (5%) 
    0/100 
    0/100 
Dose interrupted/delayed 
    0/100 
    5/100  (5%) 
    2/100  (2%) 
Not applicable 
    5/100 (10%) 
    0/100 
    0/100 
 
 
 
 
Action Taken (% based on subjects with the Event)[3] 
 
 
 
Background Therapy [4] withdrawn 
   20/50  (40%) 
   10/40 (25%) 
    8/40 (20%) 
Dose reduced 
   10/50  (20%) 
   20/40 (50%) 
   30/40 (75%) 
Dose not changed 
    5/50  (10%) 
    0/40 
    0/40 
Dose interrupted/delayed 
    0/50   
    5/40 (13%) 
    2/40  (5%) 
Not applicable 
    5/50  (10%) 
    0/40 
    0/40 
 
 
 
 
Note: [1] Subjects may be included in more than one category for ‘Event Characteristics’. 
Note: [2] Outcome worst case hierarchy: Fatal > Not Recovered/Not Resolved > Recovered/Resolved with sequelae > 
Recovering/Resolving > Recovered/Resolved 
Note: [3] Subjects are counted once under each action that was taken. 
Note: [4] Background therapy is methotrexate. 
 


 
CONFIDENTIAL 
 
 
201790 
 
209 
 
 
Example: SAFE_T5 
Protocol: 201790                                                                                                Page 1 of n 
Population: Safety 
Table 3.x 
Summary of Injection Site Reaction (Period X) 
 
 
Treatment 1 
N=xx 
 n (%) [#] 
Treatment 2 
N=xx 
 n (%) [#] 
Treatment 3 
N=xx 
 n (%) [#] 
Treatment 4 
N=xx 
 n (%) [#] 
Any injection site reactions 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
<= 1 Day post injection 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
> 1 Day post injection $ 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Reported as a non-serious AE 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
Reported as an SAE 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Type of Reactions 
 
 
 
 
  Itching/Pruritus 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Redness/Erythema 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Pain 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Bruising 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Swelling/Edema 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Warm to Touch 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Note: n=number of subjects with at least one event. #=number of individual occurrences. ($) until 1 day before next injection.  
 
 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
210 
 
 
Example: SAFE_T6 
Protocol: 201790                                                                                                Page 1 of n 
Population: Safety  
Table 3.x 
Summary of Serious or Adjudicated Opportunistic Infections (Period X)  
 
 
Treatment 1 
N=xx 
 n (%) [#] 
Treatment 2 
N=xx 
 n (%) [#] 
Treatment 3 
N=xx 
 n (%) [#] 
Treatment 4 
N=xx 
 n (%) [#] 
Any serious or opportunistic infections 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
 
 
 
 
 
Reported as a non-serious AE 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
Reported as an SAE 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Type of Infection 
 
 
 
 
  Bacterial – Gram Positive 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Bacterial – Gram Negative 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Bacterial - Atypical  
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Bacterial - Unknown 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Bacterial – Other 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Viral - Zoster/shingles 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Viral - Simplex, orogenital 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Viral - EBV 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Viral - HCV 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Viral - HBV 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Viral - HBV Reactivation 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Viral - Unknown 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Viral - Other 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Note: n=number of subjects with at least one event. #=number of individual occurrences. 
Note: $ until 1 day before next injection. 
Note: Adjudication of serious hypersensitivity reactions was done internally.  
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
211 
 
Example: SAFE_T6 (continued) 
Protocol: 201790                                                                                                Page 2 of n 
Population: Safety  
Table 3.x 
Summary of Serious or Adjudicated Opportunistic Infections (Period X) 
 
 
Treatment 1 
N=xx 
 n (%) [#] 
Treatment 2 
N=xx 
 n (%) [#] 
Treatment 3 
N=xx 
 n (%) [#] 
Treatment 4 
N=xx 
 n (%) [#] 
Type of Infection 
 
 
 
 
  Opportunistic - Esophageal candidiasis 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - CMV viremia 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - CMV invasive 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - Pneumocystis Jiroveci 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - Cryptococcus 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - Disseminated herpes zoster 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - BK virus encephalitis 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - Fungal 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - Protozoal/helminthic 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - Latent tuberculosis 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - Active tuberculosis 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - Atypical mycobacterial 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - Aspergillus 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - Fungal non aspergillus 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - Fungal non cryptococcal 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - Unknown 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Opportunistic - Other 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Note: n=number of subjects with at least one event. #=number of individual occurrences. 
Note: $ until 1 day before next injection. 
Note: Adjudication of serious hypersensitivity reactions was done internally.  
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
212 
 
Example: SAFE_T6 (continued) 
Protocol: 201790                                                                                                Page 3 of n 
Population: Safety 
Table 3.x 
Summary of Serious or Adjudicated Opportunistic Infections (Period X) 
 
 
Treatment 1 
N=xx 
 n (%) [#] 
Treatment 2 
N=xx 
 n (%) [#] 
Treatment 3 
N=xx 
 n (%) [#] 
Treatment 4 
N=xx 
 n (%) [#] 
Origin of Infection 
 
 
 
 
  Community 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Hospital 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  ICU  
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Unknown 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Parenteral antibiotics or antimicrobial medication administered   x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Culture/swab taken 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Diagnostic imaging or other diagnostic tests performed 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Had grade 3 neutropenia or worse at the time of infection 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Note: n=number of subjects with at least one event. #=number of individual occurrences.  
Note: $ until 1 day before next injection. 
Note: Adjudication of serious hypersensitivity reactions was done internally. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
213 
 
Example: SAFE_T7 
Protocol: 201790                                                                                                Page 1 of n 
Population: Safety 
Table 3.x 
Summary of Adjudicated Serious Hypersensitivity Reactions (Period X) 
 
 
Treatment 1 
N=xx 
 n (%) [#] 
Treatment 2 
N=xx 
 n (%) [#] 
Treatment 3 
N=xx 
 n (%) [#] 
Treatment 4 
N=xx 
 n (%) [#] 
Any serious hypersensitivity reactions 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
<= 1 Day post injection 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
> 1 Day post injection $ 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Reported as a non-serious AE 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
Reported as an SAE 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Type of Systemic Reactions 
 
 
 
 
  Headache 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Pruritus 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Urticaria 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Rash 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Angioedema 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Fatigue 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Myalgia 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Arthralgia 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Bronchospasm 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Hypotension requiring vasopressors 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Hypotension not requiring vasopressors 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Dizziness 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Syncope 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Crampy abdominal pain 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Respiratory failure requiring intubation 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  ICU Management required 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Other 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Note: n=number of subjects with at least one event. #=number of individual occurrences. ($) until 1 day before next injection.  
 
 


 
CONFIDENTIAL 
 
 
201790 
 
214 
 
Example: SAFE_T7 (continued) 
Protocol: 201790                                                                                                Page 2 of n 
Population: Safety 
 
Table 3.x 
Summary of Adjudicated Serious Hypersensitivity Reactions (Period X) 
 
 
Treatment 1 
N=xx 
 n (%) [#] 
Treatment 2 
N=xx 
 n (%) [#] 
Treatment 3 
N=xx 
 n (%) [#] 
Treatment 4 
N=xx 
 n (%) [#] 
Met anaphylaxis criteria 
 
 
 
 
  Criterion 1 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Criterion 2 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  Criterion 3 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
  x (x) [x] 
 
 
 
 
 
Note: n=number of subjects with at least one event. #=number of individual occurrences. ($) until 1 day before next injection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
215 
 
Example: SAFE_T8 
Protocol: 201790                                                                                   Page 1 of n 
Population: Safety 
Table 3.x 
Summary of Pulmonary Findings (Period X) 
 
 
Note: Cough includes subjects who reported cough of any grade. 
Note: Abnormal lung auscultation includes subjects with any abnormality recorded. 
Note: Dyspnoea includes subjects who reported dyspnoea of any grade. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subjects with at least one 
event of 
Treatment 1 
N=xx 
 
Treatment 2 
N=xx 
 
Treatment 3 
N=xx 
 
Treatment 4 
N=xx 
 
 
 
 
 
 
Cough 
xx (xx) 
xx (xx) 
xx (xx) 
xx (xx) 
 
 
 
 
 
Abnormal lung auscultation 
xx (xx) 
xx (xx) 
xx (xx) 
xx (xx) 
 
 
 
 
 
Dyspnoea 
xx (xx) 
xx (xx) 
xx (xx) 
xx (xx) 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
216 
 
 
Example: SAFE_T9 
Protocol: 201790                                                                                   Page 1 of n 
Population: Safety 
Table 3.x 
Summary of Pulse Oximetry Results (Period X) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Visit 
  Blood Oxygen 
Treatment 1 
N=xx 
 
Treatment 2 
N=xx 
 
Treatment 3 
N=xx 
 
Treatment 4 
N=xx 
 
 
 
 
 
 
Baseline 
 
 
 
 
   n 
   xx 
      xx 
    xx 
  xx 
   <80% 
xx (xx) 
xx (xx) 
xx (xx) 
xx (xx) 
   80% to <90% 
xx (xx) 
xx (xx) 
xx (xx) 
xx (xx) 
   >=90% 
xx (xx) 
xx (xx) 
xx (xx) 
xx (xx) 
 
 
 
 
 
Worst Post-Baseline Result 
 
 
 
 
   n 
      xx 
      xx 
       xx 
     xx 
   <80% 
xx (xx) 
xx (xx) 
xx (xx) 
xx (xx) 
   80% to 90% 
xx (xx) 
xx (xx) 
xx (xx) 
xx (xx) 
   >=90%    
xx (xx) 
xx (xx) 
xx (xx) 
xx (xx) 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
217 
 
 
 
Example: LB16A (modified) 
Protocol: 201790  
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 1 of n 
Population: Safety 
Table 3.76 
Summary of Worst Case Chemistry Results by Maximum Grade Shift Post-Baseline Relative to Baseline 
(Period 1) 
Test (units): Alanine Aminotransferase (IU/L) 
Term: Alanine aminotransferase increased 
 
Treatment  
 
 
 
Planned Time   
 
Change Categories [2] 
------------------------------------------------------------------------------------------------------------ 
Pooled PBO (N=78)   
Baseline  
 
 
 
n  
 
 
 
 
xx 
Grade 1  
 
 
 
xx (xx%) 
Grade 2  
 
 
 
xx (xx%)  
Grade 3  
 
 
 
xx (xx%) 
Grade 4  
 
 
 
xx (xx%) 
 
Maximum Grade Shift Post  n  
 
 
 
 
xx 
Baseline 
Worsen to Grade 1   
xx (xx%) 
Worsen to Grade 2   
xx (xx%) 
Worsen to Grade 3   
xx (xx%) 
Worsen to Grade 4   
xx (xx%) 
Worsen to Grades 1 to 4  
xx (xx%) 
Worsen to Grades 2 to 4  
xx (xx%) 
Worsen to Grades 3 to 4  
xx (xx%) 
 
 
OTI 90mg QW (N=157)  
Baseline  
 
 
 
n  
 
 
 
 
xx 
Grade 1  
 
 
 
xx (xx%) 
Grade 2  
 
 
 
xx (xx%) 
Grade 3  
 
 
 
xx (xx%) 
Grade 4  
 
 
 
xx (xx%) 
--------------------------------------------------------------------------------------------------------------- 
Note: A worsening is defined as a worsening in grade relative to baseline grade. Subjects with missing 
baseline values are assumed to have baseline value of grade 0. 
[1] Grades were derived based on numeric criteria as defined in CTCAEv5.0 and did not take into 
consideration of clinical signs or symptoms, concomitant medication usage which is needed for the final 
grade associated with the adverse event. 
[2] n = number of subjects with values at the specified planned time. 


 
CONFIDENTIAL 
 
 
201790 
 
218 
 
 
 
Example: SAFE_T10 
Protocol: 201790                                                                                   Page 1 of n 
Population: Safety 
Table 3.x 
Summary of Anti-GSK3196165 Antibodies (ADA) 
 
 
Note: A subject is considered to have a positive ADA result if they have a positive screening assay, a positive 
confirmation assay and a titre value. A baseline ADA result is the closest ADA sample prior to the subject receiving the 
first dose of GSK3196165. Only confirmed ADA positive samples were tested in the Neutralizing Antibody assay. 
 
 
 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Baseline ADA results 
 
 
 
   n 
xx 
xx 
xx 
   Negative  ADA 
xx (xx) 
xx (xx) 
xx (xx) 
   Confirmed positive ADA 
xx (xx) 
xx (xx) 
xx (xx) 
At least one confirmed positive ADA that 
subsequently tested positive for 
Neutralising Antibodies 
xx (xx) 
xx (xx) 
xx (xx) 
At least one confirmed positive ADA that 
subsequently tested negative for 
Neutralising Antibodies 
xx (xx) 
xx (xx) 
xx (xx) 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
219 
 
 
 
Example: SAFE_T10 (continued) 
Protocol: 201790                                                                                   Page 2 of n 
Population: Safety 
Table 3.x 
Summary of Anti-GSK3196165 Antibodies (ADA) 
 
 
Note: A subject is considered to have a positive ADA result if they have a positive screening assay, a positive 
confirmation assay and a titre value. A baseline ADA result is the closest ADA sample prior to the subject receiving the 
first dose of GSK3196165. Only confirmed ADA positive samples were tested in the Neutralizing Antibody assay. 
 
 
 
 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Post-baseline ADA results 
 
 
 
    n 
xx 
xx 
xx 
At least one confirmed positive ADA 
result 
xx (xx) 
xx (xx) 
xx (xx) 
All negative ADA results  
xx (xx) 
xx (xx) 
xx (xx) 
Confirmed positive ADA result that are 
positive for Neutralising Antibodies 
xx (xx) 
xx (xx) 
xx (xx) 
Confirmed positive ADA result that are 
negative for Neutralising Antibodies 
xx (xx) 
xx (xx) 
xx (xx) 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
220 
 
 
 
Example: SAFE_T11 
Protocol: 201790                                                                                   Page 1 of n 
Population: Safety 
Table 3.x 
Summary of Binding Antibody at Each Assessment Visit 
 
Note: The values shown at the Any Time post baseline visit are based on each subject’s highest post baseline titre. 
Note: Any Time Post Baseline would be positive for a subject who had negative and positive post baseline results. 
Note: Transient positive is defined as a single positive immunogenic response where the previous visit is negative, that does 
not occur at the final study assessment and persistent positive is defined as a positive immunogenic response where the 
previous visit is positive of the final study assessment is positive. 
Visit 
Assay Result 
 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Baseline 
n 
 
xx 
xx 
xx 
 
Negative 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
Positive 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
Titre Value 
Median 
xx.x 
xx.x 
xx.x 
 
 
Min. 
xx 
xx 
xx 
 
 
Max. 
xx 
xx 
xx 
 
 
 
 
 
 
Week 2 
n 
 
xx 
xx 
xx 
 
Negative 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
Positive 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
Titre Value 
Median 
xx.x 
xx.x 
xx.x 
 
 
Min. 
xx 
xx 
xx 
 
 
Max. 
xx 
xx 
xx 
 
 
 
 
 
 
… 
 
 
 
 
 
 
 
 
 
 
 
ANY TIME POST 
BASELINE 
n 
 
xx 
xx 
xx 
 
Negative 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
Positive 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
  Persistent positive 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
  Transient positive 
 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
Titre Value 
Median 
xx.x 
xx.x 
xx.x 
 
 
Min. 
xx 
xx 
xx 
 
 
Max. 
xx 
xx 
xx 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
221 
 
Note: The titre value includes the method sample dilution of 1/10. 
 
Example: SAFE_T12 
Protocol: 201790                                                                                               Page 1 of n 
Population: Safety 
Table 3.x 
Summary of Neutralising Antibody at Each Assessment Visit 
 
Note: NAb assay result is only presented for subjects with a positive ADA assay. 
Note: Any Time Post Baseline would be positive for a subject who had negative and positive post baseline results. 
 
 
 
 
 
 
 
 
 
 
Visit 
Assay Result 
Treatment 1 
N=xx 
Treatment 2 
N=xx 
Treatment 3 
N=xx 
Baseline 
n 
xx 
xx 
xx 
 
Negative 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
Positive 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
Week 2 
n 
xx 
xx 
xx 
 
Negative 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
Positive 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
… 
 
 
 
 
 
 
 
 
 
ANY TIME POST 
BASELINE 
n 
xx 
xx 
xx 
 
Negative 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
Positive 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
222 
 
 
Example: SAFE_T13 
Protocol: 201790                                                                                           Page 1 of n 
Population: Safety 
Table 3.x 
Summary of Adjudicated Serious Cases of COVID-19 Infections (Period X) 
 
 
Treatment 1 
N=xx 
 n (%)  
Treatment 2 
N=xx 
 n (%)  
Treatment 3 
N=xx 
 n (%) 
Treatment 4 
N=xx 
 n (%) 
Confirmed Cases of COVID-19 
 
   Non Hospitalised (WHO grade 1 and 2) 
   Hospitalised (WHO grade 3, 4 and 5) 
   Hospitalised (WHO grade 6 and 7) 
   Death 
 
Probable Cases of COVID-19 
   Non Hospitalised (WHO grade 1 and 2) 
   Hospitalised (WHO grade 3, 4 and 5) 
   Hospitalised (WHO grade 6 and 7) 
   Death 
 
     x (x) 
     x (x)   
     x (x) 
     x (x) 
     x (x)   
      
     x (x) 
     x (x) 
     x (x) 
     x (x) 
     x (x) 
 
           
     x (x) 
      
     x (x) 
 
     x (x) 
 
     x (x) 
 
     x (x) 
 
 
 
     x (x) 
 
     x (x) 
 
     x (x) 
 
     x (x) 
 
     x (x) 
     x (x) 
     
     x (x) 
 
     x (x) 
 
     x (x) 
 
     x (x) 
 
      
      
     x (x) 
 
     x (x) 
 
     x (x) 
 
     x (x) 
 
     x (x) 
     x (x) 
     
     x (x) 
 
     x (x) 
 
     x (x) 
 
     x (x) 
 
 
     
     x (x) 
 
     x (x) 
 
     x (x) 
 
     x (x) 
 
     x (x) 
 
Note: WHO original scale - non hospitalised (grade 1-
 grade 2-
(grade 3-
 grade 4-
; grade 5-
 grade 6- 
 grade 7-
)). 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI


 
CONFIDENTIAL 
 
 
201790 
 
223 
 
 
 
Example: SAFE_T14  
Protocol: 201790                                                                                               Page 1 of n 
Population: Safety 
Table 1.x 
Summary of Common (>=2%) Adverse Events by Time from Randomisation  
 
Time From Randomisation : [<=12 weeks / >12 weeks and <=24 weeks / >24 weeks and <=36 weeks / >36 weeks and <=52 
weeks / >52 weeks] 
 
Treatment 1 
N=xx 
Treatment 
2 
N=xx 
Treatment 
3 
N=xx 
Treatment 4 
N=xx 
Treatment 5 
N=xx 
Treatment 6 
N=xx 
Any Adverse Event 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
    XXXXX 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
224 
 
 
 
Example: SAFE_T15 
Protocol: 201790                                                                                           Page 1 of x 
Population: Safety 
Table 3.x 
Summary of COVID-19 Infections (Period X) 
 
 
 
Treatment 1 
(N=xx) 
Treatment 2 
(N=xx) 
Treatment 3 
(N=xx) 
Treatment 4 
(N=xx) 
 
 
 
 
 
Any COVID-19 Infection 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
Any Non-Serious COVID-19 
Infection 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
   Confirmed COVID-19 Infection 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
   Suspected COVID-19 Infection 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
   Probable COVID-19 Infection 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
Any Serious COVID-19 Infection 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
   Confirmed COVID-19 Infection 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
   Suspected COVID-19 Infection 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
   Probable COVID-19 Infection 
xx (xx%) 
xx (xx%) 
xx (xx%) 
xx (xx%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 


 
CONFIDENTIAL 
 
 
201790 
 
225 
 
 
 
Example: SAFE_L1 
Protocol: 201790                                                                                   Page 1 of n 
Population: Safety 
Listing x 
Listing of Neutrophils and Associated Infections 
Subset of Subjects who experienced grade 3 or 4 Neutropenia 
 
Site=xxx; Subject=xxxxxx.xxxxxx; Arm=xxxxxxxxxxx; 
Sex=x; Age(YEARS)=xx; Race Details=xxxxxxxx; Weight(kg)=xx.xx 
 
 
 
Neutrophils (unit)  
 Associated Infections  
Treatment/ 
Period 
Visit 
Analysis 
Visit 
Date 
Study 
Day 
Result
Out of 
Normal 
Toxicity 
Grade 
 
Preferred Term/ 
VERBATIM TEXT 
Placebo/ 
1 
SCREENING 
SCREENING xxxx-xx-xx 
x
x.xx 
 
 
BASELINE 
BASELINE 
xxxx-xx-xx 
xx
x.xx 
xxx 
x 
WEEK 1 
WEEK 1 
xxxx-xx-xx 
xx
x.xx 
xxx 
x 
WEEK 2 
WEEK 2 
xxxx-xx-xx 
xx
x.xx 
 
 
UNSCHEDULED WEEK 2 
xxxx-xx-xx 
xx
x.xx 
xxx 
x 
WEEK 4 
WEEK 4 
xxxx-xx-xx 
xx
x.xx 
 
 
 
 
 
 
Note: Lower Limit of Normal: xx, Upper Limit of Normal: xx 
 
 
 
 
 
 
 
 
 
 
 


Signature Page for  201790 TMF-14870067 v1.0
Signature Page for TMF-14870067 v1.0
Reason for signing: Approved
Name: 
Role: Approver
Date of signature: 08-Aug-2022 08:25:50 GMT+0000
Reason for signing: Approved
Name:
Role: Approver
Date of signature: 08-Aug-2022 08:27:55 GMT+0000
PPD
PPD